{"PMC7256583": [["IntroductionDrone swarms are collections of remotely or autonomously controlled aerial vehicles which maintain some form of internal structure between the individuals.", [["collections", "PROBLEM", 29, 40], ["aerial vehicles", "OBSERVATION", 80, 95], ["internal structure", "OBSERVATION", 124, 142]]], ["These swarms have utility in many domains and tasks; surveillance (coverage), search and rescue, construction, and defense related activities [9, 16].", [["surveillance (coverage)", "TREATMENT", 53, 76]]], ["Swarms typically rely on some kind of position feedback to maintain the prescribed structure of the swarm.", [["swarm", "OBSERVATION", 100, 105]]], ["Referred to as localization, this task is typically achieved by utilizing GPS data and other sensor modalities [10, 20].", [["GPS data", "TEST", 74, 82]]], ["Without position feedback, maintaining a safe, collision-free flight within a crowded airspace becomes an increasingly difficult task [1, 17].IntroductionIn domains where adversaries or technical issues might disable or impede the efficacy of position feedback, drone swarms are at risk of losing the position information prerequisites that allow for safe, collision-free flight.", [["airspace", "MULTI-TISSUE_STRUCTURE", 86, 94], ["a crowded airspace", "PROBLEM", 76, 94], ["adversaries", "PROBLEM", 171, 182], ["technical issues", "PROBLEM", 186, 202], ["airspace", "OBSERVATION", 86, 94]]], ["In these GPS-denied environments, other methods must be used to provide position information to the drones, or to provide other navigation schemes that allow for safe flight.", [["navigation schemes", "TREATMENT", 128, 146]]], ["This paper seeks to investigate a method for coping with a GPS-denied environment without incurring these systemic costs of complex sensor fusion and navigational calculation.", [["complex sensor fusion", "TREATMENT", 124, 145], ["navigational calculation", "TEST", 150, 174]]], ["Given a set of drones with the most basic of intra-drone communication, and with a limited computational budget, are there still navigation methods that can cope with the loss of GPS provided position feedback?", [["the loss of GPS", "PROBLEM", 167, 182]]], ["One of the simplest methods for dealing with the lack direct positional feedback operate is the technique of dead reckoning.", [["dead reckoning", "PROBLEM", 109, 123]]], ["In such an approach, the current estimate of a drones position is taken as the \u2018true\u2019 position, and new control signals are calculated based on the relative location of this position to a desired position.IntroductionApplying the method of dead reckoning to a drone swarm introduces a new source of error that might lead to collisions of drones within a swarm due to environmental deviations.", [["dead reckoning", "PROBLEM", 240, 254], ["a drone swarm", "PROBLEM", 258, 271], ["collisions of drones", "PROBLEM", 324, 344], ["a swarm", "PROBLEM", 352, 359], ["environmental deviations", "PROBLEM", 367, 391], ["new", "OBSERVATION_MODIFIER", 100, 103], ["environmental deviations", "OBSERVATION", 367, 391]]], ["Dead reckoning assumes the position estimate at the prior time-step is accurate, and only influenced by the action of the drone.", [["Dead reckoning", "PROBLEM", 0, 14], ["position", "OBSERVATION_MODIFIER", 27, 35]]], ["Radio frequency sensors, or simple optical systems may provide such feedback [7, 12].", [["Radio frequency sensors", "TEST", 0, 23]]], ["This work assumes the existence of a simple inter-drone communication channel.", [["inter-drone communication channel", "PROTEIN", 44, 77], ["a simple inter-drone communication channel", "TREATMENT", 35, 77]]], ["The history of drone locations over time, coupled with this graph, provides a spatio-temporal data-set.IntroductionThis work hypothesizes that such a spatio-temporal data-set can be used to train a model which will improve upon the efficacy of dead reckoning in GPS-denied environments by predicting future environmental deviations based on changes in the structure of the swarm network.", [["swarm network", "MULTI-TISSUE_STRUCTURE", 373, 386], ["this graph", "TEST", 55, 65], ["dead reckoning", "PROBLEM", 244, 258], ["environmental deviations", "PROBLEM", 307, 331]]], ["We hypothesize that such a network encodes some information about the environmental deviations that introduce the accumulated errors of dead reckoning.", [["the environmental deviations", "PROBLEM", 66, 94], ["dead reckoning", "PROBLEM", 136, 150]]], ["In turn, this will reduce the accumulation of error, and lead to position estimates that are closer to their true value when the model is used versus pure dead reckoning.IntroductionThe novelty of the proposed procedure is that it provides a framework to safely navigate a swarm of drones in a GPS-denied environment with a purposefully simplified set of sensor modalities and computational capabilities.", [["the accumulation of error", "PROBLEM", 26, 51], ["pure dead reckoning", "PROBLEM", 150, 169], ["the proposed procedure", "TREATMENT", 197, 219]]], ["To support this, in this study we answer the following research questions: 1) Can a prediction-based approach properly estimate a drones trajectory after communication loss? 2) If so, do structure-based models improve this prediction capability? 3) Can a method for avoiding collisions between swarms be implemented, using the variance of the structured model as input?Prior WorkThe past decade has seen substantial work on the issues of collision avoidance, localization, and mapping [6].", [["this study", "TEST", 20, 30], ["communication loss", "PROBLEM", 154, 172], ["collision avoidance", "TREATMENT", 438, 457]]], ["The prevalence of these swarms has incentivized the creation of high fidelity models of both individual drones [8] and of swarms of these individuals [2, 18].Prior WorkDue to their prevalence, the security and consistency of communication within a swarm becomes paramount [3].", [["these swarms", "PROBLEM", 18, 30], ["swarms", "OBSERVATION", 24, 30], ["high fidelity", "OBSERVATION_MODIFIER", 64, 77]]], ["The manner of communication that enables the localization of drones within the swarms becomes an attack surface.", [["surface", "ANATOMY", 104, 111], ["surface", "CELLULAR_COMPONENT", 104, 111], ["attack", "OBSERVATION_MODIFIER", 97, 103], ["surface", "OBSERVATION_MODIFIER", 104, 111]]], ["On board visual sensors have been utilized to localize drones with respect to observations of visual indicators applied to each drone [14].", [["board visual sensors", "TREATMENT", 3, 23]]], ["The bearing of the swarm were combined with observed landmarks to implement a sufficient simultaneous localization and mapping (SLAM) framework.", [["SLAM", "PROTEIN", 128, 132]]], ["This can provide a means of inter-drone localization within a swarm by observing the received signal strength of RF signals from neighboring drones [12].Prior WorkWhen position feedback is lost, the technique of dead reckoning can be used.", [["RF", "PROTEIN", 113, 115], ["dead reckoning", "TREATMENT", 212, 226]]], ["This manner of control simply assumes the current position estimate of the drone location is correct, and flies accordingly.", [["This manner of control", "TREATMENT", 0, 22]]], ["Such a system is prone to quick accumulation of error when used in isolation.", [["quick accumulation of error", "PROBLEM", 26, 53]]], ["The combination of dead reckoning, and observations using a Kalman filter can still allow for improved trajectory tracking [21].", [["dead reckoning", "TREATMENT", 19, 33], ["a Kalman filter", "TREATMENT", 58, 73]]], ["Dead reckoning can also be combined with other localization methods to improve its accuracy.", [["Dead reckoning", "PROBLEM", 0, 14]]], ["Such a method is proposed in which the received signal strength of neighboring drone broadcasts is combined with a dead reckoning scheme to enable accurate localization [19].Problem Statement ::: MethodAssume a swarm of D drones that is heading towards a certain destination in a stochastic environment.", [["a method", "TREATMENT", 5, 13], ["a dead reckoning scheme", "PROBLEM", 113, 136], ["a swarm of D drones", "TREATMENT", 209, 228], ["swarm", "OBSERVATION_MODIFIER", 211, 216]]], ["Given that global communication (e.g., GPS communication) is lost on the way towards the destination, the objective is to predict the positions of all drones at all subsequent time-steps.Problem Statement ::: MethodFormally, a swarm", [["swarm", "OBSERVATION", 227, 232]]]], "PMC7159351": [["INTRODUCTIONCanine parvovirus type 2 (CPV\u20102) is a small, non\u2010enveloped single\u2010stranded DNA virus, recently included in the specie Carnivore protoparvovirus 1, a member of the Protoparvovirus genus (family Parvoviridae, subfamily Parvovirinae) (Cotmore et al., 2019).", [["INTRODUCTIONCanine parvovirus type 2", "ORGANISM", 0, 36], ["CPV\u20102", "ORGANISM", 38, 43], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["Carnivore protoparvovirus 1", "ORGANISM", 130, 157], ["Protoparvovirus genus", "ORGANISM", 175, 196], ["Carnivore protoparvovirus", "SPECIES", 130, 155], ["CPV", "SPECIES", 38, 41], ["Carnivore protoparvovirus 1", "SPECIES", 130, 157], ["INTRODUCTIONCanine parvovirus type", "TREATMENT", 0, 34], ["a small, non\u2010enveloped single\u2010stranded DNA virus", "PROBLEM", 48, 96], ["small", "OBSERVATION_MODIFIER", 50, 55]]], ["Its genome consists of an approximately 5,200 nucleotide (nt) DNA molecule containing two large open reading frames (ORFs), encoding two nonstructural (NS1 and NS2) and two structural (VP1 and VP2) proteins, generated through alternative splicing of the same mRNAs (Decaro & Buonavoglia, 2012; Reed, Jones, & Miller, 1988).INTRODUCTIONIn susceptible non\u2010immunized dogs, CPV\u20102 causes an acute and often lethal disease, whose clinical signs are characterized by vomiting, enteritis and acute lymphopenia (Decaro & Buonavoglia, 2012).", [["CPV\u20102", "DISEASE", 370, 375], ["vomiting", "DISEASE", 460, 468], ["enteritis", "DISEASE", 470, 479], ["lymphopenia", "DISEASE", 490, 501], ["nucleotide", "CHEMICAL", 46, 56], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["NS1", "GENE_OR_GENE_PRODUCT", 152, 155], ["NS2", "GENE_OR_GENE_PRODUCT", 160, 163], ["VP1", "GENE_OR_GENE_PRODUCT", 185, 188], ["VP2", "GENE_OR_GENE_PRODUCT", 193, 196], ["dogs", "ORGANISM", 364, 368], ["CPV\u20102", "ORGANISM", 370, 375], ["5,200 nucleotide (nt) DNA molecule", "DNA", 40, 74], ["open reading frames", "DNA", 96, 115], ["ORFs", "DNA", 117, 121], ["NS1", "PROTEIN", 152, 155], ["NS2", "PROTEIN", 160, 163], ["structural (VP1 and VP2) proteins", "PROTEIN", 173, 206], ["mRNAs", "RNA", 259, 264], ["dogs", "SPECIES", 364, 368], ["CPV\u20102", "SPECIES", 370, 375], ["an approximately 5,200 nucleotide (nt) DNA molecule", "PROBLEM", 23, 74], ["two large open reading frames (ORFs", "PROBLEM", 86, 121], ["two structural (VP1 and VP2) proteins", "TEST", 169, 206], ["an acute and often lethal disease", "PROBLEM", 383, 416], ["vomiting", "PROBLEM", 460, 468], ["enteritis", "PROBLEM", 470, 479], ["acute lymphopenia", "PROBLEM", 484, 501], ["genome", "OBSERVATION", 4, 10], ["large", "OBSERVATION_MODIFIER", 90, 95], ["open", "OBSERVATION", 96, 100], ["acute", "OBSERVATION_MODIFIER", 386, 391], ["enteritis", "OBSERVATION", 470, 479], ["acute", "OBSERVATION_MODIFIER", 484, 489], ["lymphopenia", "OBSERVATION", 490, 501]]], ["CPV\u20102 emerged as dog pathogen in the late 1970s, most likely as host variant of feline parvovirus (FPV) or a related strain (Truyen, 2006), displaying an intrinsic high rate of nucleotide changes (Decaro et al., 2009; Pereira, Leal, & Durigon, 2007; Shackelton, Parrish, Truyen, & Holmes, 2005).", [["feline parvovirus", "DISEASE", 80, 97], ["nucleotide", "CHEMICAL", 177, 187], ["nucleotide", "CHEMICAL", 177, 187], ["dog", "ORGANISM", 17, 20], ["feline parvovirus", "ORGANISM", 80, 97], ["FPV", "ORGANISM", 99, 102], ["feline parvovirus", "SPECIES", 80, 97], ["CPV", "SPECIES", 0, 3], ["feline parvovirus", "SPECIES", 80, 97], ["FPV", "SPECIES", 99, 102], ["CPV", "PROBLEM", 0, 3], ["dog pathogen", "PROBLEM", 17, 29], ["feline parvovirus", "PROBLEM", 80, 97], ["a related strain", "PROBLEM", 107, 123], ["an intrinsic high rate of nucleotide changes", "PROBLEM", 151, 195], ["most likely", "UNCERTAINTY", 49, 60], ["feline parvovirus", "OBSERVATION", 80, 97]]], ["After its emergence, the original type CPV\u20102 was replaced by three antigenic variants termed CPV\u20102a, CPV\u20102b and CPV\u20102c (Buonavoglia et al., 2001; Parrish et al., 1991; Parrish, O\u2019Connell, Evermann, & Carmichael, 1985).", [["CPV", "ORGANISM", 39, 42], ["CPV\u20102a", "ORGANISM", 93, 99], ["CPV\u20102b", "ORGANISM", 101, 107], ["CPV\u20102", "DNA", 39, 44], ["CPV", "SPECIES", 39, 42], ["CPV\u20102a", "SPECIES", 93, 99], ["CPV", "SPECIES", 101, 104], ["CPV", "SPECIES", 112, 115], ["the original type CPV\u20102", "TREATMENT", 21, 44], ["CPV\u20102b", "TREATMENT", 101, 107]]], ["During the years, several amino acid (aa) changes were accounted in the VP2 gene sequence (Battilani et al., 2001; Geng et al., 2015; Jeoung, Ahn, & Kim, 2008; Nakamura et al., 2004; Truyen, 1999) and, only recently, the analysis of the NS1 gene sequence was included in the CPV phylogenies (Canuti, Rodrigues, Whitney, & Lang, 2017; Grecco et al., 2018; Han et al., 2015; Li et al., 2018; Mira et al., 2019; P\u00e9rez et al., 2014; Zhuang et al., 2019).INTRODUCTIONPrevious studies provided information on the CPV strains spreading in Italy (Decaro, Desario, et al., 2007; Decaro et al., 2013, 2006; Dei Giudici et al., 2017; Mira, Dowgier, et al., 2018; Purpari et al., 2018; Tucciarone et al., 2018), suggesting the need of a continuous epidemiological survey to evaluate the CPV circulation and evolution, whereas limited data are available on the spread of novel strains imported from other continents (Mira, Purpari, Lorusso, et al., 2018).", [["amino acid", "CHEMICAL", 26, 36], ["amino acid", "CHEMICAL", 26, 36], ["amino acid", "AMINO_ACID", 26, 36], ["VP2", "GENE_OR_GENE_PRODUCT", 72, 75], ["NS1", "GENE_OR_GENE_PRODUCT", 237, 240], ["CPV", "ORGANISM", 507, 510], ["VP2 gene sequence", "DNA", 72, 89], ["NS1 gene sequence", "DNA", 237, 254], ["CPV", "SPECIES", 275, 278], ["CPV", "SPECIES", 507, 510], ["CPV", "SPECIES", 775, 778], ["several amino acid (aa) changes", "PROBLEM", 18, 49], ["the analysis", "TEST", 217, 229], ["the NS1 gene sequence", "TEST", 233, 254], ["a continuous epidemiological survey", "TEST", 723, 758], ["novel strains", "PROBLEM", 858, 871]]], ["The aim of this study was the detection and molecular analysis of CPV strains displaying genetic features of Asian viruses spreading in southern Italy.MATERIALS AND METHODSDuring an epidemiological survey, rectal swabs (n = 3) and tissue samples (n = 19) from seven dogs suspected of CPV infection (Table 1), collected in southern Italy (Sicily) from August 2018 to March 2019, were analysed at the Istituto Zooprofilattico Sperimentale della Sicilia \u201cA. Mirri\u201d (Palermo, Italy) for diagnostic purposes.", [["rectal swabs", "ANATOMY", 206, 218], ["tissue samples", "ANATOMY", 231, 245], ["Asian viruses", "DISEASE", 109, 122], ["CPV infection", "DISEASE", 284, 297], ["CPV", "ORGANISM", 66, 69], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 206, 218], ["tissue samples", "TISSUE", 231, 245], ["dogs", "ORGANISM", 266, 270], ["CPV", "ORGANISM", 284, 287], ["dogs", "SPECIES", 266, 270], ["CPV", "SPECIES", 66, 69], ["Asian viruses", "SPECIES", 109, 122], ["CPV", "SPECIES", 284, 287], ["this study", "TEST", 11, 21], ["the detection", "TEST", 26, 39], ["molecular analysis", "TEST", 44, 62], ["CPV strains", "PROBLEM", 66, 77], ["Asian viruses", "PROBLEM", 109, 122], ["an epidemiological survey", "TEST", 179, 204], ["rectal swabs", "TEST", 206, 218], ["tissue samples", "TEST", 231, 245], ["CPV infection", "PROBLEM", 284, 297], ["diagnostic purposes", "TEST", 483, 502], ["Asian viruses", "OBSERVATION", 109, 122], ["rectal", "ANATOMY", 206, 212], ["CPV infection", "OBSERVATION", 284, 297]]], ["DNA and RNA were extracted from swab/organ homogenates, obtained as previously described (Purpari et al., 2018), using the DNeasy Blood & Tissue Kit (Qiagen S.p.A.) and QIAmp Viral RNA Mini Kit (Qiagen S.p.A.), respectively, according to the manufacturer's instructions.", [["swab", "ANATOMY", 32, 36], ["organ homogenates", "ANATOMY", 37, 54], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["swab", "TISSUE", 32, 36], ["organ", "ORGAN", 37, 42], ["homogenates", "ORGANISM_SUBSTANCE", 43, 54], ["DNA and RNA", "PROBLEM", 0, 11], ["swab/organ homogenates", "TEST", 32, 54], ["the DNeasy Blood & Tissue Kit (Qiagen S.p.A.)", "TREATMENT", 119, 164], ["QIAmp Viral RNA", "TREATMENT", 169, 184], ["organ", "ANATOMY", 37, 42]]], ["Presence of CPV DNA was evaluated by a diagnostic PCR using a primer pair targeting the VP2 gene (Touihri et al., 2009), as previously described (Mira, Purpari, Lorusso, et al., 2018), and each amplicon was analysed by electrophoresis on a 3% agarose gel supplemented with ethidium bromide.MATERIALS AND METHODSSequencing encompassing both ORFs (NS and VP genes) was carried out using primer pairs developed by P\u00e9rez et al. (2014), as previously described (Mira et al., 2019).", [["ethidium bromide", "CHEMICAL", 273, 289], ["ethidium bromide", "CHEMICAL", 273, 289], ["CPV", "ORGANISM", 12, 15], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["VP2", "GENE_OR_GENE_PRODUCT", 88, 91], ["agarose", "SIMPLE_CHEMICAL", 243, 250], ["ethidium bromide", "SIMPLE_CHEMICAL", 273, 289], ["CPV DNA", "DNA", 12, 19], ["VP2 gene", "DNA", 88, 96], ["ORFs", "DNA", 340, 344], ["NS", "DNA", 346, 348], ["VP genes", "DNA", 353, 361], ["CPV", "SPECIES", 12, 15], ["CPV DNA", "PROBLEM", 12, 19], ["a diagnostic PCR", "TEST", 37, 53], ["a primer pair", "TREATMENT", 60, 73], ["each amplicon", "TREATMENT", 189, 202], ["a 3% agarose gel", "TREATMENT", 238, 254], ["ethidium bromide", "TREATMENT", 273, 289], ["METHODSSequencing", "TREATMENT", 304, 321], ["NS and VP genes", "TREATMENT", 346, 361], ["CPV DNA", "OBSERVATION", 12, 19]]], ["Assembled nucleotide sequences were submitted to nBLAST program (Zhang, Schwartz, Wagner, & Miller, 2000) to search related sequences in public domain databases.", [["nucleotide", "CHEMICAL", 10, 20], ["nucleotide", "CHEMICAL", 10, 20], ["Assembled nucleotide sequences", "TEST", 0, 30]]], ["These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession numbers MK802679\u201085.", [["These sequence data", "TEST", 0, 19]]], ["The obtained sequences were aligned with reference sequences retrieved from the GenBank database, which included the sequence (accession number MF510157) of a CPV\u20102c strain collected from the same region and previously analysed (Mira, Purpari, Lorusso, et al., 2018).MATERIALS AND METHODSTo elucidate the genetic relationships of the analysed CPV strains, two phylogenetic trees, based on the full\u2010length VP2 and NS1 gene sequences, were constructed with the MEGA X software (Kumar, Stecher, Li, Knyaz, & Tamura, 2018), using the maximum\u2010likelihood method according to the Tamura 3\u2010parameter (T92) and Hasegawa\u2013Kishino\u2013Yano (HKY) models, with discrete Gamma distribution (five rate categories) (G) and invariant sites (I) (bootstrap analyses with 1,000 replicates).", [["CPV", "ORGANISM", 343, 346], ["VP2", "GENE_OR_GENE_PRODUCT", 405, 408], ["NS1", "GENE_OR_GENE_PRODUCT", 413, 416], ["full\u2010length VP2 and NS1 gene sequences", "DNA", 393, 431], ["CPV\u20102c", "SPECIES", 159, 165], ["CPV", "SPECIES", 343, 346], ["reference sequences", "TEST", 41, 60], ["the GenBank database", "TEST", 76, 96], ["a CPV\u20102c strain", "TREATMENT", 157, 172], ["the analysed CPV strains", "PROBLEM", 330, 354], ["the full\u2010length VP2 and NS1 gene sequences", "TEST", 389, 431], ["the maximum\u2010likelihood method", "TREATMENT", 526, 555], ["Hasegawa", "TEST", 602, 610], ["discrete Gamma distribution", "PROBLEM", 643, 670], ["bootstrap analyses", "TEST", 723, 741], ["discrete", "OBSERVATION_MODIFIER", 643, 651], ["Gamma distribution", "OBSERVATION", 652, 670]]], ["The models selection was performed using the best\u2010fit model of nucleotide substitution with MEGA X software (VP2 gene: T92+G+I; NS1 gene: HKY+G).MATERIALS AND METHODSExtracted DNA/RNA were also amplified using a set of PCR assays for the detection of canine distemper virus (CDV) (Elia et al., 2006), canine adenovirus (CAdV) type 1 and type 2 (Dowgier et al., 2016), canine herpesvirus (CaHV\u20101) (Decaro et al., 2010), canine coronavirus (CCoV) (Decaro et al., 2004) and canine rotavirus (CRoV) (Freeman, Kerin, Hull, McCaustland, & Gentsch, 2008).RESULTS AND DISCUSSIONAll tissue samples tested positive for CPV by conventional PCR assay and negative for CDV, CAdVs, CaHV\u20101, CCoV and CRoV by gel\u2010based or real\u2010time (RT) PCR assays.", [["tissue samples", "ANATOMY", 574, 588], ["nucleotide", "CHEMICAL", 63, 73], ["canine distemper", "DISEASE", 251, 267], ["canine herpesvirus", "DISEASE", 368, 386], ["canine coronavirus", "DISEASE", 419, 437], ["canine rotavirus", "DISEASE", 471, 487], ["nucleotide", "CHEMICAL", 63, 73], ["T92+G+I", "GENE_OR_GENE_PRODUCT", 119, 126], ["HKY+G", "GENE_OR_GENE_PRODUCT", 138, 143], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["canine distemper virus", "ORGANISM", 251, 273], ["CDV", "ORGANISM", 275, 278], ["canine adenovirus", "ORGANISM", 301, 318], ["CAdV) type 1", "ORGANISM", 320, 332], ["canine herpesvirus", "ORGANISM", 368, 386], ["CaHV\u20101", "ORGANISM", 388, 394], ["canine coronavirus", "ORGANISM", 419, 437], ["CCoV", "ORGANISM", 439, 443], ["canine rotavirus", "ORGANISM", 471, 487], ["tissue samples", "CANCER", 574, 588], ["CPV", "ORGANISM", 609, 612], ["CDV", "ORGANISM", 656, 659], ["CAdVs", "GENE_OR_GENE_PRODUCT", 661, 666], ["CaHV\u20101", "GENE_OR_GENE_PRODUCT", 668, 674], ["CCoV", "GENE_OR_GENE_PRODUCT", 676, 680], ["CRoV", "GENE_OR_GENE_PRODUCT", 685, 689], ["MEGA X software", "DNA", 92, 107], ["VP2 gene", "DNA", 109, 117], ["T92", "DNA", 119, 122], ["NS1 gene", "DNA", 128, 136], ["HKY", "DNA", 138, 141], ["METHODSExtracted DNA", "DNA", 159, 179], ["CCoV", "PROTEIN", 676, 680], ["canine distemper virus", "SPECIES", 251, 273], ["canine", "SPECIES", 301, 307], ["canine herpesvirus", "SPECIES", 368, 386], ["canine coronavirus", "SPECIES", 419, 437], ["canine rotavirus", "SPECIES", 471, 487], ["canine distemper virus", "SPECIES", 251, 273], ["CDV", "SPECIES", 275, 278], ["canine adenovirus", "SPECIES", 301, 318], ["CAdV", "SPECIES", 320, 324], ["canine herpesvirus (CaHV\u20101", "SPECIES", 368, 394], ["canine coronavirus", "SPECIES", 419, 437], ["CCoV", "SPECIES", 439, 443], ["canine rotavirus", "SPECIES", 471, 487], ["CRoV", "SPECIES", 489, 493], ["CPV", "SPECIES", 609, 612], ["CDV", "SPECIES", 656, 659], ["CaHV", "SPECIES", 668, 672], ["CCoV", "SPECIES", 676, 680], ["CRoV", "SPECIES", 685, 689], ["The models selection", "TEST", 0, 20], ["nucleotide substitution", "TREATMENT", 63, 86], ["MEGA X software", "TEST", 92, 107], ["VP2 gene", "TEST", 109, 117], ["T92", "TEST", 119, 122], ["METHODSExtracted DNA/RNA", "PROBLEM", 159, 183], ["PCR assays", "TEST", 219, 229], ["the detection", "TEST", 234, 247], ["canine distemper virus", "PROBLEM", 251, 273], ["canine adenovirus (CAdV) type 1", "PROBLEM", 301, 332], ["Dowgier et al.", "TEST", 345, 359], ["canine herpesvirus (CaHV\u2010", "TEST", 368, 393], ["canine coronavirus", "PROBLEM", 419, 437], ["DISCUSSIONAll tissue samples", "TEST", 560, 588], ["CPV", "PROBLEM", 609, 612], ["conventional PCR assay", "TEST", 616, 638], ["CDV", "PROBLEM", 656, 659], ["CAdVs", "TEST", 661, 666], ["CaHV", "TEST", 668, 672], ["PCR assays", "TEST", 721, 731], ["distemper virus", "OBSERVATION", 258, 273], ["canine coronavirus", "ANATOMY", 419, 437]]], ["By sequence amplifications, the nearly complete CPV\u2010genome sequences including both ORFs (4,269 nt) were obtained.", [["CPV\u2010genome sequences", "DNA", 48, 68], ["ORFs", "DNA", 84, 88], ["4,269 nt", "DNA", 90, 98], ["CPV", "SPECIES", 48, 51]]], ["Based on the VP2\u2010426 amino acid residue, all detected strains were characterized as CPV\u20102c.", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["VP2", "GENE_OR_GENE_PRODUCT", 13, 16], ["amino acid", "AMINO_ACID", 21, 31], ["residue", "AMINO_ACID", 32, 39], ["CPV\u20102c", "SPECIES", 84, 90], ["the VP2", "TEST", 9, 16], ["amino acid residue", "PROBLEM", 21, 39], ["all detected strains", "PROBLEM", 41, 61]]], ["NS1 and VP2 sequences of CPV strains analysed in this study showed 100%\u201399.95% and 100%\u201399.82% reciprocal nucleotide identities, respectively.", [["nucleotide", "CHEMICAL", 106, 116], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["VP2", "GENE_OR_GENE_PRODUCT", 8, 11], ["CPV strains", "ORGANISM", 25, 36], ["NS1 and VP2 sequences", "DNA", 0, 21], ["CPV", "SPECIES", 25, 28], ["NS1", "TEST", 0, 3], ["VP2 sequences", "TEST", 8, 21], ["CPV strains", "TEST", 25, 36], ["this study", "TEST", 49, 59]]], ["The complete genome sequences showed 99.95%\u201399.93% and 99.95%\u201399.91% nucleotide identities with CPV strains of Asian origin, such as CPV_IZSSI_2743_17 (Italy, 2017; accession number MF510157), CPV\u2010SH1516 (China, 2017; acc. no. MG013488) and Canine/China/14/2017 (China, 2017; acc. no. MH476583).RESULTS AND DISCUSSIONSequence analysis revealed amino acid changes previously described in Asian CPV\u20102c strains (NS1: 60V, 544F, 545F, 630P\u2014NS2: 60V, 151N, 152V\u2014VP2: 5A/G, 267Y, 297A, 324I, 370R) (Table S1).", [["nucleotide", "CHEMICAL", 69, 79], ["amino acid", "CHEMICAL", 344, 354], ["amino acid", "CHEMICAL", 344, 354], ["amino acid", "AMINO_ACID", 344, 354], ["CPV\u20102c strains", "ORGANISM", 393, 407], ["NS1: 60V", "ORGANISM", 409, 417], ["152V", "PROTEIN", 452, 456], ["CPV", "SPECIES", 96, 99], ["CPV_IZSSI_2743_17", "SPECIES", 133, 150], ["CPV\u2010SH1516", "SPECIES", 193, 203], ["Canine/China/14/2017", "SPECIES", 241, 261], ["Asian CPV\u20102c", "SPECIES", 387, 399], ["The complete genome sequences", "TEST", 0, 29], ["nucleotide identities", "TEST", 69, 90], ["CPV strains of Asian origin", "PROBLEM", 96, 123], ["DISCUSSIONSequence analysis", "TEST", 307, 334], ["amino acid changes", "PROBLEM", 344, 362], ["NS1", "TEST", 409, 412], ["NS2", "TEST", 436, 439], ["VP2", "TEST", 457, 460], ["G", "TEST", 465, 466], ["CPV strains", "OBSERVATION", 96, 107], ["amino acid", "OBSERVATION", 344, 354]]], ["CPV strain IZSSI_PA5632/19 evidenced an additional change at residue 492 of NS1 protein (Table S1).", [["CPV", "ORGANISM", 0, 3], ["NS1 protein (Table S1", "GENE_OR_GENE_PRODUCT", 76, 97], ["NS1 protein", "PROTEIN", 76, 87], ["Table S1", "PROTEIN", 89, 97], ["CPV", "SPECIES", 0, 3], ["CPV strain", "TREATMENT", 0, 10], ["an additional change at residue", "PROBLEM", 37, 68], ["NS1 protein", "TEST", 76, 87]]], ["Only one mutation (A/G) was observed among the analysed strains at residue 5 of the VP2 protein, which suggests the circulation of two different but related CPV\u20102c strains in southern Italy.RESULTS AND DISCUSSIONAmino acid change I60V in NS1 also lies at the same residue in the NS2\u2010encoding sequence, while change at codon 630 of NS1 sequences did not result in any changes in the encoded NS2 protein.", [["DISCUSSIONAmino acid", "CHEMICAL", 202, 222], ["VP2", "GENE_OR_GENE_PRODUCT", 84, 87], ["CPV\u20102c", "ORGANISM", 157, 163], ["NS1", "GENE_OR_GENE_PRODUCT", 238, 241], ["NS1", "GENE_OR_GENE_PRODUCT", 331, 334], ["NS2", "GENE_OR_GENE_PRODUCT", 390, 393], ["VP2 protein", "PROTEIN", 84, 95], ["NS1", "PROTEIN", 238, 241], ["NS2\u2010encoding sequence", "DNA", 279, 300], ["codon 630", "DNA", 318, 327], ["NS1 sequences", "DNA", 331, 344], ["NS2 protein", "PROTEIN", 390, 401], ["CPV\u20102c", "SPECIES", 157, 163], ["A/G)", "TEST", 19, 23], ["the analysed strains at residue", "PROBLEM", 43, 74], ["the VP2 protein", "TEST", 80, 95], ["DISCUSSIONAmino acid change I60V", "TREATMENT", 202, 234], ["NS1", "TREATMENT", 238, 241], ["NS1 sequences", "TEST", 331, 344]]], ["Additional two amino acid changes in the NS2\u2010encoding sequences were observed among the analysed strains: D151N and M152V (Table S1).", [["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 15, 25], ["amino acid", "AMINO_ACID", 15, 25], ["NS2\u2010encoding sequences", "DNA", 41, 63], ["Additional two amino acid changes", "TREATMENT", 0, 33], ["the NS2\u2010encoding sequences", "TREATMENT", 37, 63], ["D151N", "TREATMENT", 106, 111], ["amino acid", "OBSERVATION", 15, 25]]], ["These changes resulted in silent mutations in the corresponding encoded NS1 protein.RESULTS AND DISCUSSIONPhylogenetic analysis inferred from VP2 sequences indicated that analysed strains are more related to Asian than to European CPV strains, clustering in a separate clade (Figure 1).", [["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["VP2", "GENE_OR_GENE_PRODUCT", 142, 145], ["CPV", "ORGANISM", 231, 234], ["NS1 protein", "PROTEIN", 72, 83], ["VP2 sequences", "DNA", 142, 155], ["European CPV", "SPECIES", 222, 234], ["silent mutations", "PROBLEM", 26, 42], ["DISCUSSIONPhylogenetic analysis", "TEST", 96, 127], ["VP2 sequences", "TEST", 142, 155], ["analysed strains", "PROBLEM", 171, 187], ["European CPV strains", "PROBLEM", 222, 242], ["silent mutations", "OBSERVATION", 26, 42]]], ["Phylogenetic tree inferred from NS1 gene sequences shows that strains clustered within the phylogeny according to the geographical origin and the year of collection rather than to the CPV variant (Figure 2).RESULTS AND DISCUSSIONThe present molecular analysis of CPV strains detected in southern Italy provides new data about the viral spread and dynamics of CPV mutants circulating in Italy.", [["NS1", "GENE_OR_GENE_PRODUCT", 32, 35], ["CPV", "ORGANISM", 263, 266], ["CPV", "ORGANISM", 359, 362], ["NS1 gene sequences", "DNA", 32, 50], ["CPV", "SPECIES", 184, 187], ["CPV", "SPECIES", 263, 266], ["CPV", "SPECIES", 359, 362], ["Phylogenetic tree", "PROBLEM", 0, 17], ["NS1 gene sequences", "TEST", 32, 50], ["strains", "PROBLEM", 62, 69], ["CPV strains", "PROBLEM", 263, 274], ["the viral spread", "PROBLEM", 326, 342], ["collection", "OBSERVATION", 154, 164], ["CPV variant", "OBSERVATION", 184, 195], ["CPV strains", "OBSERVATION", 263, 274]]], ["In the last decades, several studies analysed the spread of CPV strains in Italy, and in 2001, the emergence of the CPV\u20102c variant was firstly reported (Buonavoglia et al., 2001).", [["CPV", "ORGANISM", 60, 63], ["CPV\u20102c", "ORGANISM", 116, 122], ["CPV", "SPECIES", 60, 63], ["CPV\u20102c", "SPECIES", 116, 122], ["several studies", "TEST", 21, 36], ["CPV strains", "PROBLEM", 60, 71]]], ["In the following years, all three CPV variants were described in Italy, with a slightly higher prevalence of the CPV\u20102a and CPV\u20102c variants (Decaro, Desario, et al., 2007; Decaro et al., 2013, 2006; Tucciarone et al., 2018).", [["CPV", "ORGANISM", 34, 37], ["CPV\u20102a", "ORGANISM", 113, 119], ["CPV\u20102c", "GENE_OR_GENE_PRODUCT", 124, 130], ["CPV", "SPECIES", 34, 37], ["CPV\u20102a", "SPECIES", 113, 119], ["CPV", "SPECIES", 124, 127]]], ["More recently, a CPV\u20102c strain displaying genetic signatures typical of Asian viruses was detected in southern Italy (Mira, Purpari, Lorusso, et al., 2018), thus suggesting the introduction of the virus from other countries, as reported for other canine viruses (Decaro, Campolo, et al., 2007; Martella et al., 2006; Mira, Purpari, Bella, et al., 2018).", [["Asian viruses", "DISEASE", 72, 85], ["CPV\u20102c", "ORGANISM", 17, 23], ["canine", "ORGANISM", 247, 253], ["CPV", "SPECIES", 17, 20], ["Asian viruses", "SPECIES", 72, 85], ["a CPV", "TEST", 15, 20], ["Asian viruses", "PROBLEM", 72, 85], ["the virus", "PROBLEM", 193, 202], ["Asian viruses", "OBSERVATION", 72, 85]]], ["Therefore, a continuous molecular survey was assessed to point out eventual introduction and spread of CPV strains originated from other geographic areas in the Italian canine population.RESULTS AND DISCUSSIONSince August 2018, CPV\u20102c strains with specific molecular signatures were detected from stray and owned dogs.", [["CPV", "ORGANISM", 103, 106], ["canine", "ORGANISM", 169, 175], ["dogs", "ORGANISM", 313, 317], ["canine", "SPECIES", 169, 175], ["dogs", "SPECIES", 313, 317], ["CPV", "SPECIES", 103, 106], ["CPV", "SPECIES", 228, 231], ["a continuous molecular survey", "TEST", 11, 40], ["CPV strains", "PROBLEM", 103, 114], ["specific molecular signatures", "TEST", 248, 277], ["geographic", "OBSERVATION_MODIFIER", 137, 147], ["areas", "OBSERVATION_MODIFIER", 148, 153]]], ["Despite the close genetic relationship with the previous Asian CPV\u20102c strain reported in Italy, its absence in the following months suggests a second introduction of Asian CPV\u20102c strains.", [["CPV\u20102c strain", "ORGANISM", 63, 76], ["CPV\u20102c", "ORGANISM", 172, 178], ["Asian CPV\u20102c", "SPECIES", 57, 69], ["Asian CPV\u20102c", "SPECIES", 166, 178], ["Asian CPV", "TREATMENT", 166, 175]]], ["Alternatively, the silent circulation of the original Asian strain in the field with accumulation of few point mutation should be hypothesized.", [["few point mutation", "PROBLEM", 101, 119], ["silent", "OBSERVATION_MODIFIER", 19, 25], ["circulation", "OBSERVATION_MODIFIER", 26, 37], ["few", "OBSERVATION_MODIFIER", 101, 104], ["point mutation", "OBSERVATION", 105, 119]]], ["The evidence in rescued stray dogs and in dogs without anamnesis of previous movements, as well as the different dates and places of collection, suggested the active spread of these strains in the field.", [["stray dogs", "ORGANISM", 24, 34], ["dogs", "ORGANISM", 42, 46], ["dogs", "SPECIES", 30, 34], ["dogs", "SPECIES", 42, 46], ["these strains in the field", "PROBLEM", 176, 202], ["rescued stray", "OBSERVATION", 16, 29], ["active", "OBSERVATION_MODIFIER", 159, 165], ["spread", "OBSERVATION_MODIFIER", 166, 172]]], ["It remains unclear how these strains have been introduced in Italy, if directly through infected animals or indirectly due to the extreme stability of the CPV in the environment (Hoelzer & Parrish, 2010).", [["CPV", "ORGANISM", 155, 158], ["CPV", "SPECIES", 155, 158]]], ["According to this study, the spread of Asian CPV strains in a separate geographical area different from Asian countries could be suggested, as previously described in South America (Grecco et al., 2018; Maya et al., 2013).RESULTS AND DISCUSSIONWhereas CPV\u20102a and CPV\u20102b are the prevalent variants circulating in Asia (Yi, Tong, Cheng, Song, & Cheng, 2016), and more recently, CPV\u20102c has been described in the same continent (Chiang, Wu, Chiou, Chang, & Lin, 2016; Geng et al., 2015; Nakamura et al., 2004; Wang et al., 2016; Zhao et al., 2017; Zhou, Zeng, Zhang, & Li, 2017; Zhuang et al., 2019), showing molecular signatures different from those of other continents.", [["CPV", "ORGANISM", 45, 48], ["CPV\u20102a", "ORGANISM", 252, 258], ["CPV", "ORGANISM", 263, 266], ["\u20102b", "GENE_OR_GENE_PRODUCT", 266, 269], ["CPV\u20102c", "GENE_OR_GENE_PRODUCT", 376, 382], ["Asian CPV", "SPECIES", 39, 48], ["CPV\u20102a", "SPECIES", 252, 258], ["CPV\u20102", "SPECIES", 263, 268], ["CPV", "SPECIES", 376, 379], ["this study", "TEST", 13, 23], ["Asian CPV strains", "PROBLEM", 39, 56], ["molecular signatures", "PROBLEM", 605, 625]]], ["Indeed, the Asian CPV\u20102c variant shows specific amino acids in NS1 (60V, 544F, 545V, 630P) and VP2 (5A/G, 267Y, 297A, 324I, 370R) gene sequences.", [["amino acids", "CHEMICAL", 48, 59], ["amino acids", "CHEMICAL", 48, 59], ["CPV\u20102c", "GENE_OR_GENE_PRODUCT", 18, 24], ["amino acids", "AMINO_ACID", 48, 59], ["NS1", "GENE_OR_GENE_PRODUCT", 63, 66], ["Asian CPV\u20102c variant", "PROTEIN", 12, 32], ["Asian CPV", "SPECIES", 12, 21], ["specific amino acids", "TEST", 39, 59], ["NS1", "TEST", 63, 66], ["VP2", "TEST", 95, 98], ["G", "TEST", 103, 104], ["gene sequences", "TEST", 130, 144]]], ["Most of these amino acids have been described in the VP2 of CPV\u20102a/2b/2c strains collected in China, Vietnam, India, Taiwan, South Korea, Thailand and Japan (Chiang et al., 2016; Geng et al., 2015; Han et al., 2015; Jeoung et al., 2008; Lin et al., 2014; Mukhopadhyay et al., 2014; Nakamura et al., 2004; Phromnoi, Sirinarumitr, & Sirinarumitr, 2010; Soma, Taharaguchi, Ohinata, Ishii, & Hara, 2013; Xu et al., 2015; Yi et al., 2016; Zhang et al., 2010).", [["amino acids", "CHEMICAL", 14, 25], ["amino acids", "CHEMICAL", 14, 25], ["amino acids", "AMINO_ACID", 14, 25], ["CPV\u20102a/2b/2c", "ORGANISM", 60, 72], ["VP2", "PROTEIN", 53, 56], ["CPV", "SPECIES", 60, 63], ["these amino acids", "TREATMENT", 8, 25], ["CPV", "TEST", 60, 63], ["2b/2c strains", "TREATMENT", 67, 80], ["Phromnoi", "TREATMENT", 305, 313]]], ["In particular, CPV\u20102c strains displaying the amino acid glycine (G) instead of the highly conserved alanine (A) at residue 5 of the VP2 have been previously detected in China (Wang et al., 2016) and Italy (Mira, Purpari, Lorusso, et al., 2018).", [["amino acid", "CHEMICAL", 45, 55], ["glycine", "CHEMICAL", 56, 63], ["alanine", "CHEMICAL", 100, 107], ["amino acid", "CHEMICAL", 45, 55], ["glycine", "CHEMICAL", 56, 63], ["alanine", "CHEMICAL", 100, 107], ["CPV\u20102c strains", "ORGANISM", 15, 29], ["amino acid", "AMINO_ACID", 45, 55], ["glycine", "AMINO_ACID", 56, 63], ["G", "AMINO_ACID", 65, 66], ["alanine", "AMINO_ACID", 100, 107], ["VP2", "GENE_OR_GENE_PRODUCT", 132, 135], ["VP2", "PROTEIN", 132, 135], ["CPV", "SPECIES", 15, 18], ["CPV\u20102c strains", "TREATMENT", 15, 29], ["the amino acid glycine", "TREATMENT", 41, 63], ["alanine (A) at residue", "TREATMENT", 100, 122], ["the VP2", "TREATMENT", 128, 135]]], ["More recently, molecular analyses including the NS1 gene sequence showed the presence of molecular signatures of the Asian CPV strains even in this region (Han et al., 2015; Mira, Purpari, Lorusso, et al., 2018; Zhuang et al., 2019).", [["NS1", "GENE_OR_GENE_PRODUCT", 48, 51], ["CPV", "ORGANISM", 123, 126], ["NS1 gene sequence", "DNA", 48, 65], ["Asian CPV", "SPECIES", 117, 126], ["molecular analyses", "TEST", 15, 33], ["the NS1 gene sequence", "TEST", 44, 65], ["the Asian CPV strains", "PROBLEM", 113, 134]]], ["Indeed, it results critical to extend the analysis to other genomic regions to properly infer the spread of the genetic CPV variants (Grecco et al., 2018).RESULTS AND DISCUSSIONMoreover, the evidence in the NS1/NS2 gene sequences of amino acid mutations with respect to the other CPV strains spreading worldwide (NS1: 60V, 544F, 545F, 630P \u2010 NS2: 60V, 151N, 152V) could contribute to further elucidate its evolution (Mira et al., 2019).RESULTS AND DISCUSSIONThe classification system based on single amino acids (426 and 297) of the VP2 protein does not clearly reflect the phylogenetic relationships of the strains, better supported to proposed \u201cclade\u201d or \u201clineage/sub\u2010lineage\u201d new classification criteria (Grecco et al., 2018; Zhuang et al., 2019; Mira et al., 2019).", [["amino acid", "CHEMICAL", 233, 243], ["amino acids", "CHEMICAL", 500, 511], ["amino acid", "CHEMICAL", 233, 243], ["amino acids", "CHEMICAL", 500, 511], ["CPV", "ORGANISM", 120, 123], ["NS1", "GENE_OR_GENE_PRODUCT", 207, 210], ["amino acid", "AMINO_ACID", 233, 243], ["CPV strains", "ORGANISM", 280, 291], ["amino acids", "AMINO_ACID", 500, 511], ["VP2", "GENE_OR_GENE_PRODUCT", 533, 536], ["genomic regions", "DNA", 60, 75], ["NS1/NS2 gene sequences", "DNA", 207, 229], ["VP2 protein", "PROTEIN", 533, 544], ["CPV", "SPECIES", 120, 123], ["CPV", "SPECIES", 280, 283], ["the analysis", "TEST", 38, 50], ["the NS1/NS2 gene sequences", "TREATMENT", 203, 229], ["amino acid mutations", "PROBLEM", 233, 253], ["NS1", "TEST", 313, 316], ["NS2", "TEST", 342, 345], ["single amino acids", "TEST", 493, 511], ["the VP2 protein", "TEST", 529, 544], ["the strains", "PROBLEM", 604, 615]]], ["As observed also in this study, phylogeny lacks any clustering based on the single VP2 aa residue 426 (CPV\u20102a/2b/2c), as well as on the geographic origin and period of sample collection.", [["sample", "ANATOMY", 168, 174], ["this study", "TEST", 20, 30], ["the single VP2 aa residue", "TEST", 72, 97], ["CPV", "TEST", 103, 106], ["sample collection", "PROBLEM", 168, 185], ["sample", "OBSERVATION_MODIFIER", 168, 174], ["collection", "OBSERVATION", 175, 185]]], ["Therefore, a wider evolutionary analysis further supports the thesis to consider the CPV antigenic variants as variants of CPV\u20102a rather than distinct subtypes (Organtini, Allison, Lukk, Parrish, & Hafenstein, 2015) and could be considered as a more reliable tool in outbreak tracing.RESULTS AND DISCUSSIONThis study reported the early evidence and spread of CPV\u20102c strains of Asian origin in the Italian canine population.", [["CPV", "ORGANISM", 85, 88], ["CPV\u20102a", "ORGANISM", 123, 129], ["CPV\u20102c", "ORGANISM", 359, 365], ["canine", "ORGANISM", 405, 411], ["canine", "SPECIES", 405, 411], ["CPV", "SPECIES", 85, 88], ["CPV\u20102a", "SPECIES", 123, 129], ["CPV", "SPECIES", 359, 362], ["canine", "SPECIES", 405, 411], ["a wider evolutionary analysis", "TEST", 11, 40], ["the CPV antigenic variants", "PROBLEM", 81, 107], ["CPV", "PROBLEM", 123, 126], ["DISCUSSIONThis study", "TEST", 296, 316]]], ["As observed in South America (Grecco et al., 2018), studies based on the complete coding genome are useful to monitor the spread of CPV strains with Asian origin in a different continent and highlight the need of further studies to evaluate the CPV evolution due to the coexistence of genetically divergent strains in the same geographical environment.CONFLICT OF INTERESTThe authors of this manuscript declare that there are no conflicts of interest.", [["CPV strains", "ORGANISM", 132, 143], ["coding genome", "DNA", 82, 95], ["CPV", "SPECIES", 132, 135], ["CPV", "SPECIES", 245, 248], ["CPV strains", "PROBLEM", 132, 143], ["further studies", "TEST", 213, 228], ["the CPV evolution", "TEST", 241, 258], ["genetically divergent strains", "PROBLEM", 285, 314], ["no", "UNCERTAINTY", 426, 428]]]], "22620d6950a0bb21eac0980bd1c7acafecc511a0": [["BACKGROUNDThe recent outbreak of COVID-19 (SARS-CoV-2) became an international pandemic in a short space of time.", [["COVID-19", "CHEMICAL", 33, 41], ["SARS-CoV-2", "CHEMICAL", 43, 53], ["COVID-19", "ORGANISM", 33, 41], ["SARS-CoV-2", "ORGANISM", 43, 53], ["COVID-19", "SPECIES", 33, 41], ["SARS-CoV-2", "SPECIES", 43, 53], ["COVID", "TEST", 33, 38], ["CoV", "TEST", 48, 51], ["an international pandemic", "PROBLEM", 62, 87], ["pandemic", "OBSERVATION", 79, 87]]], ["The majority of patients with COVID-19 infection demonstrate fever and respiratory illness.", [["respiratory", "ANATOMY", 71, 82], ["COVID-19", "CHEMICAL", 30, 38], ["infection", "DISEASE", 39, 48], ["fever", "DISEASE", 61, 66], ["respiratory illness", "DISEASE", 71, 90], ["patients", "ORGANISM", 16, 24], ["COVID-19", "ORGANISM", 30, 38], ["patients", "SPECIES", 16, 24], ["COVID", "TEST", 30, 35], ["infection", "PROBLEM", 39, 48], ["fever", "PROBLEM", 61, 66], ["respiratory illness", "PROBLEM", 71, 90], ["infection", "OBSERVATION", 39, 48], ["fever", "OBSERVATION", 61, 66], ["respiratory illness", "OBSERVATION", 71, 90]]], ["Here, we report a case of a patient with COVID-19 who presented with Guillain-Barr\u00e9 syndrome.CASE PRESENTATIONWe report the case of a Georgian construction worker in his 30s who presented to the emergency department having developed numbness in his hands the day before, and now with hand weakness, making it difficult to squeeze a lemon, followed by subjective leg weakness.", [["hand", "ANATOMY", 284, 288], ["leg", "ANATOMY", 362, 365], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 69, 92], ["numbness", "DISEASE", 233, 241], ["hand weakness", "DISEASE", 284, 297], ["patient", "ORGANISM", 28, 35], ["Guillain-Barr\u00e9", "ORGANISM", 69, 83], ["hand", "ORGANISM_SUBDIVISION", 284, 288], ["lemon", "ORGANISM_SUBDIVISION", 332, 337], ["leg", "ORGANISM_SUBDIVISION", 362, 365], ["patient", "SPECIES", 28, 35], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 69, 92], ["numbness in his hands", "PROBLEM", 233, 254], ["hand weakness", "PROBLEM", 284, 297], ["subjective leg weakness", "PROBLEM", 351, 374], ["Barr\u00e9 syndrome", "OBSERVATION", 78, 92], ["numbness", "OBSERVATION", 233, 241], ["hands", "ANATOMY", 249, 254], ["hand", "ANATOMY", 284, 288], ["weakness", "OBSERVATION", 289, 297], ["leg", "ANATOMY", 362, 365], ["weakness", "OBSERVATION", 366, 374]]], ["On examination, power was Medical Research Council (MRC) grade 4/5 in his dominant left hand and was felt to be normal in both legs with downgoing plantar responses.", [["left hand", "ANATOMY", 83, 92], ["legs", "ANATOMY", 127, 131], ["plantar", "ANATOMY", 147, 154], ["hand", "ORGANISM_SUBDIVISION", 88, 92], ["legs", "ORGANISM_SUBDIVISION", 127, 131], ["plantar", "ORGANISM_SUBDIVISION", 147, 154], ["examination", "TEST", 3, 14], ["left", "ANATOMY_MODIFIER", 83, 87], ["hand", "ANATOMY", 88, 92], ["normal", "OBSERVATION", 112, 118], ["both", "ANATOMY_MODIFIER", 122, 126], ["legs", "ANATOMY", 127, 131], ["plantar", "ANATOMY", 147, 154]]], ["Deep tendon reflexes were not recorded.", [["tendon", "ANATOMY", 5, 11], ["tendon", "MULTI-TISSUE_STRUCTURE", 5, 11], ["Deep tendon reflexes", "TEST", 0, 20], ["tendon", "ANATOMY", 5, 11]]], ["He was reviewed by the acute medical team and CT head was normal.", [["head", "ANATOMY", 49, 53], ["head", "ORGAN", 49, 53], ["CT head", "TEST", 46, 53], ["head", "ANATOMY", 49, 53], ["normal", "OBSERVATION", 58, 64]]], ["He was discharged home, to return if needed.CASE PRESENTATIONHe returned the following day, now with pain in his forearms and calves, and increased weakness and numbness in his feet.", [["forearms", "ANATOMY", 113, 121], ["feet", "ANATOMY", 177, 181], ["pain", "DISEASE", 101, 105], ["weakness", "DISEASE", 148, 156], ["numbness", "DISEASE", 161, 169], ["forearms", "ORGANISM_SUBDIVISION", 113, 121], ["calves", "ORGANISM", 126, 132], ["feet", "ORGANISM_SUBDIVISION", 177, 181], ["calves", "SPECIES", 126, 132], ["pain in his forearms and calves", "PROBLEM", 101, 132], ["increased weakness", "PROBLEM", 138, 156], ["numbness in his feet", "PROBLEM", 161, 181], ["pain", "OBSERVATION", 101, 105], ["forearms", "ANATOMY", 113, 121], ["calves", "ANATOMY", 126, 132], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["weakness", "OBSERVATION", 148, 156], ["numbness", "OBSERVATION", 161, 169], ["feet", "ANATOMY", 177, 181]]], ["Review by the orthopaedic team found power to be of MRC grade 4/5 in bilateral wrist flexors and normal in his legs, although he had difficulty standing from sitting.", [["wrist flexors", "ANATOMY", 79, 92], ["legs", "ANATOMY", 111, 115], ["wrist flexors", "ORGANISM_SUBDIVISION", 79, 92], ["legs", "ORGANISM_SUBDIVISION", 111, 115], ["MRC grade", "TEST", 52, 61], ["bilateral", "ANATOMY_MODIFIER", 69, 78], ["wrist flexors", "ANATOMY", 79, 92], ["normal", "OBSERVATION", 97, 103], ["legs", "ANATOMY", 111, 115]]], ["Deep tendon reflexes were not recorded.", [["tendon", "ANATOMY", 5, 11], ["tendon", "MULTI-TISSUE_STRUCTURE", 5, 11], ["Deep tendon reflexes", "TEST", 0, 20], ["tendon", "ANATOMY", 5, 11]]], ["Cervical and lumbar spine X-rays were normal.", [["Cervical", "ANATOMY", 0, 8], ["lumbar spine", "ANATOMY", 13, 25], ["Cervical", "MULTI-TISSUE_STRUCTURE", 0, 8], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 13, 25], ["Cervical and lumbar spine X-rays", "TEST", 0, 32], ["lumbar spine", "ANATOMY", 13, 25], ["normal", "OBSERVATION", 38, 44]]], ["Urgent MRI of the cervical spine could not be performed due to a bullet in his left hand, confirmed on X-ray.", [["cervical spine", "ANATOMY", 18, 32], ["left hand", "ANATOMY", 79, 88], ["cervical spine", "MULTI-TISSUE_STRUCTURE", 18, 32], ["hand", "ORGANISM_SUBDIVISION", 84, 88], ["Urgent MRI of the cervical spine", "TEST", 0, 32], ["a bullet in his left hand", "PROBLEM", 63, 88], ["X-ray", "TEST", 103, 108], ["cervical spine", "ANATOMY", 18, 32], ["bullet", "OBSERVATION", 65, 71], ["left", "ANATOMY_MODIFIER", 79, 83], ["hand", "ANATOMY", 84, 88]]], ["He was discharged home with advice to return if required.CASE PRESENTATIONHe came for the third time to the emergency department 2 days later, day 5 of weakness, this time with cough and fever starting on day 4, unable fully to lift his arms and with difficulty standing.", [["weakness", "DISEASE", 152, 160], ["cough", "DISEASE", 177, 182], ["fever", "DISEASE", 187, 192], ["weakness", "PROBLEM", 152, 160], ["cough", "PROBLEM", 177, 182], ["fever", "PROBLEM", 187, 192], ["difficulty standing", "PROBLEM", 251, 270], ["weakness", "OBSERVATION", 152, 160], ["cough", "OBSERVATION", 177, 182], ["fever", "OBSERVATION", 187, 192], ["arms", "ANATOMY", 237, 241]]], ["He was normally fit and well and was taking no medications.", [["He", "ORGANISM", 0, 2], ["medications", "TREATMENT", 47, 58]]], ["He had no history of recent illness, no spinal pain and no sphincter disturbance.", [["spinal", "ANATOMY", 40, 46], ["sphincter", "ANATOMY", 59, 68], ["spinal pain", "DISEASE", 40, 51], ["sphincter disturbance", "DISEASE", 59, 80], ["spinal", "ORGANISM_SUBDIVISION", 40, 46], ["sphincter", "ORGANISM_SUBDIVISION", 59, 68], ["recent illness", "PROBLEM", 21, 35], ["spinal pain", "PROBLEM", 40, 51], ["sphincter disturbance", "PROBLEM", 59, 80], ["no", "UNCERTAINTY", 7, 9], ["illness", "OBSERVATION", 28, 35], ["no", "UNCERTAINTY", 37, 39], ["spinal", "ANATOMY", 40, 46], ["pain", "OBSERVATION", 47, 51], ["no", "UNCERTAINTY", 56, 58], ["sphincter", "ANATOMY", 59, 68], ["disturbance", "OBSERVATION", 69, 80]]], ["He had experienced regular epistaxis for over 2-3 weeks which had not occurred since childhood.", [["epistaxis", "DISEASE", 27, 36], ["regular epistaxis", "PROBLEM", 19, 36], ["epistaxis", "OBSERVATION", 27, 36]]], ["He lived with his partner, was an ex-smoker and had travelled to Latvia for Christmas 3 months before and to Prague 4 weeks before, with a brief change in bowel habit.", [["bowel", "ANATOMY", 155, 160], ["He", "ORGANISM", 0, 2], ["bowel", "ORGAN", 155, 160], ["a brief change in bowel habit", "PROBLEM", 137, 166], ["bowel", "ANATOMY", 155, 160], ["habit", "OBSERVATION", 161, 166]]], ["There had been no insect bites.", [["insect bites", "DISEASE", 18, 30], ["insect bites", "PROBLEM", 18, 30], ["no", "UNCERTAINTY", 15, 17], ["insect bites", "OBSERVATION", 18, 30]]], ["He had already decided to stop work on the day the weakness started as he was worried there was insufficient social distancing on-site to protect against COVID-19.", [["the weakness", "PROBLEM", 47, 59], ["weakness", "OBSERVATION", 51, 59]]], ["He was worried that the weakness was due to thyroid dysfunction, of which he had a family history.CASE PRESENTATIONExamination identified a temperature of 38.3\u00b0C, blood pressure of 174/110 mm Hg and heart rate of 101 beats per minute.", [["thyroid", "ANATOMY", 44, 51], ["blood", "ANATOMY", 163, 168], ["heart", "ANATOMY", 199, 204], ["weakness", "DISEASE", 24, 32], ["thyroid dysfunction", "DISEASE", 44, 63], ["Hg", "CHEMICAL", 192, 194], ["He", "ORGANISM", 0, 2], ["thyroid", "ORGAN", 44, 51], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["heart", "ORGAN", 199, 204], ["the weakness", "PROBLEM", 20, 32], ["thyroid dysfunction", "PROBLEM", 44, 63], ["a temperature", "TEST", 138, 151], ["blood pressure", "TEST", 163, 177], ["heart rate", "TEST", 199, 209], ["weakness", "OBSERVATION", 24, 32], ["thyroid", "ANATOMY", 44, 51], ["dysfunction", "OBSERVATION", 52, 63], ["heart", "ANATOMY", 199, 204]]], ["There was no facial weakness, but there was symmetrical limb weakness, with an MRC grade of 3/5 for shoulder abduction, 4/5 for wrist dorsiflexion, 2/5 for finger extension, 3/5 for hip flexion, 3/5 for ankle dorsiflexion and 4/5 for ankle plantar flexion.", [["facial", "ANATOMY", 13, 19], ["limb", "ANATOMY", 56, 60], ["shoulder", "ANATOMY", 100, 108], ["wrist", "ANATOMY", 128, 133], ["finger", "ANATOMY", 156, 162], ["hip", "ANATOMY", 182, 185], ["ankle", "ANATOMY", 203, 208], ["plantar", "ANATOMY", 240, 247], ["weakness", "DISEASE", 61, 69], ["limb", "ORGANISM_SUBDIVISION", 56, 60], ["shoulder", "ORGANISM_SUBDIVISION", 100, 108], ["wrist", "ORGANISM_SUBDIVISION", 128, 133], ["finger", "ORGANISM_SUBDIVISION", 156, 162], ["hip", "ORGANISM_SUBDIVISION", 182, 185], ["ankle", "ORGANISM_SUBDIVISION", 203, 208], ["ankle", "ORGANISM_SUBDIVISION", 234, 239], ["plantar", "ORGANISM_SUBDIVISION", 240, 247], ["facial weakness", "PROBLEM", 13, 28], ["symmetrical limb weakness", "PROBLEM", 44, 69], ["an MRC grade", "TEST", 76, 88], ["shoulder abduction", "TEST", 100, 118], ["wrist dorsiflexion", "TEST", 128, 146], ["finger extension", "TEST", 156, 172], ["hip flexion", "TEST", 182, 193], ["ankle dorsiflexion", "TEST", 203, 221], ["ankle plantar flexion", "TEST", 234, 255], ["no", "UNCERTAINTY", 10, 12], ["facial", "ANATOMY", 13, 19], ["weakness", "OBSERVATION", 20, 28], ["symmetrical", "OBSERVATION_MODIFIER", 44, 55], ["limb", "ANATOMY", 56, 60], ["weakness", "OBSERVATION", 61, 69], ["shoulder abduction", "ANATOMY", 100, 118], ["wrist dorsiflexion", "ANATOMY", 128, 146], ["hip flexion", "ANATOMY", 182, 193], ["ankle dorsiflexion", "ANATOMY", 203, 221], ["ankle plantar", "ANATOMY", 234, 247]]], ["He was areflexic with downgoing plantar responses.", [["plantar", "ANATOMY", 32, 39], ["He", "ORGANISM", 0, 2], ["plantar", "ORGANISM_SUBDIVISION", 32, 39], ["plantar", "ANATOMY", 32, 39]]], ["Vibration, joint position sense, temperature and light touch sensation were all intact.", [["joint", "ANATOMY", 11, 16], ["light touch sensation", "TEST", 49, 70], ["joint", "ANATOMY", 11, 16], ["intact", "OBSERVATION", 80, 86]]], ["Forced vital capacity (FVC) was 4.7 L (85% predicted).CASE PRESENTATIONHe was admitted with suspected COVID-19 infection and potential Guillain-Barr\u00e9 syndrome.INVESTIGATIONSUrea and electrolytes, liver function tests, thyroid function tests and creatine kinase were normal.", [["liver", "ANATOMY", 196, 201], ["thyroid", "ANATOMY", 218, 225], ["infection", "DISEASE", 111, 120], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 135, 158], ["creatine", "CHEMICAL", 245, 253], ["creatine", "CHEMICAL", 245, 253], ["Guillain-Barr\u00e9", "ORGANISM", 135, 149], ["liver", "ORGAN", 196, 201], ["thyroid", "ORGAN", 218, 225], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 245, 260], ["creatine kinase", "PROTEIN", 245, 260], ["Forced vital capacity", "TEST", 0, 21], ["FVC", "TEST", 23, 26], ["suspected COVID-19 infection", "PROBLEM", 92, 120], ["Barr\u00e9 syndrome", "PROBLEM", 144, 158], ["electrolytes", "TEST", 182, 194], ["liver function tests", "TEST", 196, 216], ["thyroid function tests", "TEST", 218, 240], ["creatine kinase", "TEST", 245, 260], ["infection", "OBSERVATION", 111, 120], ["Barr\u00e9 syndrome", "OBSERVATION", 144, 158], ["liver", "ANATOMY", 196, 201], ["thyroid", "ANATOMY", 218, 225]]], ["Total white cell count and C-reactive protein were initially normal.", [["white cell", "ANATOMY", 6, 16], ["white cell", "CELL", 6, 16], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 27, 45], ["C-reactive protein", "PROTEIN", 27, 45], ["Total white cell count", "TEST", 0, 22], ["C-reactive protein", "TEST", 27, 45], ["white cell count", "OBSERVATION", 6, 22], ["reactive protein", "OBSERVATION", 29, 45], ["normal", "OBSERVATION", 61, 67]]], ["There was lymphopaenia of 0.81\u00d710\u2079/L (reference range 1.0-4.5\u00d710\u2079/L), raised monocyte count of 1.02\u00d710 9 /L (reference range 0.2-0.8\u00d710 9 / L), patchy perihilar airspace shadowing on chest X-ray and COVID-19 RNA was positive on nasal and throat swab.", [["monocyte", "ANATOMY", 77, 85], ["perihilar airspace", "ANATOMY", 151, 169], ["chest", "ANATOMY", 183, 188], ["nasal", "ANATOMY", 228, 233], ["throat swab", "ANATOMY", 238, 249], ["monocyte", "CELL", 77, 85], ["airspace", "MULTI-TISSUE_STRUCTURE", 161, 169], ["nasal", "ORGANISM_SUBDIVISION", 228, 233], ["COVID-19 RNA", "RNA", 199, 211], ["lymphopaenia", "TEST", 10, 22], ["raised monocyte count", "TEST", 70, 91], ["patchy perihilar airspace shadowing", "PROBLEM", 144, 179], ["chest X-ray", "TEST", 183, 194], ["COVID", "TEST", 199, 204], ["nasal and throat swab", "TEST", 228, 249], ["patchy", "OBSERVATION_MODIFIER", 144, 150], ["perihilar", "ANATOMY_MODIFIER", 151, 160], ["airspace", "ANATOMY_MODIFIER", 161, 169], ["shadowing", "OBSERVATION", 170, 179], ["chest", "ANATOMY", 183, 188], ["nasal", "ANATOMY", 228, 233], ["throat", "ANATOMY", 238, 244]]], ["His 12-lead ECG showed mild first-degree heart block of 220 ms PR interval, while echocardiogram was unremarkable.INVESTIGATIONSLumbar puncture yielded cerebrospinal fluid (CSF) with white cell count <0.001\u00d710 9 /L (<1/mm 3 ), protein 1.15 g/L (reference range 0.15-0.45 g/L), CSF glucose 3.3 mmol/L and plasma glucose 5.3 mmol/L (normal CSF glucose approximately two-thirds the plasma glucose).", [["heart", "ANATOMY", 41, 46], ["cerebrospinal fluid", "ANATOMY", 152, 171], ["white cell", "ANATOMY", 183, 193], ["plasma", "ANATOMY", 304, 310], ["plasma", "ANATOMY", 379, 385], ["glucose", "CHEMICAL", 281, 288], ["glucose", "CHEMICAL", 311, 318], ["glucose", "CHEMICAL", 342, 349], ["glucose", "CHEMICAL", 386, 393], ["glucose", "CHEMICAL", 281, 288], ["glucose", "CHEMICAL", 311, 318], ["glucose", "CHEMICAL", 342, 349], ["glucose", "CHEMICAL", 386, 393], ["heart", "ORGAN", 41, 46], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 152, 171], ["CSF", "ORGANISM_SUBSTANCE", 173, 176], ["white cell", "CELL", 183, 193], ["CSF", "ORGANISM_SUBSTANCE", 277, 280], ["glucose", "SIMPLE_CHEMICAL", 281, 288], ["plasma", "ORGANISM_SUBSTANCE", 304, 310], ["glucose", "SIMPLE_CHEMICAL", 311, 318], ["CSF", "ORGANISM_SUBSTANCE", 338, 341], ["glucose", "SIMPLE_CHEMICAL", 342, 349], ["plasma", "ORGANISM_SUBSTANCE", 379, 385], ["glucose", "SIMPLE_CHEMICAL", 386, 393], ["PR", "PROTEIN", 63, 65], ["His 12-lead ECG", "TEST", 0, 15], ["mild first-degree heart block", "PROBLEM", 23, 52], ["PR interval", "TEST", 63, 74], ["echocardiogram", "TEST", 82, 96], ["INVESTIGATIONSLumbar puncture", "TEST", 114, 143], ["cerebrospinal fluid (CSF", "TEST", 152, 176], ["white cell count", "TEST", 183, 199], ["protein", "TEST", 227, 234], ["CSF glucose", "TEST", 277, 288], ["plasma glucose", "TEST", 304, 318], ["CSF glucose", "TEST", 338, 349], ["the plasma glucose", "TEST", 375, 393], ["mild", "OBSERVATION_MODIFIER", 23, 27], ["unremarkable", "OBSERVATION", 101, 113], ["cerebrospinal fluid", "OBSERVATION", 152, 171]]], ["Herpes simplex virus types 1 and 2 New disease DNA, varicella zoster virus DNA, enterovirus RNA and COVID-19 RNA were not detected in CSF.INVESTIGATIONSSerum antiganglioside antibodies, antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA), hepatitis B, hepatitis C, HIV, syphilis, cytomegalovirus IgM, Epstein-Barr virus IgM, Mycoplasma IgM tests and Lyme disease serology were negative, as were urinary Legionella and pneumococcal antigen tests.", [["urinary", "ANATOMY", 419, 426], ["Herpes simplex virus", "DISEASE", 0, 20], ["varicella zoster", "DISEASE", 52, 68], ["hepatitis B", "DISEASE", 263, 274], ["hepatitis C, HIV, syphilis", "DISEASE", 276, 302], ["Lyme disease", "DISEASE", 374, 386], ["Herpes simplex virus types 1", "ORGANISM", 0, 28], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["varicella zoster virus", "ORGANISM", 52, 74], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["enterovirus", "ORGANISM", 80, 91], ["COVID-19", "GENE_OR_GENE_PRODUCT", 100, 108], ["CSF", "ORGANISM_SUBSTANCE", 134, 137], ["antiganglioside antibodies", "GENE_OR_GENE_PRODUCT", 158, 184], ["antinuclear antibodies", "GENE_OR_GENE_PRODUCT", 186, 208], ["ANA", "GENE_OR_GENE_PRODUCT", 210, 213], ["anti-neutrophil cytoplasmic antibodies", "GENE_OR_GENE_PRODUCT", 216, 254], ["ANCA", "GENE_OR_GENE_PRODUCT", 256, 260], ["hepatitis B", "ORGANISM", 263, 274], ["hepatitis C", "ORGANISM", 276, 287], ["HIV", "ORGANISM", 289, 292], ["cytomegalovirus", "ORGANISM", 304, 319], ["IgM", "ORGANISM", 320, 323], ["Epstein-Barr virus", "ORGANISM", 325, 343], ["IgM", "ORGANISM", 344, 347], ["Mycoplasma IgM", "ORGANISM", 349, 363], ["urinary", "ORGANISM_SUBSTANCE", 419, 426], ["pneumococcal antigen", "GENE_OR_GENE_PRODUCT", 442, 462], ["varicella zoster virus DNA, enterovirus RNA", "RNA", 52, 95], ["COVID-19 RNA", "RNA", 100, 112], ["CSF", "PROTEIN", 134, 137], ["antiganglioside antibodies", "PROTEIN", 158, 184], ["antinuclear antibodies", "PROTEIN", 186, 208], ["ANA", "PROTEIN", 210, 213], ["anti-neutrophil cytoplasmic antibodies", "PROTEIN", 216, 254], ["ANCA", "PROTEIN", 256, 260], ["cytomegalovirus IgM", "PROTEIN", 304, 323], ["IgM", "PROTEIN", 344, 347], ["Herpes simplex virus", "SPECIES", 0, 20], ["varicella zoster virus", "SPECIES", 52, 74], ["HIV", "SPECIES", 289, 292], ["Herpes simplex virus", "SPECIES", 0, 20], ["varicella zoster virus", "SPECIES", 52, 74], ["hepatitis B", "SPECIES", 263, 274], ["HIV", "SPECIES", 289, 292], ["cytomegalovirus", "SPECIES", 304, 319], ["Epstein-Barr virus", "SPECIES", 325, 343], ["pneumococcal", "SPECIES", 442, 454], ["Herpes simplex virus types 1", "PROBLEM", 0, 28], ["New disease DNA", "PROBLEM", 35, 50], ["varicella zoster virus DNA", "PROBLEM", 52, 78], ["enterovirus RNA", "TEST", 80, 95], ["COVID", "TEST", 100, 105], ["INVESTIGATIONSSerum antiganglioside antibodies", "TEST", 138, 184], ["antinuclear antibodies", "TEST", 186, 208], ["ANA", "TEST", 210, 213], ["anti-neutrophil cytoplasmic antibodies", "TEST", 216, 254], ["ANCA", "TEST", 256, 260], ["hepatitis B", "PROBLEM", 263, 274], ["hepatitis C", "PROBLEM", 276, 287], ["HIV", "PROBLEM", 289, 292], ["syphilis", "PROBLEM", 294, 302], ["cytomegalovirus IgM", "TEST", 304, 323], ["Epstein", "TEST", 325, 332], ["Barr virus IgM", "TEST", 333, 347], ["Mycoplasma IgM tests", "TEST", 349, 369], ["Lyme disease serology", "TEST", 374, 395], ["urinary Legionella", "TEST", 419, 437], ["pneumococcal antigen tests", "TEST", 442, 468], ["simplex virus", "OBSERVATION", 7, 20], ["New", "OBSERVATION_MODIFIER", 35, 38], ["disease", "OBSERVATION", 39, 46], ["varicella zoster virus", "OBSERVATION", 52, 74], ["urinary", "ANATOMY", 419, 426]]], ["Stool samples were not taken.INVESTIGATIONSNerve conduction studies were not performed initially due to coronavirus restrictions, but were performed 4 weeks after the onset of weakness.", [["Stool samples", "ANATOMY", 0, 13], ["weakness", "DISEASE", 176, 184], ["Stool samples", "ORGANISM_SUBSTANCE", 0, 13], ["coronavirus", "ORGANISM", 104, 115], ["Stool samples", "TEST", 0, 13], ["INVESTIGATIONSNerve conduction studies", "TEST", 29, 67], ["coronavirus restrictions", "PROBLEM", 104, 128], ["weakness", "PROBLEM", 176, 184], ["weakness", "OBSERVATION", 176, 184]]], ["These showed the following: \u25ba All recorded motor responses were low in amplitude in both the upper and lower limbs, supporting axonal loss, proximal greater than distal.", [["upper", "ANATOMY", 93, 98], ["lower limbs", "ANATOMY", 103, 114], ["axonal", "ANATOMY", 127, 133], ["axonal loss", "DISEASE", 127, 138], ["upper", "ORGANISM_SUBDIVISION", 93, 98], ["lower limbs", "ORGANISM_SUBDIVISION", 103, 114], ["All recorded motor responses", "TEST", 30, 58], ["axonal loss", "PROBLEM", 127, 138], ["low", "OBSERVATION_MODIFIER", 64, 67], ["both", "ANATOMY_MODIFIER", 84, 88], ["upper", "ANATOMY_MODIFIER", 93, 98], ["lower limbs", "ANATOMY", 103, 114], ["axonal loss", "OBSERVATION", 127, 138], ["proximal", "OBSERVATION_MODIFIER", 140, 148], ["greater", "OBSERVATION_MODIFIER", 149, 156], ["distal", "ANATOMY_MODIFIER", 162, 168]]], ["For example, right tibial nerve response amplitude when stimulated at the popliteal fossa was 1.0 mV and at the ankle was 2.1 mV (tibial nerve amplitude normal at \u22654 mV). \u25ba All recorded motor conduction velocities were borderline slow, for example, the conduction velocity of the right tibial nerve segment from popliteal fossa to ankle was 39 m/sec (normal \u226541 m/sec).", [["right tibial nerve", "ANATOMY", 13, 31], ["popliteal fossa", "ANATOMY", 74, 89], ["ankle", "ANATOMY", 112, 117], ["tibial nerve", "ANATOMY", 130, 142], ["right tibial nerve", "ANATOMY", 280, 298], ["popliteal fossa", "ANATOMY", 312, 327], ["ankle", "ANATOMY", 331, 336], ["tibial nerve", "MULTI-TISSUE_STRUCTURE", 19, 31], ["popliteal fossa", "MULTI-TISSUE_STRUCTURE", 74, 89], ["ankle", "ORGANISM_SUBDIVISION", 112, 117], ["tibial nerve", "MULTI-TISSUE_STRUCTURE", 130, 142], ["tibial nerve", "MULTI-TISSUE_STRUCTURE", 286, 298], ["popliteal fossa", "MULTI-TISSUE_STRUCTURE", 312, 327], ["ankle", "ORGANISM_SUBDIVISION", 331, 336], ["right tibial nerve response amplitude", "TEST", 13, 50], ["tibial nerve amplitude", "TEST", 130, 152], ["All recorded motor conduction velocities", "TEST", 173, 213], ["the conduction velocity", "TEST", 249, 272], ["ankle", "TEST", 331, 336], ["right", "ANATOMY_MODIFIER", 13, 18], ["tibial nerve", "ANATOMY", 19, 31], ["response amplitude", "OBSERVATION", 32, 50], ["popliteal fossa", "ANATOMY", 74, 89], ["ankle", "ANATOMY", 112, 117], ["tibial nerve", "ANATOMY", 130, 142], ["conduction velocity", "OBSERVATION", 253, 272], ["right", "ANATOMY_MODIFIER", 280, 285], ["tibial nerve", "ANATOMY", 286, 298], ["segment", "ANATOMY_MODIFIER", 299, 306], ["popliteal fossa", "ANATOMY", 312, 327], ["ankle", "ANATOMY", 331, 336]]], ["(Normal values given will vary with age, height and temperature.)DIFFERENTIAL DIAGNOSISDifferential diagnoses included acute pathologies of the nerve roots (radiculopathies), brachial and lumbosacral plexuses, peripheral nerves, neuromuscular junctions and muscle, with conditions including Guillain-Barr\u00e9 syndrome, plexopathies, vasculitic neuropathy and Lyme disease (prevalent in Latvia).", [["nerve roots", "ANATOMY", 144, 155], ["radiculopathies", "ANATOMY", 157, 172], ["brachial", "ANATOMY", 175, 183], ["lumbosacral plexuses", "ANATOMY", 188, 208], ["peripheral nerves", "ANATOMY", 210, 227], ["neuromuscular junctions", "ANATOMY", 229, 252], ["muscle", "ANATOMY", 257, 263], ["pathologies of the nerve roots", "DISEASE", 125, 155], ["radiculopathies", "DISEASE", 157, 172], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 291, 314], ["plexopathies", "DISEASE", 316, 328], ["vasculitic neuropathy", "DISEASE", 330, 351], ["Lyme disease", "DISEASE", 356, 368], ["nerve roots", "MULTI-TISSUE_STRUCTURE", 144, 155], ["brachial", "MULTI-TISSUE_STRUCTURE", 175, 183], ["lumbosacral plexuses", "MULTI-TISSUE_STRUCTURE", 188, 208], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 210, 227], ["neuromuscular junctions", "TISSUE", 229, 252], ["muscle", "ORGAN", 257, 263], ["acute pathologies of the nerve roots (radiculopathies)", "PROBLEM", 119, 173], ["brachial and lumbosacral plexuses, peripheral nerves, neuromuscular junctions", "PROBLEM", 175, 252], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 291, 314], ["plexopathies", "PROBLEM", 316, 328], ["vasculitic neuropathy", "PROBLEM", 330, 351], ["Lyme disease", "PROBLEM", 356, 368], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["pathologies", "OBSERVATION", 125, 136], ["nerve roots", "ANATOMY", 144, 155], ["brachial", "ANATOMY", 175, 183], ["lumbosacral plexuses", "ANATOMY", 188, 208], ["peripheral", "ANATOMY_MODIFIER", 210, 220], ["nerves", "ANATOMY", 221, 227], ["neuromuscular junctions", "ANATOMY", 229, 252], ["muscle", "ANATOMY", 257, 263], ["Barr\u00e9 syndrome", "OBSERVATION", 300, 314], ["vasculitic neuropathy", "OBSERVATION", 330, 351], ["Lyme disease", "OBSERVATION", 356, 368]]], ["The sensory symptoms and normal creatine kinase pointed away from a muscle disorder.", [["muscle", "ANATOMY", 68, 74], ["creatine", "CHEMICAL", 32, 40], ["muscle disorder", "DISEASE", 68, 83], ["creatine", "CHEMICAL", 32, 40], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 32, 47], ["muscle", "ORGAN", 68, 74], ["creatine kinase", "PROTEIN", 32, 47], ["The sensory symptoms", "PROBLEM", 0, 20], ["a muscle disorder", "PROBLEM", 66, 83], ["creatine kinase", "OBSERVATION", 32, 47], ["muscle", "ANATOMY", 68, 74], ["disorder", "OBSERVATION", 75, 83]]], ["The history, the symmetry on examination and CSF analysis were typical of Guillain-Barr\u00e9 syndrome or Lyme polyradiculoneuritis, with albuminocytological dissociation (high CSF protein with normal cells).", [["cells", "ANATOMY", 196, 201], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 74, 97], ["Lyme polyradiculoneuritis", "DISEASE", 101, 126], ["Guillain-Barr\u00e9", "ORGANISM", 74, 88], ["CSF", "GENE_OR_GENE_PRODUCT", 172, 175], ["cells", "CELL", 196, 201], ["high CSF protein", "PROTEIN", 167, 183], ["normal cells", "CELL_TYPE", 189, 201], ["examination", "TEST", 29, 40], ["CSF analysis", "TEST", 45, 57], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 74, 97], ["Lyme polyradiculoneuritis", "PROBLEM", 101, 126], ["albuminocytological dissociation", "PROBLEM", 133, 165], ["high CSF protein", "PROBLEM", 167, 183], ["Barr\u00e9 syndrome", "OBSERVATION", 83, 97], ["Lyme polyradiculoneuritis", "OBSERVATION", 101, 126], ["normal cells", "OBSERVATION", 189, 201]]], ["Nerve conduction studies supported a motor process affecting the axons both in the roots and nerves: a motor polyradiculoneuropathy.", [["Nerve", "ANATOMY", 0, 5], ["axons", "ANATOMY", 65, 70], ["roots", "ANATOMY", 83, 88], ["nerves", "ANATOMY", 93, 99], ["polyradiculoneuropathy", "DISEASE", 109, 131], ["axons", "MULTI-TISSUE_STRUCTURE", 65, 70], ["roots", "TISSUE", 83, 88], ["nerves", "MULTI-TISSUE_STRUCTURE", 93, 99], ["Nerve conduction studies", "TEST", 0, 24], ["a motor process", "PROBLEM", 35, 50], ["a motor polyradiculoneuropathy", "PROBLEM", 101, 131], ["motor process", "OBSERVATION", 37, 50], ["axons", "ANATOMY_MODIFIER", 65, 70], ["roots", "ANATOMY", 83, 88], ["nerves", "ANATOMY", 93, 99], ["motor polyradiculoneuropathy", "OBSERVATION", 103, 131]]], ["Negative Lyme serology gave a diagnosis of acute motor axonal neuropathy subtype of Guillain-Barr\u00e9 syndrome.TREATMENTIntravenous immunoglobulins were given at 0.4 g/kg/day for 5 days.", [["axonal", "ANATOMY", 55, 61], ["axonal neuropathy", "DISEASE", 55, 72], ["Guillain-Barr\u00e9 syndrome.", "DISEASE", 84, 108], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 129, 144], ["Guillain-Barr\u00e9 syndrome.", "SPECIES", 84, 108], ["Lyme serology", "TEST", 9, 22], ["acute motor axonal neuropathy", "PROBLEM", 43, 72], ["Barr\u00e9 syndrome.", "PROBLEM", 93, 108], ["TREATMENTIntravenous immunoglobulins", "TREATMENT", 108, 144], ["Lyme", "OBSERVATION", 9, 13], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["motor axonal neuropathy", "OBSERVATION", 49, 72]]], ["FVC and limb power were closely monitored.", [["limb", "ANATOMY", 8, 12], ["limb", "ORGANISM_SUBDIVISION", 8, 12], ["FVC", "TEST", 0, 3], ["limb power", "TEST", 8, 18], ["limb", "ANATOMY", 8, 12], ["power", "OBSERVATION_MODIFIER", 13, 18]]], ["Subcutaneous low molecular weight heparin was given, particularly important in this patient with an increased risk of thrombosis from both lower motor neurone syndrome and COVID-19, which can result in a hypercoagulable state.", [["lower motor neurone", "ANATOMY", 139, 158], ["heparin", "CHEMICAL", 34, 41], ["thrombosis", "DISEASE", 118, 128], ["lower motor neurone syndrome", "DISEASE", 139, 167], ["COVID-19", "CHEMICAL", 172, 180], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 13, 41], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Subcutaneous low molecular weight heparin", "TREATMENT", 0, 41], ["thrombosis", "PROBLEM", 118, 128], ["both lower motor neurone syndrome", "PROBLEM", 134, 167], ["COVID", "TEST", 172, 177], ["a hypercoagulable state", "PROBLEM", 202, 225], ["low", "OBSERVATION_MODIFIER", 13, 16], ["thrombosis", "OBSERVATION", 118, 128], ["lower", "ANATOMY_MODIFIER", 139, 144], ["motor neurone syndrome", "OBSERVATION", 145, 167], ["hypercoagulable state", "OBSERVATION", 204, 225]]], ["The patient received daily physiotherapy, focusing both on respiratory and physical function.OUTCOME AND FOLLOW-UPFollowing immunoglobulin therapy, the patient showed significant improvement, with power in all limb muscle groups in the range MRC grade 4\u2212/5 to 4+/5.", [["respiratory", "ANATOMY", 59, 70], ["limb muscle", "ANATOMY", 210, 221], ["patient", "ORGANISM", 4, 11], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 124, 138], ["patient", "ORGANISM", 152, 159], ["limb muscle", "ORGANISM_SUBDIVISION", 210, 221], ["immunoglobulin", "PROTEIN", 124, 138], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 152, 159], ["daily physiotherapy", "TREATMENT", 21, 40], ["immunoglobulin therapy", "TREATMENT", 124, 146], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["improvement", "OBSERVATION", 179, 190], ["all", "ANATOMY_MODIFIER", 206, 209], ["limb muscle", "ANATOMY", 210, 221]]], ["He remained areflexic with no sensory nor autonomic disturbance, except for the prolonged PR interval.", [["PR", "PROTEIN", 90, 92], ["areflexic", "PROBLEM", 12, 21], ["sensory nor autonomic disturbance", "PROBLEM", 30, 63], ["the prolonged PR interval", "PROBLEM", 76, 101], ["areflexic", "OBSERVATION", 12, 21], ["no", "UNCERTAINTY", 27, 29]]], ["Post-treatment FVC was 4.9 L (89% predicted).OUTCOME AND FOLLOW-UPThe patient was discharged from the hospital after a stay of 12 days, able to mobilise with residual weakness predominantly in his hands and feet.", [["weakness", "DISEASE", 167, 175], ["patient", "ORGANISM", 70, 77], ["hands", "ORGANISM_SUBDIVISION", 197, 202], ["feet", "ORGANISM_SUBDIVISION", 207, 211], ["patient", "SPECIES", 70, 77], ["treatment FVC", "TEST", 5, 18], ["residual weakness predominantly in his hands and feet", "PROBLEM", 158, 211], ["weakness", "OBSERVATION", 167, 175], ["hands", "ANATOMY", 197, 202], ["feet", "ANATOMY", 207, 211]]], ["Power was restored except for MRC grade 4+/5 for finger extension and abduction in his non-dominant right hand, 3/5 for the left great toe dorsiflexion and 4+/5 for dorsiflexion of the left toes.", [["finger", "ANATOMY", 49, 55], ["right hand", "ANATOMY", 100, 110], ["toe", "ANATOMY", 135, 138], ["left toes", "ANATOMY", 185, 194], ["finger", "ORGANISM_SUBDIVISION", 49, 55], ["hand", "ORGANISM_SUBDIVISION", 106, 110], ["toe", "ORGANISM_SUBDIVISION", 135, 138], ["toes", "ORGANISM_SUBDIVISION", 190, 194], ["MRC grade", "TEST", 30, 39], ["finger extension", "TEST", 49, 65], ["abduction", "TEST", 70, 79], ["abduction", "OBSERVATION", 70, 79], ["non-dominant", "ANATOMY_MODIFIER", 87, 99], ["right", "ANATOMY_MODIFIER", 100, 105], ["hand", "ANATOMY", 106, 110], ["left", "ANATOMY_MODIFIER", 124, 128], ["great toe", "ANATOMY", 129, 138], ["dorsiflexion", "ANATOMY", 139, 151], ["left toes", "ANATOMY", 185, 194]]], ["He was able to stand on his toes but not on his heels, and walking was mildly affected.", [["toes", "ANATOMY", 28, 32], ["He", "ORGANISM", 0, 2], ["toes", "ORGANISM_SUBDIVISION", 28, 32], ["mildly affected", "PROBLEM", 71, 86], ["toes", "ANATOMY", 28, 32], ["heels", "ANATOMY", 48, 53]]], ["Reflexes were now present and there remained no sensory signs.OUTCOME AND FOLLOW-UPHe was able to return to work 6 weeks after admission, but remained affected with intermittent chest pain and shortness of breath on going upstairs.DISCUSSIONGuillain-Barr\u00e9 syndrome is preceded by infection or other immune stimulus such as vaccination which induces an autoimmune response targeting the nervous system, 1 in this case the spinal roots and peripheral nerves.", [["chest", "ANATOMY", 178, 183], ["nervous system", "ANATOMY", 386, 400], ["spinal roots", "ANATOMY", 421, 433], ["peripheral nerves", "ANATOMY", 438, 455], ["chest pain", "DISEASE", 178, 188], ["shortness of breath", "DISEASE", 193, 212], ["infection", "DISEASE", 280, 289], ["chest", "ORGANISM_SUBDIVISION", 178, 183], ["nervous system", "ANATOMICAL_SYSTEM", 386, 400], ["spinal roots", "MULTI-TISSUE_STRUCTURE", 421, 433], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 438, 455], ["sensory signs", "PROBLEM", 48, 61], ["intermittent chest pain", "PROBLEM", 165, 188], ["shortness of breath", "PROBLEM", 193, 212], ["Barr\u00e9 syndrome", "PROBLEM", 250, 264], ["infection", "PROBLEM", 280, 289], ["other immune stimulus", "PROBLEM", 293, 314], ["vaccination", "TREATMENT", 323, 334], ["an autoimmune response targeting the nervous system", "PROBLEM", 349, 400], ["no", "UNCERTAINTY", 45, 47], ["sensory signs", "OBSERVATION", 48, 61], ["chest", "ANATOMY", 178, 183], ["Barr\u00e9 syndrome", "OBSERVATION", 250, 264], ["infection", "OBSERVATION", 280, 289], ["autoimmune", "OBSERVATION", 352, 362], ["nervous system", "ANATOMY", 386, 400], ["spinal roots", "ANATOMY", 421, 433], ["peripheral nerves", "ANATOMY", 438, 455]]], ["It is characterised by progressive weakness and areflexia, with pain preceding weakness in one-third of adult patients.", [["weakness", "DISEASE", 35, 43], ["areflexia", "DISEASE", 48, 57], ["pain", "DISEASE", 64, 68], ["weakness", "DISEASE", 79, 87], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["progressive weakness", "PROBLEM", 23, 43], ["areflexia", "PROBLEM", 48, 57], ["pain preceding weakness", "PROBLEM", 64, 87], ["progressive", "OBSERVATION_MODIFIER", 23, 34], ["weakness", "OBSERVATION", 35, 43], ["areflexia", "OBSERVATION", 48, 57]]], ["2 Subtypes include demyelinating types, in which the affected myelin sheath causes aberrant conduction, and the axonal forms affecting the axons themselves.", [["myelin sheath", "ANATOMY", 62, 75], ["axonal", "ANATOMY", 112, 118], ["axons", "ANATOMY", 139, 144], ["myelin sheath", "TISSUE", 62, 75], ["axonal forms", "CELLULAR_COMPONENT", 112, 124], ["axons", "CELLULAR_COMPONENT", 139, 144], ["demyelinating types", "PROBLEM", 19, 38], ["the affected myelin sheath", "TREATMENT", 49, 75], ["aberrant conduction", "PROBLEM", 83, 102], ["demyelinating types", "OBSERVATION", 19, 38], ["myelin sheath", "OBSERVATION", 62, 75], ["aberrant conduction", "OBSERVATION", 83, 102]]], ["3 This case highlights the difficulty of diagnosing Guillain-Barr\u00e9 syndrome as a cause of subacute weakness, when in a typical district general hospital covering 400 000 people we might expect 4-8 cases per year (1-2 per 100 000 population per year).", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 52, 75], ["Guillain-Barr\u00e9", "ORGANISM", 52, 66], ["people", "ORGANISM", 170, 176], ["people", "SPECIES", 170, 176], ["Barr\u00e9 syndrome", "PROBLEM", 61, 75], ["subacute weakness", "PROBLEM", 90, 107], ["Barr\u00e9 syndrome", "OBSERVATION", 61, 75], ["subacute", "OBSERVATION_MODIFIER", 90, 98], ["weakness", "OBSERVATION", 99, 107]]], ["The patient presented to the hospital three times before a diagnosis of Guillain-Barr\u00e9 syndrome was considered.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 72, 95], ["patient", "ORGANISM", 4, 11], ["Guillain-Barr\u00e9", "ORGANISM", 72, 86], ["patient", "SPECIES", 4, 11], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 72, 95], ["Barr\u00e9 syndrome", "OBSERVATION", 81, 95]]], ["There was neither facial weakness nor spinal pain to point towards the diagnosis.DISCUSSIONAlso highlighted is that evaluation of weakness based on loss of function can be more sensitive than physical examination: no lower limb weakness was identified on examination despite the patient having difficulty standing from a chair.", [["facial", "ANATOMY", 18, 24], ["spinal", "ANATOMY", 38, 44], ["lower limb", "ANATOMY", 217, 227], ["spinal pain", "DISEASE", 38, 49], ["weakness", "DISEASE", 130, 138], ["spinal", "ORGANISM_SUBDIVISION", 38, 44], ["lower limb", "ORGANISM_SUBDIVISION", 217, 227], ["patient", "ORGANISM", 279, 286], ["patient", "SPECIES", 279, 286], ["facial weakness", "PROBLEM", 18, 33], ["spinal pain", "PROBLEM", 38, 49], ["evaluation", "TEST", 116, 126], ["weakness", "PROBLEM", 130, 138], ["loss of function", "PROBLEM", 148, 164], ["physical examination", "TEST", 192, 212], ["lower limb weakness", "PROBLEM", 217, 236], ["examination", "TEST", 255, 266], ["facial", "ANATOMY", 18, 24], ["weakness", "OBSERVATION", 25, 33], ["spinal", "ANATOMY", 38, 44], ["pain", "OBSERVATION", 45, 49], ["weakness", "OBSERVATION", 130, 138], ["no", "UNCERTAINTY", 214, 216], ["lower limb", "ANATOMY", 217, 227], ["weakness", "OBSERVATION", 228, 236]]], ["It is invaluable to record one or two reflexes in both the upper and lower limbs in any patient with subjective weakness to alert the clinician to a potential upper or lower motor neurone disorder and as a baseline for future examination.", [["upper", "ANATOMY", 59, 64], ["lower limbs", "ANATOMY", 69, 80], ["lower motor neurone", "ANATOMY", 168, 187], ["neurone disorder", "DISEASE", 180, 196], ["upper", "ORGANISM_SUBDIVISION", 59, 64], ["lower limbs", "ORGANISM_SUBDIVISION", 69, 80], ["patient", "ORGANISM", 88, 95], ["upper", "ORGANISM_SUBDIVISION", 159, 164], ["patient", "SPECIES", 88, 95], ["two reflexes", "TEST", 34, 46], ["subjective weakness", "PROBLEM", 101, 120], ["a potential upper or lower motor neurone disorder", "PROBLEM", 147, 196], ["future examination", "TEST", 219, 237], ["both", "ANATOMY_MODIFIER", 50, 54], ["upper", "ANATOMY_MODIFIER", 59, 64], ["lower limbs", "ANATOMY", 69, 80], ["lower motor", "ANATOMY", 168, 179], ["neurone disorder", "OBSERVATION", 180, 196]]], ["Recording of reflexes on prior attendances may have shortened the time to diagnosis.", [["reflexes", "OBSERVATION", 13, 21]]], ["This case raises the issue of whether the concurrent COVID-19 infection was a coincidence or could have been related to the Guillain-Barr\u00e9 syndrome.", [["infection", "DISEASE", 62, 71], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 124, 147], ["COVID-19", "ORGANISM", 53, 61], ["Guillain-Barr\u00e9", "ORGANISM", 124, 138], ["the concurrent COVID-19 infection", "PROBLEM", 38, 71], ["the Guillain-Barr\u00e9 syndrome", "PROBLEM", 120, 147], ["infection", "OBSERVATION", 62, 71], ["Barr\u00e9 syndrome", "OBSERVATION", 133, 147]]], ["COVID-19 is a disease caused by a newly emergent virus species of the Betacoronavirus genus, other species of which have caused the common cold, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).", [["COVID-19", "CHEMICAL", 0, 8], ["acute respiratory syndrome", "DISEASE", 152, 178], ["SARS", "DISEASE", 180, 184], ["Middle East respiratory syndrome", "DISEASE", 190, 222], ["Betacoronavirus genus", "ORGANISM", 70, 91], ["COVID-19", "SPECIES", 0, 8], ["Middle East respiratory syndrome (MERS)", "SPECIES", 190, 229], ["a disease", "PROBLEM", 12, 21], ["a newly emergent virus species", "PROBLEM", 32, 62], ["the Betacoronavirus genus", "PROBLEM", 66, 91], ["the common cold", "PROBLEM", 128, 143], ["severe acute respiratory syndrome", "PROBLEM", 145, 178], ["SARS)", "PROBLEM", 180, 185], ["Middle East respiratory syndrome", "PROBLEM", 190, 222], ["disease", "OBSERVATION", 14, 21], ["virus", "OBSERVATION", 49, 54], ["common cold", "ANATOMY", 132, 143], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["respiratory syndrome", "OBSERVATION", 158, 178], ["Middle", "ANATOMY_MODIFIER", 190, 196], ["respiratory syndrome", "OBSERVATION", 202, 222]]], ["The new virus has been called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been identified as the cause of an outbreak of a respiratory illness that originated in Wuhan City, Hubei Province, China, in December 2019.", [["respiratory", "ANATOMY", 148, 159], ["acute respiratory syndrome coronavirus", "DISEASE", 37, 75], ["respiratory illness", "DISEASE", 148, 167], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 30, 77], ["SARS-CoV-2", "ORGANISM", 79, 89], ["severe acute respiratory syndrome coronavirus", "SPECIES", 30, 75], ["SARS-CoV-2", "SPECIES", 79, 89], ["The new virus", "PROBLEM", 0, 13], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 30, 75], ["SARS-CoV", "TEST", 79, 87], ["a respiratory illness", "PROBLEM", 146, 167], ["new", "OBSERVATION_MODIFIER", 4, 7], ["virus", "OBSERVATION", 8, 13], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome coronavirus", "OBSERVATION", 43, 75], ["respiratory illness", "OBSERVATION", 148, 167]]], ["4 The WHO named the disease 'coronavirus disease 2019' (COVID-19) and in March 2020 declared the COVID-19 outbreak a pandemic.DISCUSSIONSARS-CoV-2 has similar characteristics to SARS and MERS coronaviruses.", [["coronavirus disease", "DISEASE", 29, 48], ["SARS", "DISEASE", 178, 182], ["CoV-2", "GENE_OR_GENE_PRODUCT", 141, 146], ["MERS coronaviruses", "ORGANISM", 187, 205], ["coronavirus", "SPECIES", 29, 40], ["MERS coronaviruses", "SPECIES", 187, 205], ["the disease 'coronavirus disease", "PROBLEM", 16, 48], ["COVID", "TEST", 56, 61], ["the COVID", "TEST", 93, 102], ["SARS", "PROBLEM", 178, 182], ["MERS coronaviruses", "PROBLEM", 187, 205]]], ["5 Species of Betacoronavirus genus are known to be potentially neuroinvasive.", [["Betacoronavirus genus", "ORGANISM", 13, 34], ["Betacoronavirus genus", "PROBLEM", 13, 34], ["known to be potentially", "UNCERTAINTY", 39, 62], ["neuroinvasive", "OBSERVATION", 63, 76]]], ["Previously MERS was found to be associated with Guillain-Barr\u00e9 syndrome in two patients.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 48, 71], ["Guillain-Barr\u00e9", "ORGANISM", 48, 62], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 48, 71], ["Barr\u00e9 syndrome", "OBSERVATION", 57, 71]]], ["6 Neurological manifestations associated with COVID-19 include stroke, impaired consciousness and encephalopathy.", [["COVID-19", "CHEMICAL", 46, 54], ["stroke", "DISEASE", 63, 69], ["impaired consciousness", "DISEASE", 71, 93], ["encephalopathy", "DISEASE", 98, 112], ["COVID-19", "CHEMICAL", 46, 54], ["Neurological manifestations", "PROBLEM", 2, 29], ["COVID", "TEST", 46, 51], ["stroke", "PROBLEM", 63, 69], ["impaired consciousness", "PROBLEM", 71, 93], ["encephalopathy", "PROBLEM", 98, 112], ["stroke", "OBSERVATION", 63, 69], ["encephalopathy", "OBSERVATION", 98, 112]]], ["7 There have been at least 12 cases reported in the literature as of 2 May 2020 linking Guillain-Barr\u00e9 syndrome with SARS-CoV-2 (COVID-19).", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 88, 111], ["SARS", "DISEASE", 117, 121], ["Guillain-Barr\u00e9", "ORGANISM", 88, 102], ["Barr\u00e9 syndrome", "PROBLEM", 97, 111], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125], ["COVID", "TEST", 129, 134], ["Barr\u00e9 syndrome", "OBSERVATION", 97, 111]]], ["[8] [9] [10] [11] [12] [13] [14] [15] As with our patient, four of these cases had signs of Guillain-Barr\u00e9 syndrome at initial presentation.", [["[8] [9] [10] [11] [12]", "CHEMICAL", 0, 22], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 92, 115], ["[8] [9] [10] [11] [12] [13] [14] [15] As", "CHEMICAL", 0, 40], ["[8] [9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 0, 37], ["patient", "ORGANISM", 50, 57], ["Guillain-Barr\u00e9", "ORGANISM", 92, 106], ["patient", "SPECIES", 50, 57], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 92, 115], ["Barr\u00e9 syndrome", "OBSERVATION", 101, 115]]], ["8 14-17 UK-wide surveillance via notification portals identified three confirmed cases of Guillain-Barr\u00e9 syndrome reported from 2 April 2020 to 26 April 2020, of which this patient was one.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 90, 113], ["Guillain-Barr\u00e9", "ORGANISM", 90, 104], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["Barr\u00e9 syndrome", "PROBLEM", 99, 113], ["Barr\u00e9 syndrome", "OBSERVATION", 99, 113]]], ["18 Our patient developed signs of Guillain-Barr\u00e9 syndrome before COVID-19 respiratory symptoms started on day 4 of weakness.", [["respiratory", "ANATOMY", 74, 85], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 34, 57], ["respiratory symptoms", "DISEASE", 74, 94], ["patient", "ORGANISM", 7, 14], ["Guillain-Barr\u00e9", "ORGANISM", 34, 48], ["patient", "SPECIES", 7, 14], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 34, 57], ["COVID", "TEST", 65, 70], ["respiratory symptoms", "PROBLEM", 74, 94], ["weakness", "PROBLEM", 115, 123], ["Barr\u00e9 syndrome", "OBSERVATION", 43, 57], ["weakness", "OBSERVATION", 115, 123]]], ["The question is posed whether this could be a parainfectious phenomenon, due to direct neuroinvasion by the virus.", [["a parainfectious phenomenon", "PROBLEM", 44, 71], ["direct neuroinvasion", "PROBLEM", 80, 100], ["the virus", "PROBLEM", 104, 113], ["parainfectious phenomenon", "OBSERVATION", 46, 71]]], ["Or could it be postinfectious with the incubation period for respiratory symptoms overlapping that for immune-mediated neurological symptoms?", [["respiratory", "ANATOMY", 61, 72], ["neurological", "ANATOMY", 119, 131], ["respiratory symptoms", "PROBLEM", 61, 81], ["immune-mediated neurological symptoms", "PROBLEM", 103, 140], ["postinfectious", "OBSERVATION", 15, 29]]], ["Guillain-Barr\u00e9 syndrome usually follows an immune stimulus from day 1 to 4 weeks later.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 0, 23], ["Guillain-Barr\u00e9", "ORGANISM", 0, 14], ["Barr\u00e9 syndrome", "PROBLEM", 9, 23], ["Barr\u00e9 syndrome", "OBSERVATION", 9, 23]]], ["Possible causes of the New disease case presented here are the bowel disturbance in Prague 4 weeks before and the SARS-CoV-2 infection.", [["bowel", "ANATOMY", 63, 68], ["bowel disturbance", "DISEASE", 63, 80], ["SARS", "DISEASE", 114, 118], ["infection", "DISEASE", 125, 134], ["bowel", "ORGAN", 63, 68], ["SARS-CoV-2", "ORGANISM", 114, 124], ["SARS-CoV-2", "SPECIES", 114, 124], ["the New disease case", "PROBLEM", 19, 39], ["the bowel disturbance", "PROBLEM", 59, 80], ["the SARS-CoV-2 infection", "PROBLEM", 110, 134], ["New", "OBSERVATION_MODIFIER", 23, 26], ["disease", "OBSERVATION", 27, 34], ["bowel", "ANATOMY", 63, 68], ["infection", "OBSERVATION", 125, 134]]], ["It is intriguing that the length of the presymptomatic phase of SARS-CoV-2 before respiratory symptoms (the incubation period) is up to at least 14 days.Patient's perspectiveFirst of all I would like to thank all nurses and doctors who took care of me in Southend Hospital.", [["respiratory", "ANATOMY", 82, 93], ["SARS", "DISEASE", 64, 68], ["respiratory symptoms", "DISEASE", 82, 102], ["SARS-CoV-2", "ORGANISM", 64, 74], ["Patient", "SPECIES", 153, 160], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["respiratory symptoms", "PROBLEM", 82, 102], ["length", "OBSERVATION_MODIFIER", 26, 32]]], ["I agree with what's said in the report regarding accepting and examining patients coming to A&E -I was only admitted and treated only the 3rd time I came to hospital.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["However, the care I received after that was brilliant and it was re-assuring to hear stories from a doctor who had suffered GBS before.", [["GBS", "DISEASE", 124, 127], ["GBS", "PROBLEM", 124, 127]]], ["He told me everything will be as it was.", [["He", "ORGANISM", 0, 2]]], ["This was a stressful time for me and my family and I am still not 100% recovered, but I have started to go to work (around 1.5 months after first symptoms) and am expected to make full recovery.", [["first symptoms", "PROBLEM", 140, 154]]], ["Thank you again.Learning points\u25ba Consideration of function as well as physical examination of power to determine the location of weakness are important. \u25ba Examining reflexes and checking for plantar responses in any patient with weakness are also important. \u25ba With the backdrop of the COVID-19 pandemic, the presence of a concurrent COVID-19 infection needs to be considered in patients presenting with symptoms and signs of Guillain-Barr\u00e9 syndrome. \u25ba If neurological manifestations of COVID-19 infection could appear before respiratory symptoms, it would be of utmost importance to use effective personal protective equipment, in particular for aerosol-generating procedures such as spirometry, in patients presenting with Guillain-Barr\u00e9 syndrome.", [["plantar", "ANATOMY", 191, 198], ["neurological", "ANATOMY", 455, 467], ["respiratory", "ANATOMY", 525, 536], ["weakness", "DISEASE", 129, 137], ["weakness", "DISEASE", 229, 237], ["infection", "DISEASE", 342, 351], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 425, 448], ["COVID-19", "CHEMICAL", 486, 494], ["infection", "DISEASE", 495, 504], ["respiratory symptoms", "DISEASE", 525, 545], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 724, 747], ["plantar", "ORGANISM_SUBDIVISION", 191, 198], ["patient", "ORGANISM", 216, 223], ["COVID-19", "ORGANISM", 333, 341], ["patients", "ORGANISM", 378, 386], ["Guillain-Barr\u00e9", "ORGANISM", 425, 439], ["COVID-19", "ORGANISM", 486, 494], ["patients", "ORGANISM", 699, 707], ["Guillain-Barr\u00e9", "ORGANISM", 724, 738], ["patient", "SPECIES", 216, 223], ["patients", "SPECIES", 378, 386], ["patients", "SPECIES", 699, 707], ["COVID-19", "SPECIES", 333, 341], ["physical examination", "TEST", 70, 90], ["weakness", "PROBLEM", 129, 137], ["Examining reflexes", "TEST", 155, 173], ["checking for plantar responses", "TEST", 178, 208], ["weakness", "PROBLEM", 229, 237], ["the COVID", "TEST", 281, 290], ["a concurrent COVID-19 infection", "PROBLEM", 320, 351], ["symptoms", "PROBLEM", 403, 411], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 425, 448], ["COVID-19 infection", "PROBLEM", 486, 504], ["respiratory symptoms", "PROBLEM", 525, 545], ["personal protective equipment", "TREATMENT", 597, 626], ["aerosol-generating procedures", "TREATMENT", 646, 675], ["Barr\u00e9 syndrome", "PROBLEM", 733, 747], ["weakness", "OBSERVATION", 129, 137], ["weakness", "OBSERVATION", 229, 237], ["infection", "OBSERVATION", 342, 351], ["Barr\u00e9 syndrome", "OBSERVATION", 434, 448], ["Barr\u00e9 syndrome", "OBSERVATION", 733, 747]]]], "0e76160729d01c33942105e505724f59a5db1a44": [["IntroductionSevere acute respiratory syndrome (SARS) is a newly emerged disease caused by SARS coronavirus (SCoV).", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["SARS coronavirus", "DISEASE", 90, 106], ["SARS coronavirus", "ORGANISM", 90, 106], ["SCoV", "CANCER", 108, 112], ["SARS coronavirus", "SPECIES", 90, 106], ["SCoV", "SPECIES", 108, 112], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["a newly emerged disease", "PROBLEM", 56, 79], ["SARS coronavirus", "PROBLEM", 90, 106], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["SARS originated in Southern China in 2002 and spread to five different continents causing >8000 infection and >700 deaths before its apparent eradication as a human infection in 2004 [1] .", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 96, 105], ["deaths", "DISEASE", 115, 121], ["infection", "DISEASE", 165, 174], ["human", "ORGANISM", 159, 164], ["human", "SPECIES", 159, 164], ["human", "SPECIES", 159, 164], ["SARS", "PROBLEM", 0, 4], [">8000 infection", "PROBLEM", 90, 105], ["a human infection", "PROBLEM", 157, 174], ["infection", "OBSERVATION", 96, 105]]], ["Healthcare systems in affected areas were severely stressed and additional economic costs in trade and travel were very high.", [["affected areas", "PROBLEM", 22, 36], ["severely stressed", "PROBLEM", 42, 59], ["severely", "OBSERVATION_MODIFIER", 42, 50], ["stressed", "OBSERVATION", 51, 59]]], ["It is not known if the virus will be reintroduced into the human population but ancestral coronaviruses are widely distributed in bats and are thought to have adapted to civets and then to humans in recent time periods [2, 3] .", [["human", "ORGANISM", 59, 64], ["coronaviruses", "ORGANISM", 90, 103], ["humans", "ORGANISM", 189, 195], ["human", "SPECIES", 59, 64], ["humans", "SPECIES", 189, 195], ["human", "SPECIES", 59, 64], ["humans", "SPECIES", 189, 195], ["the virus", "PROBLEM", 19, 28], ["ancestral coronaviruses", "PROBLEM", 80, 103], ["not known", "UNCERTAINTY", 6, 15], ["virus", "OBSERVATION", 23, 28], ["ancestral coronaviruses", "OBSERVATION", 80, 103]]], ["Because emerging viruses tend to reemerge as conditions change [4] , it is highly desirable to develop safe and efficacious vaccines and/or antivirals to prevent SCoV infections.IntroductionAll coronaviruses, including SCoV, carry four structural proteins: nucleocapsid (N) protein and three envelope proteins, namely spike (S) protein, a type I transmembrane glycoprotein; envelope (E) protein; and membrane (M) protein, which has three membrane-spanning domains.", [["membrane", "ANATOMY", 400, 408], ["membrane", "ANATOMY", 438, 446], ["infections", "DISEASE", 167, 177], ["SCoV", "GENE_OR_GENE_PRODUCT", 162, 166], ["coronaviruses", "ORGANISM", 194, 207], ["SCoV", "GENE_OR_GENE_PRODUCT", 219, 223], ["nucleocapsid (N) protein", "GENE_OR_GENE_PRODUCT", 257, 281], ["spike (S) protein", "GENE_OR_GENE_PRODUCT", 318, 335], ["type I transmembrane glycoprotein; envelope (E) protein", "GENE_OR_GENE_PRODUCT", 339, 394], ["membrane", "CELLULAR_COMPONENT", 400, 408], ["membrane", "CELLULAR_COMPONENT", 438, 446], ["SCoV", "PROTEIN", 219, 223], ["structural proteins", "PROTEIN", 236, 255], ["nucleocapsid (N) protein", "PROTEIN", 257, 281], ["envelope proteins", "PROTEIN", 292, 309], ["spike (S) protein", "PROTEIN", 318, 335], ["type I transmembrane glycoprotein", "PROTEIN", 339, 372], ["envelope (E) protein", "PROTEIN", 374, 394], ["membrane (M) protein", "PROTEIN", 400, 420], ["membrane-spanning domains", "PROTEIN", 438, 463], ["SCoV", "SPECIES", 162, 166], ["emerging viruses", "PROBLEM", 8, 24], ["safe and efficacious vaccines", "TREATMENT", 103, 132], ["antivirals", "TREATMENT", 140, 150], ["SCoV infections", "PROBLEM", 162, 177], ["All coronaviruses", "PROBLEM", 190, 207], ["nucleocapsid (N) protein", "TEST", 257, 281], ["three envelope proteins", "TEST", 286, 309], ["protein", "TEST", 328, 335], ["a type I transmembrane glycoprotein", "TEST", 337, 372], ["envelope (E) protein", "TEST", 374, 394], ["membrane (M) protein", "TEST", 400, 420], ["viruses", "OBSERVATION", 17, 24], ["infections", "OBSERVATION", 167, 177]]], ["Coronavirus S protein is responsible for virus adsorption to susceptible cells through a specific virus-receptor interaction and induces membrane fusion between viral envelope and host cell membrane [5] .", [["cells", "ANATOMY", 73, 78], ["membrane", "ANATOMY", 137, 145], ["cell membrane", "ANATOMY", 185, 198], ["Coronavirus S protein", "GENE_OR_GENE_PRODUCT", 0, 21], ["cells", "CELL", 73, 78], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["host cell membrane", "CELLULAR_COMPONENT", 180, 198], ["Coronavirus S protein", "PROTEIN", 0, 21], ["susceptible cells", "CELL_TYPE", 61, 78], ["Coronavirus S protein", "TEST", 0, 21], ["virus adsorption", "PROBLEM", 41, 57], ["susceptible cells", "PROBLEM", 61, 78], ["a specific virus", "PROBLEM", 87, 103], ["receptor interaction", "TREATMENT", 104, 124], ["membrane fusion", "TREATMENT", 137, 152], ["viral envelope", "PROBLEM", 161, 175], ["host cell membrane", "TREATMENT", 180, 198], ["membrane fusion", "OBSERVATION", 137, 152], ["host cell membrane", "OBSERVATION", 180, 198]]], ["S protein is a main player for determining coronavirus tissue tropism, host specificity and viral pathogenicity [6] [7] [8] [9] [10] [11] [12] .", [["tissue", "ANATOMY", 55, 61], ["coronavirus", "ORGANISM", 43, 54], ["tissue", "TISSUE", 55, 61], ["[6] [7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 112, 142], ["S protein", "PROTEIN", 0, 9], ["coronavirus", "SPECIES", 43, 54], ["coronavirus tissue tropism", "PROBLEM", 43, 69], ["host specificity", "TEST", 71, 87], ["viral pathogenicity", "TEST", 92, 111]]], ["Because most coronavirus neutralizing antibodies recognize S protein [1, 13] , it is not surprising that most of the current SCoV vaccine candidates are either the S protein subunit itself or those carrying S protein [14] [15] [16] [17] [18] [19] .", [["coronavirus", "ORGANISM", 13, 24], ["SCoV", "GENE_OR_GENE_PRODUCT", 125, 129], ["[14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 217, 246], ["coronavirus neutralizing antibodies", "PROTEIN", 13, 48], ["S protein", "PROTEIN", 59, 68], ["S protein subunit", "PROTEIN", 164, 181], ["S protein", "PROTEIN", 207, 216], ["coronavirus", "SPECIES", 13, 24], ["most coronavirus neutralizing antibodies", "TEST", 8, 48], ["S protein", "TEST", 59, 68], ["the current SCoV vaccine", "TREATMENT", 113, 137], ["those carrying S protein", "TEST", 192, 216]]], ["Furthermore, prophylactic administration of monoclonal antibodies directed at the SCoV S protein protects animals against subsequent SCoV challenge [20] [21] [22] [23] .", [["SCoV", "CHEMICAL", 133, 137], ["SCoV S protein", "GENE_OR_GENE_PRODUCT", 82, 96], ["SCoV", "SIMPLE_CHEMICAL", 133, 137], ["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 148, 167], ["monoclonal antibodies", "PROTEIN", 44, 65], ["SCoV S protein", "PROTEIN", 82, 96], ["prophylactic administration of monoclonal antibodies", "TREATMENT", 13, 65], ["the SCoV S protein protects animals", "TREATMENT", 78, 113], ["subsequent SCoV challenge", "TREATMENT", 122, 147]]], ["These studies point out that neutralizing antibodies that recognize SCoV S protein are sufficient to prevent or decrease the morbidity and mortality associated with SCoV infection by primarily suppressing replication of the challenge virus.IntroductionCoronavirus-like particles (VLPs) are produced from the cells coexpressing the S, M, and E proteins [24] ; expression of the latter two proteins are sufficient for VLP production [24] .", [["cells", "ANATOMY", 308, 313], ["infection", "DISEASE", 170, 179], ["SCoV S", "GENE_OR_GENE_PRODUCT", 68, 74], ["SCoV", "GENE_OR_GENE_PRODUCT", 165, 169], ["Coronavirus-like particles", "GENE_OR_GENE_PRODUCT", 252, 278], ["VLPs", "ORGANISM", 280, 284], ["cells", "CELL", 308, 313], ["neutralizing antibodies", "PROTEIN", 29, 52], ["SCoV S protein", "PROTEIN", 68, 82], ["S, M, and E proteins", "PROTEIN", 331, 351], ["SCoV", "SPECIES", 165, 169], ["These studies", "TEST", 0, 13], ["neutralizing antibodies", "PROBLEM", 29, 52], ["SCoV S protein", "PROBLEM", 68, 82], ["the morbidity", "PROBLEM", 121, 134], ["SCoV infection", "PROBLEM", 165, 179], ["the challenge virus", "TREATMENT", 220, 239], ["IntroductionCoronavirus", "TEST", 240, 263], ["the S, M, and E proteins", "TEST", 327, 351], ["the latter two proteins", "PROBLEM", 373, 396], ["VLP production", "PROBLEM", 416, 430], ["morbidity", "OBSERVATION", 125, 134]]], ["M protein plays a central role in virus assembly, while S protein is assembled into coronavirus particles through S protein-M protein interaction [25] [26] [27] [28] .", [["S protein", "GENE_OR_GENE_PRODUCT", 56, 65], ["coronavirus", "ORGANISM", 84, 95], ["[25] [26] [27] [28]", "SIMPLE_CHEMICAL", 146, 165], ["M protein", "PROTEIN", 0, 9], ["S protein", "PROTEIN", 56, 65], ["S protein", "PROTEIN", 114, 123], ["S protein", "TEST", 56, 65], ["S protein", "TEST", 114, 123], ["protein interaction", "TEST", 126, 145]]], ["Further, interactions of the M protein with the RNA packaging signal of the viral RNA [29] and with N protein [29] [30] [31] [32] drive incorporation of the helical nucleocapsid complex, which consists of the viral genome and N protein, into virus particles.", [["M protein", "PROTEIN", 29, 38], ["N protein", "PROTEIN", 100, 109], ["helical nucleocapsid complex", "PROTEIN", 157, 185], ["viral genome", "DNA", 209, 221], ["N protein", "PROTEIN", 226, 235], ["the M protein", "TREATMENT", 25, 38], ["the viral RNA", "TEST", 72, 85], ["N protein", "TEST", 100, 109], ["the helical nucleocapsid complex", "PROBLEM", 153, 185], ["the viral genome", "PROBLEM", 205, 221], ["viral genome", "OBSERVATION", 209, 221]]], ["Vaccinia virus and/or alphavirus replicons have been used to express coronavirus proteins to enable generation of VLPs [33] [34] [35] , while we have reported production of SCoV VLPs from 293T cells that are co-transfected with four eukaryotic pCAGGS-based expression plasmids, each of which encodes SCoV S, M, N and E proteins [36] .", [["293T cells", "ANATOMY", 188, 198], ["plasmids", "ANATOMY", 268, 276], ["Vaccinia virus", "ORGANISM", 0, 14], ["alphavirus replicons", "ORGANISM", 22, 42], ["coronavirus", "ORGANISM", 69, 80], ["SCoV VLPs", "CELL", 173, 182], ["293T cells", "CELL", 188, 198], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 244, 250], ["SCoV S", "GENE_OR_GENE_PRODUCT", 300, 306], ["coronavirus proteins", "PROTEIN", 69, 89], ["SCoV VLPs", "PROTEIN", 173, 182], ["293T cells", "CELL_LINE", 188, 198], ["eukaryotic pCAGGS-based expression plasmids", "DNA", 233, 276], ["SCoV S, M, N and E proteins", "PROTEIN", 300, 327], ["Vaccinia virus", "SPECIES", 0, 14], ["Vaccinia virus", "SPECIES", 0, 14], ["Vaccinia virus", "TREATMENT", 0, 14], ["alphavirus replicons", "TREATMENT", 22, 42], ["coronavirus proteins", "PROBLEM", 69, 89], ["VLPs", "TEST", 114, 118], ["production of SCoV VLPs", "PROBLEM", 159, 182], ["four eukaryotic pCAGGS", "TREATMENT", 228, 250], ["based expression plasmids", "TREATMENT", 251, 276], ["SCoV S", "TEST", 300, 306]]], ["Others have also reported production of SCoV VLP from insect cells [37, 38] and mammalian cells [39] .IntroductionDuring our studies of coronavirus assembly, we found an efficient production of chimeric VLPs carrying SCoV S protein and murine coronavirus (mouse hepatitis virus or MHV) M, N and E proteins from cells coexpressing those proteins.", [["cells", "ANATOMY", 61, 66], ["cells", "ANATOMY", 90, 95], ["cells", "ANATOMY", 311, 316], ["mouse hepatitis virus", "DISEASE", 256, 277], ["SCoV VLP", "ORGANISM", 40, 48], ["insect cells", "CELL", 54, 66], ["mammalian cells", "CELL", 80, 95], ["coronavirus", "ORGANISM", 136, 147], ["SCoV S protein", "GENE_OR_GENE_PRODUCT", 217, 231], ["murine coronavirus", "ORGANISM", 236, 254], ["mouse hepatitis virus", "ORGANISM", 256, 277], ["MHV", "ORGANISM", 281, 284], ["cells", "CELL", 311, 316], ["SCoV VLP", "PROTEIN", 40, 48], ["insect cells", "CELL_TYPE", 54, 66], ["mammalian cells", "CELL_TYPE", 80, 95], ["chimeric VLPs", "PROTEIN", 194, 207], ["SCoV S protein", "PROTEIN", 217, 231], ["M, N and E proteins", "PROTEIN", 286, 305], ["murine", "SPECIES", 236, 242], ["coronavirus", "SPECIES", 243, 254], ["mouse", "SPECIES", 256, 261], ["hepatitis virus", "SPECIES", 262, 277], ["SCoV", "SPECIES", 40, 44], ["coronavirus", "SPECIES", 136, 147], ["murine coronavirus", "SPECIES", 236, 254], ["mouse hepatitis virus", "SPECIES", 256, 277], ["MHV", "SPECIES", 281, 284], ["SCoV VLP", "PROBLEM", 40, 48], ["mammalian cells", "TEST", 80, 95], ["coronavirus", "PROBLEM", 136, 147], ["chimeric VLPs", "PROBLEM", 194, 207], ["murine coronavirus (mouse hepatitis virus", "PROBLEM", 236, 277]]], ["In mice immunized with the chimeric VLPs, the present study describes elicitation of antibodies that neutralized SCoV and suppressed challenged SCoV replication in the lungs.", [["SCoV", "ANATOMY", 144, 148], ["lungs", "ANATOMY", 168, 173], ["mice", "ORGANISM", 3, 7], ["SCoV", "GENE_OR_GENE_PRODUCT", 113, 117], ["SCoV", "GENE_OR_GENE_PRODUCT", 144, 148], ["lungs", "ORGAN", 168, 173], ["chimeric VLPs", "PROTEIN", 27, 40], ["antibodies", "PROTEIN", 85, 95], ["SCoV", "PROTEIN", 113, 117], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["SCoV", "SPECIES", 113, 117], ["SCoV", "SPECIES", 144, 148], ["the chimeric VLPs", "TREATMENT", 23, 40], ["the present study", "TEST", 42, 59], ["antibodies", "TREATMENT", 85, 95], ["neutralized SCoV", "PROBLEM", 101, 117], ["lungs", "ANATOMY", 168, 173]]], ["These findings suggest that the use of chimeric VLP is an effective vaccine strategy against SCoV infection.Cells and virusVero E6 cells, 293T cells and CHO cells were grown in Dulbecco's modified minimum essential medium (DMEM) supplemented with penicillin (100 units/ml), streptomycin (100 g/ml), 0.2% sodium bicarbonate and 10% fetal bovine serum (FBS).", [["Cells", "ANATOMY", 108, 113], ["Vero E6 cells", "ANATOMY", 123, 136], ["293T cells", "ANATOMY", 138, 148], ["CHO cells", "ANATOMY", 153, 162], ["fetal bovine serum", "ANATOMY", 331, 349], ["FBS", "ANATOMY", 351, 354], ["SCoV infection", "DISEASE", 93, 107], ["penicillin", "CHEMICAL", 247, 257], ["streptomycin", "CHEMICAL", 274, 286], ["sodium bicarbonate", "CHEMICAL", 304, 322], ["penicillin", "CHEMICAL", 247, 257], ["streptomycin", "CHEMICAL", 274, 286], ["sodium bicarbonate", "CHEMICAL", 304, 322], ["chimeric VLP", "ORGANISM", 39, 51], ["SCoV", "CANCER", 93, 97], ["Cells", "CELL", 108, 113], ["Vero E6 cells", "CELL", 123, 136], ["293T cells", "CELL", 138, 148], ["CHO cells", "CELL", 153, 162], ["penicillin", "SIMPLE_CHEMICAL", 247, 257], ["streptomycin", "SIMPLE_CHEMICAL", 274, 286], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 304, 322], ["bovine", "ORGANISM", 337, 343], ["serum", "ORGANISM_SUBSTANCE", 344, 349], ["FBS", "ORGANISM_SUBSTANCE", 351, 354], ["virusVero E6 cells", "CELL_LINE", 118, 136], ["293T cells", "CELL_LINE", 138, 148], ["CHO cells", "CELL_LINE", 153, 162], ["bovine", "SPECIES", 337, 343], ["SCoV", "SPECIES", 93, 97], ["Vero E6", "SPECIES", 123, 130], ["bovine", "SPECIES", 337, 343], ["chimeric VLP", "TREATMENT", 39, 51], ["an effective vaccine strategy", "TREATMENT", 55, 84], ["SCoV infection", "PROBLEM", 93, 107], ["Cells", "TEST", 108, 113], ["virusVero E6 cells", "TEST", 118, 136], ["CHO cells", "TEST", 153, 162], ["Dulbecco's modified minimum essential medium (DMEM", "TREATMENT", 177, 227], ["penicillin", "TREATMENT", 247, 257], ["streptomycin", "TREATMENT", 274, 286], ["0.2% sodium bicarbonate", "TREATMENT", 299, 322], ["10% fetal bovine serum (FBS", "TREATMENT", 327, 354], ["infection", "OBSERVATION", 98, 107], ["E6 cells", "OBSERVATION", 128, 136]]], ["The Urbani strain of SCoV was obtained from T.G. Ksiazek at the Centers for Disease Control and Prevention (Atlanta, GA), and a working stock of this virus was prepared by serially passaging a portion of the seed virus twice in Vero E6 cells.", [["cells", "ANATOMY", 236, 241], ["SCoV", "CELL", 21, 25], ["Vero E6 cells", "CELL", 228, 241], ["Vero E6 cells", "CELL_LINE", 228, 241], ["SCoV", "SPECIES", 21, 25], ["Vero E6", "SPECIES", 228, 235], ["The Urbani strain of SCoV", "PROBLEM", 0, 25], ["Disease Control", "TREATMENT", 76, 91], ["this virus", "PROBLEM", 145, 155], ["the seed virus", "PROBLEM", 204, 218], ["Vero E6 cells", "TREATMENT", 228, 241], ["E6 cells", "OBSERVATION", 233, 241]]], ["The culture fluid from infected cells was clarified by low-speed centrifugation and was filtered using a 0.45 m filter, portioned, and frozen at \u221280 \u2022 C. Medium from uninfected Vero E6 cells was similarly treated and processed.Plasmid constructionThe plasmids, pCAGGS-MHV-A59/S, pCAGGS-MHV-A59/E, pCAGGS-MHV-A59/M, and pCAGGS-A59/N, were constructed by inserting the entire region of MHV structural proteins, S, E, M and N, respectively, into a chicken beta-actin promoterbased expression plasmid, pCAGGS-MCS; plasmid pMH54 [40] was obtained from Paul Masters and used as a template for PCR amplification of MHV structural genes.", [["culture fluid", "ANATOMY", 4, 17], ["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 185, 190], ["plasmids", "ANATOMY", 251, 259], ["plasmid", "ANATOMY", 489, 496], ["cells", "CELL", 32, 37], ["Vero E6 cells", "CELL", 177, 190], ["pCAGGS-MHV-A59", "ORGANISM", 261, 275], ["pCAGGS-MHV", "ORGANISM", 279, 289], ["chicken", "ORGANISM", 445, 452], ["beta-actin", "GENE_OR_GENE_PRODUCT", 453, 463], ["pCAGGS-MCS", "GENE_OR_GENE_PRODUCT", 498, 508], ["MHV", "ORGANISM", 608, 611], ["infected cells", "CELL_TYPE", 23, 37], ["uninfected Vero E6 cells", "CELL_LINE", 166, 190], ["plasmids", "DNA", 251, 259], ["pCAGGS", "DNA", 261, 267], ["MHV", "DNA", 268, 271], ["A59", "DNA", 272, 275], ["S", "DNA", 276, 277], ["pCAGGS", "DNA", 279, 285], ["MHV", "DNA", 286, 289], ["A59", "DNA", 290, 293], ["E", "DNA", 294, 295], ["pCAGGS", "DNA", 297, 303], ["MHV", "DNA", 304, 307], ["A59", "DNA", 308, 311], ["pCAGGS", "DNA", 319, 325], ["A59", "DNA", 326, 329], ["N", "DNA", 330, 331], ["MHV structural proteins", "PROTEIN", 384, 407], ["chicken beta-actin promoterbased expression plasmid", "DNA", 445, 496], ["pCAGGS", "DNA", 498, 504], ["MCS", "DNA", 505, 508], ["MHV structural genes", "DNA", 608, 628], ["chicken", "SPECIES", 445, 452], ["Vero E6", "SPECIES", 177, 184], ["MHV", "SPECIES", 384, 387], ["chicken", "SPECIES", 445, 452], ["MHV", "SPECIES", 608, 611], ["The culture fluid", "TEST", 0, 17], ["infected cells", "PROBLEM", 23, 37], ["a 0.45 m filter", "TREATMENT", 103, 118], ["uninfected Vero E6 cells", "PROBLEM", 166, 190], ["Plasmid construction", "TREATMENT", 227, 247], ["The plasmids", "TEST", 247, 259], ["pCAGGS", "TEST", 261, 267], ["MHV", "TEST", 268, 271], ["pCAGGS", "TEST", 279, 285], ["MHV", "TEST", 286, 289], ["pCAGGS", "TEST", 297, 303], ["MHV", "TEST", 304, 307], ["pCAGGS", "TREATMENT", 319, 325], ["a chicken beta-actin promoterbased expression plasmid", "TREATMENT", 443, 496], ["a template", "TREATMENT", 572, 582], ["PCR amplification of MHV structural genes", "PROBLEM", 587, 628], ["fluid", "OBSERVATION", 12, 17], ["infected cells", "OBSERVATION", 23, 37], ["Vero E6 cells", "OBSERVATION", 177, 190], ["MHV", "OBSERVATION", 384, 387]]], ["Construction of plasmids, pCAGGS-S expressing SCoV S protein, pCAGGS-E expressing SCoV E protein, pCAGGS-M expressing SCoV M protein, and pCAGGS-N expressing SCoV N protein, was described previously [36] .Preparation and purification of VLPsFor preparation of MHV VLPs, subconfluent 293T cell cultures in 100-mm tissue culture dishes were cotransfected with 14 g of pCAGGS-MHV-A59/S, 0.4 g of pCAGGS-MHV-A59/E, 3.5 g of pCAGGS-MHV-A59/M, and 14 g of pCAGGS-A59/N using TransIT-293 reagent (Mirus).", [["plasmids", "ANATOMY", 16, 24], ["293T cell cultures", "ANATOMY", 283, 301], ["tissue", "ANATOMY", 312, 318], ["TransIT-293", "CHEMICAL", 469, 480], ["pCAGGS-S", "GENE_OR_GENE_PRODUCT", 26, 34], ["SCoV S protein", "GENE_OR_GENE_PRODUCT", 46, 60], ["pCAGGS-E", "GENE_OR_GENE_PRODUCT", 62, 70], ["SCoV E", "GENE_OR_GENE_PRODUCT", 82, 88], ["pCAGGS-M", "GENE_OR_GENE_PRODUCT", 98, 106], ["SCoV M", "GENE_OR_GENE_PRODUCT", 118, 124], ["pCAGGS-N", "GENE_OR_GENE_PRODUCT", 138, 146], ["SCoV N", "GENE_OR_GENE_PRODUCT", 158, 164], ["MHV VLPs", "ORGANISM", 260, 268], ["293T cell cultures", "CELL", 283, 301], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 366, 372], ["MHV", "ORGANISM", 373, 376], ["pCAGGS-MHV-A59/E", "ORGANISM", 393, 409], ["pCAGGS-MHV", "ORGANISM", 420, 430], ["pCAGGS", "ORGANISM", 450, 456], ["TransIT-293 reagent", "CELL", 469, 488], ["Mirus", "CELL", 490, 495], ["plasmids", "DNA", 16, 24], ["pCAGGS", "DNA", 26, 32], ["S", "DNA", 33, 34], ["SCoV S protein", "PROTEIN", 46, 60], ["pCAGGS", "PROTEIN", 62, 68], ["E", "PROTEIN", 69, 70], ["SCoV E protein", "PROTEIN", 82, 96], ["pCAGGS", "PROTEIN", 98, 104], ["SCoV M protein", "PROTEIN", 118, 132], ["pCAGGS", "PROTEIN", 138, 144], ["N", "PROTEIN", 145, 146], ["SCoV N protein", "PROTEIN", 158, 172], ["subconfluent 293T cell cultures", "CELL_LINE", 270, 301], ["pCAGGS", "PROTEIN", 366, 372], ["pCAGGS", "PROTEIN", 393, 399], ["MHV", "PROTEIN", 400, 403], ["pCAGGS", "PROTEIN", 420, 426], ["MHV", "PROTEIN", 427, 430], ["pCAGGS", "PROTEIN", 450, 456], ["A59", "PROTEIN", 457, 460], ["MHV", "SPECIES", 260, 263], ["TransIT-293", "SPECIES", 469, 480], ["Construction of plasmids", "TREATMENT", 0, 24], ["pCAGGS", "TEST", 26, 32], ["SCoV S protein", "TEST", 46, 60], ["pCAGGS", "TEST", 62, 68], ["SCoV E protein", "TEST", 82, 96], ["pCAGGS", "TEST", 98, 104], ["SCoV M protein", "TEST", 118, 132], ["pCAGGS", "TEST", 138, 144], ["purification of VLPs", "TREATMENT", 221, 241], ["MHV VLPs", "TREATMENT", 260, 268], ["subconfluent 293T cell cultures", "TEST", 270, 301], ["tissue culture dishes", "TEST", 312, 333], ["pCAGGS", "TEST", 366, 372], ["MHV", "TEST", 373, 376], ["pCAGGS", "TEST", 393, 399], ["MHV", "TEST", 400, 403], ["pCAGGS", "TEST", 420, 426], ["MHV", "TEST", 427, 430], ["pCAGGS", "TEST", 450, 456], ["TransIT", "TEST", 469, 476]]], ["At 3 days posttransfection, the culture media were collected, centrifuged at 1550 \u00d7 g for 10 min and filtered through a 0.45-m filter to remove cell debris.", [["cell", "ANATOMY", 144, 148], ["cell", "CELL", 144, 148], ["the culture media", "TEST", 28, 45], ["a 0.45-m filter", "TREATMENT", 118, 133], ["cell debris", "PROBLEM", 144, 155], ["cell debris", "OBSERVATION", 144, 155]]], ["The MHV VLPs were pelleted down through 20% sucrose cushion at 26,000 rpm for 3 h by using a Beckman SW 28 rotor.", [["sucrose", "CHEMICAL", 44, 51], ["sucrose", "CHEMICAL", 44, 51], ["MHV VLPs", "ORGANISM", 4, 12], ["MHV", "SPECIES", 4, 7], ["The MHV VLPs", "TREATMENT", 0, 12], ["20% sucrose cushion", "TREATMENT", 40, 59], ["a Beckman SW 28 rotor", "TREATMENT", 91, 112], ["MHV VLPs", "ANATOMY", 4, 12]]], ["After the pellets were suspended in NTE buffer (100 mM NaCl, 10 mM Tris-HCl, pH 7.0, 1 mM EDTA), the VLPs were centrifuged using a Beckman SW 28 rotor at 26,000 rpm for 3 h on a discontinuous sucrose gradient consisting of 60, 50, 30, and 20% sucrose.", [["NaCl", "CHEMICAL", 55, 59], ["Tris-HCl", "CHEMICAL", 67, 75], ["sucrose", "CHEMICAL", 192, 199], ["sucrose", "CHEMICAL", 243, 250], ["NaCl", "CHEMICAL", 55, 59], ["Tris-HCl", "CHEMICAL", 67, 75], ["EDTA", "CHEMICAL", 90, 94], ["sucrose", "CHEMICAL", 192, 199], ["sucrose", "CHEMICAL", 243, 250], ["Tris-HCl", "SIMPLE_CHEMICAL", 67, 75], ["EDTA", "SIMPLE_CHEMICAL", 90, 94], ["VLPs", "ORGANISM", 101, 105], ["sucrose", "SIMPLE_CHEMICAL", 192, 199], ["sucrose", "SIMPLE_CHEMICAL", 243, 250], ["the pellets", "TREATMENT", 6, 17], ["Tris", "TEST", 67, 71], ["pH", "TEST", 77, 79], ["the VLPs", "TREATMENT", 97, 105], ["a Beckman SW 28 rotor", "TREATMENT", 129, 150], ["a discontinuous sucrose gradient", "TREATMENT", 176, 208]]], ["The VLPs at the interface of 30 and 50% sucrose were collected, diluted and further purified on a discontinuous sucrose gradient consisting of 60, 50, 30, and 20% sucrose at 26,000 rpm for 18 h.", [["sucrose", "CHEMICAL", 40, 47], ["sucrose", "CHEMICAL", 112, 119], ["sucrose", "CHEMICAL", 163, 170], ["sucrose", "CHEMICAL", 40, 47], ["sucrose", "CHEMICAL", 112, 119], ["sucrose", "CHEMICAL", 163, 170], ["VLPs", "ORGANISM", 4, 8], ["sucrose", "SIMPLE_CHEMICAL", 40, 47], ["sucrose", "SIMPLE_CHEMICAL", 112, 119], ["sucrose", "SIMPLE_CHEMICAL", 163, 170], ["The VLPs", "TREATMENT", 0, 8], ["50% sucrose", "TREATMENT", 36, 47], ["a discontinuous sucrose gradient", "TREATMENT", 96, 128]]], ["Purified and concentrated VLPs at the interface between 50 and 30% sucrose were collected, diluted and pelleted through a 20% sucrose cushion at 26,000 rpm for 2 h.", [["sucrose", "CHEMICAL", 67, 74], ["sucrose", "CHEMICAL", 126, 133], ["sucrose", "CHEMICAL", 67, 74], ["sucrose", "CHEMICAL", 126, 133], ["VLPs", "ORGANISM", 26, 30], ["sucrose", "SIMPLE_CHEMICAL", 67, 74], ["concentrated VLPs", "TREATMENT", 13, 30], ["a 20% sucrose cushion", "TREATMENT", 120, 141], ["concentrated", "OBSERVATION_MODIFIER", 13, 25], ["VLPs", "OBSERVATION", 26, 30]]], ["The pellets were suspended in NTE buffer and kept at \u221280 \u2022 C until further use.", [["The pellets", "TREATMENT", 0, 11], ["NTE buffer", "TREATMENT", 30, 40]]], ["For preparation of SCoV VLP, a mixture of 2.8 g of pCAGGS-S, 13.2 g of pCAGGS-E, 1.4 g of pCAGGS-M, and 2.8 g of pCAGGS-N was cotransfected into 293T cells grown on a 100-mm tissue culture plate.", [["293T cells", "ANATOMY", 145, 155], ["tissue", "ANATOMY", 174, 180], ["pCAGGS-S", "CHEMICAL", 51, 59], ["pCAGGS-E", "CHEMICAL", 71, 79], ["pCAGGS-M", "CHEMICAL", 90, 98], ["pCAGGS-N", "CHEMICAL", 113, 121], ["pCAGGS-S", "SIMPLE_CHEMICAL", 51, 59], ["pCAGGS-E", "SIMPLE_CHEMICAL", 71, 79], ["pCAGGS-N", "SIMPLE_CHEMICAL", 113, 121], ["293T cells", "CELL", 145, 155], ["pCAGGS", "PROTEIN", 113, 119], ["293T cells", "CELL_LINE", 145, 155], ["SCoV", "SPECIES", 19, 23], ["preparation of SCoV VLP", "TREATMENT", 4, 27], ["pCAGGS", "TEST", 51, 57], ["pCAGGS", "TEST", 71, 77], ["pCAGGS", "TEST", 90, 96], ["pCAGGS", "TEST", 113, 119], ["tissue culture plate", "TEST", 174, 194]]], ["Chimeric VLPs were generated by transfecting 293T cells or CHO cells in a 100-mm tissue culture plate with 14 g of pCAGGS-S, 0.4 g of pCAGGS-MHV-A59/E, 3.5 g of pCAGGS-MHV-A59/M, and 14 g of pCAGGS-A59/N. SCoV VLPs and chimeric VLPs were purified using the same procedure as described for the MHV VLP purification.Quantitation of VLP amountsThe total protein concentration of VLPs was quantitated by Bio-Rad DC protein assay according to the manufacturer's instructions (BIO-RAD, CA).Western blot analysisWestern blotting was performed as described previously [36] .", [["293T cells", "ANATOMY", 45, 55], ["CHO cells", "ANATOMY", 59, 68], ["tissue", "ANATOMY", 81, 87], ["pCAGGS-S", "CHEMICAL", 115, 123], ["pCAGGS-MHV-A59/E", "CHEMICAL", 134, 150], ["VLPs", "ORGANISM", 9, 13], ["293T cells", "CELL", 45, 55], ["CHO cells", "CELL", 59, 68], ["pCAGGS", "ORGANISM", 134, 140], ["MHV-A59/E", "ORGANISM", 141, 150], ["pCAGGS-MHV", "ORGANISM", 161, 171], ["pCAGGS-A59", "ORGANISM", 191, 201], ["N. SCoV VLPs", "ORGANISM", 202, 214], ["VLPs", "ORGANISM", 228, 232], ["MHV", "ORGANISM", 293, 296], ["VLPs", "ORGANISM", 376, 380], ["293T cells", "CELL_LINE", 45, 55], ["CHO cells", "CELL_LINE", 59, 68], ["pCAGGS", "PROTEIN", 134, 140], ["MHV", "PROTEIN", 141, 144], ["pCAGGS", "PROTEIN", 161, 167], ["MHV", "PROTEIN", 168, 171], ["pCAGGS", "PROTEIN", 191, 197], ["A59", "PROTEIN", 198, 201], ["chimeric VLPs", "PROTEIN", 219, 232], ["SCoV", "SPECIES", 205, 209], ["MHV", "SPECIES", 293, 296], ["Chimeric VLPs", "TEST", 0, 13], ["CHO cells", "TEST", 59, 68], ["culture plate", "TEST", 88, 101], ["pCAGGS", "TEST", 115, 121], ["S", "TEST", 122, 123], ["pCAGGS", "TEST", 134, 140], ["MHV", "TEST", 141, 144], ["pCAGGS", "TEST", 161, 167], ["MHV", "TEST", 168, 171], ["pCAGGS", "TEST", 191, 197], ["A59", "TEST", 198, 201], ["chimeric VLPs", "TREATMENT", 219, 232], ["the same procedure", "TREATMENT", 253, 271], ["the MHV VLP purification", "TREATMENT", 289, 313], ["Quantitation of VLP amounts", "PROBLEM", 314, 341], ["The total protein concentration of VLPs", "TREATMENT", 341, 380], ["blot analysisWestern blotting", "TEST", 492, 521], ["VLP amounts", "OBSERVATION_MODIFIER", 330, 341]]], ["For detection of MHV S, M and N proteins, we used anti-MHV serum, which was produced by immunizing rabbits with a purified JHM strain of MHV, kindly provided by Susan Baker, Loyola University of Chicago.", [["anti-MHV serum", "ANATOMY", 50, 64], ["MHV S", "GENE_OR_GENE_PRODUCT", 17, 22], ["anti-MHV", "ORGANISM", 50, 58], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["rabbits", "ORGANISM", 99, 106], ["MHV", "ORGANISM", 137, 140], ["MHV S, M and N proteins", "PROTEIN", 17, 40], ["rabbits", "SPECIES", 99, 106], ["MHV", "SPECIES", 17, 20], ["anti-MHV", "SPECIES", 50, 58], ["rabbits", "SPECIES", 99, 106], ["MHV", "SPECIES", 137, 140], ["MHV S", "PROBLEM", 17, 22], ["anti-MHV serum", "TEST", 50, 64], ["MHV", "OBSERVATION", 17, 20]]], ["For detection of SCoV S protein, a mixture of purified rabbit polyclonal anti-SCoV S protein antibody (ABGENT, cat. no. AP6000a) and polyclonal rabbit anti-SCoV S protein antibody (IMGENEX, cat. no. IMG 541) was used.", [["SCoV S", "GENE_OR_GENE_PRODUCT", 17, 23], ["rabbit", "ORGANISM", 55, 61], ["anti-SCoV S protein antibody", "GENE_OR_GENE_PRODUCT", 73, 101], ["cat.", "ORGANISM", 111, 115], ["anti-SCoV S protein antibody", "GENE_OR_GENE_PRODUCT", 151, 179], ["cat.", "ORGANISM", 190, 194], ["SCoV S protein", "PROTEIN", 17, 31], ["purified rabbit polyclonal anti-SCoV S protein antibody", "PROTEIN", 46, 101], ["ABGENT", "PROTEIN", 103, 109], ["AP6000a", "PROTEIN", 120, 127], ["polyclonal rabbit anti-SCoV S protein antibody", "PROTEIN", 133, 179], ["IMGENEX", "PROTEIN", 181, 188], ["rabbit", "SPECIES", 55, 61], ["rabbit", "SPECIES", 144, 150], ["SCoV", "SPECIES", 17, 21], ["rabbit", "SPECIES", 55, 61], ["rabbit", "SPECIES", 144, 150], ["SCoV S protein", "TEST", 17, 31], ["purified rabbit polyclonal anti-SCoV S protein antibody", "TEST", 46, 101], ["ABGENT", "TEST", 103, 109], ["cat.", "TEST", 111, 115], ["polyclonal rabbit anti-SCoV S protein antibody", "TEST", 133, 179], ["IMGENEX", "TEST", 181, 188], ["cat.", "TEST", 190, 194]]], ["SCoV N protein was detected by using rabbit polyclonal anti-SCoV N protein antibody (IMGENEX, cat. no. IMG 548), and SCoV M protein was detected by using a mixture of SCoV PUPM antibody-N-terminal (ABGENT, cat. no. AP6008a), SCoV PUPM antibody C-terminal (ABGENT, cat. no. AP6008b) and anti-SCoV M antibodies (ProSci, cat. no. 3527P and cat no. 3529P).Colloidal Coomassie blue stainingAfter washing the gel with water, proteins in the gel were stained by soaking the gel with Bio-Safe Coomassie Stain (BIO-RAD) with gentle agitation for 1 h.", [["Coomassie blue", "CHEMICAL", 362, 376], ["agitation", "DISEASE", 523, 532], ["C", "CHEMICAL", 244, 245], ["Coomassie blue", "CHEMICAL", 362, 376], ["Coomassie", "CHEMICAL", 485, 494], ["SCoV N", "GENE_OR_GENE_PRODUCT", 0, 6], ["rabbit", "ORGANISM", 37, 43], ["SCoV M", "GENE_OR_GENE_PRODUCT", 117, 123], ["anti-SCoV M antibodies", "GENE_OR_GENE_PRODUCT", 286, 308], ["water", "SIMPLE_CHEMICAL", 412, 417], ["SCoV N protein", "PROTEIN", 0, 14], ["rabbit polyclonal anti-SCoV N protein antibody", "PROTEIN", 37, 83], ["IMGENEX", "PROTEIN", 85, 92], ["SCoV M protein", "PROTEIN", 117, 131], ["SCoV PUPM antibody", "PROTEIN", 167, 185], ["N-terminal", "PROTEIN", 186, 196], ["ABGENT", "PROTEIN", 198, 204], ["AP6008a", "PROTEIN", 215, 222], ["SCoV PUPM antibody C-terminal (ABGENT, cat. no. AP6008b", "PROTEIN", 225, 280], ["anti-SCoV M antibodies", "PROTEIN", 286, 308], ["ProSci", "PROTEIN", 310, 316], ["cat", "PROTEIN", 318, 321], ["no. 3527P", "PROTEIN", 323, 332], ["cat no. 3529P", "PROTEIN", 337, 350], ["rabbit", "SPECIES", 37, 43], ["rabbit", "SPECIES", 37, 43], ["SCoV N protein", "TEST", 0, 14], ["rabbit polyclonal anti-SCoV N protein antibody", "TEST", 37, 83], ["IMG", "TEST", 103, 106], ["SCoV M protein", "TEST", 117, 131], ["SCoV PUPM antibody", "TEST", 167, 185], ["cat.", "TEST", 206, 210], ["SCoV PUPM antibody C", "TEST", 225, 245], ["ABGENT", "TEST", 256, 262], ["cat.", "TEST", 264, 268], ["anti-SCoV M antibodies", "TEST", 286, 308], ["Colloidal Coomassie blue staining", "PROBLEM", 352, 385], ["the gel with water", "TREATMENT", 399, 417], ["proteins in the gel", "TREATMENT", 419, 438], ["the gel", "TREATMENT", 463, 470], ["Coomassie Stain", "TEST", 485, 500], ["gentle agitation", "PROBLEM", 516, 532], ["Coomassie blue staining", "OBSERVATION", 362, 385]]], ["The gel was rinsed extensively with water overnight.Electron microscopic analysis of chimeric VLPCarbon-coated, 200-mesh copper grids were floated on drops of chimeric VLP for 10 min.", [["VLPCarbon", "CHEMICAL", 94, 103], ["copper", "CHEMICAL", 121, 127], ["copper", "CHEMICAL", 121, 127], ["VLPCarbon", "SIMPLE_CHEMICAL", 94, 103], ["copper grids", "SIMPLE_CHEMICAL", 121, 133], ["chimeric VLPCarbon", "PROTEIN", 85, 103], ["chimeric VLP", "PROTEIN", 159, 171], ["The gel", "TREATMENT", 0, 7], ["Electron microscopic analysis", "TEST", 52, 81], ["chimeric VLPCarbon-coated", "TREATMENT", 85, 110], ["mesh copper grids", "TREATMENT", 116, 133], ["chimeric VLP", "TREATMENT", 159, 171]]], ["After washing the grids with water three times, negative staining was performed using 2% phosphotungstic acid (pH 7.0) for 1 min.", [["phosphotungstic acid", "CHEMICAL", 89, 109], ["phosphotungstic acid", "CHEMICAL", 89, 109], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 89, 109], ["2% phosphotungstic acid", "TREATMENT", 86, 109], ["pH", "TEST", 111, 113]]], ["After air drying of the grids, the sample was examined under a Philips 201 transmission electron microscope, and pictures were taken at 60 kV.AnimalsSix-to 8-week-old, female Balb/c mice (Charles River laboratory, Wilmington, MA) were housed in cages covered with barrier filters in an approval biosafety level 3 animal facility maintained by the University of Texas Medical Branch at Galveston, Texas.", [["sample", "ANATOMY", 35, 41], ["Balb/c mice", "ORGANISM", 175, 186], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 182, 186], ["barrier filters", "TREATMENT", 264, 279], ["air drying", "OBSERVATION", 6, 16], ["barrier filters", "OBSERVATION", 264, 279]]], ["All of the mouse experiments were performed using experimental protocols approved by the University of Texas Medical Branch Investigational Animal Care and Use Committee; all of the experiments were carried out following National Institutes of Health and United States Department of Agriculture guidelines.Procedures for immunization and SCoV challengeMHV VLPs, chimeric VLPs or influenza virus vaccine were adjusted to twice their desired final concentration (g/0.1 ml) and then mixed with an equal volume of phosphate buffered saline (PBS) or alum adjuvant (Imject alum, Pierce, cat. no. 77161).", [["phosphate", "CHEMICAL", 510, 519], ["alum", "CHEMICAL", 545, 549], ["phosphate", "CHEMICAL", 510, 519], ["alum", "CHEMICAL", 545, 549], ["mouse", "ORGANISM", 11, 16], ["SCoV challengeMHV VLPs", "ORGANISM", 338, 360], ["chimeric VLPs", "ORGANISM", 362, 375], ["influenza virus", "ORGANISM", 379, 394], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 510, 535], ["PBS", "SIMPLE_CHEMICAL", 537, 540], ["alum", "SIMPLE_CHEMICAL", 545, 549], ["chimeric VLPs", "PROTEIN", 362, 375], ["mouse", "SPECIES", 11, 16], ["influenza virus vaccine", "SPECIES", 379, 402], ["mouse", "SPECIES", 11, 16], ["SCoV", "SPECIES", 338, 342], ["influenza virus", "SPECIES", 379, 394], ["the mouse experiments", "TEST", 7, 28], ["experimental protocols", "TREATMENT", 50, 72], ["immunization", "TREATMENT", 321, 333], ["SCoV challengeMHV VLPs", "TREATMENT", 338, 360], ["chimeric VLPs", "TREATMENT", 362, 375], ["influenza virus vaccine", "TREATMENT", 379, 402], ["an equal volume of phosphate buffered saline (PBS", "TREATMENT", 491, 540], ["alum adjuvant", "TREATMENT", 545, 558]]], ["At day 0, they were administered intramuscularly (i.m.) using 1-ml tuberculin syringes (Norm-Ject, Tuttingen, Germany) and 26-g, 3/8-in. beveled needles (Becton Dickinson, cat. no. 305110).", [["1-ml tuberculin syringes", "TREATMENT", 62, 86]]], ["In control groups, mice were inoculated i.m. with Vero E6 cell culture fluid, a mixture of influenza vaccine and alum, or alum alone, or they were left untreated.", [["cell", "ANATOMY", 58, 62], ["alum", "CHEMICAL", 113, 117], ["alum", "CHEMICAL", 122, 126], ["alum", "CHEMICAL", 113, 117], ["alum", "CHEMICAL", 122, 126], ["mice", "ORGANISM", 19, 23], ["E6 cell", "CELL", 55, 62], ["influenza", "ORGANISM", 91, 100], ["alum", "SIMPLE_CHEMICAL", 113, 117], ["alum", "SIMPLE_CHEMICAL", 122, 126], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["Vero E6", "SPECIES", 50, 57], ["Vero E6 cell culture fluid", "TEST", 50, 76], ["influenza vaccine", "TREATMENT", 91, 108], ["alum, or alum alone", "TREATMENT", 113, 132], ["left", "ANATOMY_MODIFIER", 147, 151]]], ["Mice were inoculated on day 0 and, as indicated in the body of the paper a second injection was given on day 28 in most experiments.", [["body", "ANATOMY", 55, 59], ["Mice", "ORGANISM", 0, 4], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["a second injection", "TREATMENT", 73, 91]]], ["SCoV was inoculated directly into the nares of mice (40 l) that were lightly anesthetized with isoflurane (IsoFlo; Abbott Laboratories; North Chicago, IL).", [["nares", "ANATOMY", 38, 43], ["isoflurane", "CHEMICAL", 95, 105], ["Iso", "CHEMICAL", 107, 110], ["isoflurane", "CHEMICAL", 95, 105], ["Iso", "CHEMICAL", 107, 110], ["SCoV", "SIMPLE_CHEMICAL", 0, 4], ["nares", "ORGANISM_SUBDIVISION", 38, 43], ["mice", "ORGANISM", 47, 51], ["isoflurane", "SIMPLE_CHEMICAL", 95, 105], ["mice", "SPECIES", 47, 51], ["SCoV", "SPECIES", 0, 4], ["mice", "SPECIES", 47, 51], ["SCoV", "TREATMENT", 0, 4], ["isoflurane", "TREATMENT", 95, 105], ["nares", "ANATOMY", 38, 43]]], ["Mice that were inoculated with 1 \u00d7 10 6 TCID 50 of SCoV at day 0 to provide post-infection immunity did not undergo a second inoculation.", [["SCoV", "CHEMICAL", 51, 55], ["Mice", "ORGANISM", 0, 4], ["SCoV", "ORGANISM", 51, 55], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["SCoV", "TREATMENT", 51, 55], ["a second inoculation", "TREATMENT", 116, 136]]], ["In most of our experiments, immunized mice were challenged by intranasal (i.n.) inoculation of 1 \u00d7 10 6 TCID 50 of SCoV at day 56 and they were euthanized at day 58, while in some experiments mice were inoculated with SCoV at day 28 and they were euthanized at day 30.", [["mice", "ORGANISM", 38, 42], ["mice", "ORGANISM", 192, 196], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 192, 196], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 192, 196], ["SCoV", "SPECIES", 218, 222], ["immunized mice", "TREATMENT", 28, 42], ["SCoV", "TREATMENT", 218, 222]]], ["Day 2 post inoculation was chosen because of reports that peak titer occurs at that time [23] and this was confirmed in our laboratory.Titration of SCoV-specific neutralizing antibodiesMice were anesthetized with isoflurane and then bled from the retro-orbital sinus plexus.", [["retro-orbital sinus plexus", "ANATOMY", 247, 273], ["SCoV", "CHEMICAL", 148, 152], ["isoflurane", "CHEMICAL", 213, 223], ["isoflurane", "CHEMICAL", 213, 223], ["SCoV", "SIMPLE_CHEMICAL", 148, 152], ["Mice", "ORGANISM", 185, 189], ["isoflurane", "SIMPLE_CHEMICAL", 213, 223], ["retro-orbital sinus plexus", "MULTI-TISSUE_STRUCTURE", 247, 273], ["SCoV", "PROTEIN", 148, 152], ["neutralizing antibodies", "PROTEIN", 162, 185], ["Mice", "SPECIES", 185, 189], ["inoculation", "TREATMENT", 11, 22], ["peak titer", "PROBLEM", 58, 68], ["SCoV", "TREATMENT", 148, 152], ["specific neutralizing antibodiesMice", "TREATMENT", 153, 189], ["isoflurane", "TREATMENT", 213, 223], ["retro-orbital sinus plexus", "ANATOMY", 247, 273]]], ["After heat inactivation at 56 \u2022 C for 30 min, sera were stored at 4 \u2022 C. The assay for virusspecific neutralizing antibodies was performed on serial 2-fold diluted samples of each serum beginning at a dilution of 1:5 using 2% FBS-DMEM as the diluent in 96-well tissue culture plates (Falcon 3072); the final volume of the serially diluted samples in each well was 60 l.", [["sera", "ANATOMY", 46, 50], ["samples", "ANATOMY", 164, 171], ["serum", "ANATOMY", 180, 185], ["samples", "ANATOMY", 339, 346], ["Falcon 3072", "CHEMICAL", 284, 295], ["sera", "ORGANISM_SUBSTANCE", 46, 50], ["serum", "ORGANISM_SUBSTANCE", 180, 185], ["FBS", "ORGANISM_SUBSTANCE", 226, 229], ["virusspecific neutralizing antibodies", "PROTEIN", 87, 124], ["heat inactivation", "PROBLEM", 6, 23], ["sera", "TEST", 46, 50], ["The assay", "TEST", 73, 82], ["virusspecific neutralizing antibodies", "TEST", 87, 124], ["each serum", "TEST", 175, 185], ["2% FBS", "TREATMENT", 223, 229], ["the diluent", "TEST", 238, 249], ["the serially diluted samples", "TREATMENT", 318, 346]]], ["After addition of 120 TCID 50 of SCoV in 60 l into each well, the samples were incubated for 45-60 min at room temperature.", [["samples", "ANATOMY", 66, 73], ["SCoV", "CHEMICAL", 33, 37], ["SCoV", "TREATMENT", 33, 37], ["the samples", "TEST", 62, 73]]], ["Then 100 l of these mixtures, containing 100 TCID 50 of SCoV, were transferred into duplicate wells of confluent Vero E6 cells grown in 96-well microtiter plates.", [["cells", "ANATOMY", 121, 126], ["SCoV", "GENE_OR_GENE_PRODUCT", 56, 60], ["Vero E6 cells", "CELL", 113, 126], ["confluent Vero E6 cells", "CELL_LINE", 103, 126], ["Vero E6", "SPECIES", 113, 120], ["these mixtures", "TREATMENT", 14, 28], ["SCoV", "TREATMENT", 56, 60], ["confluent Vero E6 cells", "TEST", 103, 126], ["confluent", "OBSERVATION_MODIFIER", 103, 112], ["Vero E6 cells", "OBSERVATION", 113, 126]]], ["After 72 h incubation, when the virus control wells exhibited advanced virus-induced CPE, the neutralizing capacity of individual serum samples was assessed by determining the presence or absence of virusinduced CPE.", [["serum samples", "ANATOMY", 130, 143], ["CPE", "CHEMICAL", 85, 88], ["serum samples", "ORGANISM_SUBSTANCE", 130, 143], ["the virus control wells", "TREATMENT", 28, 51], ["advanced virus", "PROBLEM", 62, 76], ["CPE", "PROBLEM", 85, 88], ["the neutralizing capacity", "TEST", 90, 115], ["individual serum samples", "TEST", 119, 143], ["virusinduced CPE", "PROBLEM", 199, 215], ["virusinduced CPE", "OBSERVATION", 199, 215]]], ["SCoV-specific neutralizing antibody titers were expressed as the reciprocal of the last dilution of serum that completely inhibited virus-induced CPE.Collection of lungs, histology, immunohistochemistry, and virus titrationTwo days post SCoV challenge, mice were euthanized and their lungs were removed.", [["serum", "ANATOMY", 100, 105], ["lungs", "ANATOMY", 164, 169], ["lungs", "ANATOMY", 284, 289], ["SCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["lungs", "ORGAN", 164, 169], ["mice", "ORGANISM", 253, 257], ["lungs", "ORGAN", 284, 289], ["SCoV", "PROTEIN", 0, 4], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 253, 257], ["SCoV", "TEST", 0, 4], ["specific neutralizing antibody titers", "TEST", 5, 42], ["virus", "PROBLEM", 132, 137], ["CPE", "PROBLEM", 146, 149], ["Collection of lungs", "TEST", 150, 169], ["histology", "TEST", 171, 180], ["immunohistochemistry", "TEST", 182, 202], ["virus titration", "TREATMENT", 208, 223], ["SCoV challenge", "TREATMENT", 237, 251], ["lungs", "ANATOMY", 164, 169], ["lungs", "ANATOMY", 284, 289]]], ["Lung lobes, including right middle lobe, right lower lobe, accessory lobe and left lobe, were removed and placed in 10% buffered formalin for subsequent histological examination and immunohistochemistry (IHC) as described previously [41] .", [["Lung lobes", "ANATOMY", 0, 10], ["right middle lobe", "ANATOMY", 22, 39], ["right lower lobe", "ANATOMY", 41, 57], ["accessory lobe", "ANATOMY", 59, 73], ["left lobe", "ANATOMY", 78, 87], ["formalin", "CHEMICAL", 129, 137], ["Lung lobes", "MULTI-TISSUE_STRUCTURE", 0, 10], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 28, 39], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 47, 57], ["accessory lobe", "MULTI-TISSUE_STRUCTURE", 59, 73], ["left lobe", "MULTI-TISSUE_STRUCTURE", 78, 87], ["formalin", "SIMPLE_CHEMICAL", 129, 137], ["Lung lobes, including right middle lobe, right lower lobe, accessory lobe and left lobe", "PROBLEM", 0, 87], ["subsequent histological examination", "TEST", 142, 177], ["immunohistochemistry", "TEST", 182, 202], ["lobes", "ANATOMY_MODIFIER", 5, 10], ["right middle lobe", "ANATOMY", 22, 39], ["right lower lobe", "ANATOMY", 41, 57], ["accessory lobe", "ANATOMY", 59, 73], ["left lobe", "ANATOMY", 78, 87]]], ["For virus titration, the remaining lobes of the lungs were weighed and frozen at \u221280 \u2022 C before being homogenized in PBS/10% FBS solution using the TissueLyser (Qiagen; Retsch, Haan, Germany).", [["lobes", "ANATOMY", 35, 40], ["lungs", "ANATOMY", 48, 53], ["FBS", "ANATOMY", 125, 128], ["lobes", "ORGAN", 35, 40], ["lungs", "ORGAN", 48, 53], ["FBS", "ORGANISM_SUBSTANCE", 125, 128], ["virus titration", "TREATMENT", 4, 19], ["PBS/10% FBS solution", "TREATMENT", 117, 137], ["lobes", "ANATOMY_MODIFIER", 35, 40], ["lungs", "ANATOMY", 48, 53]]], ["The homogenates were then centrifuged, and SCoV titers in the clarified fluid were determined in a TCID 50 assay in quadruplicate wells of Vero E6 cells in 96-well plates.", [["homogenates", "ANATOMY", 4, 15], ["fluid", "ANATOMY", 72, 77], ["cells", "ANATOMY", 147, 152], ["SCoV", "SIMPLE_CHEMICAL", 43, 47], ["fluid", "ORGANISM_SUBSTANCE", 72, 77], ["Vero E6 cells", "CELL", 139, 152], ["Vero E6 cells", "CELL_LINE", 139, 152], ["Vero E6", "SPECIES", 139, 146], ["SCoV titers", "TEST", 43, 54], ["a TCID", "TEST", 97, 103], ["Vero E6 cells", "TREATMENT", 139, 152]]], ["Titers of virus in lung homogenates were expressed as TCID 50 /gram of the lungs (log 10 ) and the minimal detectable level of virus was 2.3 log 10 TCID 50 /g.Collection of lungs, histology, immunohistochemistry, and virus titrationFormalin-fixed and paraffin-embedded tissue sections were subjected to the standard hematoxylin and eosin and IHC staining for evaluating histopathology and detecting SCoV antigen, respectively [41] .Statistical analysisBy using a statistical program Instat, (version 3, Graphpad Software, Inc., San Diego, CA), we performed the Kruskal-Wallis non-parametric analysis of variance (ANOVA) test to compare arithmetic mean SCoV lung titers and neutralizing antibody titers; undetectable virus titers were assigned a value of 1.8 (the minimal detection limit being 2.3 log 10 /g lung) and undetectable virus-specific neutralizing titers were assigned a value of 10.Production and characterization of chimeric VLPsWe have previously reported the successful production of SCoV VLPs from 293T cells cotransfected with four pCAGGSbased plasmids, each of which encodes SCoV S, M, N or E proteins [36] without using exogenous viruses for protein expression.", [["lung homogenates", "ANATOMY", 19, 35], ["lungs", "ANATOMY", 75, 80], ["lungs", "ANATOMY", 173, 178], ["tissue sections", "ANATOMY", 269, 284], ["lung", "ANATOMY", 657, 661], ["lung", "ANATOMY", 807, 811], ["293T cells", "ANATOMY", 1013, 1023], ["plasmids", "ANATOMY", 1060, 1068], ["hematoxylin", "CHEMICAL", 316, 327], ["eosin", "CHEMICAL", 332, 337], ["lung", "ORGAN", 19, 23], ["lungs", "ORGAN", 75, 80], ["lungs", "ORGAN", 173, 178], ["tissue sections", "CANCER", 269, 284], ["hematoxylin", "SIMPLE_CHEMICAL", 316, 327], ["eosin", "SIMPLE_CHEMICAL", 332, 337], ["SCoV antigen", "GENE_OR_GENE_PRODUCT", 399, 411], ["lung", "ORGAN", 657, 661], ["lung", "ORGAN", 807, 811], ["VLPsWe", "GENE_OR_GENE_PRODUCT", 937, 943], ["SCoV VLPs", "CELL", 998, 1007], ["293T cells", "CELL", 1013, 1023], ["SCoV S", "GENE_OR_GENE_PRODUCT", 1092, 1098], ["M, N or E proteins", "GENE_OR_GENE_PRODUCT", 1100, 1118], ["SCoV antigen", "PROTEIN", 399, 411], ["chimeric VLPsWe", "PROTEIN", 928, 943], ["SCoV VLPs", "PROTEIN", 998, 1007], ["293T cells", "CELL_LINE", 1013, 1023], ["pCAGGSbased plasmids", "DNA", 1048, 1068], ["SCoV S, M, N or E proteins", "PROTEIN", 1092, 1118], ["SCoV", "SPECIES", 399, 403], ["SCoV", "SPECIES", 998, 1002], ["virus in lung homogenates", "PROBLEM", 10, 35], ["TCID", "TEST", 54, 58], ["the minimal detectable level of virus", "PROBLEM", 95, 132], ["Collection of lungs", "TEST", 159, 178], ["histology", "TEST", 180, 189], ["immunohistochemistry", "TEST", 191, 211], ["virus titrationFormalin", "TREATMENT", 217, 240], ["fixed and paraffin-embedded tissue sections", "TREATMENT", 241, 284], ["IHC staining", "TEST", 342, 354], ["histopathology", "TEST", 370, 384], ["SCoV antigen", "PROBLEM", 399, 411], ["ANOVA) test", "TEST", 613, 624], ["arithmetic mean SCoV lung titers", "TEST", 636, 668], ["neutralizing antibody titers", "TEST", 673, 701], ["undetectable virus titers", "PROBLEM", 703, 728], ["a value", "TEST", 743, 750], ["undetectable virus", "PROBLEM", 817, 835], ["specific neutralizing titers", "TEST", 836, 864], ["SCoV VLPs", "TREATMENT", 998, 1007], ["293T cells cotransfected", "TREATMENT", 1013, 1037], ["four pCAGGSbased plasmids", "TREATMENT", 1043, 1068], ["exogenous viruses", "PROBLEM", 1138, 1155], ["protein expression", "PROBLEM", 1160, 1178], ["virus", "OBSERVATION", 10, 15], ["lung", "ANATOMY", 19, 23], ["lungs", "ANATOMY", 75, 80], ["lungs", "ANATOMY", 173, 178], ["lung", "ANATOMY", 657, 661], ["lung", "ANATOMY", 807, 811]]], ["In the study reported here we varied the amount of each plasmid for cotransfection and were able to generate approximately 1.3 g of SCoV VLPs from 2 \u00d7 10 7 293T cells.", [["plasmid", "ANATOMY", 56, 63], ["293T cells", "ANATOMY", 156, 166], ["293T cells", "CELL", 156, 166], ["plasmid", "DNA", 56, 63], ["293T cells", "CELL_LINE", 156, 166], ["SCoV", "SPECIES", 132, 136], ["the study", "TEST", 3, 12], ["cotransfection", "TREATMENT", 68, 82], ["SCoV VLPs", "TREATMENT", 132, 141]]], ["Colloidal Coomassie blue staining and Western blot analysis identified SCoV S, N and M proteins in the purified SCoV VLPs (Fig. 1A) .", [["Coomassie blue", "CHEMICAL", 10, 24], ["SCoV S", "GENE_OR_GENE_PRODUCT", 71, 77], ["SCoV VLPs", "ORGANISM", 112, 121], ["SCoV S, N and M proteins", "PROTEIN", 71, 95], ["SCoV VLPs", "PROTEIN", 112, 121], ["Colloidal Coomassie blue staining", "TEST", 0, 33], ["Western blot analysis", "TEST", 38, 59], ["SCoV S", "TEST", 71, 77]]], ["Likewise, transfection of four pCAGGSbased plasmids, each of which encoded MHV S, E, M or N proteins, resulted in production of MHV VLPs (Fig. 1A) .", [["plasmids", "ANATOMY", 43, 51], ["pCAGGSbased", "GENE_OR_GENE_PRODUCT", 31, 42], ["MHV S", "GENE_OR_GENE_PRODUCT", 75, 80], ["E", "GENE_OR_GENE_PRODUCT", 82, 83], ["MHV VLPs", "ORGANISM", 128, 136], ["pCAGGSbased plasmids", "DNA", 31, 51], ["MHV S, E, M or N proteins", "PROTEIN", 75, 100], ["MHV VLPs", "PROTEIN", 128, 136], ["MHV", "SPECIES", 75, 78], ["MHV", "SPECIES", 128, 131], ["four pCAGGSbased plasmids", "TREATMENT", 26, 51], ["MHV VLPs", "TREATMENT", 128, 136]]], ["After optimization, we obtained approximately 22.3 g of purified MHV VLPs from 2 \u00d7 10 7 293T cells, demonstrating that the efficiency of MHV VLP production was substantially better than that of SCoV VLP production.", [["293T cells", "ANATOMY", 88, 98], ["MHV", "ORGANISM", 65, 68], ["293T cells", "CELL", 88, 98], ["MHV VLP", "ORGANISM", 137, 144], ["SCoV VLP", "ORGANISM", 194, 202], ["293T cells", "CELL_LINE", 88, 98], ["MHV", "SPECIES", 65, 68], ["MHV", "SPECIES", 137, 140], ["SCoV", "SPECIES", 194, 198], ["purified MHV VLPs", "TREATMENT", 56, 73], ["MHV VLP production", "TREATMENT", 137, 155], ["SCoV VLP production", "PROBLEM", 194, 213], ["MHV", "OBSERVATION_MODIFIER", 137, 140], ["VLP", "OBSERVATION", 141, 144]]], ["Because M and E proteins drive VLP assembly and release [24] , and coronavirus S protein is incorporated into VLPs through M-S interaction [25, 27, 28, 42] , these data indicated that MHV M and E proteins resulted in more efficient VLP production than did SCoV M and E proteins.Production and characterization of chimeric VLPsWe next tested whether coexpression of SCoV S protein and MHV E, N and M protein could result in the efficient production of chimeric VLPs which would contain high concentrations of the SCoV S protein.", [["E", "GENE_OR_GENE_PRODUCT", 14, 15], ["VLP", "GENE_OR_GENE_PRODUCT", 31, 34], ["coronavirus S protein", "GENE_OR_GENE_PRODUCT", 67, 88], ["VLPs", "GENE_OR_GENE_PRODUCT", 110, 114], ["MHV M", "GENE_OR_GENE_PRODUCT", 184, 189], ["E", "GENE_OR_GENE_PRODUCT", 194, 195], ["SCoV M", "GENE_OR_GENE_PRODUCT", 256, 262], ["E proteins", "GENE_OR_GENE_PRODUCT", 267, 277], ["VLPsWe", "GENE_OR_GENE_PRODUCT", 322, 328], ["SCoV S", "GENE_OR_GENE_PRODUCT", 365, 371], ["MHV E", "GENE_OR_GENE_PRODUCT", 384, 389], ["M protein", "GENE_OR_GENE_PRODUCT", 397, 406], ["VLPs", "ORGANISM", 460, 464], ["SCoV S protein", "GENE_OR_GENE_PRODUCT", 512, 526], ["M and E proteins", "PROTEIN", 8, 24], ["coronavirus S protein", "PROTEIN", 67, 88], ["MHV M and E proteins", "PROTEIN", 184, 204], ["SCoV M and E proteins", "PROTEIN", 256, 277], ["chimeric VLPsWe", "PROTEIN", 313, 328], ["SCoV S protein", "PROTEIN", 365, 379], ["MHV E, N and M protein", "PROTEIN", 384, 406], ["chimeric VLPs", "PROTEIN", 451, 464], ["SCoV S protein", "PROTEIN", 512, 526], ["MHV", "SPECIES", 184, 187], ["MHV", "SPECIES", 384, 387], ["M and E proteins drive VLP", "TREATMENT", 8, 34], ["coronavirus S protein", "TEST", 67, 88], ["these data", "TEST", 158, 168], ["MHV M and E proteins", "TEST", 184, 204], ["chimeric VLPsWe", "TEST", 313, 328], ["SCoV S protein", "TEST", 365, 379], ["MHV E, N and M protein", "TEST", 384, 406], ["chimeric VLPs", "PROBLEM", 451, 464], ["the SCoV S protein", "TREATMENT", 508, 526], ["MHV", "OBSERVATION", 184, 187], ["high concentrations", "OBSERVATION_MODIFIER", 485, 504]]], ["If SCoV S protein interacts with MHV M protein, then the robust VLP production machinery driven by MHV M and E proteins, could result in efficient chimeric VLP production.", [["SCoV S", "GENE_OR_GENE_PRODUCT", 3, 9], ["MHV M", "GENE_OR_GENE_PRODUCT", 33, 38], ["MHV M", "GENE_OR_GENE_PRODUCT", 99, 104], ["E", "GENE_OR_GENE_PRODUCT", 109, 110], ["VLP", "GENE_OR_GENE_PRODUCT", 156, 159], ["SCoV S protein", "PROTEIN", 3, 17], ["MHV M protein", "PROTEIN", 33, 46], ["MHV M and E proteins", "PROTEIN", 99, 119], ["MHV", "SPECIES", 33, 36], ["MHV", "SPECIES", 99, 102], ["SCoV S protein interacts", "PROBLEM", 3, 27], ["MHV M protein", "TREATMENT", 33, 46], ["the robust VLP production machinery", "TREATMENT", 53, 88], ["efficient chimeric VLP production", "PROBLEM", 137, 170], ["VLP", "OBSERVATION", 156, 159]]], ["Chimeric VLP production, indeed, occurred from 293T cells that were cotransfected with plasmids, each of which expressed SCoV S protein, MHV N protein, MHV M protein or MHV E protein (Fig. 1A) .", [["293T cells", "ANATOMY", 47, 57], ["plasmids", "ANATOMY", 87, 95], ["VLP", "GENE_OR_GENE_PRODUCT", 9, 12], ["293T cells", "CELL", 47, 57], ["SCoV S protein", "GENE_OR_GENE_PRODUCT", 121, 135], ["MHV N protein", "GENE_OR_GENE_PRODUCT", 137, 150], ["MHV M protein", "GENE_OR_GENE_PRODUCT", 152, 165], ["MHV E", "GENE_OR_GENE_PRODUCT", 169, 174], ["293T cells", "CELL_LINE", 47, 57], ["plasmids", "DNA", 87, 95], ["SCoV S protein", "PROTEIN", 121, 135], ["MHV N protein", "PROTEIN", 137, 150], ["MHV M protein", "PROTEIN", 152, 165], ["MHV E protein", "PROTEIN", 169, 182], ["1A", "PROTEIN", 189, 191], ["MHV", "SPECIES", 137, 140], ["MHV", "SPECIES", 152, 155], ["MHV", "SPECIES", 169, 172], ["Chimeric VLP production", "PROBLEM", 0, 23], ["plasmids", "TREATMENT", 87, 95], ["MHV M protein", "TEST", 152, 165], ["MHV E protein", "TEST", 169, 182], ["VLP production", "OBSERVATION", 9, 23]]], ["Colloidal Coomassie blue staining and Western blot analysis of purified chimeric VLP showed the presence of SCoV S, MHV N and MHV M proteins in chimeric VLPs, with only a low level of host protein contamination.", [["Coomassie blue", "CHEMICAL", 10, 24], ["SCoV S", "GENE_OR_GENE_PRODUCT", 108, 114], ["MHV N", "ORGANISM", 116, 121], ["MHV M proteins", "GENE_OR_GENE_PRODUCT", 126, 140], ["chimeric VLPs", "ORGANISM", 144, 157], ["chimeric VLP", "PROTEIN", 72, 84], ["SCoV S", "PROTEIN", 108, 114], ["MHV N and MHV M proteins", "PROTEIN", 116, 140], ["chimeric VLPs", "PROTEIN", 144, 157], ["MHV", "SPECIES", 116, 119], ["MHV", "SPECIES", 126, 129], ["Colloidal Coomassie blue staining", "TEST", 0, 33], ["Western blot analysis", "TEST", 38, 59], ["purified chimeric VLP", "TEST", 63, 84], ["SCoV S", "PROBLEM", 108, 114], ["MHV N", "PROBLEM", 116, 121], ["MHV M proteins in chimeric VLPs", "PROBLEM", 126, 157], ["host protein contamination", "PROBLEM", 184, 210], ["blue staining", "OBSERVATION", 20, 33], ["MHV", "OBSERVATION_MODIFIER", 126, 129], ["chimeric VLPs", "ANATOMY", 144, 157], ["low level", "OBSERVATION_MODIFIER", 171, 180], ["host protein contamination", "OBSERVATION", 184, 210]]], ["Negative staining of chimeric VLP revealed a typical spherical coronavirus structure with peplomers (Fig. 1B) .", [["chimeric VLP", "PROTEIN", 21, 33], ["chimeric VLP", "TEST", 21, 33], ["a typical spherical coronavirus structure", "PROBLEM", 43, 84], ["chimeric VLP", "OBSERVATION", 21, 33], ["typical", "OBSERVATION_MODIFIER", 45, 52], ["spherical coronavirus structure", "OBSERVATION", 53, 84]]], ["After optimization, approximately 8.7 g of purified chimeric VLPs was produced from 2 \u00d7 10 7 293T cells; the efficiency of chimeric VLP production was about 8 times better than that of SCoV VLPs.Production and characterization of chimeric VLPsWe next tested efficiencies of chimeric VLP production from Vero and CHO cells, both of which have been used for the preparation of human vaccines [43] [44] [45] [46] [47] .", [["293T cells", "ANATOMY", 93, 103], ["Vero", "ANATOMY", 303, 307], ["CHO cells", "ANATOMY", 312, 321], ["VLPs", "ORGANISM", 61, 65], ["293T cells", "CELL", 93, 103], ["VLP", "ORGANISM", 132, 135], ["SCoV VLPs", "ORGANISM", 185, 194], ["VLPsWe", "GENE_OR_GENE_PRODUCT", 239, 245], ["VLP", "ORGANISM", 283, 286], ["Vero", "CELL", 303, 307], ["CHO cells", "CELL", 312, 321], ["human", "ORGANISM", 375, 380], ["[43] [44] [45] [46", "SIMPLE_CHEMICAL", 390, 408], ["293T cells", "CELL_LINE", 93, 103], ["chimeric VLPsWe", "PROTEIN", 230, 245], ["Vero and CHO cells", "CELL_LINE", 303, 321], ["human", "SPECIES", 375, 380], ["SCoV", "SPECIES", 185, 189], ["human", "SPECIES", 375, 380], ["purified chimeric VLPs", "TREATMENT", 43, 65], ["chimeric VLP production", "PROBLEM", 123, 146], ["SCoV VLPs", "TREATMENT", 185, 194], ["chimeric VLPsWe", "PROBLEM", 230, 245], ["chimeric VLP production", "PROBLEM", 274, 297], ["Vero and CHO cells", "TREATMENT", 303, 321], ["human vaccines", "TREATMENT", 375, 389], ["VLP", "OBSERVATION", 132, 135]]], ["By using various DNA transfection reagents and combinations of different concentrations of each plasmid for transfection, the efficiencies of chimeric VLP production from Vero cells were about 10 times lower than those from 293T cells (data not shown).", [["plasmid", "ANATOMY", 96, 103], ["Vero cells", "ANATOMY", 171, 181], ["293T cells", "ANATOMY", 224, 234], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["VLP", "ORGANISM", 151, 154], ["Vero cells", "CELL", 171, 181], ["293T cells", "CELL", 224, 234], ["Vero cells", "CELL_LINE", 171, 181], ["293T cells", "CELL_LINE", 224, 234], ["various DNA transfection reagents", "TREATMENT", 9, 42], ["different concentrations of each plasmid", "TREATMENT", 63, 103], ["transfection", "TREATMENT", 108, 120], ["chimeric VLP production", "PROBLEM", 142, 165], ["Vero cells", "PROBLEM", 171, 181], ["Vero cells", "OBSERVATION", 171, 181]]], ["We found that when we used TransIT-293, the production of chimeric VLPs from CHO cells was about one-third of those from 293T cells in repeated experiments (data not shown).", [["TransIT-293", "ANATOMY", 27, 38], ["CHO cells", "ANATOMY", 77, 86], ["293T cells", "ANATOMY", 121, 131], ["TransIT-293", "CHEMICAL", 27, 38], ["TransIT-293", "CELL", 27, 38], ["VLPs", "CELL", 67, 71], ["CHO cells", "CELL", 77, 86], ["293T cells", "CELL", 121, 131], ["TransIT-293", "CELL_LINE", 27, 38], ["chimeric VLPs", "PROTEIN", 58, 71], ["CHO cells", "CELL_LINE", 77, 86], ["293T cells", "CELL_LINE", 121, 131], ["TransIT", "TEST", 27, 34], ["chimeric VLPs", "PROBLEM", 58, 71], ["CHO cells", "PROBLEM", 77, 86]]], ["Prolonged incubation of transfected 293T cells and CHO cells for more than 4 days posttransfection did not improve the accumulation of chimeric VLPs in the supernatant (data not shown).Serum neutralizing antibody titers and lung SCoV titers in the mice immunized once with chimeric VLPsFor assessing the usefulness of chimeric VLPs as a SCoV vaccine candidate, we first tested the effects of immunization of mice with chimeric VLPs on serum neutralizing antibody production and inhibition of SCoV replication in the lung.", [["293T cells", "ANATOMY", 36, 46], ["CHO cells", "ANATOMY", 51, 60], ["supernatant", "ANATOMY", 156, 167], ["Serum", "ANATOMY", 185, 190], ["lung", "ANATOMY", 224, 228], ["serum", "ANATOMY", 435, 440], ["lung", "ANATOMY", 516, 520], ["293T cells", "CELL", 36, 46], ["CHO cells", "CELL", 51, 60], ["Serum", "ORGANISM_SUBSTANCE", 185, 190], ["lung", "ORGAN", 224, 228], ["mice", "ORGANISM", 248, 252], ["VLPs", "ORGANISM", 327, 331], ["mice", "ORGANISM", 408, 412], ["VLPs", "ORGANISM", 427, 431], ["serum", "ORGANISM_SUBSTANCE", 435, 440], ["SCoV", "GENE_OR_GENE_PRODUCT", 492, 496], ["lung", "ORGAN", 516, 520], ["transfected 293T cells", "CELL_LINE", 24, 46], ["CHO cells", "CELL_LINE", 51, 60], ["chimeric VLPs", "PROTEIN", 135, 148], ["chimeric VLPs", "PROTEIN", 273, 286], ["chimeric VLPs", "PROTEIN", 318, 331], ["chimeric VLPs", "PROTEIN", 418, 431], ["serum neutralizing antibody", "PROTEIN", 435, 462], ["mice", "SPECIES", 248, 252], ["mice", "SPECIES", 408, 412], ["SCoV", "SPECIES", 229, 233], ["mice", "SPECIES", 248, 252], ["SCoV", "SPECIES", 337, 341], ["mice", "SPECIES", 408, 412], ["SCoV", "SPECIES", 492, 496], ["Prolonged incubation", "TREATMENT", 0, 20], ["CHO cells", "TREATMENT", 51, 60], ["chimeric VLPs", "TREATMENT", 135, 148], ["Serum neutralizing antibody titers", "TEST", 185, 219], ["lung SCoV titers", "TEST", 224, 240], ["chimeric VLPs", "TREATMENT", 273, 286], ["chimeric VLPs", "TREATMENT", 318, 331], ["a SCoV vaccine", "TREATMENT", 335, 349], ["immunization of mice", "TREATMENT", 392, 412], ["chimeric VLPs", "TREATMENT", 418, 431], ["serum neutralizing antibody production", "TREATMENT", 435, 473], ["SCoV replication in the lung", "PROBLEM", 492, 520], ["transfected 293T cells", "OBSERVATION", 24, 46], ["lung", "ANATOMY", 224, 228], ["lung", "ANATOMY", 516, 520]]], ["Sixto 8-week-old female Balb/c mice were inoculated i.m. once with a mixture of 2 g of chimeric VLPs prepared from 293T with placebo (medium from Vero E6 cells), a mixture of 2 g chimeric VLP and PBS or a mixture of 2 g chimeric VLP and alum or i.n. with 1 \u00d7 10 6 TCID 50 of infectious SCoV.", [["293T", "ANATOMY", 115, 119], ["cells", "ANATOMY", 154, 159], ["alum", "CHEMICAL", 237, 241], ["Balb/c mice", "ORGANISM", 24, 35], ["VLPs", "ORGANISM", 96, 100], ["Vero E6 cells", "CELL", 146, 159], ["VLP", "ORGANISM", 188, 191], ["PBS", "SIMPLE_CHEMICAL", 196, 199], ["VLP", "ORGANISM", 229, 232], ["alum", "SIMPLE_CHEMICAL", 237, 241], ["SCoV", "CANCER", 286, 290], ["Vero E6 cells", "CELL_LINE", 146, 159], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["SCoV", "SPECIES", 286, 290], ["Balb/c mice", "TREATMENT", 24, 35], ["chimeric VLPs", "TREATMENT", 87, 100], ["placebo (medium from Vero E6 cells", "TREATMENT", 125, 159], ["2 g chimeric VLP", "TREATMENT", 175, 191], ["PBS", "TREATMENT", 196, 199], ["a mixture", "TREATMENT", 203, 212], ["2 g chimeric VLP", "TREATMENT", 216, 232], ["infectious", "OBSERVATION", 275, 285]]], ["After 28 days, these mice were challenged with 1 \u00d7 10 6 TCID 50 of SCoV.", [["mice", "ORGANISM", 21, 25], ["SCoV", "CANCER", 67, 71], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25]]], ["Two days later, mice were sacrificed and the virus titers in the lungs were determined as shown in the graph.", [["lungs", "ANATOMY", 65, 70], ["mice", "ORGANISM", 16, 20], ["lungs", "ORGAN", 65, 70], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["the virus titers", "TEST", 41, 57], ["lungs", "ANATOMY", 65, 70]]], ["The lengths of the bars indicate mean pulmonary virus titers in each indicated group (log 10 /lung).", [["pulmonary", "ANATOMY", 38, 47], ["lung", "ANATOMY", 94, 98], ["pulmonary", "ORGAN", 38, 47], ["virus", "ORGANISM", 48, 53], ["lung", "ORGAN", 94, 98], ["mean pulmonary virus titers", "PROBLEM", 33, 60], ["pulmonary", "ANATOMY", 38, 47], ["virus titers", "OBSERVATION", 48, 60], ["lung", "ANATOMY", 94, 98]]], ["The vertical dashed line denotes the minimal virus detection level in this assay (i.e., 2.3 log 10 /lung).", [["lung", "ANATOMY", 100, 104], ["lung", "ORGAN", 100, 104], ["vertical dashed line", "CELL_LINE", 4, 24], ["The vertical dashed line", "TREATMENT", 0, 24], ["the minimal virus detection level", "PROBLEM", 33, 66], ["this assay", "TEST", 70, 80], ["vertical", "OBSERVATION_MODIFIER", 4, 12], ["dashed line", "OBSERVATION", 13, 24], ["minimal", "OBSERVATION_MODIFIER", 37, 44], ["virus", "OBSERVATION", 45, 50], ["lung", "ANATOMY", 100, 104]]], ["Number of animals/group = 5. cells and PBS or 2 g of chimeric VLP mixed with alum.", [["cells", "ANATOMY", 29, 34], ["alum", "CHEMICAL", 77, 81], ["alum", "CHEMICAL", 77, 81], ["cells", "CELL", 29, 34], ["VLP", "ORGANISM", 62, 65], ["alum", "SIMPLE_CHEMICAL", 77, 81], ["cells", "CELL_TYPE", 29, 34], ["chimeric VLP", "PROTEIN", 53, 65], ["cells", "TEST", 29, 34], ["PBS", "TREATMENT", 39, 42], ["chimeric VLP", "TREATMENT", 53, 65], ["alum", "OBSERVATION", 77, 81]]], ["As a placebo, mice were inoculated i.m. with Vero E6 cell culture fluid, while another group of mice were inoculated i.n. with 1 \u00d7 10 6 TCID 50 of SCoV to produce solid post-infection immunity.", [["cell culture fluid", "ANATOMY", 53, 71], ["mice", "ORGANISM", 14, 18], ["E6 cell", "CELL", 50, 57], ["mice", "ORGANISM", 96, 100], ["SCoV", "SIMPLE_CHEMICAL", 147, 151], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 14, 18], ["Vero E6", "SPECIES", 45, 52], ["mice", "SPECIES", 96, 100], ["SCoV", "SPECIES", 147, 151], ["a placebo", "TREATMENT", 3, 12], ["Vero E6 cell culture fluid", "TEST", 45, 71], ["SCoV", "PROBLEM", 147, 151], ["solid post-infection immunity", "PROBLEM", 163, 192], ["solid post-infection immunity", "OBSERVATION", 163, 192]]], ["Twenty-eight days later, the mice were bled for determining the serum neutralizing antibody titers ( Fig. 2A) .", [["serum", "ANATOMY", 64, 69], ["mice", "ORGANISM", 29, 33], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["the serum neutralizing antibody titers", "TEST", 60, 98]]], ["Subsequently, the mice were challenged i.n. with 1 \u00d7 10 6 TCID 50 of SCoV and the lung virus titers at 2 days post SCoV challenge were determined (Fig. 2B) .", [["lung", "ANATOMY", 82, 86], ["SCoV", "CHEMICAL", 115, 119], ["mice", "ORGANISM", 18, 22], ["SCoV", "CANCER", 69, 73], ["lung", "ORGAN", 82, 86], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["SCoV", "SPECIES", 69, 73], ["SCoV", "SPECIES", 115, 119], ["SCoV", "TREATMENT", 69, 73], ["the lung virus titers", "TREATMENT", 78, 99], ["SCoV challenge", "TREATMENT", 115, 129], ["lung", "ANATOMY", 82, 86], ["virus", "OBSERVATION", 87, 92]]], ["No SCoV-specific neutralizing antibodies were detectable in the sera of the mice inoculated i.m. with placebo.", [["sera", "ANATOMY", 64, 68], ["SCoV", "GENE_OR_GENE_PRODUCT", 3, 7], ["sera", "ORGANISM_SUBSTANCE", 64, 68], ["mice", "ORGANISM", 76, 80], ["SCoV", "PROTEIN", 3, 7], ["neutralizing antibodies", "PROTEIN", 17, 40], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["SCoV", "PROBLEM", 3, 7], ["specific neutralizing antibodies", "TEST", 8, 40], ["placebo", "TREATMENT", 102, 109], ["neutralizing antibodies", "OBSERVATION", 17, 40]]], ["Minimal or no virus-specific neutralizing antibodies were evident in mice inoculated with chimeric VLPs mixed with PBS (mean titer 10 \u00b1 0).", [["mice", "ORGANISM", 69, 73], ["VLPs", "ORGANISM", 99, 103], ["neutralizing antibodies", "PROTEIN", 29, 52], ["chimeric VLPs", "PROTEIN", 90, 103], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["virus", "PROBLEM", 14, 19], ["specific neutralizing antibodies", "TEST", 20, 52], ["chimeric VLPs", "TREATMENT", 90, 103], ["PBS", "TEST", 115, 118], ["mean titer", "TEST", 120, 130], ["no", "UNCERTAINTY", 11, 13], ["virus", "OBSERVATION", 14, 19], ["neutralizing antibodies", "OBSERVATION", 29, 52]]], ["The mean serum neutralizing titers for the groups of mice inoculated with live virus (70 \u00b1 20) or chimeric VLP administered with alum (60 \u00b1 23) were not statistically different from each other, but were statistically significantly higher (p < 0.05) than those of the mice immunized with a mixture of chimeric VLPs and PBS and the placebo group.", [["serum", "ANATOMY", 9, 14], ["alum", "CHEMICAL", 129, 133], ["alum", "CHEMICAL", 129, 133], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["mice", "ORGANISM", 53, 57], ["live virus", "ORGANISM", 74, 84], ["chimeric VLP", "ORGANISM", 98, 110], ["mice", "ORGANISM", 267, 271], ["VLPs", "ORGANISM", 309, 313], ["chimeric VLP", "PROTEIN", 98, 110], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 267, 271], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 267, 271], ["The mean serum neutralizing titers", "TEST", 0, 34], ["live virus", "PROBLEM", 74, 84], ["chimeric VLP", "TREATMENT", 98, 110], ["alum", "TREATMENT", 129, 133], ["chimeric VLPs", "TREATMENT", 300, 313], ["PBS", "TREATMENT", 318, 321], ["the placebo group", "TREATMENT", 326, 343]]], ["After challenge, the mice immunized with Vero E6 cell culture fluid (placebo) or with a mixture of 2 g chimeric VLP and PBS had high mean virus titers of 6.5 log 10 /lung and 5.2 log 10 /lung, respectively.", [["cell", "ANATOMY", 49, 53], ["lung", "ANATOMY", 166, 170], ["lung", "ANATOMY", 187, 191], ["mice", "ORGANISM", 21, 25], ["VLP", "ORGANISM", 112, 115], ["lung", "ORGAN", 166, 170], ["lung", "ORGAN", 187, 191], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["Vero E6", "SPECIES", 41, 48], ["the mice immunized", "TREATMENT", 17, 35], ["Vero E6 cell culture fluid (placebo", "TREATMENT", 41, 76], ["a mixture", "TREATMENT", 86, 95], ["2 g chimeric VLP", "TREATMENT", 99, 115], ["PBS", "TEST", 120, 123], ["high mean virus titers", "PROBLEM", 128, 150], ["lung", "TEST", 166, 170], ["lung", "ANATOMY", 166, 170], ["lung", "ANATOMY", 187, 191]]], ["In contrast, no virus was detectable in the lungs of the mice previously administered either live SCoV or 2 g of chimeric VLP mixed with alum.", [["lungs", "ANATOMY", 44, 49], ["SCoV", "CHEMICAL", 98, 102], ["alum", "CHEMICAL", 137, 141], ["alum", "CHEMICAL", 137, 141], ["lungs", "ORGAN", 44, 49], ["mice", "ORGANISM", 57, 61], ["VLP", "ORGANISM", 122, 125], ["alum", "SIMPLE_CHEMICAL", 137, 141], ["chimeric VLP", "PROTEIN", 113, 125], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["virus", "PROBLEM", 16, 21], ["live SCoV", "TREATMENT", 93, 102], ["chimeric VLP mixed with alum", "TREATMENT", 113, 141], ["no", "UNCERTAINTY", 13, 15], ["virus", "OBSERVATION", 16, 21], ["lungs", "ANATOMY", 44, 49]]], ["The SCoV titers in the lungs of these mice two days post virus challenge were inversely proportional to their serum virus-neutralizing antibody titers.Effects of chimeric VLP amounts on neutralizing antibody titers and inhibition of challenged SCoV replication in the lungsTo study the immunogenicity of chimeric VLPs, three groups of mice were inoculated i.m. with 0.5, 1, or 2 g mixed with alum.", [["lungs", "ANATOMY", 23, 28], ["serum", "ANATOMY", 110, 115], ["lungs", "ANATOMY", 268, 273], ["alum", "CHEMICAL", 392, 396], ["SCoV", "GENE_OR_GENE_PRODUCT", 4, 8], ["lungs", "ORGAN", 23, 28], ["mice", "ORGANISM", 38, 42], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["SCoV", "GENE_OR_GENE_PRODUCT", 244, 248], ["lungs", "ORGAN", 268, 273], ["mice", "ORGANISM", 335, 339], ["alum", "SIMPLE_CHEMICAL", 392, 396], ["chimeric VLPs", "PROTEIN", 304, 317], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 335, 339], ["mice", "SPECIES", 38, 42], ["SCoV", "SPECIES", 244, 248], ["mice", "SPECIES", 335, 339], ["The SCoV titers", "TEST", 0, 15], ["virus challenge", "TEST", 57, 72], ["their serum virus", "TEST", 104, 121], ["neutralizing antibody titers", "TEST", 122, 150], ["chimeric VLP amounts", "PROBLEM", 162, 182], ["neutralizing antibody titers", "TEST", 186, 214], ["challenged SCoV replication", "TREATMENT", 233, 260], ["chimeric VLPs", "TREATMENT", 304, 317], ["lungs", "ANATOMY", 23, 28], ["chimeric VLP", "OBSERVATION_MODIFIER", 162, 174], ["lungs", "ANATOMY", 268, 273]]], ["Other groups of mice received a mixture of 2 g of chimeric VLPs and PBS, 2 g of MHV VLPs and alum, 1 g of Influenza A virus vaccine and alum, Vero E6 cell culture fluid, live SCoV, or alum alone, or the mice received no treatment.", [["cell", "ANATOMY", 150, 154], ["SCoV", "ANATOMY", 175, 179], ["alum", "CHEMICAL", 93, 97], ["alum", "CHEMICAL", 184, 188], ["alum", "CHEMICAL", 93, 97], ["mice", "ORGANISM", 16, 20], ["VLPs", "ORGANISM", 59, 63], ["MHV", "ORGANISM", 80, 83], ["VLPs", "ORGANISM", 84, 88], ["alum", "SIMPLE_CHEMICAL", 93, 97], ["Influenza A virus", "ORGANISM", 106, 123], ["alum", "SIMPLE_CHEMICAL", 136, 140], ["Vero E6 cell", "CELL", 142, 154], ["alum", "SIMPLE_CHEMICAL", 184, 188], ["mice", "ORGANISM", 203, 207], ["mice", "SPECIES", 16, 20], ["Influenza A virus", "SPECIES", 106, 123], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 16, 20], ["MHV", "SPECIES", 80, 83], ["Influenza A virus", "SPECIES", 106, 123], ["Vero E6", "SPECIES", 142, 149], ["mice", "SPECIES", 203, 207], ["chimeric VLPs", "TREATMENT", 50, 63], ["PBS", "TREATMENT", 68, 71], ["MHV VLPs", "TREATMENT", 80, 88], ["alum", "TREATMENT", 93, 97], ["Influenza A virus vaccine", "TREATMENT", 106, 131], ["alum", "TREATMENT", 136, 140], ["Vero E6 cell culture fluid", "TREATMENT", 142, 168], ["alum alone", "TREATMENT", 184, 194], ["treatment", "TREATMENT", 220, 229]]], ["Mean neutralizing titers at 28 days post inoculation in mice receiving 0.5, 1, or 2 g chimeric VLPs with alum were 20 \u00b1 10, 84 \u00b1 75, and 110 \u00b1 60, respectively (Fig. 3A) .", [["alum", "CHEMICAL", 105, 109], ["mice", "ORGANISM", 56, 60], ["VLPs", "ORGANISM", 95, 99], ["alum", "SIMPLE_CHEMICAL", 105, 109], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["Mean neutralizing titers", "TEST", 0, 24], ["alum", "TEST", 105, 109]]], ["In the absence of alum, 2 g chimeric VLPs induced a lower but significant neutralizing antibody response of 12.5 \u00b1 5.", [["alum", "CHEMICAL", 18, 22], ["alum", "CHEMICAL", 18, 22], ["alum", "SIMPLE_CHEMICAL", 18, 22], ["VLPs", "ORGANISM", 37, 41], ["neutralizing antibody", "PROTEIN", 74, 95], ["alum", "TREATMENT", 18, 22], ["2 g chimeric VLPs", "TREATMENT", 24, 41], ["significant neutralizing antibody response", "TEST", 62, 104], ["alum", "OBSERVATION", 18, 22]]], ["The mice infected with SCoV had the neutralizing titer of 70 \u00b1 20.", [["SCoV", "CHEMICAL", 23, 27], ["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["SCoV", "SPECIES", 23, 27], ["SCoV", "TREATMENT", 23, 27], ["the neutralizing titer", "TEST", 32, 54], ["infected", "OBSERVATION", 9, 17]]], ["The mice inoculated with 2 g of MHV VLP had no detectable virus-specific neutralizing antibodies, demonstrating that MHV S protein did not elicit neutralizing antibodies against SCoV.", [["mice", "ORGANISM", 4, 8], ["MHV VLP", "ORGANISM", 32, 39], ["MHV S", "GENE_OR_GENE_PRODUCT", 117, 122], ["SCoV", "GENE_OR_GENE_PRODUCT", 178, 182], ["neutralizing antibodies", "PROTEIN", 73, 96], ["MHV S protein", "PROTEIN", 117, 130], ["neutralizing antibodies", "PROTEIN", 146, 169], ["SCoV", "PROTEIN", 178, 182], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["MHV", "SPECIES", 32, 35], ["MHV", "SPECIES", 117, 120], ["SCoV", "SPECIES", 178, 182], ["MHV VLP", "TREATMENT", 32, 39], ["detectable virus", "PROBLEM", 47, 63], ["specific neutralizing antibodies", "TEST", 64, 96], ["MHV S protein", "TEST", 117, 130], ["neutralizing antibodies", "TEST", 146, 169], ["SCoV", "PROBLEM", 178, 182]]], ["The neutralizing antibody titers at 28 days post inoculation were not investigated in the groups of mice inoculated with Influenza vaccine and alum, alum alone, or in those receiving no treatment.Effects of chimeric VLP amounts on neutralizing antibody titers and inhibition of challenged SCoV replication in the lungsAt day 28, these mice, except for those untreated and those that had been inoculated with live SCoV, were boosted with the same material.", [["lungs", "ANATOMY", 313, 318], ["Influenza", "DISEASE", 121, 130], ["alum, alum", "CHEMICAL", 143, 153], ["alum", "CHEMICAL", 143, 147], ["mice", "ORGANISM", 100, 104], ["Influenza", "ORGANISM", 121, 130], ["alum", "SIMPLE_CHEMICAL", 143, 147], ["alum", "SIMPLE_CHEMICAL", 149, 153], ["SCoV", "GENE_OR_GENE_PRODUCT", 289, 293], ["lungs", "ORGAN", 313, 318], ["mice", "ORGANISM", 335, 339], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 335, 339], ["mice", "SPECIES", 100, 104], ["SCoV", "SPECIES", 289, 293], ["mice", "SPECIES", 335, 339], ["The neutralizing antibody titers", "TEST", 0, 32], ["Influenza vaccine", "TREATMENT", 121, 138], ["alum, alum alone", "TREATMENT", 143, 159], ["treatment", "TREATMENT", 186, 195], ["chimeric VLP amounts", "PROBLEM", 207, 227], ["neutralizing antibody titers", "TEST", 231, 259], ["challenged SCoV replication", "TREATMENT", 278, 305], ["live SCoV", "TREATMENT", 408, 417], ["chimeric VLP", "OBSERVATION_MODIFIER", 207, 219], ["lungs", "ANATOMY", 313, 318]]], ["Then the neutralizing antibody titers at day 56 were determined (Fig. 3B ).", [["the neutralizing antibody titers", "TEST", 5, 37]]], ["Mice injected with chimeric VLPs and alum had no increase in titer at the lowest dose, but 1-and 2-g doses resulted in marked booster responses.", [["alum", "CHEMICAL", 37, 41], ["Mice", "ORGANISM", 0, 4], ["VLPs", "ORGANISM", 28, 32], ["alum", "SIMPLE_CHEMICAL", 37, 41], ["Mice", "SPECIES", 0, 4], ["chimeric VLPs", "TREATMENT", 19, 32], ["alum", "TREATMENT", 37, 41], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["marked", "OBSERVATION_MODIFIER", 119, 125]]], ["Animals receiving the highest dose developed titers of 200 \u00b1 97.7, while those infected with SCoV had the neutralizing titer of 97 \u00b1 60.", [["SCoV", "CHEMICAL", 93, 97], ["Animals", "ORGANISM", 0, 7], ["SCoV", "SPECIES", 93, 97], ["titers", "TEST", 45, 51], ["the neutralizing titer", "TEST", 102, 124]]], ["A second inoculation of a mixture of 2 g chimeric VLPs with PBS efficiently boosted median neutralizing antibody titers to 57 \u00b1 21, which was higher than the titer following 0.5 g of chimeric VLP mixed with alum (15 \u00b1 5.7).", [["alum", "CHEMICAL", 207, 211], ["alum", "CHEMICAL", 207, 211], ["VLPs", "ORGANISM", 50, 54], ["VLP", "ORGANISM", 192, 195], ["2 g chimeric VLPs", "TREATMENT", 37, 54], ["median neutralizing antibody titers", "TEST", 84, 119], ["chimeric VLP", "TREATMENT", 183, 195], ["alum", "TREATMENT", 207, 211]]], ["No neutralizing antibodies were detected at the lowest dilution tested in groups receiving MHV VLP, influenza vaccine and alum, alum alone, or placebo or in those left untreated.Effects of chimeric VLP amounts on neutralizing antibody titers and inhibition of challenged SCoV replication in the lungsAll mice were challenged i.n. with live SCoV on day 56 and sacrificed 2 days later.", [["lungs", "ANATOMY", 295, 300], ["alum", "CHEMICAL", 122, 126], ["alum", "CHEMICAL", 128, 132], ["alum", "CHEMICAL", 122, 126], ["MHV VLP", "ORGANISM", 91, 98], ["influenza", "ORGANISM", 100, 109], ["alum", "SIMPLE_CHEMICAL", 122, 126], ["alum", "SIMPLE_CHEMICAL", 128, 132], ["SCoV", "GENE_OR_GENE_PRODUCT", 271, 275], ["lungs", "ORGAN", 295, 300], ["mice", "ORGANISM", 304, 308], ["neutralizing antibodies", "PROTEIN", 3, 26], ["mice", "SPECIES", 304, 308], ["MHV", "SPECIES", 91, 94], ["SCoV", "SPECIES", 271, 275], ["mice", "SPECIES", 304, 308], ["neutralizing antibodies", "PROBLEM", 3, 26], ["MHV VLP", "TREATMENT", 91, 98], ["influenza vaccine", "TREATMENT", 100, 117], ["alum, alum alone", "TREATMENT", 122, 138], ["placebo", "TREATMENT", 143, 150], ["chimeric VLP amounts", "PROBLEM", 189, 209], ["neutralizing antibody titers", "TEST", 213, 241], ["challenged SCoV replication", "TREATMENT", 260, 287], ["neutralizing", "OBSERVATION_MODIFIER", 3, 15], ["antibodies", "OBSERVATION", 16, 26], ["left", "ANATOMY_MODIFIER", 163, 167], ["chimeric VLP", "OBSERVATION_MODIFIER", 189, 201], ["lungs", "ANATOMY", 295, 300]]], ["As expected, maximal pulmonary virus titers were detected in the groups of mice inoculated with placebo (6.9 log 10 \u00b10.7), MHV VLPs (6.2 log 10 \u00b10.4), influenza vaccine and alum (7.5 \u00b1 0.1), alum alone (7.3 \u00b1 0), and in those left untreated (8.5 \u00b1 0) (Fig. 3C) .", [["pulmonary", "ANATOMY", 21, 30], ["alum", "CHEMICAL", 173, 177], ["alum", "CHEMICAL", 191, 195], ["alum", "CHEMICAL", 173, 177], ["alum", "CHEMICAL", 191, 195], ["pulmonary", "ORGAN", 21, 30], ["virus", "ORGANISM", 31, 36], ["mice", "ORGANISM", 75, 79], ["MHV VLPs", "ORGANISM", 123, 131], ["alum", "SIMPLE_CHEMICAL", 173, 177], ["alum", "SIMPLE_CHEMICAL", 191, 195], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["MHV", "SPECIES", 123, 126], ["maximal pulmonary virus titers", "PROBLEM", 13, 43], ["placebo", "TEST", 96, 103], ["MHV VLPs", "TEST", 123, 131], ["influenza vaccine", "TREATMENT", 151, 168], ["alum", "TEST", 173, 177], ["pulmonary", "ANATOMY", 21, 30], ["virus titers", "OBSERVATION", 31, 43], ["left", "ANATOMY_MODIFIER", 226, 230]]], ["Partial protection was obtained in groups of mice inoculated twice with 0.5 g chimeric VLP mixed with alum (5.5 log 10 \u00b10.6), 2 g chimeric VLPs and PBS (3.9 log 10 \u00b11.1) or 1 g chimeric VLPs mixed with alum (3.1 log 10 \u00b10.5).", [["alum", "CHEMICAL", 102, 106], ["alum", "CHEMICAL", 202, 206], ["alum", "CHEMICAL", 102, 106], ["alum", "CHEMICAL", 202, 206], ["mice", "ORGANISM", 45, 49], ["VLP", "ORGANISM", 87, 90], ["alum", "SIMPLE_CHEMICAL", 102, 106], ["VLPs", "ORGANISM", 139, 143], ["VLPs", "ORGANISM", 186, 190], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["Partial protection", "TREATMENT", 0, 18], ["0.5 g chimeric VLP mixed with alum", "TREATMENT", 72, 106], ["2 g chimeric VLPs", "TREATMENT", 126, 143], ["PBS", "TEST", 148, 151], ["1 g chimeric VLPs", "TREATMENT", 173, 190], ["alum", "TREATMENT", 202, 206]]], ["Notably, no virus SCoV-specific neutralizing serum antibody titers in the immunized mice and SCoV titers in lungs of mice 2 days after intranasal challenge with SCoV at day 56.", [["serum", "ANATOMY", 45, 50], ["lungs", "ANATOMY", 108, 113], ["SCoV", "CHEMICAL", 161, 165], ["SCoV", "GENE_OR_GENE_PRODUCT", 18, 22], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["mice", "ORGANISM", 84, 88], ["SCoV", "GENE_OR_GENE_PRODUCT", 93, 97], ["lungs", "ORGAN", 108, 113], ["mice", "ORGANISM", 117, 121], ["serum antibody", "PROTEIN", 45, 59], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 84, 88], ["SCoV", "SPECIES", 93, 97], ["mice", "SPECIES", 117, 121], ["SCoV", "SPECIES", 161, 165], ["virus SCoV", "TEST", 12, 22], ["specific neutralizing serum antibody titers", "TEST", 23, 66], ["the immunized mice", "TREATMENT", 70, 88], ["SCoV titers", "TEST", 93, 104], ["intranasal challenge", "TREATMENT", 135, 155], ["SCoV", "TREATMENT", 161, 165], ["no", "UNCERTAINTY", 9, 11], ["virus", "OBSERVATION", 12, 17], ["lungs", "ANATOMY", 108, 113]]], ["On day 0, mice were either left untreated or were inoculated i.n. with 1 \u00d7 10 6 TCID 50 of SCoV or injected i.m. with placebo (medium from Vero E6 cells), a mixture of 2 g MHV VLPs and PBS, a mixture of 2 g chimeric VLP and PBS, a mixture of 2 g chimeric VLP and alum, a mixture of 1 g chimeric VLP and alum, a mixture of 0.5 g chimeric VLP and alum, a mixture of 1 g influenza virus vaccine and alum, or alum alone.", [["cells", "ANATOMY", 147, 152], ["SCoV", "CHEMICAL", 91, 95], ["alum", "CHEMICAL", 263, 267], ["alum", "CHEMICAL", 303, 307], ["alum", "CHEMICAL", 345, 349], ["alum", "CHEMICAL", 396, 400], ["alum", "CHEMICAL", 405, 409], ["alum", "CHEMICAL", 303, 307], ["alum", "CHEMICAL", 345, 349], ["alum", "CHEMICAL", 396, 400], ["alum", "CHEMICAL", 405, 409], ["mice", "ORGANISM", 10, 14], ["SCoV", "SIMPLE_CHEMICAL", 91, 95], ["Vero E6 cells", "CELL", 139, 152], ["MHV", "ORGANISM", 172, 175], ["VLPs", "ORGANISM", 176, 180], ["VLP", "ORGANISM", 216, 219], ["PBS", "SIMPLE_CHEMICAL", 224, 227], ["VLP", "ORGANISM", 255, 258], ["alum", "SIMPLE_CHEMICAL", 263, 267], ["VLP", "ORGANISM", 295, 298], ["alum", "SIMPLE_CHEMICAL", 303, 307], ["VLP", "ORGANISM", 337, 340], ["alum", "SIMPLE_CHEMICAL", 345, 349], ["influenza virus", "ORGANISM", 368, 383], ["alum", "SIMPLE_CHEMICAL", 396, 400], ["alum", "SIMPLE_CHEMICAL", 405, 409], ["Vero E6 cells", "CELL_LINE", 139, 152], ["mice", "SPECIES", 10, 14], ["influenza virus vaccine", "SPECIES", 368, 391], ["mice", "SPECIES", 10, 14], ["SCoV", "SPECIES", 91, 95], ["MHV", "SPECIES", 172, 175], ["SCoV", "TREATMENT", 91, 95], ["placebo (medium from Vero E6 cells", "TREATMENT", 118, 152], ["2 g MHV VLPs", "TREATMENT", 168, 180], ["PBS", "TREATMENT", 185, 188], ["2 g chimeric VLP", "TREATMENT", 203, 219], ["PBS", "TREATMENT", 224, 227], ["a mixture of 2 g chimeric VLP", "TREATMENT", 229, 258], ["1 g chimeric VLP", "TREATMENT", 282, 298], ["0.5 g chimeric VLP", "TREATMENT", 322, 340], ["alum", "TREATMENT", 345, 349], ["1 g influenza virus vaccine", "TREATMENT", 364, 391], ["alum", "TREATMENT", 396, 400], ["left", "ANATOMY_MODIFIER", 27, 31]]], ["(A) The graph represents virus-specific serum neutralizing antibody titers at 28 days post inoculation.", [["serum", "ANATOMY", 40, 45], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["virus", "PROBLEM", 25, 30], ["specific serum neutralizing antibody titers", "TEST", 31, 74], ["inoculation", "PROBLEM", 91, 102], ["virus", "OBSERVATION", 25, 30]]], ["(B) At 56 days blood samples were collected, and then the mice, excluding those inoculated with live SCoV and left untreated, were re-inoculated with the same material.", [["blood samples", "ANATOMY", 15, 28], ["SCoV", "ANATOMY", 101, 105], ["blood samples", "ORGANISM_SUBSTANCE", 15, 28], ["mice", "ORGANISM", 58, 62], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["SCoV", "SPECIES", 101, 105], ["blood samples", "TEST", 15, 28], ["left", "ANATOMY_MODIFIER", 110, 114]]], ["The graph represents virus-specific, serumneutralizing antibody titers at 56 days after initial inoculation.", [["virus", "PROBLEM", 21, 26], ["serumneutralizing antibody titers", "PROBLEM", 37, 70], ["initial inoculation", "TREATMENT", 88, 107], ["virus", "OBSERVATION", 21, 26]]], ["The vertical dashed lines in (A) and (B) denote the minimal antibody detection level in this assay (1/10 dilution).", [["lines", "CELL", 20, 25], ["vertical dashed lines", "CELL_LINE", 4, 25], ["The vertical dashed lines", "TREATMENT", 0, 25], ["the minimal antibody detection level", "TEST", 48, 84], ["this assay", "TEST", 88, 98], ["vertical", "OBSERVATION_MODIFIER", 4, 12], ["dashed lines", "OBSERVATION", 13, 25], ["minimal", "OBSERVATION_MODIFIER", 52, 59], ["antibody", "OBSERVATION", 60, 68]]], ["(C) Mice were inoculated with 1 \u00d7 10 6 TCID 50 of SCoV at day 56.", [["Mice", "ORGANISM", 4, 8], ["Mice", "SPECIES", 4, 8]]], ["After 2 days, mice were euthanized, and the lung virus titers were determined.", [["lung", "ANATOMY", 44, 48], ["mice", "ORGANISM", 14, 18], ["lung", "ORGAN", 44, 48], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["the lung virus titers", "TEST", 40, 61], ["lung", "ANATOMY", 44, 48], ["virus", "OBSERVATION", 49, 54]]], ["The vertical dashed line in (C) denotes the minimal virus detection level in this assay (2.3 log 10 TCID 50 /g lung).", [["lung", "ANATOMY", 111, 115], ["lung", "ORGAN", 111, 115], ["vertical dashed line", "CELL_LINE", 4, 24], ["The vertical dashed line", "TREATMENT", 0, 24], ["the minimal virus detection level", "PROBLEM", 40, 73], ["this assay", "TEST", 77, 87], ["vertical", "OBSERVATION_MODIFIER", 4, 12], ["dashed line", "OBSERVATION", 13, 24], ["minimal", "OBSERVATION_MODIFIER", 44, 51], ["virus", "OBSERVATION", 52, 57], ["lung", "ANATOMY", 111, 115]]], ["The number of mice used for (B) and (C) were: 7 for placebo, SCoV, and 2 g chimeric VLP with PBS; 6 for 2 g chimeric VLP with alum; 5 for MHV VLP with alum and 1 g chimeric VLP with alum; 4 for 0.5 g chimeric VLP with alum; and 3 for all other groups. was detectable in the lungs of any of the mice given live virus i.n. or two doses of 2 g chimeric VLP mixed with alum.", [["lungs", "ANATOMY", 274, 279], ["alum", "CHEMICAL", 126, 130], ["alum", "CHEMICAL", 151, 155], ["alum", "CHEMICAL", 365, 369], ["alum", "CHEMICAL", 126, 130], ["alum", "CHEMICAL", 151, 155], ["alum", "CHEMICAL", 182, 186], ["alum", "CHEMICAL", 218, 222], ["alum", "CHEMICAL", 365, 369], ["mice", "ORGANISM", 14, 18], ["VLP", "ORGANISM", 117, 120], ["MHV", "ORGANISM", 138, 141], ["alum", "SIMPLE_CHEMICAL", 151, 155], ["lungs", "ORGAN", 274, 279], ["mice", "ORGANISM", 294, 298], ["VLP", "ORGANISM", 350, 353], ["alum", "SIMPLE_CHEMICAL", 365, 369], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 294, 298], ["mice", "SPECIES", 14, 18], ["MHV", "SPECIES", 138, 141], ["mice", "SPECIES", 294, 298], ["placebo", "TREATMENT", 52, 59], ["SCoV", "TREATMENT", 61, 65], ["2 g chimeric VLP with PBS", "TREATMENT", 71, 96], ["2 g chimeric VLP with alum", "TREATMENT", 104, 130], ["MHV VLP", "TREATMENT", 138, 145], ["alum", "TREATMENT", 151, 155], ["1 g chimeric VLP with alum", "TREATMENT", 160, 186], ["0.5 g chimeric VLP with alum", "TREATMENT", 194, 222], ["live virus i.n.", "TREATMENT", 305, 320], ["2 g chimeric VLP", "TREATMENT", 337, 353], ["alum", "TREATMENT", 365, 369], ["lungs", "ANATOMY", 274, 279]]], ["The mean lung virus titers for the latter two groups were statistically different from the mean pulmonary SCoV titer seen in the placebo control group when these means were compared using a non-parametric ANOVA test (both p values being <0.01).", [["lung", "ANATOMY", 9, 13], ["pulmonary", "ANATOMY", 96, 105], ["lung", "ORGAN", 9, 13], ["virus", "ORGANISM", 14, 19], ["pulmonary", "ORGAN", 96, 105], ["The mean lung virus titers", "TEST", 0, 26], ["the mean pulmonary SCoV titer", "TEST", 87, 116], ["a non-parametric ANOVA test", "TEST", 188, 215], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["lung", "ANATOMY", 9, 13], ["virus titers", "OBSERVATION", 14, 26], ["pulmonary", "ANATOMY", 96, 105], ["SCoV titer", "OBSERVATION", 106, 116]]], ["Overall, the virus levels in these animals generally correlated inversely with those of SCoVspecific neutralizing antibodies present in the sera of the mice.Histopathological examination and IHC of the lungs of the immunized mice after SCoV challengeHistopathological examination of the groups of mice that neither produced neutralizing antibodies nor suppressed SCoV replication in the lungs (i.e., mice treated with Vero E6 cell culture fluid, inoculated with a mixture of influenza virus vaccine and alum, and with alum alone, as well as those left untreated), revealed moderate interstitial pneumonia ( Fig. 4A and B) .", [["sera", "ANATOMY", 140, 144], ["lungs", "ANATOMY", 202, 207], ["lungs", "ANATOMY", 387, 392], ["cell", "ANATOMY", 426, 430], ["interstitial", "ANATOMY", 582, 594], ["alum", "CHEMICAL", 518, 522], ["interstitial pneumonia", "DISEASE", 582, 604], ["alum", "CHEMICAL", 518, 522], ["sera", "ORGANISM_SUBSTANCE", 140, 144], ["mice", "ORGANISM", 152, 156], ["lungs", "ORGAN", 202, 207], ["mice", "ORGANISM", 225, 229], ["mice", "ORGANISM", 297, 301], ["SCoV", "GENE_OR_GENE_PRODUCT", 363, 367], ["lungs", "ORGAN", 387, 392], ["mice", "ORGANISM", 400, 404], ["Vero E6 cell", "CELL", 418, 430], ["influenza virus", "ORGANISM", 475, 490], ["alum", "SIMPLE_CHEMICAL", 503, 507], ["alum", "SIMPLE_CHEMICAL", 518, 522], ["SCoVspecific neutralizing antibodies", "PROTEIN", 88, 124], ["neutralizing antibodies", "PROTEIN", 324, 347], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 225, 229], ["mice", "SPECIES", 297, 301], ["mice", "SPECIES", 400, 404], ["influenza virus vaccine", "SPECIES", 475, 498], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 225, 229], ["SCoV", "SPECIES", 236, 240], ["mice", "SPECIES", 297, 301], ["SCoV", "SPECIES", 363, 367], ["mice", "SPECIES", 400, 404], ["Vero", "SPECIES", 418, 422], ["the virus levels", "TEST", 9, 25], ["SCoVspecific neutralizing antibodies", "TREATMENT", 88, 124], ["Histopathological examination", "TEST", 157, 186], ["IHC", "TEST", 191, 194], ["the immunized mice", "TREATMENT", 211, 229], ["SCoV challenge", "TREATMENT", 236, 250], ["Histopathological examination", "TEST", 250, 279], ["neutralizing antibodies", "PROBLEM", 324, 347], ["SCoV replication in the lungs", "PROBLEM", 363, 392], ["Vero E6 cell culture fluid", "TREATMENT", 418, 444], ["influenza virus vaccine", "TREATMENT", 475, 498], ["alum", "TREATMENT", 503, 507], ["alum alone", "TREATMENT", 518, 528], ["moderate interstitial pneumonia", "PROBLEM", 573, 604], ["virus", "OBSERVATION", 13, 18], ["neutralizing antibodies", "OBSERVATION", 101, 124], ["lungs", "ANATOMY", 202, 207], ["lungs", "ANATOMY", 387, 392], ["moderate", "OBSERVATION_MODIFIER", 573, 581], ["interstitial", "ANATOMY_MODIFIER", 582, 594], ["pneumonia", "OBSERVATION", 595, 604]]], ["The bronchial epithelium appeared to be the main affected target with prominent cellular cytoplasmic swelling and blebbing.", [["bronchial epithelium", "ANATOMY", 4, 24], ["cellular", "ANATOMY", 80, 88], ["cytoplasmic", "ANATOMY", 89, 100], ["swelling", "DISEASE", 101, 109], ["bronchial epithelium", "TISSUE", 4, 24], ["cellular", "CELL", 80, 88], ["cytoplasmic", "ORGANISM_SUBSTANCE", 89, 100], ["prominent cellular cytoplasmic swelling", "PROBLEM", 70, 109], ["blebbing", "PROBLEM", 114, 122], ["bronchial epithelium", "ANATOMY", 4, 24], ["main", "OBSERVATION_MODIFIER", 44, 48], ["prominent", "OBSERVATION_MODIFIER", 70, 79], ["cellular", "OBSERVATION_MODIFIER", 80, 88], ["cytoplasmic", "OBSERVATION_MODIFIER", 89, 100], ["swelling", "OBSERVATION", 101, 109], ["blebbing", "OBSERVATION_MODIFIER", 114, 122]]], ["Extensive accumulation of cellular debris and necrotic epithelial cells, accompanied by inflammatory infiltrates, occurred in some bronchioles (Fig. 4A) .", [["cellular debris", "ANATOMY", 26, 41], ["necrotic epithelial cells", "ANATOMY", 46, 71], ["bronchioles", "ANATOMY", 131, 142], ["necrotic", "DISEASE", 46, 54], ["cellular debris", "CELLULAR_COMPONENT", 26, 41], ["necrotic epithelial cells", "CELL", 46, 71], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 131, 142], ["necrotic epithelial cells", "CELL_TYPE", 46, 71], ["cellular debris", "PROBLEM", 26, 41], ["necrotic epithelial cells", "PROBLEM", 46, 71], ["inflammatory infiltrates", "PROBLEM", 88, 112], ["accumulation", "OBSERVATION_MODIFIER", 10, 22], ["cellular debris", "OBSERVATION", 26, 41], ["necrotic", "OBSERVATION_MODIFIER", 46, 54], ["epithelial cells", "OBSERVATION", 55, 71], ["inflammatory", "OBSERVATION_MODIFIER", 88, 100], ["infiltrates", "OBSERVATION", 101, 112], ["some", "ANATOMY_MODIFIER", 126, 130], ["bronchioles", "ANATOMY", 131, 142]]], ["We also observed a moderate infiltration of mononuclear cells around peribronchiolar and perivascular regions of infected tissues and a mild-to-moderate thickening of the bronchiolar interstitial tissues and alveolar walls with mononuclear cell infiltration (Fig. 4B) .", [["mononuclear cells", "ANATOMY", 44, 61], ["peribronchiolar", "ANATOMY", 69, 84], ["perivascular regions", "ANATOMY", 89, 109], ["tissues", "ANATOMY", 122, 129], ["bronchiolar interstitial tissues", "ANATOMY", 171, 203], ["alveolar walls", "ANATOMY", 208, 222], ["mononuclear cell", "ANATOMY", 228, 244], ["mononuclear cells", "CELL", 44, 61], ["peribronchiolar", "CELL", 69, 84], ["perivascular regions", "TISSUE", 89, 109], ["tissues", "TISSUE", 122, 129], ["bronchiolar interstitial tissues", "TISSUE", 171, 203], ["alveolar walls", "TISSUE", 208, 222], ["mononuclear cell", "CELL", 228, 244], ["mononuclear cells", "CELL_TYPE", 44, 61], ["a moderate infiltration of mononuclear cells", "PROBLEM", 17, 61], ["peribronchiolar and perivascular regions of infected tissues", "PROBLEM", 69, 129], ["a mild-to-moderate thickening of the bronchiolar interstitial tissues", "PROBLEM", 134, 203], ["mononuclear cell infiltration", "PROBLEM", 228, 257], ["moderate", "OBSERVATION_MODIFIER", 19, 27], ["infiltration", "OBSERVATION", 28, 40], ["mononuclear cells", "OBSERVATION", 44, 61], ["peribronchiolar", "ANATOMY_MODIFIER", 69, 84], ["perivascular", "ANATOMY_MODIFIER", 89, 101], ["infected tissues", "OBSERVATION", 113, 129], ["mild", "OBSERVATION_MODIFIER", 136, 140], ["-to-moderate", "OBSERVATION_MODIFIER", 140, 152], ["thickening", "OBSERVATION", 153, 163], ["bronchiolar", "ANATOMY_MODIFIER", 171, 182], ["interstitial tissues", "ANATOMY", 183, 203], ["alveolar", "ANATOMY_MODIFIER", 208, 216], ["walls", "ANATOMY_MODIFIER", 217, 222], ["mononuclear cell infiltration", "OBSERVATION", 228, 257]]], ["IHC staining demonstrated the presence of SCoV N protein within bronchiolar epithelial cells, but not within cells of alveolar lining (Fig. 4C) .", [["bronchiolar epithelial cells", "ANATOMY", 64, 92], ["cells", "ANATOMY", 109, 114], ["alveolar lining", "ANATOMY", 118, 133], ["SCoV N", "GENE_OR_GENE_PRODUCT", 42, 48], ["bronchiolar epithelial cells", "CELL", 64, 92], ["cells", "CELL", 109, 114], ["alveolar lining", "TISSUE", 118, 133], ["SCoV N protein", "PROTEIN", 42, 56], ["bronchiolar epithelial cells", "CELL_TYPE", 64, 92], ["IHC staining", "TEST", 0, 12], ["SCoV N protein within bronchiolar epithelial cells", "PROBLEM", 42, 92], ["bronchiolar epithelial cells", "OBSERVATION", 64, 92], ["alveolar", "ANATOMY_MODIFIER", 118, 126], ["lining", "ANATOMY_MODIFIER", 127, 133]]], ["In contrast to the prominent pathology and viral replication in the lungs of the control animals, mild interstitial pneumonia was found, upon viral challenge, in the mice previously immunized with mixtures of either chimeric VLP and PBS, or chimeric VLP and alum, and in those infected with live SCoV (Fig. 4D, E, G, H) .", [["lungs", "ANATOMY", 68, 73], ["interstitial", "ANATOMY", 103, 115], ["interstitial pneumonia", "DISEASE", 103, 125], ["lungs", "ORGAN", 68, 73], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 115], ["mice", "ORGANISM", 166, 170], ["chimeric VLP", "ORGANISM", 216, 228], ["PBS", "SIMPLE_CHEMICAL", 233, 236], ["chimeric VLP", "ORGANISM", 241, 253], ["alum", "SIMPLE_CHEMICAL", 258, 262], ["chimeric VLP", "PROTEIN", 216, 228], ["chimeric VLP", "PROTEIN", 241, 253], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 166, 170], ["the prominent pathology", "PROBLEM", 15, 38], ["viral replication", "TREATMENT", 43, 60], ["mild interstitial pneumonia", "PROBLEM", 98, 125], ["viral challenge", "TEST", 142, 157], ["chimeric VLP", "TREATMENT", 216, 228], ["PBS", "PROBLEM", 233, 236], ["chimeric VLP", "PROBLEM", 241, 253], ["prominent", "OBSERVATION_MODIFIER", 19, 28], ["pathology", "OBSERVATION", 29, 38], ["viral replication", "OBSERVATION", 43, 60], ["lungs", "ANATOMY", 68, 73], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["interstitial", "ANATOMY_MODIFIER", 103, 115], ["pneumonia", "OBSERVATION", 116, 125], ["chimeric VLP", "ANATOMY", 241, 253]]], ["Specifically, cytopathology, i.e., swelling and blebbing, was rarely observed in bronchiolar epithelial cells, despite the presence of some desquamated cells within the airway lumen.", [["bronchiolar epithelial cells", "ANATOMY", 81, 109], ["cells", "ANATOMY", 152, 157], ["airway lumen", "ANATOMY", 169, 181], ["swelling", "DISEASE", 35, 43], ["bronchiolar epithelial cells", "CELL", 81, 109], ["cells", "CELL", 152, 157], ["airway lumen", "MULTI-TISSUE_STRUCTURE", 169, 181], ["bronchiolar epithelial cells", "CELL_TYPE", 81, 109], ["desquamated cells", "CELL_TYPE", 140, 157], ["cytopathology", "TEST", 14, 27], ["swelling", "PROBLEM", 35, 43], ["blebbing", "PROBLEM", 48, 56], ["bronchiolar epithelial cells", "PROBLEM", 81, 109], ["some desquamated cells within the airway lumen", "PROBLEM", 135, 181], ["swelling", "OBSERVATION", 35, 43], ["blebbing", "OBSERVATION", 48, 56], ["bronchiolar epithelial cells", "OBSERVATION", 81, 109], ["some", "OBSERVATION_MODIFIER", 135, 139], ["desquamated cells", "OBSERVATION", 140, 157], ["airway", "ANATOMY", 169, 175], ["lumen", "ANATOMY_MODIFIER", 176, 181]]], ["Additionally, the thickening of bronchiolar interstitial tissues and the alveolar wall and cellular infiltration were less prominent when compared with those of the control groups.", [["bronchiolar interstitial tissues", "ANATOMY", 32, 64], ["alveolar wall", "ANATOMY", 73, 86], ["cellular", "ANATOMY", 91, 99], ["bronchiolar interstitial tissues", "TISSUE", 32, 64], ["alveolar wall", "TISSUE", 73, 86], ["cellular", "CELL", 91, 99], ["the thickening of bronchiolar interstitial tissues", "PROBLEM", 14, 64], ["the alveolar wall", "PROBLEM", 69, 86], ["cellular infiltration", "PROBLEM", 91, 112], ["thickening", "OBSERVATION", 18, 28], ["bronchiolar", "ANATOMY_MODIFIER", 32, 43], ["interstitial tissues", "ANATOMY", 44, 64], ["alveolar", "ANATOMY_MODIFIER", 73, 81], ["wall", "ANATOMY_MODIFIER", 82, 86], ["cellular infiltration", "OBSERVATION", 91, 112], ["less", "OBSERVATION_MODIFIER", 118, 122], ["prominent", "OBSERVATION_MODIFIER", 123, 132]]], ["There was no big difference in the lung pathology between mice inoculated with VLP and PBS and those inoculated with VLP and alum.", [["lung", "ANATOMY", 35, 39], ["lung", "ORGAN", 35, 39], ["mice", "ORGANISM", 58, 62], ["alum", "SIMPLE_CHEMICAL", 125, 129], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["big difference in the lung pathology", "PROBLEM", 13, 49], ["VLP and PBS", "TREATMENT", 79, 90], ["VLP and alum", "TREATMENT", 117, 129], ["no", "UNCERTAINTY", 10, 12], ["big", "OBSERVATION_MODIFIER", 13, 16], ["difference", "OBSERVATION_MODIFIER", 17, 27], ["lung", "ANATOMY", 35, 39], ["pathology", "OBSERVATION", 40, 49], ["alum", "OBSERVATION", 125, 129]]], ["We noticed that inflammatory mononuclear cells seemed to be the main, if not only, cellular component of the cellular infiltrates around the peribronchiolar and perivascular regions of mice initially primed with live SCoV.Histopathological examination and IHC of the lungs of the immunized mice after SCoV challengeIn addition to inflammatory mononuclear cells, we observed the infiltration of neutrophils and eosinophils around the bronchioles and blood vessels of mice inoculated with a mixture of chimeric VLPs and PBS and that of chimeric VLPs and alum ( Fig. 4D and E) ; counting of the infiltrating cells at the five fields of each mouse's lung tissues revealed that infiltrating eosinophils represented 13.2 \u00b1 9.6% and 22.2 \u00b1 9.9% of all the infiltrating cells in mice inoculated with a mixture of chimeric VLP and PBS and in those inoculated with chimeric VLP and alum, respectively.", [["inflammatory mononuclear cells", "ANATOMY", 16, 46], ["cellular", "ANATOMY", 83, 91], ["cellular infiltrates", "ANATOMY", 109, 129], ["peribronchiolar", "ANATOMY", 141, 156], ["perivascular regions", "ANATOMY", 161, 181], ["lungs", "ANATOMY", 267, 272], ["inflammatory mononuclear cells", "ANATOMY", 330, 360], ["neutrophils", "ANATOMY", 394, 405], ["eosinophils", "ANATOMY", 410, 421], ["bronchioles", "ANATOMY", 433, 444], ["blood vessels", "ANATOMY", 449, 462], ["infiltrating cells", "ANATOMY", 592, 610], ["lung tissues", "ANATOMY", 646, 658], ["infiltrating eosinophils", "ANATOMY", 673, 697], ["infiltrating cells", "ANATOMY", 749, 767], ["inflammatory mononuclear cells", "CELL", 16, 46], ["cellular", "CELL", 83, 91], ["cellular", "CELL", 109, 117], ["peribronchiolar", "TISSUE", 141, 156], ["perivascular regions", "TISSUE", 161, 181], ["mice", "ORGANISM", 185, 189], ["SCoV", "GENE_OR_GENE_PRODUCT", 217, 221], ["lungs", "ORGAN", 267, 272], ["mice", "ORGANISM", 290, 294], ["inflammatory mononuclear cells", "CELL", 330, 360], ["neutrophils", "CELL", 394, 405], ["eosinophils", "CELL", 410, 421], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 433, 444], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 449, 462], ["mice", "ORGANISM", 466, 470], ["alum", "SIMPLE_CHEMICAL", 552, 556], ["cells", "CELL", 605, 610], ["mouse", "ORGANISM", 638, 643], ["lung tissues", "TISSUE", 646, 658], ["eosinophils", "CELL", 686, 697], ["cells", "CELL", 762, 767], ["mice", "ORGANISM", 771, 775], ["VLP", "ORGANISM", 814, 817], ["alum", "SIMPLE_CHEMICAL", 872, 876], ["inflammatory mononuclear cells", "CELL_TYPE", 16, 46], ["inflammatory mononuclear cells", "CELL_TYPE", 330, 360], ["neutrophils", "CELL_TYPE", 394, 405], ["eosinophils", "CELL_TYPE", 410, 421], ["chimeric VLPs", "PROTEIN", 500, 513], ["chimeric VLPs", "PROTEIN", 534, 547], ["infiltrating cells", "CELL_TYPE", 592, 610], ["infiltrating eosinophils", "CELL_TYPE", 673, 697], ["infiltrating cells", "CELL_TYPE", 749, 767], ["chimeric VLP", "PROTEIN", 805, 817], ["chimeric VLP", "PROTEIN", 855, 867], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 290, 294], ["mice", "SPECIES", 466, 470], ["mouse", "SPECIES", 638, 643], ["mice", "SPECIES", 771, 775], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 290, 294], ["SCoV", "SPECIES", 301, 305], ["mice", "SPECIES", 466, 470], ["mouse", "SPECIES", 638, 643], ["mice", "SPECIES", 771, 775], ["inflammatory mononuclear cells", "PROBLEM", 16, 46], ["the cellular infiltrates", "PROBLEM", 105, 129], ["Histopathological examination", "TEST", 222, 251], ["IHC", "TEST", 256, 259], ["the immunized mice", "TREATMENT", 276, 294], ["SCoV challenge", "TREATMENT", 301, 315], ["inflammatory mononuclear cells", "PROBLEM", 330, 360], ["the infiltration of neutrophils", "PROBLEM", 374, 405], ["eosinophils", "TEST", 410, 421], ["chimeric VLPs", "TREATMENT", 500, 513], ["PBS", "TREATMENT", 518, 521], ["chimeric VLPs", "TREATMENT", 534, 547], ["the infiltrating cells", "PROBLEM", 588, 610], ["infiltrating eosinophils", "TEST", 673, 697], ["chimeric VLP", "TREATMENT", 805, 817], ["PBS", "TEST", 822, 825], ["chimeric VLP", "TREATMENT", 855, 867], ["inflammatory mononuclear cells", "OBSERVATION", 16, 46], ["main", "OBSERVATION_MODIFIER", 64, 68], ["cellular", "OBSERVATION_MODIFIER", 83, 91], ["component", "OBSERVATION_MODIFIER", 92, 101], ["cellular", "OBSERVATION_MODIFIER", 109, 117], ["infiltrates", "OBSERVATION", 118, 129], ["peribronchiolar", "ANATOMY_MODIFIER", 141, 156], ["perivascular", "ANATOMY_MODIFIER", 161, 173], ["lungs", "ANATOMY", 267, 272], ["inflammatory mononuclear cells", "OBSERVATION", 330, 360], ["infiltration", "OBSERVATION", 378, 390], ["neutrophils", "OBSERVATION", 394, 405], ["eosinophils", "OBSERVATION", 410, 421], ["bronchioles", "ANATOMY", 433, 444], ["blood vessels", "ANATOMY", 449, 462], ["chimeric VLPs", "ANATOMY", 534, 547], ["infiltrating cells", "OBSERVATION", 592, 610], ["lung tissues", "ANATOMY", 646, 658], ["infiltrating", "OBSERVATION", 673, 685], ["infiltrating cells", "OBSERVATION", 749, 767], ["chimeric VLP", "ANATOMY", 855, 867]]], ["In contrast, infiltrating eosinophils represented merely 1.42 \u00b1 1.42%, 0%, 0% and 0.77 \u00b1 0.33% of all infiltrating cells in mice inoculated, respectively, with Vero E6 cell culture fluid, a mixture of influenza virus vaccine and alum, alum alone, and in those left untreated.DiscussionThe present study tested the efficacy of immunization of mice with chimeric VLPs for elicitation of anti-SCoVneutralizing antibodies, suppression of SCoV replication in the lungs, and SCoV-mediated lung cytopathology.", [["infiltrating eosinophils", "ANATOMY", 13, 37], ["infiltrating cells", "ANATOMY", 102, 120], ["cell", "ANATOMY", 168, 172], ["lungs", "ANATOMY", 458, 463], ["lung", "ANATOMY", 483, 487], ["influenza virus", "DISEASE", 201, 216], ["alum, alum", "CHEMICAL", 229, 239], ["alum", "CHEMICAL", 229, 233], ["eosinophils", "CELL", 26, 37], ["cells", "CELL", 115, 120], ["mice", "ORGANISM", 124, 128], ["Vero E6 cell", "CELL", 160, 172], ["influenza virus", "ORGANISM", 201, 216], ["alum", "SIMPLE_CHEMICAL", 229, 233], ["alum", "SIMPLE_CHEMICAL", 235, 239], ["mice", "ORGANISM", 342, 346], ["anti-SCoVneutralizing antibodies", "GENE_OR_GENE_PRODUCT", 385, 417], ["SCoV", "GENE_OR_GENE_PRODUCT", 434, 438], ["lungs", "ORGAN", 458, 463], ["SCoV", "GENE_OR_GENE_PRODUCT", 469, 473], ["lung", "ORGAN", 483, 487], ["infiltrating eosinophils", "CELL_TYPE", 13, 37], ["infiltrating cells", "CELL_TYPE", 102, 120], ["anti-SCoVneutralizing antibodies", "PROTEIN", 385, 417], ["mice", "SPECIES", 124, 128], ["influenza virus vaccine", "SPECIES", 201, 224], ["mice", "SPECIES", 342, 346], ["mice", "SPECIES", 124, 128], ["Vero E6", "SPECIES", 160, 167], ["mice", "SPECIES", 342, 346], ["SCoV", "SPECIES", 434, 438], ["infiltrating eosinophils", "TEST", 13, 37], ["all infiltrating cells", "PROBLEM", 98, 120], ["Vero E6 cell culture fluid", "TEST", 160, 186], ["influenza virus vaccine", "TREATMENT", 201, 224], ["alum, alum alone", "TREATMENT", 229, 245], ["The present study", "TEST", 285, 302], ["immunization of mice", "TREATMENT", 326, 346], ["chimeric VLPs", "TREATMENT", 352, 365], ["anti-SCoVneutralizing antibodies", "TREATMENT", 385, 417], ["SCoV replication in the lungs", "PROBLEM", 434, 463], ["SCoV-mediated lung cytopathology", "PROBLEM", 469, 501], ["infiltrating eosinophils", "OBSERVATION", 13, 37], ["infiltrating cells", "OBSERVATION", 102, 120], ["E6 cell", "OBSERVATION", 165, 172], ["culture fluid", "OBSERVATION", 173, 186], ["influenza virus", "OBSERVATION", 201, 216], ["left", "ANATOMY_MODIFIER", 260, 264], ["lungs", "ANATOMY", 458, 463], ["lung", "ANATOMY", 483, 487], ["cytopathology", "OBSERVATION", 488, 501]]], ["Although various strategies for SCoV vaccines, including expression of SCoV S protein in other viruses [18, 48, 49] , inactivated SCoV particles [50] [51] [52] [53] , DNA vaccines [17, 54] , recombinant S protein [55, 56] and other approaches [57, 58] , have been reported, to our knowledge this is the first report testing VLPs propagated in mammalian cells as SCoV vaccine candidates.", [["cells", "ANATOMY", 353, 358], ["SCoV S", "GENE_OR_GENE_PRODUCT", 71, 77], ["SCoV", "GENE_OR_GENE_PRODUCT", 130, 134], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["VLPs", "ORGANISM", 324, 328], ["mammalian cells", "CELL", 343, 358], ["SCoV", "ORGANISM", 362, 366], ["SCoV S protein", "PROTEIN", 71, 85], ["recombinant S protein", "PROTEIN", 191, 212], ["mammalian cells", "CELL_TYPE", 343, 358], ["SCoV", "SPECIES", 32, 36], ["SCoV vaccines", "TREATMENT", 32, 45], ["SCoV S protein in other viruses", "PROBLEM", 71, 102], ["inactivated SCoV particles", "TEST", 118, 144], ["DNA vaccines", "TEST", 167, 179], ["recombinant S protein", "TEST", 191, 212], ["other approaches", "TEST", 226, 242], ["testing VLPs", "TREATMENT", 316, 328], ["mammalian cells", "TREATMENT", 343, 358], ["SCoV vaccine candidates", "TREATMENT", 362, 385]]], ["It appears that chimeric VLPs produced from mammalian cells in this study were more immunogenic than were SCoV VLPs produced by using a baculovirus-expression system [38] ; immunization of the mice four times with 100 g of the baculovirus-derived SCoV VLPs in each immunization elicited neutralizing antibody titers that were no longer higher than those obtained in the present study.", [["cells", "ANATOMY", 54, 59], ["mammalian cells", "CELL", 44, 59], ["SCoV VLPs", "ORGANISM", 106, 115], ["baculovirus", "ORGANISM", 136, 147], ["mice", "ORGANISM", 193, 197], ["baculovirus", "ORGANISM", 227, 238], ["SCoV VLPs", "ORGANISM", 247, 256], ["chimeric VLPs", "PROTEIN", 16, 29], ["mammalian cells", "CELL_TYPE", 44, 59], ["SCoV VLPs", "PROTEIN", 247, 256], ["mice", "SPECIES", 193, 197], ["SCoV", "SPECIES", 106, 110], ["baculovirus", "SPECIES", 136, 147], ["mice", "SPECIES", 193, 197], ["baculovirus", "SPECIES", 227, 238], ["SCoV", "SPECIES", 247, 251], ["chimeric VLPs", "PROBLEM", 16, 29], ["mammalian cells", "PROBLEM", 44, 59], ["this study", "TEST", 63, 73], ["SCoV VLPs", "PROBLEM", 106, 115], ["a baculovirus-expression system", "TREATMENT", 134, 165], ["immunization", "TREATMENT", 173, 185], ["the baculovirus", "TREATMENT", 223, 238], ["SCoV VLPs", "TREATMENT", 247, 256], ["each immunization", "TREATMENT", 260, 277], ["neutralizing antibody titers", "TEST", 287, 315], ["the present study", "TEST", 366, 383], ["mammalian cells", "OBSERVATION", 44, 59]]], ["Use of inactivated SCoV as a SCoV vaccine is a similar vaccine strategy that was explored in the present study.", [["SCoV", "CHEMICAL", 19, 23], ["SCoV", "CHEMICAL", 29, 33], ["SCoV", "GENE_OR_GENE_PRODUCT", 19, 23], ["SCoV", "SPECIES", 19, 23], ["SCoV", "SPECIES", 29, 33], ["inactivated SCoV", "TREATMENT", 7, 23], ["a SCoV vaccine", "TREATMENT", 27, 41], ["a similar vaccine strategy", "TREATMENT", 45, 71], ["the present study", "TEST", 93, 110]]], ["Others reported that immunizing mice twice with 1 g of double-inactivated SCoV with alum elicited high titers of neutralizing antibodies [50] .", [["SCoV", "CHEMICAL", 74, 78], ["alum", "CHEMICAL", 84, 88], ["alum", "CHEMICAL", 84, 88], ["mice", "ORGANISM", 32, 36], ["SCoV", "ORGANISM", 74, 78], ["alum", "SIMPLE_CHEMICAL", 84, 88], ["neutralizing antibodies", "PROTEIN", 113, 136], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["SCoV", "SPECIES", 74, 78], ["immunizing mice", "TREATMENT", 21, 36], ["double-inactivated SCoV", "TREATMENT", 55, 78], ["alum elicited", "PROBLEM", 84, 97], ["neutralizing antibodies", "PROBLEM", 113, 136]]], ["A major negative aspect of the use of inactivated SCoV vaccines is that extreme care must be taken to completely inactivate infectious SCoV in the vaccine preparations.", [["SCoV", "GENE_OR_GENE_PRODUCT", 50, 54], ["SCoV", "CANCER", 135, 139], ["SCoV", "SPECIES", 50, 54], ["inactivated SCoV vaccines", "TREATMENT", 38, 63], ["the vaccine preparations", "TREATMENT", 143, 167]]], ["In contrast, a VLP-based vaccine strategy eliminates this safety concern.DiscussionAccumulated data suggest the importance of the compatibility of the S protein endodomain (or a cytoplasmic tail) and M protein for assembly of S protein into coronavirus or VLPs [40, 59, 60] ; in past reports, S protein assembly occurred if these two regions are derived from the same virus, but not from different coronaviruses.", [["cytoplasmic tail", "ANATOMY", 178, 194], ["cytoplasmic tail", "CELLULAR_COMPONENT", 178, 194], ["M protein", "GENE_OR_GENE_PRODUCT", 200, 209], ["S protein", "GENE_OR_GENE_PRODUCT", 226, 235], ["coronavirus", "ORGANISM", 241, 252], ["VLPs", "GENE_OR_GENE_PRODUCT", 256, 260], ["S protein", "GENE_OR_GENE_PRODUCT", 293, 302], ["S protein endodomain", "PROTEIN", 151, 171], ["cytoplasmic tail", "PROTEIN", 178, 194], ["M protein", "PROTEIN", 200, 209], ["S protein", "PROTEIN", 226, 235], ["S protein", "PROTEIN", 293, 302], ["a VLP-based vaccine strategy", "TREATMENT", 13, 41], ["the S protein endodomain", "TEST", 147, 171], ["M protein", "TEST", 200, 209], ["S protein into coronavirus", "PROBLEM", 226, 252], ["VLPs", "TEST", 256, 260], ["S protein", "TEST", 293, 302], ["the same virus", "PROBLEM", 359, 373], ["different coronaviruses", "PROBLEM", 388, 411]]], ["Accordingly, we were surprised to find the efficient production of chimeric VLPs carrying SCoV S protein and MHV-derived N, M and E proteins.", [["VLPs", "ORGANISM", 76, 80], ["SCoV S protein", "GENE_OR_GENE_PRODUCT", 90, 104], ["chimeric VLPs", "PROTEIN", 67, 80], ["SCoV S protein", "PROTEIN", 90, 104], ["MHV-derived N, M and E proteins", "PROTEIN", 109, 140], ["MHV", "SPECIES", 109, 112], ["chimeric VLPs", "PROBLEM", 67, 80], ["SCoV S protein", "TEST", 90, 104], ["MHV", "TEST", 109, 112]]], ["The present data suggest that the endodomain of SCoV S protein interacted efficiently with MHV M protein and assembled into VLPs.", [["SCoV S", "GENE_OR_GENE_PRODUCT", 48, 54], ["MHV M protein", "GENE_OR_GENE_PRODUCT", 91, 104], ["SCoV S protein", "PROTEIN", 48, 62], ["MHV M protein", "PROTEIN", 91, 104], ["MHV", "SPECIES", 91, 94], ["SCoV S protein", "PROBLEM", 48, 62], ["MHV M protein", "TREATMENT", 91, 104]]], ["The endodomain of coronavirus S proteins has two partially overlapping sub-regions, a N-terminal, \u223c18-residue-long, cysteine-rich region and a C-terminal, \u223c27-residue-long, charge-rich region (Fig. 5) .", [["N", "CHEMICAL", 86, 87], ["cysteine", "CHEMICAL", 116, 124], ["C", "CHEMICAL", 143, 144], ["coronavirus S proteins", "GENE_OR_GENE_PRODUCT", 18, 40], ["cysteine", "AMINO_ACID", 116, 124], ["coronavirus S proteins", "PROTEIN", 18, 40], ["N-terminal, \u223c18-residue-long, cysteine-rich region", "PROTEIN", 86, 136], ["C-terminal, \u223c27-residue-long, charge-rich region", "PROTEIN", 143, 191], ["The endodomain of coronavirus S proteins", "TEST", 0, 40], ["coronavirus", "OBSERVATION", 18, 29], ["two", "OBSERVATION_MODIFIER", 45, 48], ["partially", "OBSERVATION_MODIFIER", 49, 58], ["overlapping", "OBSERVATION_MODIFIER", 59, 70], ["sub", "OBSERVATION_MODIFIER", 71, 74], ["regions", "ANATOMY_MODIFIER", 75, 82], ["terminal", "OBSERVATION_MODIFIER", 88, 96], ["rich", "ANATOMY_MODIFIER", 125, 129], ["region", "ANATOMY_MODIFIER", 130, 136], ["terminal", "ANATOMY_MODIFIER", 145, 153], ["long", "OBSERVATION_MODIFIER", 167, 171], ["rich", "ANATOMY_MODIFIER", 180, 184], ["region", "ANATOMY_MODIFIER", 185, 191]]], ["MHV lacking the very C-terminal 12-amino-acid segment of the S protein endodomain is viable and replicates well in cell culture, suggesting that the removal of 12 carboxy-terminal residues does not inhibit interactions between the mutant S protein and the M protein [25, 26] .", [["cell culture", "ANATOMY", 115, 127], ["amino-acid", "CHEMICAL", 35, 45], ["C", "CHEMICAL", 21, 22], ["amino-acid", "CHEMICAL", 35, 45], ["carboxy", "CHEMICAL", 163, 170], ["MHV", "ORGANISM", 0, 3], ["cell culture", "CELL", 115, 127], ["C-terminal 12-amino-acid segment", "PROTEIN", 21, 53], ["S protein endodomain", "PROTEIN", 61, 81], ["12 carboxy-terminal residues", "PROTEIN", 160, 188], ["mutant S protein", "PROTEIN", 231, 247], ["M protein", "PROTEIN", 256, 265], ["MHV", "SPECIES", 0, 3], ["MHV", "TEST", 0, 3], ["the S protein endodomain", "TEST", 57, 81], ["cell culture", "TEST", 115, 127], ["the removal of 12 carboxy-terminal residues", "TREATMENT", 145, 188], ["the M protein", "TEST", 252, 265]]], ["In contrast, replication is severely impaired in MHV mutants lacking the very C-terminal 22 amino acids or 25 amino acids of the S protein endodomain, i.e., constituting the majority of the charge-rich region [26] .", [["amino acids", "CHEMICAL", 92, 103], ["amino acids", "CHEMICAL", 110, 121], ["C", "CHEMICAL", 78, 79], ["amino acids", "CHEMICAL", 92, 103], ["amino acids", "CHEMICAL", 110, 121], ["MHV", "ORGANISM", 49, 52], ["amino acids", "AMINO_ACID", 92, 103], ["amino acids", "AMINO_ACID", 110, 121], ["C-terminal 22 amino acids", "PROTEIN", 78, 103], ["S protein endodomain", "PROTEIN", 129, 149], ["charge-rich region", "PROTEIN", 190, 208], ["MHV", "SPECIES", 49, 52], ["severely impaired", "PROBLEM", 28, 45], ["amino acids", "TEST", 92, 103], ["amino acids", "TEST", 110, 121], ["the S protein endodomain", "TEST", 125, 149], ["severely", "OBSERVATION_MODIFIER", 28, 36], ["impaired", "OBSERVATION", 37, 45]]], ["Furthermore, a single point mutation of a charged amino acid to alanine in the charge-rich region of the endodomain has no detectable effect on the incorporation of a heterologous protein containing MHV S endodomain into virions, whereas mutants containing multiple charged residues-toalanine significantly reduce the incorporation of the protein into virions [26] .", [["virions", "ANATOMY", 221, 228], ["amino acid", "CHEMICAL", 50, 60], ["alanine", "CHEMICAL", 64, 71], ["toalanine", "CHEMICAL", 283, 292], ["amino acid", "CHEMICAL", 50, 60], ["alanine", "CHEMICAL", 64, 71], ["toalanine", "CHEMICAL", 283, 292], ["amino acid", "AMINO_ACID", 50, 60], ["alanine", "AMINO_ACID", 64, 71], ["MHV S endodomain", "GENE_OR_GENE_PRODUCT", 199, 215], ["charge-rich region", "PROTEIN", 79, 97], ["endodomain", "PROTEIN", 105, 115], ["heterologous protein", "PROTEIN", 167, 187], ["MHV S endodomain", "PROTEIN", 199, 215], ["MHV", "SPECIES", 199, 202], ["a single point mutation", "PROBLEM", 13, 36], ["a charged amino acid", "TREATMENT", 40, 60], ["a heterologous protein", "TREATMENT", 165, 187], ["MHV S endodomain into virions", "TREATMENT", 199, 228], ["multiple charged residues", "PROBLEM", 257, 282], ["toalanine", "TREATMENT", 283, 292], ["no", "UNCERTAINTY", 120, 122], ["detectable effect", "OBSERVATION", 123, 140], ["multiple", "OBSERVATION_MODIFIER", 257, 265], ["charged residues", "OBSERVATION", 266, 282]]], ["These data suggest that the charge-rich region of the endodomain plays a key role in the selective inclusion of the S protein into the virion.", [["virion", "ANATOMY", 135, 141], ["virion", "CELLULAR_COMPONENT", 135, 141], ["charge-rich region", "PROTEIN", 28, 46], ["endodomain", "PROTEIN", 54, 64], ["S protein", "PROTEIN", 116, 125], ["virion", "ANATOMY", 135, 141]]], ["We noted that there were 6 charged residues between the transmembrane domain and the C-terminal 12 amino acids in both SCoV and MHV, while only 3 charged residues are found in feline infectious peritonitis virus (FIPV) (Fig. 5) .", [["transmembrane", "ANATOMY", 56, 69], ["amino acids", "CHEMICAL", 99, 110], ["feline infectious peritonitis", "DISEASE", 176, 205], ["C", "CHEMICAL", 85, 86], ["amino acids", "CHEMICAL", 99, 110], ["transmembrane", "CELLULAR_COMPONENT", 56, 69], ["amino acids", "AMINO_ACID", 99, 110], ["SCoV", "GENE_OR_GENE_PRODUCT", 119, 123], ["feline infectious peritonitis virus", "ORGANISM", 176, 211], ["transmembrane domain", "PROTEIN", 56, 76], ["C-terminal 12 amino acids", "PROTEIN", 85, 110], ["SCoV", "PROTEIN", 119, 123], ["MHV", "PROTEIN", 128, 131], ["feline infectious peritonitis virus", "SPECIES", 176, 211], ["MHV", "SPECIES", 128, 131], ["feline infectious peritonitis virus", "SPECIES", 176, 211], ["FIPV", "SPECIES", 213, 217], ["6 charged residues between the transmembrane domain", "PROBLEM", 25, 76], ["the C-terminal 12 amino acids", "TREATMENT", 81, 110], ["MHV", "TREATMENT", 128, 131], ["feline infectious peritonitis virus", "PROBLEM", 176, 211], ["MHV", "ANATOMY", 128, 131], ["feline", "OBSERVATION_MODIFIER", 176, 182], ["infectious", "OBSERVATION_MODIFIER", 183, 193], ["peritonitis", "OBSERVATION", 194, 205]]], ["FIPV S protein is not assembled into VLPs or viruses that carry MHV M, N and E proteins [25] .", [["FIPV S", "GENE_OR_GENE_PRODUCT", 0, 6], ["VLPs", "GENE_OR_GENE_PRODUCT", 37, 41], ["FIPV S protein", "PROTEIN", 0, 14], ["MHV M, N and E proteins", "PROTEIN", 64, 87], ["FIPV", "SPECIES", 0, 4], ["MHV", "SPECIES", 64, 67], ["FIPV S protein", "TEST", 0, 14], ["viruses", "PROBLEM", 45, 52], ["MHV M", "TEST", 64, 69], ["N and E proteins", "TEST", 71, 87]]], ["Accordingly, the presence of the same number of charged residues at the region of the endodomain, which is considered to be important for S protein assembly into virus particles, in both SCoV and MHV implies that both viruses had a similar structure in this portion of the endodomain, allowing them to interact with MHV M protein.DiscussionInoculation of mice with a mixture of chimeric VLPs and alum, but not that of MHV VLPs and alum, induced antibodies that neutralized SCoV (Fig. 3) .", [["alum", "CHEMICAL", 396, 400], ["alum", "CHEMICAL", 431, 435], ["alum", "CHEMICAL", 396, 400], ["alum", "CHEMICAL", 431, 435], ["S protein", "GENE_OR_GENE_PRODUCT", 138, 147], ["SCoV", "GENE_OR_GENE_PRODUCT", 187, 191], ["MHV M protein", "GENE_OR_GENE_PRODUCT", 316, 329], ["mice", "ORGANISM", 355, 359], ["VLPs", "ORGANISM", 387, 391], ["alum", "SIMPLE_CHEMICAL", 396, 400], ["MHV VLPs", "ORGANISM", 418, 426], ["alum", "SIMPLE_CHEMICAL", 431, 435], ["endodomain", "PROTEIN", 86, 96], ["S protein", "PROTEIN", 138, 147], ["SCoV", "PROTEIN", 187, 191], ["MHV M protein", "PROTEIN", 316, 329], ["chimeric VLPs", "PROTEIN", 378, 391], ["MHV VLPs", "PROTEIN", 418, 426], ["alum, induced antibodies", "PROTEIN", 431, 455], ["SCoV", "PROTEIN", 473, 477], ["mice", "SPECIES", 355, 359], ["MHV", "SPECIES", 196, 199], ["MHV", "SPECIES", 316, 319], ["mice", "SPECIES", 355, 359], ["MHV", "SPECIES", 418, 421], ["charged residues", "PROBLEM", 48, 64], ["S protein assembly into virus particles", "PROBLEM", 138, 177], ["both viruses", "PROBLEM", 213, 225], ["MHV M protein", "TREATMENT", 316, 329], ["chimeric VLPs and alum", "TREATMENT", 378, 400], ["MHV VLPs", "TREATMENT", 418, 426], ["alum", "TREATMENT", 431, 435], ["charged residues", "OBSERVATION", 48, 64], ["region", "ANATOMY_MODIFIER", 72, 78], ["considered to be", "UNCERTAINTY", 107, 123], ["both", "OBSERVATION_MODIFIER", 213, 217], ["viruses", "OBSERVATION", 218, 225], ["similar", "OBSERVATION_MODIFIER", 232, 239], ["structure", "OBSERVATION", 240, 249], ["MHV VLPs", "ANATOMY", 418, 426]]], ["The lack of heterologous protection confirmed that the SCoV S protein is the relevant constituent of the chimeric VLPs.", [["SCoV S", "GENE_OR_GENE_PRODUCT", 55, 61], ["VLPs", "GENE_OR_GENE_PRODUCT", 114, 118], ["SCoV S protein", "PROTEIN", 55, 69], ["chimeric VLPs", "PROTEIN", 105, 118], ["heterologous protection", "TREATMENT", 12, 35], ["the SCoV S protein", "TEST", 51, 69], ["the chimeric VLPs", "PROBLEM", 101, 118]]], ["As has been observed in other VLP systems [61, 62] , the particles themselves are immunogenic after 1 or 2 injections and provided protection when challenge was carried out after the second i.m. injection of only 2 g.", [["the second i.m. injection", "TREATMENT", 179, 204]]], ["Addition of alum adjuvant enhanced induction of neutralizing antibodies, and indeed titers reached those post-infection after two injections of 2 g.", [["alum", "CHEMICAL", 12, 16], ["alum", "CHEMICAL", 12, 16], ["alum", "SIMPLE_CHEMICAL", 12, 16], ["neutralizing antibodies", "PROTEIN", 48, 71], ["alum adjuvant enhanced induction", "TREATMENT", 12, 44], ["neutralizing antibodies", "TREATMENT", 48, 71], ["indeed titers", "PROBLEM", 77, 90], ["alum adjuvant", "OBSERVATION", 12, 25]]], ["All VLP groups had significant protection as evidenced by reduction in lung viral titers 2 days after virulent virus challenge, the optimum time to detect replication in the Balb/c mouse [23] .", [["lung", "ANATOMY", 71, 75], ["lung", "ORGAN", 71, 75], ["Balb/c mouse", "ORGANISM", 174, 186], ["mouse", "SPECIES", 181, 186], ["Balb/c mouse", "SPECIES", 174, 186], ["lung viral titers", "PROBLEM", 71, 88], ["virulent virus challenge", "TREATMENT", 102, 126], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["protection", "OBSERVATION", 31, 41], ["reduction", "OBSERVATION_MODIFIER", 58, 67], ["lung", "ANATOMY", 71, 75], ["viral titers", "OBSERVATION", 76, 88]]], ["Higher neutralizing antibody titers correlated with lower virus content, and the 2 g plus alum groups had no detectable virus.", [["alum", "CHEMICAL", 90, 94], ["Higher neutralizing antibody titers", "TEST", 0, 35], ["lower virus content", "PROBLEM", 52, 71], ["the 2 g plus alum groups", "TEST", 77, 101], ["detectable virus", "PROBLEM", 109, 125], ["no", "UNCERTAINTY", 106, 108], ["detectable", "OBSERVATION_MODIFIER", 109, 119], ["virus", "OBSERVATION", 120, 125]]], ["Overall, our data were in agreement with past reports revealing the importance of SCoV-specific neutralizing antibodies, most of which recognize S protein, for curbing SCoV replication in the lung [21, [63] [64] [65] [66] [67] .DiscussionImmunization of mice with Venezuelan equine encephalitis virus replicon particles encoding SCoV N protein induced an enhanced immunopathology, that included infiltrating eosinophils in the lungs, following SCoV challenge [68] , implying the possibility that a SCoV vaccine lacking N protein expression may be desirable, as it would reduce the potential risk of immunopathological changes primed by immunization.", [["lung", "ANATOMY", 192, 196], ["eosinophils", "ANATOMY", 408, 419], ["lungs", "ANATOMY", 427, 432], ["Venezuelan equine encephalitis", "DISEASE", 264, 294], ["SCoV", "CHEMICAL", 444, 448], ["SCoV", "GENE_OR_GENE_PRODUCT", 82, 86], ["S protein", "GENE_OR_GENE_PRODUCT", 145, 154], ["SCoV", "GENE_OR_GENE_PRODUCT", 168, 172], ["lung", "ORGAN", 192, 196], ["[63] [64] [65] [66", "SIMPLE_CHEMICAL", 202, 220], ["mice", "ORGANISM", 254, 258], ["Venezuelan equine encephalitis virus", "ORGANISM", 264, 300], ["SCoV N protein", "GENE_OR_GENE_PRODUCT", 329, 343], ["eosinophils", "CELL", 408, 419], ["lungs", "ORGAN", 427, 432], ["SCoV", "GENE_OR_GENE_PRODUCT", 498, 502], ["SCoV", "PROTEIN", 82, 86], ["neutralizing antibodies", "PROTEIN", 96, 119], ["S protein", "PROTEIN", 145, 154], ["SCoV N protein", "PROTEIN", 329, 343], ["infiltrating eosinophils", "CELL_TYPE", 395, 419], ["N protein", "PROTEIN", 519, 528], ["mice", "SPECIES", 254, 258], ["Venezuelan equine encephalitis virus", "SPECIES", 264, 300], ["mice", "SPECIES", 254, 258], ["Venezuelan equine encephalitis virus", "SPECIES", 264, 300], ["SCoV-specific neutralizing antibodies", "PROBLEM", 82, 119], ["Venezuelan equine encephalitis virus replicon particles", "TREATMENT", 264, 319], ["an enhanced immunopathology", "PROBLEM", 352, 379], ["infiltrating eosinophils in the lungs", "PROBLEM", 395, 432], ["SCoV challenge", "TREATMENT", 444, 458], ["a SCoV vaccine lacking N protein expression", "TREATMENT", 496, 539], ["immunopathological changes", "PROBLEM", 599, 625], ["lung", "ANATOMY", 192, 196], ["immunopathology", "OBSERVATION", 364, 379], ["infiltrating eosinophils", "OBSERVATION", 395, 419], ["lungs", "ANATOMY", 427, 432], ["immunopathological", "OBSERVATION", 599, 617]]], ["In this regard, chimeric VLPs carrying MHV N protein or those lacking N protein (unpublished data) could eliminate the possible induction of SCoV N protein-induced immunopathology.", [["immunopathology", "DISEASE", 164, 179], ["chimeric VLPs", "ORGANISM", 16, 29], ["MHV N protein", "GENE_OR_GENE_PRODUCT", 39, 52], ["SCoV N protein", "GENE_OR_GENE_PRODUCT", 141, 155], ["chimeric VLPs", "PROTEIN", 16, 29], ["MHV N protein", "PROTEIN", 39, 52], ["N protein", "PROTEIN", 70, 79], ["SCoV N protein", "PROTEIN", 141, 155], ["MHV", "SPECIES", 39, 42], ["chimeric VLPs", "TREATMENT", 16, 29], ["MHV N protein", "TREATMENT", 39, 52], ["SCoV N protein", "PROBLEM", 141, 155], ["induced immunopathology", "PROBLEM", 156, 179]]], ["The efficient production of chimeric VLP from CHO cells as we report in this study is promising as a new strategy for preparing VLP-based SCoV vaccine from mammalian cells; its suitability for preparing large quantities of VLP-based vaccine against SCoV remains to be determined.", [["CHO cells", "ANATOMY", 46, 55], ["cells", "ANATOMY", 166, 171], ["VLP", "GENE_OR_GENE_PRODUCT", 37, 40], ["CHO cells", "CELL", 46, 55], ["VLP", "ORGANISM", 128, 131], ["SCoV", "ORGANISM", 138, 142], ["mammalian cells", "CELL", 156, 171], ["VLP", "ORGANISM", 223, 226], ["SCoV", "CANCER", 249, 253], ["chimeric VLP", "PROTEIN", 28, 40], ["CHO cells", "CELL_LINE", 46, 55], ["mammalian cells", "CELL_TYPE", 156, 171], ["SCoV", "SPECIES", 138, 142], ["SCoV", "SPECIES", 249, 253], ["chimeric VLP from CHO cells", "PROBLEM", 28, 55], ["this study", "TEST", 72, 82], ["a new strategy", "TREATMENT", 99, 113], ["preparing VLP", "TREATMENT", 118, 131], ["based SCoV vaccine", "TREATMENT", 132, 150], ["mammalian cells", "TREATMENT", 156, 171], ["VLP-based vaccine", "TREATMENT", 223, 240], ["SCoV", "TREATMENT", 249, 253]]], ["Further improvements of chimeric VLP production, e.g., codon-optimization of the SCoV S gene and MHV N, M and E genes in the expression plasmids and development of an inexpensive transfection reagent and/or procedure, would be required for the substantial enhancement of chimeric VLP production.DiscussionAccumulated data suggest that antibodies against the FIPV S protein fail to protect cats from FIPV challenge and enhance virus replication in the host through antibody-dependent enhancement (ADE) [69] [70] [71] [72] [73] .", [["plasmids", "ANATOMY", 136, 144], ["FIPV", "CHEMICAL", 399, 403], ["SCoV S", "GENE_OR_GENE_PRODUCT", 81, 87], ["MHV N", "GENE_OR_GENE_PRODUCT", 97, 102], ["VLP", "GENE_OR_GENE_PRODUCT", 280, 283], ["FIPV S", "GENE_OR_GENE_PRODUCT", 358, 364], ["cats", "ORGANISM", 389, 393], ["SCoV S gene", "DNA", 81, 92], ["MHV N, M and E genes", "DNA", 97, 117], ["expression plasmids", "DNA", 125, 144], ["antibodies", "PROTEIN", 335, 345], ["FIPV S protein", "PROTEIN", 358, 372], ["cats", "SPECIES", 389, 393], ["MHV", "SPECIES", 97, 100], ["FIPV", "SPECIES", 399, 403], ["chimeric VLP production", "PROBLEM", 24, 47], ["the SCoV S gene", "TREATMENT", 77, 92], ["MHV N, M and E genes", "TREATMENT", 97, 117], ["the expression plasmids", "TREATMENT", 121, 144], ["an inexpensive transfection reagent", "TREATMENT", 164, 199], ["procedure", "TREATMENT", 207, 216], ["chimeric VLP production", "PROBLEM", 271, 294], ["antibodies", "TEST", 335, 345], ["the FIPV S protein", "TEST", 354, 372], ["FIPV challenge", "TREATMENT", 399, 413], ["enhance virus replication", "TREATMENT", 418, 443], ["chimeric VLP production", "OBSERVATION", 24, 47], ["chimeric VLP", "OBSERVATION", 271, 283]]], ["It has been reported that antibodies that neutralize most human SCoV isolates enhance entry of a SCoV isolate from the civet in the cell culture level [74] , but it is unclear whether ADE occurs in animals that are immunized with SCoV vaccine candidates.", [["cell culture", "ANATOMY", 132, 144], ["human", "ORGANISM", 58, 63], ["SCoV isolates", "ORGANISM", 64, 77], ["SCoV", "GENE_OR_GENE_PRODUCT", 97, 101], ["cell culture", "CELL", 132, 144], ["SCoV", "GENE_OR_GENE_PRODUCT", 230, 234], ["antibodies", "PROTEIN", 26, 36], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["SCoV", "SPECIES", 230, 234], ["antibodies", "TREATMENT", 26, 36], ["a SCoV isolate", "TREATMENT", 95, 109], ["the cell culture level", "TEST", 128, 150], ["SCoV vaccine candidates", "TREATMENT", 230, 253]]], ["We did not observe signs of ADE in our study; the mice that were immunized with chimeric VLPs or initially inoculated with SCoV efficiently suppressed challenged SCoV replication.", [["ADE", "DISEASE", 28, 31], ["SCoV", "CHEMICAL", 123, 127], ["mice", "ORGANISM", 50, 54], ["chimeric VLPs", "ORGANISM", 80, 93], ["SCoV", "GENE_OR_GENE_PRODUCT", 123, 127], ["SCoV", "GENE_OR_GENE_PRODUCT", 162, 166], ["SCoV", "PROTEIN", 123, 127], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["SCoV", "SPECIES", 123, 127], ["SCoV", "SPECIES", 162, 166], ["our study", "TEST", 35, 44], ["chimeric VLPs", "TREATMENT", 80, 93], ["SCoV efficiently", "TREATMENT", 123, 139], ["SCoV replication", "TREATMENT", 162, 178]]], ["S protein in chimeric VLPs was derived from a SCoV Urbani strain, which was also used as the challenge virus, and VLPs induced antibodies that readily neutralized SCoV in vitro.", [["SCoV Urbani", "ORGANISM", 46, 57], ["VLPs", "ORGANISM", 114, 118], ["SCoV", "GENE_OR_GENE_PRODUCT", 163, 167], ["S protein", "PROTEIN", 0, 9], ["chimeric VLPs", "PROTEIN", 13, 26], ["antibodies", "PROTEIN", 127, 137], ["SCoV", "PROTEIN", 163, 167], ["SCoV", "SPECIES", 163, 167], ["S protein in chimeric VLPs", "PROBLEM", 0, 26], ["a SCoV Urbani strain", "TREATMENT", 44, 64], ["the challenge virus", "TREATMENT", 89, 108], ["VLPs induced antibodies", "TREATMENT", 114, 137], ["chimeric VLPs", "ANATOMY", 13, 26]]], ["In this regard, it is worth noting that immunization of mice with a Venezuelan equine encephalitis virus replicon carrying S protein of the Urbani strain showed only limited protection against heterologous SCoV that contained S gene from the human GD03 isolate [68] .DiscussionSubbarao et al. reported mild and focal peribronchiolar mononuclear inflammatory infiltrates and SCoV antigens in bronchiolar epithelial cells in the lungs of BALB/c mice at 2 days post SCoV inoculation [23] .", [["peribronchiolar mononuclear", "ANATOMY", 317, 344], ["bronchiolar epithelial cells", "ANATOMY", 391, 419], ["lungs", "ANATOMY", 427, 432], ["Venezuelan equine encephalitis", "DISEASE", 68, 98], ["SCoV", "CHEMICAL", 463, 467], ["mice", "ORGANISM", 56, 60], ["Venezuelan equine encephalitis virus", "ORGANISM", 68, 104], ["S protein", "GENE_OR_GENE_PRODUCT", 123, 132], ["Urbani strain", "ORGANISM", 140, 153], ["SCoV", "GENE_OR_GENE_PRODUCT", 206, 210], ["human", "ORGANISM", 242, 247], ["GD03", "GENE_OR_GENE_PRODUCT", 248, 252], ["peribronchiolar mononuclear", "CELL", 317, 344], ["SCoV antigens", "GENE_OR_GENE_PRODUCT", 374, 387], ["bronchiolar epithelial cells", "CELL", 391, 419], ["lungs", "ORGAN", 427, 432], ["BALB/c mice", "ORGANISM", 436, 447], ["S protein", "PROTEIN", 123, 132], ["heterologous SCoV", "DNA", 193, 210], ["S gene", "DNA", 226, 232], ["peribronchiolar mononuclear inflammatory infiltrates", "CELL_TYPE", 317, 369], ["SCoV antigens", "PROTEIN", 374, 387], ["bronchiolar epithelial cells", "CELL_TYPE", 391, 419], ["mice", "SPECIES", 56, 60], ["Venezuelan equine encephalitis virus", "SPECIES", 68, 104], ["human", "SPECIES", 242, 247], ["mice", "SPECIES", 443, 447], ["mice", "SPECIES", 56, 60], ["Venezuelan equine encephalitis virus", "SPECIES", 68, 104], ["SCoV", "SPECIES", 206, 210], ["human", "SPECIES", 242, 247], ["mice", "SPECIES", 443, 447], ["immunization of mice", "TREATMENT", 40, 60], ["a Venezuelan equine encephalitis virus replicon", "TREATMENT", 66, 113], ["the Urbani strain", "TEST", 136, 153], ["heterologous SCoV", "PROBLEM", 193, 210], ["mild and focal peribronchiolar mononuclear inflammatory infiltrates", "PROBLEM", 302, 369], ["SCoV antigens", "PROBLEM", 374, 387], ["bronchiolar epithelial cells", "PROBLEM", 391, 419], ["SCoV inoculation", "TREATMENT", 463, 479], ["mild", "OBSERVATION_MODIFIER", 302, 306], ["focal", "OBSERVATION_MODIFIER", 311, 316], ["peribronchiolar mononuclear", "OBSERVATION", 317, 344], ["inflammatory", "OBSERVATION_MODIFIER", 345, 357], ["infiltrates", "OBSERVATION", 358, 369], ["bronchiolar epithelial cells", "OBSERVATION", 391, 419], ["lungs", "ANATOMY", 427, 432]]], ["Staining with SCoV monoclonal antibody to N protein, we also found SCoV antigen within bronchiolar epithelial cells after challenge of unimmunized mice.", [["bronchiolar epithelial cells", "ANATOMY", 87, 115], ["SCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["SCoV antigen", "GENE_OR_GENE_PRODUCT", 67, 79], ["bronchiolar epithelial cells", "CELL", 87, 115], ["mice", "ORGANISM", 147, 151], ["SCoV monoclonal antibody", "PROTEIN", 14, 38], ["N protein", "PROTEIN", 42, 51], ["SCoV antigen", "PROTEIN", 67, 79], ["bronchiolar epithelial cells", "CELL_TYPE", 87, 115], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["Staining", "TEST", 0, 8], ["SCoV monoclonal antibody", "TEST", 14, 38], ["SCoV antigen", "PROBLEM", 67, 79], ["unimmunized mice", "TREATMENT", 135, 151], ["bronchiolar epithelial cells", "OBSERVATION", 87, 115]]], ["Consistent with the SCoV titers in the lungs, no viral antigen was detected in the lungs of the mice inoculated with chimeric VLPs.", [["lungs", "ANATOMY", 39, 44], ["lungs", "ANATOMY", 83, 88], ["SCoV", "GENE_OR_GENE_PRODUCT", 20, 24], ["lungs", "ORGAN", 39, 44], ["lungs", "ORGAN", 83, 88], ["mice", "ORGANISM", 96, 100], ["viral antigen", "PROTEIN", 49, 62], ["chimeric VLPs", "PROTEIN", 117, 130], ["mice", "SPECIES", 96, 100], ["SCoV", "SPECIES", 20, 24], ["mice", "SPECIES", 96, 100], ["the SCoV titers", "TEST", 16, 31], ["viral antigen", "PROBLEM", 49, 62], ["chimeric VLPs", "TREATMENT", 117, 130], ["SCoV titers", "OBSERVATION", 20, 31], ["lungs", "ANATOMY", 39, 44], ["no", "UNCERTAINTY", 46, 48], ["viral", "OBSERVATION", 49, 54], ["lungs", "ANATOMY", 83, 88]]], ["The absence of SCoV antigen in the lungs of VLP-immunized mice or mice pre-exposed to live virus, as indicated by the results of IHC staining (Fig. 4B) , strongly argue for the efficacy of chimeric VLPs in protecting against SARS-CoV infection.", [["lungs", "ANATOMY", 35, 40], ["SARS-CoV infection", "DISEASE", 225, 243], ["SCoV antigen", "GENE_OR_GENE_PRODUCT", 15, 27], ["lungs", "ORGAN", 35, 40], ["VLP-immunized mice", "ORGANISM", 44, 62], ["mice", "ORGANISM", 66, 70], ["live virus", "ORGANISM", 86, 96], ["VLPs", "ORGANISM", 198, 202], ["SARS-CoV", "ORGANISM", 225, 233], ["SCoV antigen", "PROTEIN", 15, 27], ["chimeric VLPs", "PROTEIN", 189, 202], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 66, 70], ["SARS-CoV", "SPECIES", 225, 233], ["SCoV antigen", "PROBLEM", 15, 27], ["VLP", "TREATMENT", 44, 47], ["live virus", "PROBLEM", 86, 96], ["IHC staining", "TEST", 129, 141], ["chimeric VLPs", "TREATMENT", 189, 202], ["SARS", "PROBLEM", 225, 229], ["CoV infection", "PROBLEM", 230, 243], ["lungs", "ANATOMY", 35, 40], ["infection", "OBSERVATION", 234, 243]]], ["SCoV-induced histopathological changes that were detected in unimmunized mice in our study appeared to be similar or slightly more severe, especially with respect to the changes in the bronchioles, than those described in the report of Subbarao et al. [23] .", [["bronchioles", "ANATOMY", 185, 196], ["SCoV", "CHEMICAL", 0, 4], ["SCoV", "SIMPLE_CHEMICAL", 0, 4], ["mice", "ORGANISM", 73, 77], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 185, 196], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["SCoV", "PROBLEM", 0, 4], ["induced histopathological changes", "PROBLEM", 5, 38], ["our study", "TEST", 81, 90], ["the changes in the bronchioles", "PROBLEM", 166, 196], ["histopathological", "OBSERVATION", 13, 30], ["slightly", "OBSERVATION_MODIFIER", 117, 125], ["more severe", "OBSERVATION_MODIFIER", 126, 137], ["bronchioles", "ANATOMY", 185, 196]]], ["After SCoV challenge, the mice immunized with chimeric VLPs showed mixed peribronchiolar inflammatory infiltrates and a slight thickening of the peribronchiolar interstitium and alveolar walls.", [["peribronchiolar interstitium", "ANATOMY", 145, 173], ["alveolar walls", "ANATOMY", 178, 192], ["mice", "ORGANISM", 26, 30], ["peribronchiolar interstitium", "TISSUE", 145, 173], ["alveolar walls", "TISSUE", 178, 192], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["SCoV challenge", "TREATMENT", 6, 20], ["chimeric VLPs", "TEST", 46, 59], ["mixed peribronchiolar inflammatory infiltrates", "PROBLEM", 67, 113], ["a slight thickening of the peribronchiolar interstitium and alveolar walls", "PROBLEM", 118, 192], ["mixed", "OBSERVATION_MODIFIER", 67, 72], ["peribronchiolar", "OBSERVATION_MODIFIER", 73, 88], ["inflammatory", "OBSERVATION_MODIFIER", 89, 101], ["infiltrates", "OBSERVATION", 102, 113], ["slight", "OBSERVATION_MODIFIER", 120, 126], ["thickening", "OBSERVATION", 127, 137], ["peribronchiolar", "ANATOMY_MODIFIER", 145, 160], ["interstitium", "ANATOMY_MODIFIER", 161, 173], ["alveolar", "ANATOMY_MODIFIER", 178, 186], ["walls", "ANATOMY_MODIFIER", 187, 192]]], ["These lesions in immunized mice were milder than seen in unimmunized mice, demonstrating the effects of chimeric VLP immunization in suppressing SCoVinduced cytopathological changes in the lungs.", [["lesions", "ANATOMY", 6, 13], ["lungs", "ANATOMY", 189, 194], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["mice", "ORGANISM", 27, 31], ["mice", "ORGANISM", 69, 73], ["chimeric VLP", "ORGANISM", 104, 116], ["lungs", "ORGAN", 189, 194], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 69, 73], ["These lesions", "PROBLEM", 0, 13], ["chimeric VLP immunization", "TREATMENT", 104, 129], ["suppressing SCoVinduced cytopathological changes in the lungs", "PROBLEM", 133, 194], ["lesions", "OBSERVATION", 6, 13], ["milder", "OBSERVATION_MODIFIER", 37, 43], ["lungs", "ANATOMY", 189, 194]]], ["The mice immunized with a mixture of chimeric VLP and alum had higher neutralizing antibody titers than did those immunized with a mixture of the chimeric VLP and PBS, while both groups of the mice showed similar levels of SCoV-induced lung cytopathology, suggesting neither alum nor neutralizing antibody titers were sole determinant of the severity of inflammatory responses.", [["lung", "ANATOMY", 236, 240], ["alum", "CHEMICAL", 54, 58], ["SCoV", "CHEMICAL", 223, 227], ["alum", "CHEMICAL", 275, 279], ["mice", "ORGANISM", 4, 8], ["chimeric VLP", "ORGANISM", 37, 49], ["alum", "SIMPLE_CHEMICAL", 54, 58], ["VLP", "ORGANISM", 155, 158], ["mice", "ORGANISM", 193, 197], ["SCoV", "GENE_OR_GENE_PRODUCT", 223, 227], ["lung", "ORGAN", 236, 240], ["alum", "SIMPLE_CHEMICAL", 275, 279], ["chimeric VLP", "PROTEIN", 37, 49], ["chimeric VLP", "PROTEIN", 146, 158], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 193, 197], ["chimeric VLP", "TREATMENT", 37, 49], ["alum", "TREATMENT", 54, 58], ["higher neutralizing antibody titers", "PROBLEM", 63, 98], ["the chimeric VLP", "TREATMENT", 142, 158], ["PBS", "TEST", 163, 166], ["SCoV", "PROBLEM", 223, 227], ["induced lung cytopathology", "PROBLEM", 228, 254], ["neither alum nor neutralizing antibody titers", "PROBLEM", 267, 312], ["inflammatory responses", "PROBLEM", 354, 376], ["lung", "ANATOMY", 236, 240], ["cytopathology", "OBSERVATION", 241, 254], ["neutralizing antibody", "OBSERVATION", 284, 305], ["inflammatory", "OBSERVATION", 354, 366]]], ["Possible cellular immune responses against chimeric VLP proteins were suggested by the observation that the mice inoculated with a mixture of chimeric VLPs and PBS and that of chimeric VLPs and alum, but not other groups of mice, showed infiltration of neutrophils and eosinophils around the bronchioles and blood vessels.", [["cellular", "ANATOMY", 9, 17], ["neutrophils", "ANATOMY", 253, 264], ["eosinophils", "ANATOMY", 269, 280], ["bronchioles", "ANATOMY", 292, 303], ["blood vessels", "ANATOMY", 308, 321], ["cellular", "CELL", 9, 17], ["mice", "ORGANISM", 108, 112], ["VLPs", "ORGANISM", 151, 155], ["chimeric VLPs", "ORGANISM", 176, 189], ["alum", "SIMPLE_CHEMICAL", 194, 198], ["mice", "ORGANISM", 224, 228], ["neutrophils", "CELL", 253, 264], ["eosinophils", "CELL", 269, 280], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 292, 303], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 308, 321], ["chimeric VLP proteins", "PROTEIN", 43, 64], ["chimeric VLPs", "PROTEIN", 142, 155], ["chimeric VLPs", "PROTEIN", 176, 189], ["neutrophils", "CELL_TYPE", 253, 264], ["eosinophils", "CELL_TYPE", 269, 280], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 224, 228], ["cellular immune responses", "PROBLEM", 9, 34], ["chimeric VLP proteins", "PROBLEM", 43, 64], ["chimeric VLPs", "TREATMENT", 142, 155], ["PBS", "TREATMENT", 160, 163], ["chimeric VLPs and alum", "PROBLEM", 176, 198], ["infiltration of neutrophils", "PROBLEM", 237, 264], ["eosinophils", "TEST", 269, 280], ["cellular immune", "OBSERVATION", 9, 24], ["infiltration", "OBSERVATION", 237, 249], ["neutrophils", "OBSERVATION", 253, 264], ["eosinophils", "OBSERVATION", 269, 280], ["bronchioles", "ANATOMY", 292, 303], ["blood vessels", "ANATOMY", 308, 321]]], ["In contrast, it has been reported that immunization of mice with a mixture of inactivated SCoV with adjuvant MF59 primary elicited humoral immune response [75] .", [["SCoV", "CHEMICAL", 90, 94], ["MF59", "CHEMICAL", 109, 113], ["mice", "ORGANISM", 55, 59], ["SCoV", "GENE_OR_GENE_PRODUCT", 90, 94], ["MF59", "SIMPLE_CHEMICAL", 109, 113], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["SCoV", "SPECIES", 90, 94], ["immunization of mice", "TREATMENT", 39, 59], ["inactivated SCoV", "TREATMENT", 78, 94], ["adjuvant MF59", "TREATMENT", 100, 113]]], ["Further investigation, using not only Balb/c mice but also other SCoV susceptible mice [41, 76, 77] and other animal models [78, 79] , will be necessary to evaluate the implications and impact of cellular immune activities, including pulmonary infiltration of neutrophils and eosinophils, as well as the utility of chimeric VLPs as a SCoV vaccine.", [["cellular", "ANATOMY", 196, 204], ["pulmonary", "ANATOMY", 234, 243], ["neutrophils", "ANATOMY", 260, 271], ["eosinophils", "ANATOMY", 276, 287], ["Balb/c mice", "ORGANISM", 38, 49], ["mice", "ORGANISM", 82, 86], ["cellular", "CELL", 196, 204], ["pulmonary", "ORGAN", 234, 243], ["neutrophils", "CELL", 260, 271], ["eosinophils", "CELL", 276, 287], ["VLPs", "ORGANISM", 324, 328], ["SCoV", "CANCER", 334, 338], ["neutrophils", "CELL_TYPE", 260, 271], ["eosinophils", "CELL_TYPE", 276, 287], ["chimeric VLPs", "PROTEIN", 315, 328], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 82, 86], ["SCoV", "SPECIES", 334, 338], ["Further investigation", "TEST", 0, 21], ["other animal models", "TEST", 104, 123], ["cellular immune activities", "PROBLEM", 196, 222], ["pulmonary infiltration of neutrophils", "PROBLEM", 234, 271], ["eosinophils", "TEST", 276, 287], ["chimeric VLPs", "TREATMENT", 315, 328], ["a SCoV vaccine", "TREATMENT", 332, 346], ["cellular immune activities", "OBSERVATION", 196, 222], ["pulmonary", "ANATOMY", 234, 243], ["infiltration", "OBSERVATION", 244, 256]]]], "PMC7112794": [["IntroductionSevere acute respiratory syndrome (SARS), also called atypical pneumonia, is a human severe respiratory infectious disease that emerged recently in Asia, North America and Europe.", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["atypical pneumonia", "DISEASE", 66, 84], ["respiratory infectious disease", "DISEASE", 104, 134], ["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["atypical pneumonia", "PROBLEM", 66, 84], ["a human severe respiratory infectious disease", "PROBLEM", 89, 134], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["atypical", "OBSERVATION_MODIFIER", 66, 74], ["pneumonia", "OBSERVATION", 75, 84], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["respiratory", "ANATOMY", 104, 115], ["infectious", "OBSERVATION", 116, 126]]], ["The transmission of SARS occurs mainly by direct contact, and its incubation period is 2\u20137 days.", [["SARS", "DISEASE", 20, 24], ["SARS", "PROBLEM", 20, 24], ["SARS", "OBSERVATION", 20, 24]]], ["Infection is usually characterized by high fever, which is followed a few days, later by a dry non-productive cough and shortness of breath, and may progress to generalized interstitial infiltrates in the lung.", [["interstitial infiltrates", "ANATOMY", 173, 197], ["lung", "ANATOMY", 205, 209], ["Infection", "DISEASE", 0, 9], ["fever", "DISEASE", 43, 48], ["cough", "DISEASE", 110, 115], ["shortness of breath", "DISEASE", 120, 139], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 173, 197], ["lung", "ORGAN", 205, 209], ["Infection", "PROBLEM", 0, 9], ["high fever", "PROBLEM", 38, 48], ["a dry non-productive cough", "PROBLEM", 89, 115], ["shortness of breath", "PROBLEM", 120, 139], ["generalized interstitial infiltrates in the lung", "PROBLEM", 161, 209], ["high", "OBSERVATION_MODIFIER", 38, 42], ["fever", "OBSERVATION", 43, 48], ["non-productive", "OBSERVATION_MODIFIER", 95, 109], ["cough", "OBSERVATION", 110, 115], ["generalized", "OBSERVATION_MODIFIER", 161, 172], ["interstitial", "ANATOMY_MODIFIER", 173, 185], ["infiltrates", "OBSERVATION", 186, 197], ["lung", "ANATOMY", 205, 209]]], ["Death from progressive respiratory failure occurs in between 3\u201310% of cases (Rota et al., 2003).", [["respiratory", "ANATOMY", 23, 34], ["Death", "DISEASE", 0, 5], ["respiratory failure", "DISEASE", 23, 42], ["Death", "PROBLEM", 0, 5], ["progressive respiratory failure", "PROBLEM", 11, 42], ["progressive", "OBSERVATION_MODIFIER", 11, 22], ["respiratory failure", "OBSERVATION", 23, 42]]], ["At present, no effective therapy or vaccine is available.IntroductionA novel coronavirus, named as SARS\u2013CoV, has been identified as the main causative agent of SARS.", [["SARS", "DISEASE", 160, 164], ["coronavirus", "ORGANISM", 77, 88], ["SARS\u2013CoV", "ORGANISM", 99, 107], ["SARS\u2013CoV", "SPECIES", 99, 107], ["effective therapy", "TREATMENT", 15, 32], ["vaccine", "TREATMENT", 36, 43], ["IntroductionA novel coronavirus", "PROBLEM", 57, 88], ["no", "UNCERTAINTY", 12, 14], ["effective", "OBSERVATION_MODIFIER", 15, 24], ["therapy", "OBSERVATION", 25, 32]]], ["The virions are 80\u2013140 nm in diameter, with 20\u201340 nm complex surface projections surrounding the periphery.", [["virions", "ANATOMY", 4, 11], ["surface", "ANATOMY", 61, 68], ["virions", "OBSERVATION", 4, 11], ["140 nm", "OBSERVATION_MODIFIER", 19, 25], ["diameter", "OBSERVATION_MODIFIER", 29, 37], ["20\u201340 nm", "OBSERVATION_MODIFIER", 44, 52], ["complex", "OBSERVATION_MODIFIER", 53, 60], ["surface", "OBSERVATION_MODIFIER", 61, 68], ["periphery", "ANATOMY_MODIFIER", 97, 106]]], ["Hemagglutinin esterase type glycoprotein projections were not seen (Ksiazek et al., 2003).", [["Hemagglutinin esterase type glycoprotein", "GENE_OR_GENE_PRODUCT", 0, 40], ["Hemagglutinin esterase type glycoprotein", "PROTEIN", 0, 40], ["Hemagglutinin esterase type glycoprotein projections", "TREATMENT", 0, 52]]], ["The genome of SARS\u2013CoV is a single-stranded, positive-sense polyadenylated RNA molecule of approximately 29,727 nucleotides.", [["nucleotides", "CHEMICAL", 112, 123], ["SARS\u2013CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["SARS\u2013CoV", "DNA", 14, 22], ["single-stranded, positive-sense polyadenylated RNA molecule", "RNA", 28, 87], ["a single-stranded, positive-sense polyadenylated RNA molecule", "PROBLEM", 26, 87], ["sense polyadenylated", "OBSERVATION_MODIFIER", 54, 74], ["RNA molecule", "OBSERVATION", 75, 87]]], ["The genomic organization is typical of coronaviruses, having the characteristic gene order [5\u2032-replicase (rep), spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3\u2032] and short untranslated regions at both termini.", [["coronaviruses", "ORGANISM", 39, 52], ["rep", "GENE_OR_GENE_PRODUCT", 106, 109], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 112, 135], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["nucleocapsid (N)-3", "GENE_OR_GENE_PRODUCT", 155, 173], ["5\u2032-replicase", "DNA", 92, 104], ["rep", "DNA", 106, 109], ["E", "DNA", 133, 134], ["nucleocapsid (N)-3\u2032", "DNA", 155, 174], ["short untranslated regions", "DNA", 180, 206], ["coronaviruses", "PROBLEM", 39, 52], ["spike (S), envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 112, 171], ["short untranslated regions", "PROBLEM", 180, 206], ["genomic organization", "OBSERVATION", 4, 24], ["coronaviruses", "OBSERVATION", 39, 52], ["both", "ANATOMY_MODIFIER", 210, 214], ["termini", "ANATOMY_MODIFIER", 215, 222]]], ["The SARS\u2013CoV rep gene is predicted to encode two polyproteins that undergo co-translational proteolytic processing.", [["SARS\u2013CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["SARS\u2013CoV rep gene", "DNA", 4, 21], ["The SARS\u2013CoV rep gene", "TREATMENT", 0, 21], ["two polyproteins", "PROBLEM", 45, 61], ["co-translational proteolytic processing", "TREATMENT", 75, 114]]], ["There are four open reading frames (ORF) downstream of rep that are predicted to encode the four structural proteins S, E, M and N, which are common to all known coronavirus.", [["rep", "GENE_OR_GENE_PRODUCT", 55, 58], ["E", "GENE_OR_GENE_PRODUCT", 120, 121], ["coronavirus", "ORGANISM", 162, 173], ["open reading frames", "DNA", 15, 34], ["ORF", "DNA", 36, 39], ["rep", "DNA", 55, 58], ["S", "PROTEIN", 117, 118], ["E", "PROTEIN", 120, 121], ["N", "PROTEIN", 129, 130], ["coronavirus", "OBSERVATION", 162, 173]]], ["Additionally, SARS\u2013CoV also encodes several non-structural proteins (Rota et al., 2003).IntroductionThe clinical case definition of SARS is essentially one of fever and pneumonia, with or without a contact history.", [["SARS", "DISEASE", 132, 136], ["fever", "DISEASE", 159, 164], ["pneumonia", "DISEASE", 169, 178], ["SARS\u2013CoV", "ORGANISM", 14, 22], ["non-structural proteins", "PROTEIN", 44, 67], ["SARS\u2013CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 132, 136], ["fever", "PROBLEM", 159, 164], ["pneumonia", "PROBLEM", 169, 178], ["pneumonia", "OBSERVATION", 169, 178]]], ["There are many causes of pneumonia and in the absence of a definite history of contact with other patients with SARS, therefore, it is difficult to differentiate SARS from other causes of pneumonia in clinic diagnosis.", [["pneumonia", "DISEASE", 25, 34], ["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 162, 166], ["pneumonia", "DISEASE", 188, 197], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["pneumonia", "PROBLEM", 25, 34], ["SARS", "PROBLEM", 112, 116], ["SARS", "PROBLEM", 162, 166], ["pneumonia", "PROBLEM", 188, 197], ["pneumonia", "OBSERVATION", 25, 34], ["pneumonia", "OBSERVATION", 188, 197]]], ["Laboratory tests that can confirm a diagnosis of SARS\u2013CoV infection early in the course of the illness are, therefore, a critical clinical need (Riley et al., 2003).", [["CoV infection", "DISEASE", 54, 67], ["SARS\u2013CoV", "ORGANISM", 49, 57], ["SARS\u2013CoV", "SPECIES", 49, 57], ["Laboratory tests", "TEST", 0, 16], ["SARS\u2013CoV infection", "PROBLEM", 49, 67], ["CoV", "OBSERVATION_MODIFIER", 54, 57], ["infection", "OBSERVATION", 58, 67]]], ["Since the outbreak of SARS in 2003, several laboratory diagnostic methods have been established, including real-time RT-PCR assay, whole-virus-based immunofluorescence assay (IFA), recombinant protein-based enzyme-linked immunosorbent assay (ELISA) and immunochromatographic tests, antigen-capturing enzyme-linked immunosorbent assay, and Western blot (WB) assay.", [["SARS", "DISEASE", 22, 26], ["recombinant protein", "PROTEIN", 181, 200], ["enzyme", "PROTEIN", 207, 213], ["SARS", "PROBLEM", 22, 26], ["PCR assay", "TEST", 120, 129], ["whole-virus", "TEST", 131, 142], ["immunofluorescence assay", "TEST", 149, 173], ["IFA", "TEST", 175, 178], ["recombinant protein", "TEST", 181, 200], ["enzyme-linked immunosorbent assay", "TEST", 207, 240], ["ELISA", "TEST", 242, 247], ["immunochromatographic tests", "TEST", 253, 280], ["antigen", "TEST", 282, 289], ["enzyme", "TEST", 300, 306], ["immunosorbent assay", "TEST", 314, 333], ["Western blot", "TEST", 339, 351]]], ["These methods were critically important for controlling the transmission of SARS; furthermore, many new laboratory diagnostic methods are being developed (Poon et al., 2003, Poon et al., 2004, Shi et al., 2003, Guan et al., 2004, He et al., 2004).IntroductionThe M protein is an important structural protein of the coronavirus.", [["SARS", "DISEASE", 76, 80], ["coronavirus", "ORGANISM", 315, 326], ["M protein", "PROTEIN", 263, 272], ["structural protein", "PROTEIN", 289, 307], ["coronavirus", "SPECIES", 315, 326], ["SARS", "PROBLEM", 76, 80], ["The M protein", "TEST", 259, 272], ["the coronavirus", "PROBLEM", 311, 326]]], ["In the cases of other known coronaviruses, it is the most abundant among the structural proteins and can induce antibody-dependent complement-mediated virus neutralization (Woods et al., 1987).", [["coronaviruses", "ORGANISM", 28, 41], ["structural proteins", "PROTEIN", 77, 96], ["other known coronaviruses", "PROBLEM", 16, 41], ["antibody", "TEST", 112, 120], ["mediated virus neutralization", "PROBLEM", 142, 171], ["coronaviruses", "OBSERVATION", 28, 41]]], ["In addition, the M protein is also involved in the assembly and budding of virions together with the E protein.", [["virions", "ANATOMY", 75, 82], ["E protein", "GENE_OR_GENE_PRODUCT", 101, 110], ["M protein", "PROTEIN", 17, 26], ["E protein", "PROTEIN", 101, 110], ["the M protein", "TEST", 13, 26]]], ["The M protein contains highly conserved glycosylated sequences, and its glycosylation may be related to the interaction between virus and host (de Haan et al., 2002, de Haan et al., 1998).", [["M protein", "PROTEIN", 4, 13], ["The M protein", "TEST", 0, 13]]], ["The important role of the M protein in the life cycle of coronaviruses and inducing immunity make it an attractive target for anti-SARS drug research, vaccine development and the establishment of a serological detection assay.", [["coronaviruses", "ORGANISM", 57, 70], ["M protein", "PROTEIN", 26, 35], ["the M protein", "TREATMENT", 22, 35], ["coronaviruses", "PROBLEM", 57, 70], ["anti-SARS drug research", "TREATMENT", 126, 149], ["vaccine", "TREATMENT", 151, 158], ["a serological detection assay", "TEST", 196, 225]]], ["Here, we report the expression of recombinant M protein in P. Pastoris and its antigenicity.Gene and vector ::: Materials and methodsThe genomic cDNA of SARS\u2013CoV strain BJ01 was provided by Huada Gene Company.", [["P. Pastoris", "ORGANISM", 59, 70], ["SARS\u2013CoV", "ORGANISM", 153, 161], ["recombinant M protein", "PROTEIN", 34, 55], ["genomic cDNA", "DNA", 137, 149], ["P. Pastoris", "SPECIES", 59, 70], ["P. Pastoris", "SPECIES", 59, 70], ["SARS\u2013CoV strain BJ01", "SPECIES", 153, 173], ["recombinant M protein in P. Pastoris", "PROBLEM", 34, 70], ["SARS\u2013CoV strain BJ01", "PROBLEM", 153, 173]]], ["The P. Pastoris expression vector pPICZ\u03b1A and yeast host strain GS115 were all purchased from Invitrogen company.Human sera ::: Materials and methodsSera from healthy people and SARS patients were collected from Peking Union Medical College Hospital between April and June 2003.", [["sera", "ANATOMY", 119, 123], ["GS115", "CHEMICAL", 64, 69], ["SARS", "DISEASE", 178, 182], ["P. Pastoris", "ORGANISM", 4, 15], ["Human", "ORGANISM", 113, 118], ["sera", "ORGANISM_SUBSTANCE", 119, 123], ["Sera", "ORGANISM_SUBSTANCE", 149, 153], ["people", "ORGANISM", 167, 173], ["patients", "ORGANISM", 183, 191], ["pPICZ\u03b1", "DNA", 34, 40], ["yeast", "SPECIES", 46, 51], ["Human", "SPECIES", 113, 118], ["people", "SPECIES", 167, 173], ["patients", "SPECIES", 183, 191], ["P. Pastoris", "SPECIES", 4, 15], ["yeast", "SPECIES", 46, 51], ["Human", "SPECIES", 113, 118], ["The P. Pastoris expression vector pPICZ", "TREATMENT", 0, 39], ["A and yeast host strain GS115", "PROBLEM", 40, 69]]], ["Sample # 1\u20134 were from healthy people, sample # 5\u20138 were from four SARS patients (age 28\u201340; two males, two females) during the acute phase of infection, which were collected at day 31, 26, 22, 19 post SARS onset, respectively.", [["SARS", "DISEASE", 67, 71], ["infection", "DISEASE", 143, 152], ["SARS", "DISEASE", 202, 206], ["people", "ORGANISM", 31, 37], ["patients", "ORGANISM", 72, 80], ["people", "SPECIES", 31, 37], ["patients", "SPECIES", 72, 80], ["Sample", "TEST", 0, 6], ["sample", "TEST", 39, 45], ["infection", "PROBLEM", 143, 152], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["infection", "OBSERVATION", 143, 152]]], ["All four SARS patients had a history of contact with other patients infected with SARS, and exhibited symptoms including persistent fever (>38.0 \u00b0C), cough and shortness of breath for several days before they were hospitalized.", [["SARS", "DISEASE", 9, 13], ["SARS", "DISEASE", 82, 86], ["fever", "DISEASE", 132, 137], ["cough", "DISEASE", 150, 155], ["shortness of breath", "DISEASE", 160, 179], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 59, 67], ["SARS", "PROBLEM", 82, 86], ["symptoms", "PROBLEM", 102, 110], ["persistent fever", "PROBLEM", 121, 137], ["cough", "PROBLEM", 150, 155], ["shortness of breath", "PROBLEM", 160, 179], ["persistent", "OBSERVATION_MODIFIER", 121, 131], ["fever", "OBSERVATION", 132, 137]]], ["Patients were subsequently confirmed to be infected with SARS by clinical diagnosis combined with laboratory diagnostic methods.PCR amplification and sequence analysis of M gene fragment ::: Materials and methodsAccording to the published genomic sequence of SARS\u2013CoV strain TOR (Poutanen et al., 2003), a pair of primers were designed and synthesized.", [["SARS", "DISEASE", 57, 61], ["Patients", "ORGANISM", 0, 8], ["SARS\u2013CoV", "ORGANISM", 259, 267], ["M gene fragment", "DNA", 171, 186], ["Patients", "SPECIES", 0, 8], ["SARS\u2013CoV", "SPECIES", 259, 267], ["laboratory diagnostic methods", "TEST", 98, 127], ["PCR amplification", "TEST", 128, 145], ["sequence analysis", "TEST", 150, 167], ["SARS", "PROBLEM", 259, 263], ["a pair of primers", "TREATMENT", 304, 321], ["infected", "OBSERVATION", 43, 51]]], ["The sequence of the primers were 5\u2032-GAGCCGCGGCCGCTCAATGTGGTCATTC-3\u2032(forward primer) and 5\u2032-CGTTCTAGATGTACTAGCAAAGCAATA-3\u2032 (reverse primer), which carried a SacII and XbaI restriction site, respectively.PCR amplification and sequence analysis of M gene fragment ::: Materials and methodsThe primers were used to amplify the M gene fragment without its transmembrane domain from the genomic cDNA of SARS\u2013CoV strain BJ-01.", [["transmembrane", "ANATOMY", 351, 364], ["5\u2032-CGTTCTAGATGTACTAGCAAAGCAATA-3", "GENE_OR_GENE_PRODUCT", 88, 120], ["SacII", "GENE_OR_GENE_PRODUCT", 156, 161], ["XbaI", "GENE_OR_GENE_PRODUCT", 166, 170], ["SARS\u2013CoV", "ORGANISM", 397, 405], ["BJ-01", "CELL", 413, 418], ["forward primer", "DNA", 68, 82], ["reverse primer", "DNA", 123, 137], ["SacII and XbaI restriction site", "DNA", 156, 187], ["M gene fragment", "DNA", 245, 260], ["M gene fragment", "DNA", 323, 338], ["genomic cDNA", "DNA", 381, 393], ["SARS\u2013CoV strain BJ-01", "SPECIES", 397, 418], ["the primers", "TEST", 16, 27], ["GAGCCGCGGCCGCTCAATGTGGTCATTC", "TEST", 36, 64], ["CGTTCTAGATGTACTAGCAAAGCAATA", "TEST", 91, 118], ["a SacII and XbaI restriction site", "TREATMENT", 154, 187], ["PCR amplification", "TEST", 202, 219], ["sequence analysis", "TEST", 224, 241], ["The primers", "TREATMENT", 286, 297], ["the M gene fragment", "TREATMENT", 319, 338], ["its transmembrane domain", "PROBLEM", 347, 371], ["SARS", "PROBLEM", 397, 401]]], ["The PCR reaction contained 5 \u03bcl of cDNA, 25 pmol of each of two primers, 5 \u03bcl of buffer concentrate, 4 \u03bcl of dNTP and 0.5 \u03bcl of Ex Taq enzyme (TaKaRa, Japan), and sterile distilled water up to 50 \u03bcl.", [["dNTP", "CHEMICAL", 109, 113], ["dNTP", "CHEMICAL", 109, 113], ["dNTP", "SIMPLE_CHEMICAL", 109, 113], ["cDNA", "DNA", 35, 39], ["The PCR reaction", "TEST", 0, 16], ["cDNA", "TEST", 35, 39], ["two primers", "TREATMENT", 60, 71], ["buffer concentrate", "TREATMENT", 81, 99], ["dNTP", "TREATMENT", 109, 113], ["Ex Taq enzyme", "TREATMENT", 128, 141], ["TaKaRa", "TREATMENT", 143, 149], ["sterile distilled water", "TREATMENT", 163, 186]]], ["PCR was performed with the following settings: 95 \u00b0C for 5 min, followed by 35 cycles at 95 \u00b0C for 30 s, 50 \u00b0C for 45 s and 72 \u00b0C for 1 min, and ending with 72 \u00b0C for 10 min.PCR amplification and sequence analysis of M gene fragment ::: Materials and methodsThe amplified products were then sent to the TaKaRa Biotechnology (Dalian) Co. Ltd. for sequencing.", [["M gene fragment", "DNA", 217, 232], ["PCR", "TEST", 0, 3], ["PCR amplification", "TEST", 174, 191], ["sequence analysis", "TEST", 196, 213], ["The amplified products", "TREATMENT", 258, 280]]], ["The determined sequence was analyzed further by DNAMAN biological software.Construction of the expression plasmid ::: Materials and methodsThe M gene fragment and expression vector pPICZ\u03b1A were digested by SacII and XbaI, respectively.", [["SacII", "GENE_OR_GENE_PRODUCT", 206, 211], ["XbaI", "GENE_OR_GENE_PRODUCT", 216, 220], ["expression plasmid", "DNA", 95, 113], ["M gene fragment", "DNA", 143, 158], ["pPICZ", "DNA", 181, 186], ["SacII", "PROTEIN", 206, 211], ["The M gene fragment", "TREATMENT", 139, 158], ["expression vector pPICZ", "TREATMENT", 163, 186], ["fragment", "OBSERVATION_MODIFIER", 150, 158]]], ["The larger fragments were purified by QIAquick Gel Extraction kit (Qiagen, Germany).", [["fragments", "ANATOMY", 11, 20], ["The larger fragments", "PROBLEM", 0, 20], ["QIAquick Gel Extraction", "TREATMENT", 38, 61], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["fragments", "OBSERVATION", 11, 20]]], ["The concentrations of purified products were measured by Beckman DV-600 (Beckman, U.S.A).", [["purified products", "TREATMENT", 22, 39], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["After mixing in a 3:1 molecular ratio, the purified products were ligated by T4 DNA ligase at 16 \u00b0C overnight and then transformed into Escherichia coli Top10 competent cells.", [["cells", "ANATOMY", 169, 174], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["Escherichia coli", "ORGANISM", 136, 152], ["Top10", "GENE_OR_GENE_PRODUCT", 153, 158], ["cells", "CELL", 169, 174], ["T4 DNA ligase", "PROTEIN", 77, 90], ["Escherichia coli Top10 competent cells", "CELL_LINE", 136, 174], ["Escherichia coli", "SPECIES", 136, 152], ["Escherichia coli", "SPECIES", 136, 152], ["the purified products", "TREATMENT", 39, 60], ["T4 DNA ligase", "TEST", 77, 90], ["Escherichia coli", "TREATMENT", 136, 152], ["Escherichia coli", "OBSERVATION", 136, 152], ["competent cells", "OBSERVATION", 159, 174]]], ["Transformants selected on low-salt LB plates containing Zeocin (25 \u03bcg/ml) were screened by direct colony PCR, and by restriction digestion of purified plasmids.", [["Transformants", "ANATOMY", 0, 13], ["plasmids", "ANATOMY", 151, 159], ["Zeocin", "CHEMICAL", 56, 62], ["Zeocin", "CHEMICAL", 56, 62], ["Transformants", "CELL", 0, 13], ["Zeocin", "SIMPLE_CHEMICAL", 56, 62], ["purified plasmids", "DNA", 142, 159], ["Transformants", "TEST", 0, 13], ["low-salt LB plates containing Zeocin", "TREATMENT", 26, 62], ["purified plasmids", "TREATMENT", 142, 159]]], ["The sequence of the inserts were verified.", [["the inserts", "TREATMENT", 16, 27]]], ["The sequence data obtained were compared with the sequence of the M gene of SARS\u2013CoV strain BJ01 (accession number AY278488).Expression and purification of recombinant protein ::: Materials and methodsThe transformation of yeast cells and screening of transformants, as well as expression in P. Pastoris, were performed as described previously (David and James, 1998).", [["yeast cells", "ANATOMY", 223, 234], ["transformants", "ANATOMY", 252, 265], ["SARS\u2013CoV", "ORGANISM", 76, 84], ["yeast cells", "CELL", 223, 234], ["transformants", "CELL", 252, 265], ["P. Pastoris", "ORGANISM", 292, 303], ["M gene", "DNA", 66, 72], ["recombinant protein", "PROTEIN", 156, 175], ["yeast cells", "CELL_TYPE", 223, 234], ["yeast", "SPECIES", 223, 228], ["P. Pastoris", "SPECIES", 292, 303], ["SARS\u2013CoV", "SPECIES", 76, 84], ["yeast", "SPECIES", 223, 228], ["P. Pastoris", "SPECIES", 292, 303], ["The sequence data", "TEST", 0, 17], ["SARS", "PROBLEM", 76, 80], ["yeast cells", "PROBLEM", 223, 234], ["screening of transformants", "TEST", 239, 265], ["P. Pastoris", "TEST", 292, 303], ["yeast cells", "OBSERVATION", 223, 234]]], ["The recombinant plasmid was linearized by the restriction enzyme SacI, the purified products were transformed into yeast cells GS115 and transformants were selected on low-salt MD plates containing Zeocin (25 \u03bcg/ml).", [["plasmid", "ANATOMY", 16, 23], ["cells", "ANATOMY", 121, 126], ["transformants", "ANATOMY", 137, 150], ["Zeocin", "CHEMICAL", 198, 204], ["Zeocin", "CHEMICAL", 198, 204], ["SacI", "GENE_OR_GENE_PRODUCT", 65, 69], ["yeast cells", "CELL", 115, 126], ["GS115", "CELL", 127, 132], ["transformants", "CELL", 137, 150], ["Zeocin", "SIMPLE_CHEMICAL", 198, 204], ["recombinant plasmid", "DNA", 4, 23], ["restriction enzyme SacI", "DNA", 46, 69], ["yeast cells GS115", "CELL_LINE", 115, 132], ["yeast", "SPECIES", 115, 120], ["yeast", "SPECIES", 115, 120], ["The recombinant plasmid", "TREATMENT", 0, 23], ["the restriction enzyme SacI", "PROBLEM", 42, 69], ["the purified products", "TREATMENT", 71, 92], ["transformants", "TEST", 137, 150], ["low-salt MD plates", "TREATMENT", 168, 186], ["Zeocin", "TREATMENT", 198, 204], ["plasmid", "OBSERVATION", 16, 23], ["yeast cells", "OBSERVATION", 115, 126]]], ["The colonies of recombinant yeast cells with high copies of the M gene were screened on low-salt MD plates containing different concentrations of Zeocin (500 \u03bcg/ml, 1 and 2 mg/ml).", [["colonies", "ANATOMY", 4, 12], ["cells", "ANATOMY", 34, 39], ["Zeocin", "CHEMICAL", 146, 152], ["Zeocin", "CHEMICAL", 146, 152], ["yeast cells", "CELL", 28, 39], ["Zeocin", "SIMPLE_CHEMICAL", 146, 152], ["recombinant yeast cells", "CELL_LINE", 16, 39], ["M gene", "DNA", 64, 70], ["yeast", "SPECIES", 28, 33], ["yeast", "SPECIES", 28, 33], ["recombinant yeast cells", "PROBLEM", 16, 39], ["low-salt MD plates", "TREATMENT", 88, 106], ["Zeocin", "TREATMENT", 146, 152], ["recombinant yeast cells", "OBSERVATION", 16, 39]]], ["A screened colony of yeast cells was selected and inoculated into 100 ml of BMMY in the presence of Zeocin (25 \u03bcg/ml).", [["colony", "ANATOMY", 11, 17], ["yeast cells", "ANATOMY", 21, 32], ["BMMY", "CHEMICAL", 76, 80], ["Zeocin", "CHEMICAL", 100, 106], ["Zeocin", "CHEMICAL", 100, 106], ["yeast cells", "CELL", 21, 32], ["BMMY", "SIMPLE_CHEMICAL", 76, 80], ["Zeocin", "SIMPLE_CHEMICAL", 100, 106], ["yeast cells", "CELL_LINE", 21, 32], ["yeast", "SPECIES", 21, 26], ["yeast", "SPECIES", 21, 26], ["yeast cells", "PROBLEM", 21, 32], ["Zeocin", "TREATMENT", 100, 106], ["yeast cells", "OBSERVATION", 21, 32]]], ["The culture was grown at 28\u201330 \u00b0C until the optical density at 600 nm (OD600) reached 4.0.", [["The culture", "TEST", 0, 11], ["the optical density", "TEST", 40, 59]]], ["The culture was then centrifuged at 4 \u00b0C at 3000 \u00d7 g for 5 min, the cells were re-suspended in 1/10 prime volume of MMY, and continued to grow at 28\u201330 \u00b0C until the optical density at 600 nm (OD600) reached 2\u20136.", [["cells", "ANATOMY", 68, 73], ["MMY", "CHEMICAL", 116, 119], ["cells", "CELL", 68, 73], ["MMY", "SIMPLE_CHEMICAL", 116, 119], ["The culture", "TEST", 0, 11], ["the cells", "TEST", 64, 73]]], ["Methanol was added every 24 h to a final concentration of 0.5% to induce the expression of recombinant M protein, and the incubation was continued for further 3\u20134 days.", [["Methanol", "CHEMICAL", 0, 8], ["Methanol", "CHEMICAL", 0, 8], ["Methanol", "SIMPLE_CHEMICAL", 0, 8], ["recombinant M protein", "PROTEIN", 91, 112], ["Methanol", "TREATMENT", 0, 8], ["recombinant M protein", "TREATMENT", 91, 112], ["the incubation", "TREATMENT", 118, 132]]], ["Control cultures were processed in parallel.", [["Control cultures", "TEST", 0, 16]]], ["The recombinant M protein was secreted into the culture supernatant as soluble form.", [["supernatant", "ANATOMY", 56, 67], ["recombinant M protein", "PROTEIN", 4, 25], ["The recombinant M protein", "TEST", 0, 25], ["the culture", "TEST", 44, 55]]], ["The supernatant was harvested by centrifugation and used for analysing the expression level of recombinant M protein by SDS\u2013PAGE.Expression and purification of recombinant protein ::: Materials and methodsThe highly expressing Pichia colony was selected for inoculation into 500 ml of BMMY, and grown at 28\u201330 \u00b0C until the culture reached an OD600 = 4.0.", [["supernatant", "ANATOMY", 4, 15], ["colony", "ANATOMY", 234, 240], ["SDS", "CHEMICAL", 120, 123], ["Pichia", "ORGANISM", 227, 233], ["recombinant M protein", "PROTEIN", 95, 116], ["recombinant protein", "PROTEIN", 160, 179], ["The highly expressing Pichia colony", "PROBLEM", 205, 240], ["inoculation", "TREATMENT", 258, 269], ["the culture", "TEST", 319, 330], ["harvested", "OBSERVATION", 20, 29], ["Pichia colony", "OBSERVATION", 227, 240]]], ["The culture was centrifuged at 4 \u00b0C at 3000 \u00d7 g for 5 min, the cells were re-suspended in 1/10 prime volume of MMY, and continued to grow at 28\u201330 \u00b0C until the optical density at 600 nm (OD600) reached 2\u20136.", [["cells", "ANATOMY", 63, 68], ["MMY", "CHEMICAL", 111, 114], ["cells", "CELL", 63, 68], ["The culture", "TEST", 0, 11], ["the cells", "TEST", 59, 68]]], ["Glycerol and methanol were added every 24 h to final concentrations of 0.5 and 0.8%, respectively, to induce the expression of recombinant M protein, and the incubation was continued for a further 3\u20134 days.", [["Glycerol", "CHEMICAL", 0, 8], ["methanol", "CHEMICAL", 13, 21], ["Glycerol", "CHEMICAL", 0, 8], ["methanol", "CHEMICAL", 13, 21], ["Glycerol", "SIMPLE_CHEMICAL", 0, 8], ["methanol", "SIMPLE_CHEMICAL", 13, 21], ["recombinant M protein", "PROTEIN", 127, 148], ["Glycerol", "TREATMENT", 0, 8], ["methanol", "TREATMENT", 13, 21], ["recombinant M protein", "TREATMENT", 127, 148], ["the incubation", "TREATMENT", 154, 168]]], ["The supernatant of culture was harvested by centrifugation at 8000 \u00d7 g for 30 min at 4 \u00b0C, then ammonium sulphate was added to a final saturation of 70% to precipitate proteins.", [["supernatant", "ANATOMY", 4, 15], ["ammonium sulphate", "CHEMICAL", 96, 113], ["ammonium sulphate", "CHEMICAL", 96, 113], ["ammonium sulphate", "SIMPLE_CHEMICAL", 96, 113], ["culture", "TEST", 19, 26], ["ammonium sulphate", "TREATMENT", 96, 113]]], ["The pellet was collected by centrifugation at 8000 \u00d7 g for 1 h at 4 \u00b0C and dialyzed to 2000 ml of PBS overnight.", [["pellet", "ANATOMY", 4, 10], ["PBS", "TREATMENT", 98, 101]]], ["The dialysis buffer was replaced every 2 h until it was confirmed that the ammonium sulphate was completely removed.", [["ammonium sulphate", "CHEMICAL", 75, 92], ["ammonium sulphate", "CHEMICAL", 75, 92], ["ammonium sulphate", "SIMPLE_CHEMICAL", 75, 92], ["The dialysis buffer", "TREATMENT", 0, 19], ["the ammonium sulphate", "TREATMENT", 71, 92]]], ["The prepared sample was loaded onto an NTA column equilibrated with NiSO4.", [["sample", "ANATOMY", 13, 19], ["NiSO4", "CHEMICAL", 68, 73], ["NTA", "CHEMICAL", 39, 42], ["NiSO4", "CHEMICAL", 68, 73], ["NTA", "SIMPLE_CHEMICAL", 39, 42], ["NiSO4", "SIMPLE_CHEMICAL", 68, 73], ["an NTA column", "TREATMENT", 36, 49], ["NiSO4", "TREATMENT", 68, 73]]], ["The loaded column was first washed with a 10-fold column volume of MCAC0 (20 mM Tris, pH 8.0; 500 mM NaCl) to remove the contaminant proteins, and then eluted with 10 ml of 200 mM imidazole in MCAC0.", [["MCAC0", "CHEMICAL", 67, 72], ["NaCl", "CHEMICAL", 101, 105], ["imidazole", "CHEMICAL", 180, 189], ["MCAC0", "CHEMICAL", 193, 198], ["Tris", "CHEMICAL", 80, 84], ["NaCl", "CHEMICAL", 101, 105], ["imidazole", "CHEMICAL", 180, 189], ["MCAC0", "SIMPLE_CHEMICAL", 67, 72], ["imidazole", "SIMPLE_CHEMICAL", 180, 189], ["MCAC0", "SIMPLE_CHEMICAL", 193, 198], ["The loaded column", "TREATMENT", 0, 17], ["MCAC0", "TEST", 67, 72], ["Tris", "TEST", 80, 84], ["pH", "TEST", 86, 88], ["500 mM NaCl", "TREATMENT", 94, 105], ["the contaminant proteins", "TEST", 117, 141], ["200 mM imidazole in MCAC0", "TREATMENT", 173, 198], ["loaded column", "OBSERVATION", 4, 17]]], ["The different elution parts were analyzed by SDS\u2013PAGE, and the part containing recombinant M protein was concentrated by superfiltration.Western blotting ::: Materials and methodsTwo microgram of the purified recombinant M protein was separated by SDS\u2013PAGE and transferred to polyvinylidene difluoride membrane (PVDF) by standard methods.", [["SDS", "CHEMICAL", 45, 48], ["SDS", "CHEMICAL", 248, 251], ["polyvinylidene difluoride", "CHEMICAL", 276, 301], ["PVDF", "CHEMICAL", 312, 316], ["membrane", "CELLULAR_COMPONENT", 302, 310], ["recombinant M protein", "PROTEIN", 79, 100], ["purified recombinant M protein", "PROTEIN", 200, 230], ["The different elution parts", "TREATMENT", 0, 27], ["recombinant M protein", "TREATMENT", 79, 100], ["the purified recombinant M protein", "TREATMENT", 196, 230], ["polyvinylidene difluoride membrane (PVDF", "TREATMENT", 276, 316]]], ["After blocking with PBST (14 mmol/l NaCl, 2.7 mmol/l KCl, 10 mmol/l NaHPO4, 1.8 mmol/l KH2PO4 and 0.02% Tween-20) containing 5% non-fat milk for 1 h at 4 \u00b0C, the membrane was incubated for 3 h at room temperature with SARS\u2013CoV-positive human serum (1:3000 dilution).", [["fat milk", "ANATOMY", 132, 140], ["membrane", "ANATOMY", 162, 170], ["serum", "ANATOMY", 242, 247], ["NaCl", "CHEMICAL", 36, 40], ["KCl", "CHEMICAL", 53, 56], ["NaHPO4", "CHEMICAL", 68, 74], ["Tween-20", "CHEMICAL", 104, 112], ["NaCl", "CHEMICAL", 36, 40], ["KCl", "CHEMICAL", 53, 56], ["NaHPO4", "CHEMICAL", 68, 74], ["KH2PO4", "CHEMICAL", 87, 93], ["Tween-20", "CHEMICAL", 104, 112], ["NaHPO4", "SIMPLE_CHEMICAL", 68, 74], ["Tween-20", "SIMPLE_CHEMICAL", 104, 112], ["fat milk", "ORGANISM_SUBSTANCE", 132, 140], ["membrane", "CELLULAR_COMPONENT", 162, 170], ["SARS\u2013CoV", "GENE_OR_GENE_PRODUCT", 218, 226], ["human", "ORGANISM", 236, 241], ["serum", "ORGANISM_SUBSTANCE", 242, 247], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["PBST", "TREATMENT", 20, 24], ["NaCl", "TREATMENT", 36, 40], ["KCl", "TREATMENT", 53, 56], ["NaHPO4", "TREATMENT", 68, 74], ["KH2PO4", "TREATMENT", 87, 93], ["5% non-fat milk", "TREATMENT", 125, 140], ["SARS\u2013CoV", "TEST", 218, 226]]], ["After washing three times in an appropriate volume of PBST, the membrane was incubated for 1 h with peroxidase labeled goat anti-human IgG (1:1000, No: A-0170, Sigma).", [["membrane", "ANATOMY", 64, 72], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["peroxidase", "GENE_OR_GENE_PRODUCT", 100, 110], ["goat", "ORGANISM", 119, 123], ["peroxidase labeled goat anti-human IgG", "PROTEIN", 100, 138], ["goat", "SPECIES", 119, 123], ["goat", "SPECIES", 119, 123], ["peroxidase labeled goat anti-human IgG", "TEST", 100, 138]]], ["The membrane was washed three times with PBS-T and once with distilled water, for 10 min each time.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["PBS", "TREATMENT", 41, 44], ["membrane", "OBSERVATION_MODIFIER", 4, 12]]], ["Finally, the washed membrane was transferred into an appropriate volume of ECL solution (Amersham) and reacted at room temperature for about 1 min, then put onto a sensitization film for 1\u20133 min to develop and fix.ELISA ::: Materials and methodsThe purified recombinant M protein was diluted with 50 mmol/l carbonate buffer (15 mmol/l NaCO3, 35 mmol/l NaHCO3, [pH 9.6]), and then used to coat 96-well plates (Costar Inc.) (1 \u03bcg/well) overnight at 4 \u00b0C. After washing with PBS-T (PBS containing 0.5% Tween-20, pH 7.4) for three times, each well of the plate was incubated with blocking solution (3% BSA in carbonate buffer) for 2 h at 37 \u00b0C. The wells were washed three times with phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBS-T).", [["membrane", "ANATOMY", 20, 28], ["NaCO3", "CHEMICAL", 335, 340], ["PBS-T", "CHEMICAL", 472, 477], ["Tween-20", "CHEMICAL", 499, 507], ["phosphate", "CHEMICAL", 680, 689], ["carbonate", "CHEMICAL", 307, 316], ["NaCO3", "CHEMICAL", 335, 340], ["NaHCO3", "CHEMICAL", 352, 358], ["Tween-20", "CHEMICAL", 499, 507], ["carbonate", "CHEMICAL", 605, 614], ["phosphate", "CHEMICAL", 680, 689], ["Tween-20", "CHEMICAL", 729, 737], ["membrane", "CELLULAR_COMPONENT", 20, 28], ["carbonate", "SIMPLE_CHEMICAL", 307, 316], ["NaCO3", "SIMPLE_CHEMICAL", 335, 340], ["PBS-T", "SIMPLE_CHEMICAL", 472, 477], ["Tween-20", "SIMPLE_CHEMICAL", 499, 507], ["BSA", "SIMPLE_CHEMICAL", 598, 601], ["carbonate", "SIMPLE_CHEMICAL", 605, 614], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 680, 705], ["Tween-20", "SIMPLE_CHEMICAL", 729, 737], ["purified recombinant M protein", "PROTEIN", 249, 279], ["the washed membrane", "TREATMENT", 9, 28], ["a sensitization film", "TREATMENT", 162, 182], ["The purified recombinant M protein", "TREATMENT", 245, 279], ["l carbonate buffer", "TREATMENT", 305, 323], ["NaCO3", "TREATMENT", 335, 340], ["NaHCO3", "TREATMENT", 352, 358], ["pH", "TEST", 361, 363], ["PBS", "TREATMENT", 472, 475], ["T (PBS", "TREATMENT", 476, 482], ["pH", "TEST", 509, 511], ["blocking solution", "TREATMENT", 576, 593], ["3% BSA in carbonate buffer", "TREATMENT", 595, 621], ["The wells", "TREATMENT", 641, 650], ["phosphate-buffered saline (PBS)", "TREATMENT", 680, 711]]], ["Hundred microlitres of the primary antibody (SARS patient sera), diluted 1:800 in PBS-T, was added in duplicate and the plates were incubated for 1 h at 37 \u00b0C. After four washes with PBS-T, plates were then incubated with goat anti-human IgG antibody labeled with peroxidase (1:50,000, No.: A-0170, Sigma) for 1 h at 37 \u00b0C. TMB [3,3\u2032, 5,5\u2032-tetramethylbenzidine] substrate (100 \u03bcl/well) was added after seven washes with PBS-T and the wells were incubated for 10 min at 37 \u00b0C. Fifty microlitres of stop buffer (2 mol/l H2SO4) was added to each well and the optical density (OD) was read at 450 nm in Bio-RAD550.", [["sera", "ANATOMY", 58, 62], ["TMB [3,3\u2032, 5,5\u2032-tetramethylbenzidine", "CHEMICAL", 324, 360], ["TMB", "CHEMICAL", 324, 327], ["3,3\u2032, 5,5\u2032-tetramethylbenzidine", "CHEMICAL", 329, 360], ["H2SO4", "CHEMICAL", 518, 523], ["patient", "ORGANISM", 50, 57], ["sera", "ORGANISM_SUBSTANCE", 58, 62], ["goat", "ORGANISM", 222, 226], ["peroxidase", "GENE_OR_GENE_PRODUCT", 264, 274], ["A-0170", "SIMPLE_CHEMICAL", 291, 297], ["TMB [3,3\u2032, 5,5\u2032-tetramethylbenzidine", "SIMPLE_CHEMICAL", 324, 360], ["primary antibody", "PROTEIN", 27, 43], ["goat anti-human IgG antibody", "PROTEIN", 222, 250], ["peroxidase", "PROTEIN", 264, 274], ["patient", "SPECIES", 50, 57], ["goat", "SPECIES", 222, 226], ["goat", "SPECIES", 222, 226], ["the primary antibody", "TEST", 23, 43], ["PBS-T, plates", "TEST", 183, 196], ["goat anti-human IgG antibody", "TEST", 222, 250], ["peroxidase", "TEST", 264, 274], ["tetramethylbenzidine] substrate", "TREATMENT", 340, 371], ["PBS", "TREATMENT", 420, 423], ["stop buffer", "TREATMENT", 497, 508]]], ["The cut-off value was defined as the mean OD plus three standard deviations calculated from the four negative samples used as control.Amplification and sequence analysis of M gene ::: ResultsThe M gene fragment without transmembrane domain was amplified from the genomic cDNA of SARS\u2013CoV strain BJ01.", [["samples", "ANATOMY", 110, 117], ["transmembrane", "CELLULAR_COMPONENT", 219, 232], ["SARS\u2013CoV", "ORGANISM", 279, 287], ["M gene", "DNA", 173, 179], ["M gene fragment", "DNA", 195, 210], ["transmembrane domain", "PROTEIN", 219, 239], ["genomic cDNA", "DNA", 263, 275], ["SARS\u2013CoV", "SPECIES", 279, 287], ["The cut-off value", "TEST", 0, 17], ["The M gene fragment", "PROBLEM", 191, 210], ["transmembrane domain", "PROBLEM", 219, 239], ["SARS", "PROBLEM", 279, 283], ["CoV strain BJ01", "PROBLEM", 284, 299], ["fragment", "OBSERVATION_MODIFIER", 202, 210], ["without", "UNCERTAINTY", 211, 218]]], ["Sequence analysis indicated that the nucleotide sequence of that amplified fragment is completely identical to that of SARS\u2013CoV strain BJ01 (accession number AY278488).", [["SARS", "DISEASE", 119, 123], ["nucleotide", "CHEMICAL", 37, 47], ["SARS\u2013CoV", "ORGANISM", 119, 127], ["SARS\u2013CoV", "SPECIES", 119, 127], ["Sequence analysis", "TEST", 0, 17], ["the nucleotide sequence", "TEST", 33, 56], ["amplified fragment", "PROBLEM", 65, 83], ["SARS", "PROBLEM", 119, 123]]], ["The deduced amino acid sequence of the M protein of SARS\u2013CoV strain BJ01 has identities of 41.0% or less with the M proteins of other human or animal coronaviruses (Fig. 1).Construction of the expression plasmid ::: ResultsThe amplified product of 348 bp was cloned in the pPICZ\u03b1A expression vector, and the sequences of inserts were verified by sequencing (data not shown).", [["amino acid", "CHEMICAL", 12, 22], ["amino acid", "CHEMICAL", 12, 22], ["amino acid", "AMINO_ACID", 12, 22], ["SARS\u2013CoV strain BJ01", "ORGANISM", 52, 72], ["human", "ORGANISM", 134, 139], ["animal coronaviruses", "ORGANISM", 143, 163], ["M protein", "PROTEIN", 39, 48], ["M proteins", "PROTEIN", 114, 124], ["expression plasmid", "DNA", 193, 211], ["pPICZ\u03b1", "DNA", 273, 279], ["expression vector", "DNA", 281, 298], ["human", "SPECIES", 134, 139], ["SARS\u2013CoV", "SPECIES", 52, 60], ["human", "SPECIES", 134, 139], ["The deduced amino acid sequence", "TEST", 0, 31], ["the M protein", "TEST", 35, 48], ["SARS", "PROBLEM", 52, 56], ["CoV strain BJ01", "TEST", 57, 72], ["identities", "TEST", 77, 87], ["bp", "TEST", 252, 254], ["A expression vector", "TREATMENT", 279, 298], ["amino acid", "OBSERVATION", 12, 22]]], ["The nucleotide sequence alignment performed by DNAMAN software revealed 100% nucleotide identity between the inserted sequence and that of SARS\u2013CoV BJ01.Expression and purification of recombinant protein ::: ResultsThe M gene fragment was cloned in pPICZ\u03b1A expression vector and transformed into yeast host strain GS115.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 77, 87], ["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 77, 87], ["SARS\u2013CoV BJ01", "ORGANISM", 139, 152], ["GS115", "CELL", 314, 319], ["DNAMAN software", "DNA", 47, 62], ["SARS\u2013CoV BJ01", "DNA", 139, 152], ["recombinant protein", "PROTEIN", 184, 203], ["M gene fragment", "DNA", 219, 234], ["pPICZ", "DNA", 249, 254], ["expression vector", "DNA", 257, 274], ["yeast", "SPECIES", 296, 301], ["SARS\u2013CoV BJ01", "SPECIES", 139, 152], ["yeast", "SPECIES", 296, 301], ["The nucleotide sequence alignment", "TEST", 0, 33], ["DNAMAN software", "TEST", 47, 62], ["100% nucleotide identity between the inserted sequence", "PROBLEM", 72, 126], ["SARS", "PROBLEM", 139, 143], ["CoV BJ01", "TEST", 144, 152], ["The M gene fragment", "PROBLEM", 215, 234], ["A expression vector", "TREATMENT", 255, 274], ["fragment", "OBSERVATION_MODIFIER", 226, 234]]], ["The colonies of recombinant yeast cells with high copies of M gene were screened.", [["colonies", "ANATOMY", 4, 12], ["cells", "ANATOMY", 34, 39], ["yeast cells", "CELL", 28, 39], ["recombinant yeast cells", "CELL_LINE", 16, 39], ["M gene", "DNA", 60, 66], ["yeast", "SPECIES", 28, 33], ["yeast", "SPECIES", 28, 33], ["recombinant yeast cells", "PROBLEM", 16, 39], ["recombinant yeast cells", "OBSERVATION", 16, 39]]], ["After inducing with methanol, the supernatant of culture was harvested by centrifugation.", [["supernatant", "ANATOMY", 34, 45], ["methanol", "CHEMICAL", 20, 28], ["methanol", "CHEMICAL", 20, 28], ["methanol", "SIMPLE_CHEMICAL", 20, 28], ["methanol", "TREATMENT", 20, 28], ["culture", "TEST", 49, 56]]], ["The recombinant protein with a polyhistidine tag at the C-terminus was produced in soluble form in the culture supernatant (Fig. 2).Expression and purification of recombinant protein ::: ResultsTwenty microlitres of the supernatant (20 \u03bcg of protein) was subjected to SDS\u2013PAGE and Coomassie blue staining, and a protein band corresponding to the expected molecular mass of 14 kDa was revealed in supernatant, which was not present either in the culture before the induction or in the control culture before and after the induction.Expression and purification of recombinant protein ::: ResultsThe recombinant M protein was purified by nickel affinity chromatography and the purity was confirmed by single banding in SDS\u2013PAGE (Fig. 2).", [["supernatant", "ANATOMY", 111, 122], ["supernatant", "ANATOMY", 220, 231], ["supernatant", "ANATOMY", 396, 407], ["polyhistidine", "CHEMICAL", 31, 44], ["nickel", "CHEMICAL", 635, 641], ["polyhistidine", "CHEMICAL", 31, 44], ["SDS", "CHEMICAL", 268, 271], ["Coomassie blue", "CHEMICAL", 281, 295], ["nickel", "CHEMICAL", 635, 641], ["Coomassie", "SIMPLE_CHEMICAL", 281, 290], ["nickel", "SIMPLE_CHEMICAL", 635, 641], ["recombinant protein", "PROTEIN", 4, 23], ["polyhistidine tag", "PROTEIN", 31, 48], ["C-terminus", "PROTEIN", 56, 66], ["recombinant protein", "PROTEIN", 163, 182], ["recombinant protein", "PROTEIN", 562, 581], ["recombinant M protein", "PROTEIN", 597, 618], ["The recombinant protein", "TEST", 0, 23], ["a polyhistidine tag", "PROBLEM", 29, 48], ["the culture", "TEST", 99, 110], ["the supernatant", "TEST", 216, 231], ["Coomassie blue staining", "TEST", 281, 304], ["a protein band", "TEST", 310, 324], ["the culture", "TEST", 441, 452], ["the control culture", "TEST", 480, 499], ["the induction", "TREATMENT", 517, 530], ["The recombinant M protein", "TEST", 593, 618], ["nickel affinity chromatography", "TEST", 635, 665], ["mass", "OBSERVATION", 365, 369]]], ["Upon elution from the NTA column, the protein was >80% pure as estimated from SDS\u2013PAGE.", [["NTA", "CHEMICAL", 22, 25], ["NTA", "SIMPLE_CHEMICAL", 22, 25], ["the NTA column", "TEST", 18, 32], ["the protein", "TEST", 34, 45]]], ["Typically, 6 mg of pure recombinant M protein is obtained per liter of P. pastoris culture.Western blotting ::: ResultsIn order to test the reactivity of the recombinant M protein, Western blotting was carried out using SARS\u2013CoV-positive human serum.", [["serum", "ANATOMY", 244, 249], ["P. pastoris", "ORGANISM", 71, 82], ["\u2013CoV", "GENE_OR_GENE_PRODUCT", 224, 228], ["human", "ORGANISM", 238, 243], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["recombinant M protein", "PROTEIN", 24, 45], ["recombinant M protein", "PROTEIN", 158, 179], ["P. pastoris", "SPECIES", 71, 82], ["human", "SPECIES", 238, 243], ["P. pastoris", "SPECIES", 71, 82], ["human", "SPECIES", 238, 243], ["pure recombinant M protein", "TREATMENT", 19, 45], ["P. pastoris culture", "TEST", 71, 90], ["the recombinant M protein", "TEST", 154, 179], ["Western blotting", "TEST", 181, 197], ["SARS\u2013CoV", "TEST", 220, 228]]], ["The protein band of 14 kDa showed a strong and specific reaction with the SARS\u2013CoV-positive serum, whereas the supernatant of the induced culture of recombinant yeast without the insert of the M gene fragment did not react with the SARS\u2013CoV-positive serum (Fig. 3).", [["serum", "ANATOMY", 92, 97], ["supernatant", "ANATOMY", 111, 122], ["serum", "ANATOMY", 250, 255], ["SARS\u2013CoV", "SIMPLE_CHEMICAL", 74, 82], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["recombinant yeast", "ORGANISM", 149, 166], ["SARS\u2013CoV", "GENE_OR_GENE_PRODUCT", 232, 240], ["serum", "ORGANISM_SUBSTANCE", 250, 255], ["SARS\u2013CoV", "PROTEIN", 74, 82], ["M gene fragment", "DNA", 193, 208], ["yeast", "SPECIES", 161, 166], ["yeast", "SPECIES", 161, 166], ["SARS\u2013CoV", "SPECIES", 232, 240], ["The protein band", "TEST", 0, 16], ["kDa", "TEST", 23, 26], ["specific reaction", "PROBLEM", 47, 64], ["the SARS\u2013CoV", "TEST", 70, 82], ["positive serum", "PROBLEM", 83, 97], ["the induced culture", "TEST", 126, 145], ["recombinant yeast", "PROBLEM", 149, 166], ["the M gene fragment", "PROBLEM", 189, 208], ["the SARS", "TEST", 228, 236], ["CoV", "TEST", 237, 240]]], ["These results confirmed the authenticity of the recombinant M protein.ELISA ::: ResultsTo test whether the recombinant M protein is effective as an ELISA antigen for detecting SARS\u2013CoV patient serum, the sera from four healthy people and four SARS patients were used.", [["serum", "ANATOMY", 193, 198], ["sera", "ANATOMY", 204, 208], ["SARS", "DISEASE", 243, 247], ["M protein", "GENE_OR_GENE_PRODUCT", 60, 69], ["SARS\u2013CoV", "ORGANISM", 176, 184], ["patient", "ORGANISM", 185, 192], ["serum", "ORGANISM_SUBSTANCE", 193, 198], ["sera", "ORGANISM_SUBSTANCE", 204, 208], ["people", "ORGANISM", 227, 233], ["patients", "ORGANISM", 248, 256], ["recombinant M protein", "PROTEIN", 48, 69], ["recombinant M protein", "PROTEIN", 107, 128], ["ELISA antigen", "PROTEIN", 148, 161], ["patient", "SPECIES", 185, 192], ["people", "SPECIES", 227, 233], ["patients", "SPECIES", 248, 256], ["SARS\u2013CoV", "SPECIES", 176, 184], ["the recombinant M protein", "TEST", 103, 128], ["an ELISA antigen", "TEST", 145, 161], ["SARS", "PROBLEM", 176, 180], ["CoV patient serum", "TEST", 181, 198], ["the sera", "TEST", 200, 208]]], ["The mean and the standard deviation obtained using four SARS\u2013CoV-negative sera were 0.106 and 0.003, respectively.", [["sera", "ANATOMY", 74, 78], ["sera", "ORGANISM_SUBSTANCE", 74, 78], ["the standard deviation", "TEST", 13, 35], ["four SARS\u2013CoV", "TEST", 51, 64], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Therefore, the cut-off value of ODs was determined as 0.206.", [["ODs", "TEST", 32, 35]]], ["Sera from four SARS patients were determined to be positive using only the M protein as an ELISA antigen.", [["Sera", "ANATOMY", 0, 4], ["SARS", "DISEASE", 15, 19], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["patients", "ORGANISM", 20, 28], ["M protein", "PROTEIN", 75, 84], ["ELISA antigen", "PROTEIN", 91, 104], ["patients", "SPECIES", 20, 28], ["Sera", "TEST", 0, 4], ["the M protein", "TEST", 71, 84], ["an ELISA antigen", "TEST", 88, 104]]], ["The mean and standard deviation were 0.610 and 0.004, respectively (see Fig. 4for detailed data).ELISA ::: ResultsThe same sera from four SARS patients were also positive by whole SARS\u2013CoV ELISA in parallel, using a diagnostic kit for antibodies to coronavirus (ELISA) obtained from Beijing BGI-GBI Biotech Co., Ltd., China (unpublished results).DiscussionCoronaviruses are important pathogens in human and animals, where they cause mostly respiratory and enteric diseases.", [["sera", "ANATOMY", 123, 127], ["respiratory", "ANATOMY", 440, 451], ["SARS", "DISEASE", 138, 142], ["respiratory and enteric diseases", "DISEASE", 440, 472], ["sera", "ORGANISM_SUBSTANCE", 123, 127], ["patients", "ORGANISM", 143, 151], ["CoV", "ORGANISM", 185, 188], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 356, 369], ["human", "ORGANISM", 397, 402], ["antibodies", "PROTEIN", 235, 245], ["patients", "SPECIES", 143, 151], ["human", "SPECIES", 397, 402], ["SARS\u2013CoV", "SPECIES", 180, 188], ["human", "SPECIES", 397, 402], ["detailed data", "TEST", 82, 95], ["CoV ELISA", "TEST", 185, 194], ["a diagnostic kit", "TEST", 214, 230], ["antibodies", "PROBLEM", 235, 245], ["coronavirus", "PROBLEM", 249, 260], ["mostly respiratory and enteric diseases", "PROBLEM", 433, 472], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["respiratory", "ANATOMY", 440, 451], ["enteric diseases", "OBSERVATION", 456, 472]]], ["SARS\u2013CoV is a newly identified human coronavirus that differs from all previously known human coronaviruses (for example, HCOV-229E and HCOV-OC43) in both the speed of transmission and the severity of disease.", [["human", "ORGANISM", 31, 36], ["coronavirus", "ORGANISM", 37, 48], ["human", "ORGANISM", 88, 93], ["HCOV-229E", "CELL", 122, 131], ["HCOV-OC43", "CELL", 136, 145], ["SARS\u2013CoV", "PROTEIN", 0, 8], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 88, 93], ["human coronavirus", "SPECIES", 31, 48], ["human coronaviruses", "SPECIES", 88, 107], ["a newly identified human coronavirus", "PROBLEM", 12, 48], ["HCOV", "TEST", 122, 126], ["disease", "PROBLEM", 201, 208], ["human coronavirus", "OBSERVATION", 31, 48], ["disease", "OBSERVATION", 201, 208]]], ["Both the lack of understanding and effective methods to control the virus means that the threat of SARS still exists, and therefore, there is an urgent need to develop effective vaccines and anti-viral drugs.", [["SARS", "DISEASE", 99, 103], ["effective methods", "TREATMENT", 35, 52], ["the virus", "PROBLEM", 64, 73], ["SARS", "PROBLEM", 99, 103], ["effective vaccines", "TREATMENT", 168, 186], ["anti-viral drugs", "TREATMENT", 191, 207]]], ["The key role of the M protein in coronavirus assembly, budding and inducing virus neutralization make it an attractive target for the development of vaccines and drugs, as well as for effective diagnostic reagents.", [["coronavirus", "ORGANISM", 33, 44], ["M protein", "PROTEIN", 20, 29], ["coronavirus", "SPECIES", 33, 44], ["the M protein", "TREATMENT", 16, 29], ["coronavirus", "PROBLEM", 33, 44], ["inducing virus neutralization", "TREATMENT", 67, 96], ["vaccines", "TREATMENT", 149, 157], ["drugs", "TREATMENT", 162, 167]]], ["SARS\u2013CoV differs from other coronaviruses in nucleotide sequence, and the exact function of its M protein is unknown.", [["nucleotide", "CHEMICAL", 45, 55], ["nucleotide", "CHEMICAL", 45, 55], ["SARS\u2013CoV", "PROTEIN", 0, 8], ["M protein", "PROTEIN", 96, 105], ["other coronaviruses in nucleotide sequence", "PROBLEM", 22, 64], ["its M protein", "TEST", 92, 105]]], ["Since SARS\u2013CoV is a pathogen with high infectivity and mortality, special facilities are required when the live virus is used to prepare viral proteins given the high risk of infection.", [["infection", "DISEASE", 175, 184], ["SARS\u2013CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["viral proteins", "PROTEIN", 137, 151], ["SARS\u2013CoV", "SPECIES", 6, 14], ["a pathogen", "PROBLEM", 18, 28], ["high infectivity", "PROBLEM", 34, 50], ["the live virus", "PROBLEM", 103, 117], ["viral proteins", "TREATMENT", 137, 151], ["infection", "PROBLEM", 175, 184], ["pathogen", "OBSERVATION", 20, 28], ["high infectivity", "OBSERVATION_MODIFIER", 34, 50], ["infection", "OBSERVATION", 175, 184]]], ["Therefore, it is important to obtain large amounts of M protein by expression in vitro.DiscussionThe M protein is a structural glycoprotein, and the glycosylation modification is important for its activity.", [["M protein", "PROTEIN", 54, 63], ["M protein", "PROTEIN", 101, 110], ["structural glycoprotein", "PROTEIN", 116, 139], ["large amounts of M protein", "TREATMENT", 37, 63], ["a structural glycoprotein", "TREATMENT", 114, 139], ["the glycosylation modification", "TREATMENT", 145, 175]]], ["A previous report indicated that the recombinant M protein, when expressed in inclusion body form in E. coli, reacted weakly with human SARS sera (Yi et al., 2003).", [["body", "ANATOMY", 88, 92], ["sera", "ANATOMY", 141, 145], ["SARS", "DISEASE", 136, 140], ["M protein", "GENE_OR_GENE_PRODUCT", 49, 58], ["E. coli", "ORGANISM", 101, 108], ["human", "ORGANISM", 130, 135], ["sera", "ORGANISM_SUBSTANCE", 141, 145], ["recombinant M protein", "PROTEIN", 37, 58], ["E. coli", "SPECIES", 101, 108], ["human", "SPECIES", 130, 135], ["E. coli", "SPECIES", 101, 108], ["human", "SPECIES", 130, 135], ["the recombinant M protein", "TEST", 33, 58], ["E. coli", "PROBLEM", 101, 108], ["E. coli", "OBSERVATION", 101, 108]]], ["P. Pastoris is a eukaryotic expression system with high efficiency, and proteins expressed in this system can get appropriate post-translational modifications, including glycosylation.", [["P. Pastoris", "ORGANISM", 0, 11], ["P. Pastoris", "SPECIES", 0, 11], ["P. Pastoris", "SPECIES", 0, 11], ["high efficiency", "PROBLEM", 51, 66], ["translational modifications", "TREATMENT", 131, 158], ["glycosylation", "TREATMENT", 170, 183], ["high efficiency", "OBSERVATION", 51, 66]]], ["Therefore, the P. Pastoris system is more suitable for expression of the M protein in vitro than E. coli (Grinner and Tschopp, 1989, Kukuruzinska et al., 1987, Romanos et al., 1992).", [["P. Pastoris", "ORGANISM", 15, 26], ["M protein", "GENE_OR_GENE_PRODUCT", 73, 82], ["E. coli", "ORGANISM", 97, 104], ["M protein", "PROTEIN", 73, 82], ["E. coli", "SPECIES", 97, 104], ["P. Pastoris", "SPECIES", 15, 26], ["E. coli", "SPECIES", 97, 104], ["the P. Pastoris system", "TEST", 11, 33], ["the M protein", "TEST", 69, 82]]], ["However, we cannot rule out the possibility that the glycosylation sites of the SARS\u2013CoV M gene in P. Pastoris, while suitable for detection of antibodies, may be quite different from those present in the virus.DiscussionWe expressed successfully the M protein of SARS\u2013CoV strain BJ01 in P. Pastoris, and the expressed M protein was similar to the native protein in its immune response.", [["SARS\u2013CoV M", "GENE_OR_GENE_PRODUCT", 80, 90], ["P. Pastoris", "ORGANISM", 99, 110], ["SARS\u2013CoV strain BJ01", "ORGANISM", 264, 284], ["P. Pastoris", "ORGANISM", 288, 299], ["M protein", "GENE_OR_GENE_PRODUCT", 319, 328], ["SARS\u2013CoV M gene", "DNA", 80, 95], ["antibodies", "PROTEIN", 144, 154], ["M protein", "PROTEIN", 251, 260], ["M protein", "PROTEIN", 319, 328], ["native protein", "PROTEIN", 348, 362], ["P. Pastoris", "SPECIES", 99, 110], ["P. Pastoris", "SPECIES", 288, 299], ["P. Pastoris", "SPECIES", 99, 110], ["SARS\u2013CoV strain BJ01", "SPECIES", 264, 284], ["P. Pastoris", "SPECIES", 288, 299], ["the glycosylation sites", "PROBLEM", 49, 72], ["P. Pastoris", "TEST", 99, 110], ["antibodies", "PROBLEM", 144, 154], ["SARS\u2013CoV strain BJ01", "PROBLEM", 264, 284], ["P. Pastoris", "PROBLEM", 288, 299], ["the expressed M protein", "TEST", 305, 328], ["immune response", "OBSERVATION", 370, 385]]], ["This point can be demonstrated by the reaction of recombinant M protein with SARS-positive sera in Western blotting and ELISA.", [["sera", "ANATOMY", 91, 95], ["sera", "ORGANISM_SUBSTANCE", 91, 95], ["recombinant M protein", "PROTEIN", 50, 71], ["recombinant M protein", "TEST", 50, 71], ["SARS", "PROBLEM", 77, 81], ["positive sera", "PROBLEM", 82, 95], ["ELISA", "TEST", 120, 125]]], ["The availability of large amounts of recombinant M protein offers a better chance to study its biological characteristics and its role in SARS immunity during infection.DiscussionDue to the lack of an effective vaccine or special therapeutic drugs, the control of SARS infection relies mainly on early detection of the virus or its antibodies, and rigid quarantine measures.", [["SARS", "DISEASE", 138, 142], ["infection", "DISEASE", 159, 168], ["SARS infection", "DISEASE", 264, 278], ["recombinant M protein", "PROTEIN", 37, 58], ["antibodies", "PROTEIN", 332, 342], ["recombinant M protein", "TREATMENT", 37, 58], ["SARS immunity during infection", "PROBLEM", 138, 168], ["an effective vaccine", "TREATMENT", 198, 218], ["special therapeutic drugs", "TREATMENT", 222, 247], ["SARS infection", "PROBLEM", 264, 278], ["the virus", "PROBLEM", 315, 324], ["rigid quarantine measures", "TREATMENT", 348, 373], ["large", "OBSERVATION_MODIFIER", 20, 25], ["amounts", "OBSERVATION_MODIFIER", 26, 33]]], ["At present, well-established laboratory diagnostic methods for SARS include real-time PCR, whole-virus-based indirect immunofluorescence assay and ELISA.", [["SARS", "DISEASE", 63, 67], ["SARS", "PROBLEM", 63, 67], ["real-time PCR", "TEST", 76, 89], ["whole-virus", "PROBLEM", 91, 102], ["indirect immunofluorescence assay", "TEST", 109, 142], ["ELISA", "TEST", 147, 152]]], ["In these assays, however, the viral nucleic acid and antigens needed were commonly prepared from live pathogen, so there is a strong associated risk of individual exposure to this pathogen.", [["nucleic acid", "CHEMICAL", 36, 48], ["antigens", "PROTEIN", 53, 61], ["these assays", "TEST", 3, 15], ["the viral nucleic acid", "TEST", 26, 48], ["this pathogen", "PROBLEM", 175, 188]]], ["Compared with these methods, preparing viral antigens by expression in vitro is both easier and safer.", [["viral antigens", "PROTEIN", 39, 53], ["these methods", "TEST", 14, 27]]], ["Among the proteins encoded by the SARS coronavirus, the M protein can induce an immunological response and thus may be used for detection of SARS\u2013CoV antibodies.", [["SARS coronavirus", "DISEASE", 34, 50], ["SARS coronavirus", "ORGANISM", 34, 50], ["SARS\u2013CoV antibodies", "GENE_OR_GENE_PRODUCT", 141, 160], ["M protein", "PROTEIN", 56, 65], ["SARS\u2013CoV antibodies", "PROTEIN", 141, 160], ["coronavirus", "SPECIES", 39, 50], ["SARS coronavirus", "SPECIES", 34, 50], ["SARS\u2013CoV", "SPECIES", 141, 149], ["the SARS coronavirus", "PROBLEM", 30, 50], ["the M protein", "TEST", 52, 65], ["SARS\u2013CoV antibodies", "PROBLEM", 141, 160]]], ["ELISA with the expressed recombinant M protein of canine coronavirus has been reported, and was demonstrated to be a valid and effective detection method (Elia et al., 2003).", [["canine coronavirus", "ORGANISM", 50, 68], ["recombinant M protein", "PROTEIN", 25, 46], ["canine coronavirus", "SPECIES", 50, 68], ["canine coronavirus", "SPECIES", 50, 68], ["canine coronavirus", "PROBLEM", 50, 68], ["canine coronavirus", "OBSERVATION", 50, 68]]], ["In order to evaluate whether our expressed recombinant M protein could be applied as a diagnostic antigen for SARS, we used it as an ELISA antigen to detect eight collected SARS-positive and SARS-negative human sera.", [["sera", "ANATOMY", 211, 215], ["SARS", "DISEASE", 110, 114], ["SARS", "DISEASE", 173, 177], ["human", "ORGANISM", 205, 210], ["sera", "ORGANISM_SUBSTANCE", 211, 215], ["recombinant M protein", "PROTEIN", 43, 64], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 205, 210], ["our expressed recombinant M protein", "PROBLEM", 29, 64], ["a diagnostic antigen", "TEST", 85, 105], ["SARS", "PROBLEM", 110, 114], ["an ELISA antigen", "TEST", 130, 146], ["collected SARS", "TEST", 163, 177], ["SARS", "TEST", 191, 195]]], ["The results were in complete accordance with those of other assays, thus indicating that the recombinant M protein may be useful as an ELISA antigen for detecting specific antibodies to SARS\u2013CoV in human sera.", [["sera", "ANATOMY", 204, 208], ["SARS\u2013CoV", "ORGANISM", 186, 194], ["human", "ORGANISM", 198, 203], ["sera", "ORGANISM_SUBSTANCE", 204, 208], ["recombinant M protein", "PROTEIN", 93, 114], ["antibodies", "PROTEIN", 172, 182], ["SARS\u2013CoV", "PROTEIN", 186, 194], ["human", "SPECIES", 198, 203], ["SARS\u2013CoV", "SPECIES", 186, 194], ["human", "SPECIES", 198, 203], ["other assays", "TEST", 54, 66], ["the recombinant M protein", "TEST", 89, 114], ["an ELISA antigen", "TEST", 132, 148], ["specific antibodies", "TEST", 163, 182]]], ["Furthermore, the recombinant M protein offers several advantages over the cell-prepared SARS\u2013CoV antigen.DiscussionIn summary, the P. Pichia system is a viable tool to express the M protein at high-levels in vitro.", [["cell", "ANATOMY", 74, 78], ["cell", "CELL", 74, 78], ["SARS\u2013CoV antigen", "GENE_OR_GENE_PRODUCT", 88, 104], ["P. Pichia", "ORGANISM", 131, 140], ["recombinant M protein", "PROTEIN", 17, 38], ["cell-prepared SARS\u2013CoV antigen", "PROTEIN", 74, 104], ["M protein", "PROTEIN", 180, 189], ["P. Pichia", "SPECIES", 131, 140], ["the recombinant M protein", "TREATMENT", 13, 38], ["the cell", "TEST", 70, 78], ["the M protein", "TEST", 176, 189]]], ["The availability of large amounts of SARS\u2013CoV recombinant M protein offers an opportunity to better investigate the biological properties of the M protein during SARS\u2013CoV infection as well as its immunological role, and thus provide a basis for development of SARS\u2013CoV vaccine and therapeutic drugs.", [["infection", "DISEASE", 171, 180], ["M protein", "GENE_OR_GENE_PRODUCT", 145, 154], ["SARS\u2013CoV", "ORGANISM", 162, 170], ["SARS\u2013CoV", "ORGANISM", 260, 268], ["SARS\u2013CoV recombinant M protein", "PROTEIN", 37, 67], ["M protein", "PROTEIN", 145, 154], ["SARS\u2013CoV", "SPECIES", 162, 170], ["SARS\u2013CoV", "SPECIES", 260, 268], ["SARS\u2013CoV recombinant M protein", "TREATMENT", 37, 67], ["SARS\u2013CoV infection", "PROBLEM", 162, 180], ["SARS", "PROBLEM", 260, 264], ["CoV vaccine", "TREATMENT", 265, 276], ["therapeutic drugs", "TREATMENT", 281, 298], ["large", "OBSERVATION_MODIFIER", 20, 25], ["amounts", "OBSERVATION_MODIFIER", 26, 33], ["infection", "OBSERVATION", 171, 180]]], ["The recombinant M protein expressed in P. Pastoris may have better antigenicity than that expressed in E. coli, and is more suitable for use as a diagnostic antigen.", [["P. Pastoris", "ORGANISM", 39, 50], ["E. coli", "ORGANISM", 103, 110], ["recombinant M protein", "PROTEIN", 4, 25], ["P. Pastoris", "SPECIES", 39, 50], ["E. coli", "SPECIES", 103, 110], ["P. Pastoris", "SPECIES", 39, 50], ["E. coli", "SPECIES", 103, 110], ["The recombinant M protein", "TREATMENT", 0, 25], ["P. Pastoris", "PROBLEM", 39, 50], ["E. coli", "PROBLEM", 103, 110], ["a diagnostic antigen", "TEST", 144, 164], ["E. coli", "OBSERVATION", 103, 110]]]], "PMC7363422": [["During the COVID-19 pandemic, slowing the spread of the disease and caring for people whose survival and health are jeopardised have rightly been prioritised.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["the COVID", "TEST", 7, 16], ["pandemic", "PROBLEM", 20, 28], ["the disease", "PROBLEM", 52, 63], ["slowing", "OBSERVATION_MODIFIER", 30, 37], ["spread", "OBSERVATION_MODIFIER", 42, 48], ["disease", "OBSERVATION", 56, 63]]], ["Now, attention is increasingly being focused on the unwelcome consequences of COVID-19 for individuals, families, communities, and society.", [["COVID", "TEST", 78, 83]]], ["To date, a potential source of collateral damage by COVID-19 has remained oddly invisible.", [["collateral", "ANATOMY", 31, 41], ["collateral damage", "DISEASE", 31, 48], ["COVID-19", "CHEMICAL", 52, 60], ["COVID-19", "CHEMICAL", 52, 60], ["collateral", "MULTI-TISSUE_STRUCTURE", 31, 41], ["collateral damage", "PROBLEM", 31, 48], ["COVID", "TEST", 52, 57], ["collateral damage", "OBSERVATION", 31, 48]]]], "PMC7527793": [["IntroductionFirst described in December of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the newest Coronavirus known to infect humans.", [["acute respiratory syndrome coronavirus", "DISEASE", 56, 94], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 49, 96], ["SARS-CoV-2", "ORGANISM", 98, 108], ["humans", "ORGANISM", 152, 158], ["humans", "SPECIES", 152, 158], ["severe acute respiratory syndrome coronavirus", "SPECIES", 49, 94], ["SARS-CoV-2", "SPECIES", 98, 108], ["humans", "SPECIES", 152, 158], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 49, 94], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["the newest Coronavirus", "PROBLEM", 113, 135], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82]]], ["Symptomatic infection is designated COVID-19 (COrona VIrus Disease 2019).", [["infection", "DISEASE", 12, 21], ["Symptomatic infection", "PROBLEM", 0, 21], ["COVID", "TEST", 36, 41], ["COrona VIrus Disease", "PROBLEM", 46, 66], ["infection", "OBSERVATION", 12, 21]]], ["Due to its highly communicable nature, lack of cross-reactive immunity to extant coronavirus strains, and delay in identification, it quickly spread and was designated a global pandemic by the World Health Organization on March 11, 2020.", [["coronavirus", "ORGANISM", 81, 92], ["extant coronavirus strains", "PROBLEM", 74, 100], ["coronavirus strains", "OBSERVATION", 81, 100]]], ["At the time of submission, COVID-19 is estimated to have infected more than 10 million individuals and deemed responsible for over 500,000 deaths.", [["deaths", "DISEASE", 139, 145], ["COVID", "TEST", 27, 32], ["infected", "OBSERVATION", 57, 65]]], ["Although adults more commonly present with symptomatic infection, children are also afflicted, but frequently exhibit a milder disease course (1).IntroductionA small subset of pediatric patients develop a rare but newly emerging syndrome associated with COVID-19 infection.", [["infection", "DISEASE", 55, 64], ["infection", "DISEASE", 263, 272], ["adults", "ORGANISM", 9, 15], ["children", "ORGANISM", 66, 74], ["patients", "ORGANISM", 186, 194], ["children", "SPECIES", 66, 74], ["patients", "SPECIES", 186, 194], ["symptomatic infection", "PROBLEM", 43, 64], ["a milder disease course", "PROBLEM", 118, 141], ["newly emerging syndrome", "PROBLEM", 214, 237], ["COVID-19 infection", "PROBLEM", 254, 272], ["symptomatic", "OBSERVATION_MODIFIER", 43, 54], ["infection", "OBSERVATION", 55, 64], ["infection", "OBSERVATION", 263, 272]]], ["Termed multisystem inflammatory syndrome in children (MIS-C), this syndrome shares characteristics with Kawasaki disease (KD), including fever, elevated inflammatory markers, and multisystem involvement (ocular, dermatologic, mucocutaneous, gastrointestinal, and cardiac).", [["ocular", "ANATOMY", 204, 210], ["mucocutaneous", "ANATOMY", 226, 239], ["gastrointestinal", "ANATOMY", 241, 257], ["cardiac", "ANATOMY", 263, 270], ["multisystem inflammatory syndrome", "DISEASE", 7, 40], ["Kawasaki disease", "DISEASE", 104, 120], ["KD", "DISEASE", 122, 124], ["fever", "DISEASE", 137, 142], ["ocular, dermatologic, mucocutaneous, gastrointestinal, and cardiac)", "DISEASE", 204, 271], ["children", "ORGANISM", 44, 52], ["gastrointestinal", "ORGAN", 241, 257], ["cardiac", "ORGAN", 263, 270], ["inflammatory markers", "PROTEIN", 153, 173], ["children", "SPECIES", 44, 52], ["Termed multisystem inflammatory syndrome", "PROBLEM", 0, 40], ["this syndrome", "PROBLEM", 62, 75], ["Kawasaki disease (KD)", "PROBLEM", 104, 125], ["fever", "PROBLEM", 137, 142], ["elevated inflammatory markers", "PROBLEM", 144, 173], ["multisystem involvement (ocular, dermatologic, mucocutaneous, gastrointestinal", "PROBLEM", 179, 257], ["multisystem", "OBSERVATION_MODIFIER", 7, 18], ["inflammatory syndrome", "OBSERVATION", 19, 40], ["Kawasaki disease", "OBSERVATION", 104, 120], ["elevated", "OBSERVATION_MODIFIER", 144, 152], ["inflammatory markers", "OBSERVATION", 153, 173], ["multisystem", "OBSERVATION_MODIFIER", 179, 190], ["involvement", "OBSERVATION", 191, 202], ["ocular", "ANATOMY", 204, 210], ["gastrointestinal", "ANATOMY", 241, 257], ["cardiac", "ANATOMY", 263, 270]]], ["MIS-C can have a protean presentation, creating a diagnostic challenge for emergency physicians.", [["MIS-C", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["We present this case to increase familiarity among emergency physicians with the clinical manifestations of this syndrome.Case ReportA 15-year-old girl presented to our Emergency Department (ED) with fevers and malaise.", [["fevers", "DISEASE", 200, 206], ["girl", "ORGANISM", 147, 151], ["girl", "SPECIES", 147, 151], ["this syndrome", "PROBLEM", 108, 121], ["fevers", "PROBLEM", 200, 206], ["malaise", "PROBLEM", 211, 218], ["fevers", "OBSERVATION", 200, 206], ["malaise", "OBSERVATION", 211, 218]]], ["She had been healthy until 2 days prior to arrival, at which point she developed elevated temperature, myalgias, fatigue, and headaches.", [["myalgias", "DISEASE", 103, 111], ["fatigue", "DISEASE", 113, 120], ["headaches", "DISEASE", 126, 135], ["elevated temperature", "PROBLEM", 81, 101], ["myalgias", "PROBLEM", 103, 111], ["fatigue", "PROBLEM", 113, 120], ["headaches", "PROBLEM", 126, 135], ["elevated", "OBSERVATION", 81, 89], ["myalgias", "OBSERVATION", 103, 111], ["headaches", "OBSERVATION", 126, 135]]], ["She also reported mild crampy abdominal pain, nonbilious, nonbloody emesis, and watery diarrhea.", [["abdominal", "ANATOMY", 30, 39], ["nonbloody", "ANATOMY", 58, 67], ["crampy abdominal pain", "DISEASE", 23, 44], ["nonbloody emesis", "DISEASE", 58, 74], ["watery diarrhea", "DISEASE", 80, 95], ["abdominal", "ORGANISM_SUBDIVISION", 30, 39], ["mild crampy abdominal pain", "PROBLEM", 18, 44], ["nonbilious", "PROBLEM", 46, 56], ["nonbloody emesis", "PROBLEM", 58, 74], ["watery diarrhea", "PROBLEM", 80, 95], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["crampy", "OBSERVATION_MODIFIER", 23, 29], ["abdominal", "ANATOMY", 30, 39], ["pain", "OBSERVATION", 40, 44], ["watery", "OBSERVATION_MODIFIER", 80, 86], ["diarrhea", "OBSERVATION", 87, 95]]], ["She denied upper or lower respiratory tract symptoms, urinary symptoms, or skin rash.", [["lower respiratory tract", "ANATOMY", 20, 43], ["urinary", "ANATOMY", 54, 61], ["skin", "ANATOMY", 75, 79], ["urinary symptoms", "DISEASE", 54, 70], ["skin rash", "DISEASE", 75, 84], ["upper", "ORGANISM_SUBDIVISION", 11, 16], ["lower", "ORGANISM_SUBDIVISION", 20, 25], ["respiratory tract", "ORGANISM_SUBDIVISION", 26, 43], ["urinary", "ORGANISM_SUBDIVISION", 54, 61], ["skin", "ORGAN", 75, 79], ["upper or lower respiratory tract symptoms", "PROBLEM", 11, 52], ["urinary symptoms", "PROBLEM", 54, 70], ["skin rash", "PROBLEM", 75, 84], ["upper", "ANATOMY_MODIFIER", 11, 16], ["lower", "ANATOMY_MODIFIER", 20, 25], ["respiratory tract", "ANATOMY", 26, 43], ["urinary", "ANATOMY", 54, 61], ["skin", "ANATOMY", 75, 79], ["rash", "OBSERVATION", 80, 84]]], ["Although she denied any known sick contacts, she reported travel to Tijuana, Mexico 3 weeks prior to the onset of her symptoms.", [["her symptoms", "PROBLEM", 114, 126]]], ["Vital signs at the time of examination included a temperature of 38.7\u00b0C (101.6\u00b0F), heart rate of 128 beats/min, blood pressure of 125/85 mm Hg, respiratory rate of 20 breaths/min, and an oxygen saturation of 99% on room air.", [["heart", "ANATOMY", 83, 88], ["blood", "ANATOMY", 112, 117], ["respiratory", "ANATOMY", 144, 155], ["oxygen", "CHEMICAL", 187, 193], ["Hg", "CHEMICAL", 140, 142], ["oxygen", "CHEMICAL", 187, 193], ["heart", "ORGAN", 83, 88], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["oxygen", "SIMPLE_CHEMICAL", 187, 193], ["Vital signs", "TEST", 0, 11], ["examination", "TEST", 27, 38], ["a temperature", "TEST", 48, 61], ["\u00b0C", "TEST", 69, 71], ["heart rate", "TEST", 83, 93], ["blood pressure", "TEST", 112, 126], ["respiratory rate", "TEST", 144, 160], ["an oxygen saturation", "TEST", 184, 204]]], ["Physical examination revealed an overall well-appearing patient.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["Physical examination", "TEST", 0, 20]]], ["She was tachycardic without any murmurs and had clear lungs to auscultation bilaterally.", [["lungs", "ANATOMY", 54, 59], ["lungs", "ORGAN", 54, 59], ["tachycardic", "PROBLEM", 8, 19], ["any murmurs", "PROBLEM", 28, 39], ["auscultation", "TEST", 63, 75], ["tachycardic", "OBSERVATION", 8, 19], ["murmurs", "OBSERVATION", 32, 39], ["clear", "OBSERVATION", 48, 53], ["lungs", "ANATOMY", 54, 59], ["auscultation", "OBSERVATION", 63, 75], ["bilaterally", "ANATOMY_MODIFIER", 76, 87]]], ["She had no abdominal tenderness on palpation.", [["abdominal", "ANATOMY", 11, 20], ["abdominal tenderness", "DISEASE", 11, 31], ["abdominal", "ORGANISM_SUBDIVISION", 11, 20], ["abdominal tenderness", "PROBLEM", 11, 31], ["palpation", "TEST", 35, 44], ["no", "UNCERTAINTY", 8, 10], ["abdominal", "ANATOMY", 11, 20], ["tenderness", "OBSERVATION", 21, 31]]], ["A chest radiograph did not have any evidence of infiltrates and her urinalysis was unremarkable.", [["chest", "ANATOMY", 2, 7], ["A chest radiograph", "TEST", 0, 18], ["infiltrates", "PROBLEM", 48, 59], ["her urinalysis", "TEST", 64, 78], ["chest", "ANATOMY", 2, 7], ["infiltrates", "OBSERVATION", 48, 59], ["unremarkable", "OBSERVATION", 83, 95]]], ["She was diagnosed with an acute viral syndrome and discharged with a COVID polymerase chain reaction test pending.", [["acute viral syndrome", "DISEASE", 26, 46], ["an acute viral syndrome", "PROBLEM", 23, 46], ["a COVID polymerase chain reaction test", "TEST", 67, 105], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["viral syndrome", "OBSERVATION", 32, 46]]], ["It returned negative the following day.Case ReportThree days later, the patient returned to our ED.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["negative", "OBSERVATION", 12, 20]]], ["During this visit she complained of ongoing fevers, was minimally responsive to antipyretics, and had painless, nonpruritic rash, which had erupted on her palms over the last 24 h.", [["palms", "ANATOMY", 155, 160], ["fevers", "DISEASE", 44, 50], ["rash", "DISEASE", 124, 128], ["palms", "ORGANISM_SUBDIVISION", 155, 160], ["ongoing fevers", "PROBLEM", 36, 50], ["minimally responsive", "PROBLEM", 56, 76], ["antipyretics", "TREATMENT", 80, 92], ["painless, nonpruritic rash", "PROBLEM", 102, 128], ["fevers", "OBSERVATION", 44, 50], ["nonpruritic", "OBSERVATION_MODIFIER", 112, 123], ["rash", "OBSERVATION", 124, 128]]], ["Vital signs at this visit were remarkable for a heart rate of 112 beats/min.", [["heart", "ANATOMY", 48, 53], ["heart", "ORGAN", 48, 53], ["Vital signs", "TEST", 0, 11], ["a heart rate", "TEST", 46, 58]]], ["Physical examination was notable for symmetric perilimbal-sparing conjunctivitis and a symmetric targetoid rash over her palms (Figure 1).", [["palms", "ANATOMY", 121, 126], ["conjunctivitis", "DISEASE", 66, 80], ["rash", "DISEASE", 107, 111], ["palms", "ORGANISM_SUBDIVISION", 121, 126], ["Physical examination", "TEST", 0, 20], ["symmetric perilimbal-sparing conjunctivitis", "PROBLEM", 37, 80], ["a symmetric targetoid rash", "PROBLEM", 85, 111], ["sparing", "OBSERVATION_MODIFIER", 58, 65], ["conjunctivitis", "OBSERVATION", 66, 80], ["symmetric", "OBSERVATION_MODIFIER", 87, 96], ["targetoid", "OBSERVATION_MODIFIER", 97, 106], ["rash", "OBSERVATION", 107, 111], ["palms", "ANATOMY", 121, 126]]], ["The remainder of her dermatologic examination was unrevealing.", [["her dermatologic examination", "TEST", 17, 45]]], ["Oral examination was within normal limits and specifically lacked findings to suggest ulcers, tongue depapillation, or lip hyperemia.", [["Oral", "ANATOMY", 0, 4], ["ulcers", "ANATOMY", 86, 92], ["tongue", "ANATOMY", 94, 100], ["lip", "ANATOMY", 119, 122], ["ulcers", "DISEASE", 86, 92], ["tongue depapillation", "DISEASE", 94, 114], ["lip hyperemia", "DISEASE", 119, 132], ["ulcers", "PATHOLOGICAL_FORMATION", 86, 92], ["tongue", "ORGANISM_SUBDIVISION", 94, 100], ["lip", "ORGAN", 119, 122], ["Oral examination", "TEST", 0, 16], ["ulcers", "PROBLEM", 86, 92], ["tongue depapillation", "PROBLEM", 94, 114], ["lip hyperemia", "PROBLEM", 119, 132], ["normal limits", "OBSERVATION_MODIFIER", 28, 41], ["ulcers", "OBSERVATION", 86, 92], ["tongue", "ANATOMY", 94, 100], ["lip", "ANATOMY", 119, 122], ["hyperemia", "OBSERVATION", 123, 132]]], ["She lacked any notable palpable lymphadenopathy, and her extremities were without acral edema or desquamation.", [["palpable lymphadenopathy", "ANATOMY", 23, 47], ["extremities", "ANATOMY", 57, 68], ["acral edema", "ANATOMY", 82, 93], ["lymphadenopathy", "DISEASE", 32, 47], ["edema", "DISEASE", 88, 93], ["desquamation", "DISEASE", 97, 109], ["extremities", "ORGANISM_SUBDIVISION", 57, 68], ["acral edema", "PATHOLOGICAL_FORMATION", 82, 93], ["any notable palpable lymphadenopathy", "PROBLEM", 11, 47], ["acral edema", "PROBLEM", 82, 93], ["desquamation", "PROBLEM", 97, 109], ["notable", "OBSERVATION_MODIFIER", 15, 22], ["palpable", "OBSERVATION_MODIFIER", 23, 31], ["lymphadenopathy", "OBSERVATION", 32, 47], ["extremities", "ANATOMY", 57, 68], ["without", "UNCERTAINTY", 74, 81], ["acral", "ANATOMY", 82, 87], ["edema", "OBSERVATION", 88, 93], ["desquamation", "OBSERVATION", 97, 109]]], ["Laboratory analysis was remarkable for mild hyponatremia at 135 mmol/L, hypochloremia at 95 mmol/L, with a slight anion gap acidosis at 19.", [["hyponatremia", "DISEASE", 44, 56], ["hypochloremia", "DISEASE", 72, 85], ["acidosis", "DISEASE", 124, 132], ["Laboratory analysis", "TEST", 0, 19], ["mild hyponatremia", "PROBLEM", 39, 56], ["hypochloremia", "PROBLEM", 72, 85], ["a slight anion gap acidosis", "PROBLEM", 105, 132], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["hyponatremia", "OBSERVATION", 44, 56], ["slight", "OBSERVATION_MODIFIER", 107, 113], ["anion gap acidosis", "OBSERVATION", 114, 132]]], ["She also had a slight transaminitis at 50 U/L and leukocytosis at 11.1/mm3.", [["transaminitis", "DISEASE", 22, 35], ["leukocytosis", "DISEASE", 50, 62], ["She", "ORGANISM", 0, 3], ["a slight transaminitis", "PROBLEM", 13, 35], ["leukocytosis", "PROBLEM", 50, 62], ["slight", "OBSERVATION_MODIFIER", 15, 21], ["transaminitis", "OBSERVATION", 22, 35], ["leukocytosis", "OBSERVATION", 50, 62]]], ["Her erythrocyte sedimentation rate and C-reactive protein (CRP) were both significantly elevated at 90 mm/h and 19.61 mg/dL, respectively.Case ReportThe patient was then transferred to the regional children's hospital for further evaluation and treatment with a clinical concern for possible MIS-C given the underlying prevalence of COVID-19.", [["erythrocyte", "ANATOMY", 4, 15], ["COVID-19", "CHEMICAL", 333, 341], ["erythrocyte", "CELL", 4, 15], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 39, 57], ["CRP", "GENE_OR_GENE_PRODUCT", 59, 62], ["patient", "ORGANISM", 153, 160], ["children", "ORGANISM", 198, 206], ["MIS-C", "SIMPLE_CHEMICAL", 292, 297], ["C-reactive protein", "PROTEIN", 39, 57], ["CRP", "PROTEIN", 59, 62], ["patient", "SPECIES", 153, 160], ["children", "SPECIES", 198, 206], ["Her erythrocyte sedimentation rate", "TEST", 0, 34], ["C-reactive protein", "TEST", 39, 57], ["CRP", "TEST", 59, 62], ["significantly elevated", "PROBLEM", 74, 96], ["further evaluation", "TEST", 222, 240], ["treatment", "TREATMENT", 245, 254], ["MIS", "TEST", 292, 295], ["COVID", "TEST", 333, 338], ["erythrocyte sedimentation", "OBSERVATION", 4, 29]]], ["She was admitted to the pediatric hospitalist service with Rheumatology, Cardiology, and Infectious Disease consultations.", [["Infectious Disease", "DISEASE", 89, 107], ["Infectious", "OBSERVATION", 89, 99]]], ["She received one 120-g dose of intravenous immunoglobulin (IVIG) on day 1 in addition to 81 mg aspirin daily throughout the admission.", [["intravenous", "ANATOMY", 31, 42], ["aspirin", "CHEMICAL", 95, 102], ["aspirin", "CHEMICAL", 95, 102], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 42], ["immunoglobulin", "SIMPLE_CHEMICAL", 43, 57], ["IVIG", "SIMPLE_CHEMICAL", 59, 63], ["aspirin", "SIMPLE_CHEMICAL", 95, 102], ["intravenous immunoglobulin", "PROTEIN", 31, 57], ["intravenous immunoglobulin (IVIG", "TREATMENT", 31, 63], ["aspirin", "TREATMENT", 95, 102]]], ["Her COVID-19 immunoglobulin G returned positive later that same day.", [["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 13, 29], ["COVID-19 immunoglobulin G", "DNA", 4, 29], ["Her COVID", "TEST", 0, 9], ["immunoglobulin G", "TEST", 13, 29]]], ["Further history noted that the patient had a close family contact who tested positive for COVID-19 approximately 1 month prior.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["COVID", "TEST", 90, 95]]], ["Admission laboratory analysis was remarkable for a CRP of 20.7 mg/dL, a ferritin of 1080 ng/dL, and an interleukin 6 level of 18.8 pg/dL.Case ReportDuring her admission, initial echocardiograms showed mild dilatation of the left main coronary artery.", [["left main coronary artery", "ANATOMY", 224, 249], ["CRP", "GENE_OR_GENE_PRODUCT", 51, 54], ["ferritin", "GENE_OR_GENE_PRODUCT", 72, 80], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 103, 116], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 234, 249], ["CRP", "PROTEIN", 51, 54], ["ferritin", "PROTEIN", 72, 80], ["interleukin 6", "PROTEIN", 103, 116], ["Admission laboratory analysis", "TEST", 0, 29], ["a CRP", "TEST", 49, 54], ["a ferritin", "TEST", 70, 80], ["an interleukin 6 level", "TEST", 100, 122], ["initial echocardiograms", "TEST", 170, 193], ["mild dilatation of the left main coronary artery", "PROBLEM", 201, 249], ["mild", "OBSERVATION_MODIFIER", 201, 205], ["dilatation", "OBSERVATION", 206, 216], ["left main coronary artery", "ANATOMY", 224, 249]]], ["On repeat echocardiogram 3 days later, this dilatation had increased from the previous study and a right coronary artery aneurysm was also identified at this time.", [["right coronary artery aneurysm", "ANATOMY", 99, 129], ["coronary artery aneurysm", "DISEASE", 105, 129], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 105, 120], ["repeat echocardiogram", "TEST", 3, 24], ["this dilatation", "PROBLEM", 39, 54], ["the previous study", "TEST", 74, 92], ["a right coronary artery aneurysm", "PROBLEM", 97, 129], ["dilatation", "OBSERVATION", 44, 54], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["right coronary artery", "ANATOMY", 99, 120], ["aneurysm", "OBSERVATION", 121, 129]]], ["These enlarging aneurysms prompted additional therapy with 5 mg of oral prednisone for 5 days.", [["oral", "ANATOMY", 67, 71], ["aneurysms", "DISEASE", 16, 25], ["prednisone", "CHEMICAL", 72, 82], ["prednisone", "CHEMICAL", 72, 82], ["oral", "ORGANISM_SUBDIVISION", 67, 71], ["prednisone", "SIMPLE_CHEMICAL", 72, 82], ["These enlarging aneurysms", "PROBLEM", 0, 25], ["additional therapy", "TREATMENT", 35, 53], ["oral prednisone", "TREATMENT", 67, 82], ["enlarging", "OBSERVATION_MODIFIER", 6, 15], ["aneurysms", "OBSERVATION", 16, 25]]], ["The patient was discharged 5 days after hospital admission on a continued prednisone taper.", [["prednisone", "CHEMICAL", 74, 84], ["prednisone", "CHEMICAL", 74, 84], ["patient", "ORGANISM", 4, 11], ["prednisone", "SIMPLE_CHEMICAL", 74, 84], ["patient", "SPECIES", 4, 11], ["a continued prednisone taper", "TREATMENT", 62, 90]]], ["At the time of discharge, her CRP had decreased to 1.6 mg/dL, her ferritin to 565 ng/dL, and interleukin 6 to 9.48 pg/dL.Initial Case Descriptions ::: DiscussionThe initial description of MIS-C was reported in April 2020 by a group of pediatric intensivists in London who described a hyperinflammatory syndrome in 8 previously healthy pediatric patients ranging from 4 to 14 years old (5).", [["hyperinflammatory syndrome", "DISEASE", 284, 310], ["CRP", "GENE_OR_GENE_PRODUCT", 30, 33], ["ferritin", "GENE_OR_GENE_PRODUCT", 66, 74], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 93, 106], ["MIS-C", "SIMPLE_CHEMICAL", 188, 193], ["patients", "ORGANISM", 345, 353], ["CRP", "PROTEIN", 30, 33], ["ferritin", "PROTEIN", 66, 74], ["interleukin 6", "PROTEIN", 93, 106], ["patients", "SPECIES", 345, 353], ["her CRP", "TEST", 26, 33], ["her ferritin", "TEST", 62, 74], ["interleukin", "TEST", 93, 104], ["a hyperinflammatory syndrome", "PROBLEM", 282, 310], ["hyperinflammatory syndrome", "OBSERVATION", 284, 310]]], ["All reported unrelenting fevers, rashes, and GI symptoms and each progressed to vasodilatory shock.", [["GI", "ANATOMY", 45, 47], ["fevers", "DISEASE", 25, 31], ["rashes", "DISEASE", 33, 39], ["GI symptoms", "DISEASE", 45, 56], ["shock", "DISEASE", 93, 98], ["unrelenting fevers", "PROBLEM", 13, 31], ["rashes", "PROBLEM", 33, 39], ["GI symptoms", "PROBLEM", 45, 56], ["vasodilatory shock", "PROBLEM", 80, 98], ["unrelenting", "OBSERVATION_MODIFIER", 13, 24], ["fevers", "OBSERVATION", 25, 31], ["rashes", "OBSERVATION", 33, 39], ["GI", "ANATOMY", 45, 47], ["vasodilatory shock", "OBSERVATION", 80, 98]]], ["Despite significant elevations in inflammatory markers, and many with recent COVID-19 exposures, all tested negative for active infection.", [["infection", "DISEASE", 128, 137], ["inflammatory markers", "PROTEIN", 34, 54], ["significant elevations in inflammatory markers", "PROBLEM", 8, 54], ["recent COVID-19 exposures", "PROBLEM", 70, 95], ["active infection", "PROBLEM", 121, 137], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["elevations", "OBSERVATION_MODIFIER", 20, 30], ["inflammatory markers", "OBSERVATION", 34, 54], ["negative for", "UNCERTAINTY", 108, 120], ["active", "OBSERVATION_MODIFIER", 121, 127], ["infection", "OBSERVATION", 128, 137]]], ["Although the majority of these patients required intubation and mechanical ventilation, all fully recovered.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["intubation", "TREATMENT", 49, 59], ["mechanical ventilation", "TREATMENT", 64, 86], ["mechanical ventilation", "OBSERVATION", 64, 86]]], ["Shortly after this sentinel report, a group in Bergamo, Italy described a cohort of 10 pediatric patients with similar hyperinflammatory findings and significant myocardial involvement (6).", [["myocardial", "ANATOMY", 162, 172], ["patients", "ORGANISM", 97, 105], ["myocardial", "MULTI-TISSUE_STRUCTURE", 162, 172], ["patients", "SPECIES", 97, 105], ["similar hyperinflammatory findings", "PROBLEM", 111, 145], ["significant myocardial involvement", "PROBLEM", 150, 184], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["myocardial", "ANATOMY", 162, 172], ["involvement", "OBSERVATION", 173, 184]]], ["In both series, the authors discovered that approximately half of patients met criteria for incomplete KD.", [["KD", "DISEASE", 103, 105], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["incomplete KD", "PROBLEM", 92, 105]]], ["Of concern, they noted a 30-fold higher rate of cardiovascular complications, including coronary aneurysms and shock, compared with patients with KD.Initial Case Descriptions ::: DiscussionMore recently, a report from New York City in June 2020 provided an analysis of 99 patients with either suspected or confirmed MIS-C (7).", [["cardiovascular", "ANATOMY", 48, 62], ["coronary", "ANATOMY", 88, 96], ["cardiovascular complications", "DISEASE", 48, 76], ["coronary aneurysms", "DISEASE", 88, 106], ["shock", "DISEASE", 111, 116], ["MIS-C", "CHEMICAL", 316, 321], ["cardiovascular", "ANATOMICAL_SYSTEM", 48, 62], ["coronary", "MULTI-TISSUE_STRUCTURE", 88, 96], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 272, 280], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 272, 280], ["cardiovascular complications", "PROBLEM", 48, 76], ["coronary aneurysms", "PROBLEM", 88, 106], ["shock", "PROBLEM", 111, 116], ["an analysis", "TEST", 254, 265], ["cardiovascular", "ANATOMY", 48, 62], ["complications", "OBSERVATION", 63, 76], ["coronary", "ANATOMY", 88, 96], ["aneurysms", "OBSERVATION", 97, 106], ["shock", "OBSERVATION", 111, 116]]], ["The majority of patients tested positive for SARS-CoV-2 infection, and all but one had evidence of immunoglobulin G antibodies to SARS-CoV-2.", [["SARS-CoV-2 infection", "DISEASE", 45, 65], ["SARS", "DISEASE", 130, 134], ["patients", "ORGANISM", 16, 24], ["SARS-CoV-2", "ORGANISM", 45, 55], ["immunoglobulin G antibodies", "GENE_OR_GENE_PRODUCT", 99, 126], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["immunoglobulin G antibodies", "PROTEIN", 99, 126], ["patients", "SPECIES", 16, 24], ["SARS-CoV-2", "SPECIES", 45, 55], ["SARS-CoV", "SPECIES", 130, 138], ["SARS", "PROBLEM", 45, 49], ["CoV", "PROBLEM", 50, 53], ["2 infection", "PROBLEM", 54, 65], ["immunoglobulin G antibodies", "TEST", 99, 126], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138], ["infection", "OBSERVATION", 56, 65]]], ["The most common complaints at the time of admission were GI (80%), dermatologic (62%), mucocutaneous (61%), and lower respiratory (40%).", [["respiratory", "ANATOMY", 118, 129], ["mucocutaneous", "DISEASE", 87, 100], ["GI", "TEST", 57, 59], ["lower", "ANATOMY_MODIFIER", 112, 117], ["respiratory", "ANATOMY", 118, 129]]], ["The median time from symptom development to admission was 4 days.", [["symptom", "PROBLEM", 21, 28]]], ["Most patients required intensive care unit admission and half required vasoactive medication support.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["vasoactive medication support", "TREATMENT", 71, 100]]], ["Cardiovascular complications were common, with half having some degree of ventricular dysfunction, a third with pericardial effusions, and a tenth with coronary artery aneurysms.", [["Cardiovascular", "ANATOMY", 0, 14], ["ventricular", "ANATOMY", 74, 85], ["pericardial", "ANATOMY", 112, 123], ["coronary artery aneurysms", "ANATOMY", 152, 177], ["Cardiovascular complications", "DISEASE", 0, 28], ["ventricular dysfunction", "DISEASE", 74, 97], ["pericardial effusions", "DISEASE", 112, 133], ["coronary artery aneurysms", "DISEASE", 152, 177], ["ventricular", "ORGAN", 74, 85], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 152, 167], ["Cardiovascular complications", "PROBLEM", 0, 28], ["ventricular dysfunction", "PROBLEM", 74, 97], ["pericardial effusions", "PROBLEM", 112, 133], ["coronary artery aneurysms", "PROBLEM", 152, 177], ["complications", "OBSERVATION", 15, 28], ["ventricular", "ANATOMY", 74, 85], ["dysfunction", "OBSERVATION", 86, 97], ["pericardial", "ANATOMY", 112, 123], ["effusions", "OBSERVATION", 124, 133], ["coronary artery", "ANATOMY", 152, 167], ["aneurysms", "OBSERVATION", 168, 177]]], ["A larger report of 186 children with MIS-C across 26 states found similar characteristics to the New York City cohort of children (8).", [["children", "ORGANISM", 23, 31], ["children", "ORGANISM", 121, 129], ["children", "SPECIES", 23, 31], ["children", "SPECIES", 121, 129], ["MIS", "PROBLEM", 37, 40], ["larger", "OBSERVATION_MODIFIER", 2, 8]]], ["The median age of affected children was 8 years old and the majority of children with MIS-C had involvement of at least four organ systems, most commonly GI (92%), cardiovascular (80%), hematologic (76%), and mucocutaneous (74%).", [["organ", "ANATOMY", 125, 130], ["GI", "ANATOMY", 154, 156], ["cardiovascular", "ANATOMY", 164, 178], ["hematologic", "ANATOMY", 186, 197], ["mucocutaneous", "ANATOMY", 209, 222], ["mucocutaneous", "DISEASE", 209, 222], ["children", "ORGANISM", 27, 35], ["children", "ORGANISM", 72, 80], ["organ", "ORGAN", 125, 130], ["GI", "CANCER", 154, 156], ["hematologic", "CANCER", 186, 197], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 72, 80], ["GI", "TEST", 154, 156], ["cardiovascular", "TEST", 164, 178], ["hematologic", "TEST", 186, 197], ["mucocutaneous", "TEST", 209, 222], ["mucocutaneous", "ANATOMY", 209, 222]]], ["Eighty percent of children were admitted to the intensive care unit, 20% required mechanical ventilation, and 4% received extracorporeal membrane oxygen support.", [["membrane", "ANATOMY", 137, 145], ["oxygen", "CHEMICAL", 146, 152], ["oxygen", "CHEMICAL", 146, 152], ["children", "ORGANISM", 18, 26], ["extracorporeal membrane oxygen", "SIMPLE_CHEMICAL", 122, 152], ["children", "SPECIES", 18, 26], ["mechanical ventilation", "TREATMENT", 82, 104], ["extracorporeal membrane oxygen support", "TREATMENT", 122, 160], ["mechanical ventilation", "OBSERVATION", 82, 104], ["oxygen support", "OBSERVATION", 146, 160]]], ["In children with clear evidence of preceding COVID infection, median time from the start of COVID to development of MIS-C was 25 days (range 6\u201351 days).", [["COVID infection", "DISEASE", 45, 60], ["COVID", "DISEASE", 92, 97], ["children", "ORGANISM", 3, 11], ["MIS-C", "GENE_OR_GENE_PRODUCT", 116, 121], ["children", "SPECIES", 3, 11], ["preceding COVID infection", "PROBLEM", 35, 60], ["MIS", "PROBLEM", 116, 119], ["infection", "OBSERVATION", 51, 60]]], ["In the above case series, children with MIS-C were typically healthy prior to development of disease.", [["children", "ORGANISM", 26, 34], ["MIS-C", "GENE_OR_GENE_PRODUCT", 40, 45], ["children", "SPECIES", 26, 34], ["disease", "PROBLEM", 93, 100], ["disease", "OBSERVATION", 93, 100]]], ["Almost all patients had significantly elevated inflammatory markers.", [["patients", "ORGANISM", 11, 19], ["inflammatory markers", "PROTEIN", 47, 67], ["patients", "SPECIES", 11, 19], ["significantly elevated inflammatory markers", "PROBLEM", 24, 67], ["elevated", "OBSERVATION_MODIFIER", 38, 46], ["inflammatory markers", "OBSERVATION", 47, 67]]], ["Mortality rates were 2% or lower.Incidence and Diagnostic Criteria ::: DiscussionThe true incidence of MIS-C is uncertain.", [["MIS-C", "SIMPLE_CHEMICAL", 103, 108], ["Mortality rates", "TEST", 0, 15], ["MIS", "PROBLEM", 103, 106]]], ["An initial lack of diagnostic criteria and underreporting, or lack of hospitalization in mild cases, likely contributed to a low disease incidence.", [["mild cases", "PROBLEM", 89, 99], ["a low disease incidence", "PROBLEM", 123, 146], ["low", "OBSERVATION_MODIFIER", 125, 128], ["disease", "OBSERVATION", 129, 136]]], ["Diagnostic criteria for MIS-C have now been provided by the Centers for Disease Control and Prevention and the World Health Organization, and can be found in Table 1.", [["MIS-C", "SIMPLE_CHEMICAL", 24, 29], ["Diagnostic criteria", "TEST", 0, 19], ["MIS", "PROBLEM", 24, 27], ["Disease Control", "TREATMENT", 72, 87]]], ["Although slight differences exist between these definitions, there is consensus that the presence of at least 1 day of fever, multisystem involvement, and elevated inflammatory markers are required for the diagnosis.", [["fever", "DISEASE", 119, 124], ["inflammatory markers", "PROTEIN", 164, 184], ["fever", "PROBLEM", 119, 124], ["multisystem involvement", "PROBLEM", 126, 149], ["elevated inflammatory markers", "PROBLEM", 155, 184], ["slight", "OBSERVATION_MODIFIER", 9, 15], ["fever", "OBSERVATION", 119, 124], ["multisystem", "OBSERVATION_MODIFIER", 126, 137], ["elevated", "OBSERVATION_MODIFIER", 155, 163], ["inflammatory markers", "OBSERVATION", 164, 184]]], ["Organs affected include cardiovascular, dermatologic, GI, neurologic, renal, and respiratory.Comparison between KD and MIS-C/Importance to Emergency Physicians ::: DiscussionKD is a childhood systemic vasculitis that affects predominantly the medium- and small-sized vessels, notably the coronary arteries.", [["Organs", "ANATOMY", 0, 6], ["cardiovascular", "ANATOMY", 24, 38], ["GI", "ANATOMY", 54, 56], ["neurologic", "ANATOMY", 58, 68], ["renal", "ANATOMY", 70, 75], ["respiratory", "ANATOMY", 81, 92], ["vessels", "ANATOMY", 267, 274], ["coronary arteries", "ANATOMY", 288, 305], ["cardiovascular, dermatologic, GI, neurologic, renal, and respiratory", "DISEASE", 24, 92], ["vasculitis", "DISEASE", 201, 211], ["Organs", "ORGAN", 0, 6], ["cardiovascular", "ANATOMICAL_SYSTEM", 24, 38], ["renal", "ORGAN", 70, 75], ["vessels", "MULTI-TISSUE_STRUCTURE", 267, 274], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 288, 305], ["a childhood systemic vasculitis", "PROBLEM", 180, 211], ["renal", "ANATOMY", 70, 75], ["respiratory", "ANATOMY", 81, 92], ["systemic", "OBSERVATION_MODIFIER", 192, 200], ["vasculitis", "OBSERVATION", 201, 211], ["medium", "OBSERVATION_MODIFIER", 243, 249], ["small", "OBSERVATION_MODIFIER", 255, 260], ["sized", "ANATOMY_MODIFIER", 261, 266], ["vessels", "ANATOMY", 267, 274], ["coronary arteries", "ANATOMY", 288, 305]]], ["The etiology of KD is uncertain.", [["KD", "DISEASE", 16, 18], ["KD", "PROBLEM", 16, 18], ["KD", "OBSERVATION", 16, 18]]], ["It is hypothesized that it is triggered by an unrecognized infectious agent in genetically predisposed children.", [["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["infectious", "OBSERVATION", 59, 69]]], ["The mean age of affected children is 3 years old, although KD is not exclusively a disease of young children.", [["children", "ORGANISM", 25, 33], ["children", "ORGANISM", 100, 108], ["children", "SPECIES", 25, 33], ["children", "SPECIES", 100, 108]]], ["Diagnosis of classic KD is clinical and requires fever for at least 5 days and the presence of four of the five criteria: conjunctival injection, oropharyngeal mucous membrane changes, cervical lymphadenopathy (one node at least > 1.5 cm), peripheral extremity changes, and a polymorphous generalized rash (10).", [["conjunctival", "ANATOMY", 122, 134], ["oropharyngeal mucous membrane", "ANATOMY", 146, 175], ["cervical lymphadenopathy", "ANATOMY", 185, 209], ["node", "ANATOMY", 215, 219], ["peripheral extremity", "ANATOMY", 240, 260], ["KD", "DISEASE", 21, 23], ["fever", "DISEASE", 49, 54], ["cervical lymphadenopathy", "DISEASE", 185, 209], ["peripheral extremity", "DISEASE", 240, 260], ["rash", "DISEASE", 301, 305], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 122, 134], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 160, 175], ["cervical lymphadenopathy", "CANCER", 185, 209], ["node", "MULTI-TISSUE_STRUCTURE", 215, 219], ["classic KD", "PROBLEM", 13, 23], ["fever", "PROBLEM", 49, 54], ["conjunctival injection", "PROBLEM", 122, 144], ["oropharyngeal mucous membrane changes", "PROBLEM", 146, 183], ["cervical lymphadenopathy", "PROBLEM", 185, 209], ["peripheral extremity changes", "PROBLEM", 240, 268], ["a polymorphous generalized rash", "PROBLEM", 274, 305], ["KD", "OBSERVATION", 21, 23], ["conjunctival", "ANATOMY", 122, 134], ["oropharyngeal", "ANATOMY", 146, 159], ["mucous membrane", "ANATOMY", 160, 175], ["cervical", "ANATOMY", 185, 193], ["lymphadenopathy", "OBSERVATION", 194, 209], ["node", "OBSERVATION", 215, 219], ["1.5 cm", "OBSERVATION_MODIFIER", 231, 237], ["peripheral", "ANATOMY_MODIFIER", 240, 250], ["extremity", "ANATOMY", 251, 260], ["changes", "OBSERVATION", 261, 268], ["polymorphous", "OBSERVATION_MODIFIER", 276, 288], ["generalized", "OBSERVATION_MODIFIER", 289, 300], ["rash", "OBSERVATION", 301, 305]]], ["Incomplete KD is defined as a patient who is febrile for > 4 days with two or three of the classic clinical criteria, and it is also important to identify as children are at risk for the same cardiovascular sequelae as complete KD (10).", [["cardiovascular", "ANATOMY", 192, 206], ["febrile", "DISEASE", 45, 52], ["cardiovascular sequelae", "DISEASE", 192, 215], ["patient", "ORGANISM", 30, 37], ["children", "ORGANISM", 158, 166], ["patient", "SPECIES", 30, 37], ["children", "SPECIES", 158, 166], ["febrile", "PROBLEM", 45, 52], ["the same cardiovascular sequelae", "PROBLEM", 183, 215], ["KD", "OBSERVATION", 11, 13]]], ["Approximately 5% of patients present with clinical signs of hypoperfusion or refractory hypotension, referred to as KD shock syndrome (11).", [["hypoperfusion", "DISEASE", 60, 73], ["hypotension", "DISEASE", 88, 99], ["KD shock syndrome", "DISEASE", 116, 133], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["hypoperfusion", "PROBLEM", 60, 73], ["refractory hypotension", "PROBLEM", 77, 99], ["KD shock syndrome", "PROBLEM", 116, 133], ["hypoperfusion", "OBSERVATION", 60, 73], ["refractory", "OBSERVATION_MODIFIER", 77, 87], ["hypotension", "OBSERVATION", 88, 99]]], ["Early treatment with IVIG and aspirin is critical.", [["IVIG", "CHEMICAL", 21, 25], ["aspirin", "CHEMICAL", 30, 37], ["aspirin", "CHEMICAL", 30, 37], ["IVIG", "SIMPLE_CHEMICAL", 21, 25], ["aspirin", "SIMPLE_CHEMICAL", 30, 37], ["Early treatment", "TREATMENT", 0, 15], ["IVIG", "TREATMENT", 21, 25], ["aspirin", "TREATMENT", 30, 37]]], ["Prior clinical trials have shown that administration of these therapies within 10 days of fever significantly decreases the incidence of coronary artery aneurysms (12,13).Comparison between KD and MIS-C/Importance to Emergency Physicians ::: DiscussionThere is some overlap between KD with MIS-C, however, some important differences exist.", [["coronary artery aneurysms", "ANATOMY", 137, 162], ["fever", "DISEASE", 90, 95], ["coronary artery aneurysms", "DISEASE", 137, 162], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 137, 152], ["these therapies", "TREATMENT", 56, 71], ["fever", "PROBLEM", 90, 95], ["coronary artery aneurysms", "PROBLEM", 137, 162], ["coronary artery", "ANATOMY", 137, 152], ["aneurysms", "OBSERVATION", 153, 162]]], ["Whether MIS-C has a similar cause of KD is unknown at this point.", [["KD", "DISEASE", 37, 39], ["MIS-C", "GENE_OR_GENE_PRODUCT", 8, 13], ["KD", "PROBLEM", 37, 39], ["KD", "OBSERVATION", 37, 39]]], ["KD disproportionately affects children of Asian descent, whereas the available evidence suggests that MIS-C occurs in children of all racial and ethnic backgrounds and may have higher rates in children of black or Hispanic heritages.", [["children", "ORGANISM", 30, 38], ["MIS-C", "GENE_OR_GENE_PRODUCT", 102, 107], ["children", "ORGANISM", 118, 126], ["children", "ORGANISM", 193, 201], ["children", "SPECIES", 30, 38], ["children", "SPECIES", 118, 126], ["children", "SPECIES", 193, 201], ["Hispanic heritages", "PROBLEM", 214, 232]]], ["Patients with MIS-C are also typically older (8 years old) than those with KD (3 years old), although there have been descriptions of neonates with suspected MIS-C.Comparison between KD and MIS-C/Importance to Emergency Physicians ::: DiscussionInitially considered a Kawasaki variant, likely secondary to uncontrolled inflammation, less than half of MIS-C patients exhibit complete Kawasaki symptoms.", [["inflammation", "DISEASE", 319, 331], ["Kawasaki symptoms", "DISEASE", 383, 400], ["Patients", "ORGANISM", 0, 8], ["MIS-C", "GENE_OR_GENE_PRODUCT", 14, 19], ["neonates", "ORGANISM", 134, 142], ["patients", "ORGANISM", 357, 365], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 357, 365], ["MIS", "PROBLEM", 14, 17], ["a Kawasaki variant", "PROBLEM", 266, 284], ["uncontrolled inflammation", "PROBLEM", 306, 331], ["complete Kawasaki symptoms", "PROBLEM", 374, 400], ["uncontrolled", "OBSERVATION_MODIFIER", 306, 318], ["inflammation", "OBSERVATION", 319, 331]]], ["In patients older than 13 years, the percentage is around 10%.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11]]], ["Children with MIS-C had a higher percentage of GI symptoms and distinct laboratory abnormalities including lymphopenia, thrombocytopenia, and elevated ferritin levels.", [["GI", "ANATOMY", 47, 49], ["lymphopenia", "DISEASE", 107, 118], ["thrombocytopenia", "DISEASE", 120, 136], ["Children", "ORGANISM", 0, 8], ["GI", "ORGANISM_SUBDIVISION", 47, 49], ["ferritin", "GENE_OR_GENE_PRODUCT", 151, 159], ["ferritin", "PROTEIN", 151, 159], ["Children", "SPECIES", 0, 8], ["MIS", "PROBLEM", 14, 17], ["GI symptoms", "PROBLEM", 47, 58], ["distinct laboratory abnormalities", "PROBLEM", 63, 96], ["lymphopenia", "PROBLEM", 107, 118], ["thrombocytopenia", "PROBLEM", 120, 136], ["elevated ferritin levels", "PROBLEM", 142, 166], ["lymphopenia", "OBSERVATION", 107, 118], ["thrombocytopenia", "OBSERVATION", 120, 136], ["elevated", "OBSERVATION_MODIFIER", 142, 150], ["ferritin levels", "OBSERVATION", 151, 166]]], ["There was a higher percentage of patients with serious cardiovascular involvement, including both vasoplegic shock and coronary aneurysms than those with KD (14).", [["cardiovascular", "ANATOMY", 55, 69], ["coronary", "ANATOMY", 119, 127], ["vasoplegic shock", "DISEASE", 98, 114], ["coronary aneurysms", "DISEASE", 119, 137], ["patients", "ORGANISM", 33, 41], ["cardiovascular", "ANATOMICAL_SYSTEM", 55, 69], ["coronary aneurysms", "PATHOLOGICAL_FORMATION", 119, 137], ["patients", "SPECIES", 33, 41], ["serious cardiovascular involvement", "PROBLEM", 47, 81], ["both vasoplegic shock", "PROBLEM", 93, 114], ["coronary aneurysms", "PROBLEM", 119, 137], ["KD", "TEST", 154, 156], ["higher", "OBSERVATION_MODIFIER", 12, 18], ["percentage", "OBSERVATION_MODIFIER", 19, 29], ["serious", "OBSERVATION_MODIFIER", 47, 54], ["vasoplegic shock", "OBSERVATION", 98, 114], ["coronary", "ANATOMY", 119, 127], ["aneurysms", "OBSERVATION", 128, 137]]], ["Importantly, in the report from Italy, children were 30 times more likely to develop coronary aneurysms compared with those afflicted with KD, although it is likely that other children in the region with milder symptoms were not included in this case series (6).", [["coronary", "ANATOMY", 85, 93], ["coronary aneurysms", "DISEASE", 85, 103], ["KD", "DISEASE", 139, 141], ["children", "ORGANISM", 39, 47], ["coronary aneurysms", "PATHOLOGICAL_FORMATION", 85, 103], ["children", "ORGANISM", 176, 184], ["children", "SPECIES", 39, 47], ["children", "SPECIES", 176, 184], ["coronary aneurysms", "PROBLEM", 85, 103], ["milder symptoms", "PROBLEM", 204, 219], ["coronary", "ANATOMY", 85, 93], ["aneurysms", "OBSERVATION", 94, 103]]], ["Although data suggest that the incidence of coronary artery aneurysms is decreased if IVIG is administered within 10 days of fever for patients with KD, the timeframe for the development of coronary aneurysms is uncertain in children with MIS-C.", [["coronary artery aneurysms", "ANATOMY", 44, 69], ["coronary aneurysms", "ANATOMY", 190, 208], ["coronary artery aneurysms", "DISEASE", 44, 69], ["fever", "DISEASE", 125, 130], ["coronary aneurysms", "DISEASE", 190, 208], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 44, 59], ["IVIG", "SIMPLE_CHEMICAL", 86, 90], ["patients", "ORGANISM", 135, 143], ["coronary", "MULTI-TISSUE_STRUCTURE", 190, 198], ["children", "ORGANISM", 225, 233], ["patients", "SPECIES", 135, 143], ["children", "SPECIES", 225, 233], ["coronary artery aneurysms", "PROBLEM", 44, 69], ["IVIG", "TREATMENT", 86, 90], ["fever", "PROBLEM", 125, 130], ["KD", "TREATMENT", 149, 151], ["coronary aneurysms", "PROBLEM", 190, 208], ["coronary artery", "ANATOMY", 44, 59], ["aneurysms", "OBSERVATION", 60, 69], ["decreased", "OBSERVATION_MODIFIER", 73, 82], ["coronary", "ANATOMY", 190, 198], ["aneurysms", "OBSERVATION", 199, 208]]], ["Finally, coronary aneurysms can develop in children with MIS-C that do not have Kawasaki-like features (15).Diagnosis and Management in the ED ::: DiscussionIdentification and early supportive care for patients with MIS-C should be the cornerstone of management in the ED.", [["coronary aneurysms", "ANATOMY", 9, 27], ["coronary aneurysms", "DISEASE", 9, 27], ["coronary aneurysms", "PATHOLOGICAL_FORMATION", 9, 27], ["children", "ORGANISM", 43, 51], ["patients", "ORGANISM", 202, 210], ["MIS-C", "SIMPLE_CHEMICAL", 216, 221], ["children", "SPECIES", 43, 51], ["patients", "SPECIES", 202, 210], ["coronary aneurysms", "PROBLEM", 9, 27], ["management", "TREATMENT", 251, 261], ["coronary", "ANATOMY", 9, 17], ["aneurysms", "OBSERVATION", 18, 27]]], ["Figure 2provides recommendations for a two-tiered diagnostic pathway in patients with potential MIS-C developed by a task force from the American College of Rheumatology (16).", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["Initial evaluation (the first tier) includes laboratory analysis with inflammatory markers, consisting of a complete blood count, a complete metabolic panel, and SARS-2-CoV serology.", [["blood", "ANATOMY", 117, 122], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["SARS-2-CoV", "GENE_OR_GENE_PRODUCT", 162, 172], ["inflammatory markers", "PROTEIN", 70, 90], ["Initial evaluation", "TEST", 0, 18], ["laboratory analysis", "TEST", 45, 64], ["inflammatory markers", "TEST", 70, 90], ["a complete blood count", "TEST", 106, 128], ["a complete metabolic panel", "TEST", 130, 156], ["SARS", "TEST", 162, 166], ["CoV serology", "TEST", 169, 181]]], ["Consideration for additional work-up should be given to other conditions that may mimic MIS-C, such as bacterial sepsis, based on clinical suspicion.", [["bacterial sepsis", "DISEASE", 103, 119], ["MIS-C", "GENE_OR_GENE_PRODUCT", 88, 93], ["additional work-up", "TEST", 18, 36], ["bacterial sepsis", "PROBLEM", 103, 119], ["clinical suspicion", "TEST", 130, 148], ["bacterial", "OBSERVATION_MODIFIER", 103, 112], ["sepsis", "OBSERVATION", 113, 119]]], ["If elevated inflammatory markers and other markers associated with COVID-19 (e.g., lymphopenia, neutrophilia, hyponatremia, or thrombocytopenia) are present, additional evaluation (the second tier), including a screening electrocardiogram and echocardiogram, if available, should be pursued.", [["lymphopenia", "DISEASE", 83, 94], ["neutrophilia", "DISEASE", 96, 108], ["hyponatremia", "DISEASE", 110, 122], ["thrombocytopenia", "DISEASE", 127, 143], ["COVID-19", "GENE_OR_GENE_PRODUCT", 67, 75], ["inflammatory markers", "PROTEIN", 12, 32], ["elevated inflammatory markers", "PROBLEM", 3, 32], ["other markers", "TEST", 37, 50], ["COVID", "TEST", 67, 72], ["lymphopenia", "PROBLEM", 83, 94], ["neutrophilia", "PROBLEM", 96, 108], ["hyponatremia", "PROBLEM", 110, 122], ["thrombocytopenia", "PROBLEM", 127, 143], ["additional evaluation", "TEST", 158, 179], ["a screening electrocardiogram", "TEST", 209, 238], ["echocardiogram", "TEST", 243, 257], ["elevated", "OBSERVATION_MODIFIER", 3, 11], ["inflammatory", "OBSERVATION", 12, 24], ["lymphopenia", "OBSERVATION", 83, 94], ["neutrophilia", "OBSERVATION", 96, 108], ["hyponatremia", "OBSERVATION", 110, 122]]], ["Importantly, patients with circulatory shock without a clear etiology should undergo extensive evaluation for MIS-C (both tier 1 and tier 2).Diagnosis and Management in the ED ::: DiscussionAlthough there have been no randomized trials completed to guide therapy for MIS-C, many patients receive high-dose IVIG (1\u20132 mg/kg) and low-dose aspirin (3\u20135 mg/kg, maximum of 81 mg) based on prior experience with KD.", [["circulatory shock", "DISEASE", 27, 44], ["IVIG", "CHEMICAL", 306, 310], ["aspirin", "CHEMICAL", 336, 343], ["aspirin", "CHEMICAL", 336, 343], ["patients", "ORGANISM", 13, 21], ["MIS-C", "SIMPLE_CHEMICAL", 267, 272], ["patients", "ORGANISM", 279, 287], ["IVIG", "SIMPLE_CHEMICAL", 306, 310], ["aspirin", "SIMPLE_CHEMICAL", 336, 343], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 279, 287], ["circulatory shock", "PROBLEM", 27, 44], ["extensive evaluation", "TEST", 85, 105], ["MIS", "TEST", 110, 113], ["randomized trials", "TREATMENT", 218, 235], ["therapy", "TREATMENT", 255, 262], ["MIS", "TREATMENT", 267, 270], ["high-dose IVIG", "TREATMENT", 296, 310], ["low-dose aspirin", "TREATMENT", 327, 343], ["circulatory shock", "OBSERVATION", 27, 44]]], ["A smaller percentage receive low-to moderate-dose corticosteroids.", [["corticosteroids", "CHEMICAL", 50, 65], ["A smaller percentage receive low", "PROBLEM", 0, 32], ["moderate-dose corticosteroids", "TREATMENT", 36, 65], ["smaller", "OBSERVATION_MODIFIER", 2, 9], ["percentage", "OBSERVATION_MODIFIER", 10, 20], ["low-to moderate", "OBSERVATION_MODIFIER", 29, 44]]], ["Appropriate fluid resuscitation and vasoactive support is required in patients who present with circulatory shock.", [["fluid", "ANATOMY", 12, 17], ["circulatory shock", "DISEASE", 96, 113], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["Appropriate fluid resuscitation", "TREATMENT", 0, 31], ["vasoactive support", "TREATMENT", 36, 54], ["circulatory shock", "PROBLEM", 96, 113], ["fluid resuscitation", "OBSERVATION", 12, 31], ["vasoactive support", "OBSERVATION", 36, 54], ["circulatory shock", "OBSERVATION", 96, 113]]], ["Patients may benefit from point-of-care ultrasound to evaluate for a depressed systolic function.", [["depressed", "DISEASE", 69, 78], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["care ultrasound", "TEST", 35, 50], ["a depressed systolic function", "PROBLEM", 67, 96], ["depressed", "OBSERVATION", 69, 78]]], ["Patients with vasopressor-refractory shock may benefit from high-dose corticosteroid administration.", [["shock", "DISEASE", 37, 42], ["Patients", "ORGANISM", 0, 8], ["corticosteroid", "SIMPLE_CHEMICAL", 70, 84], ["Patients", "SPECIES", 0, 8], ["vasopressor", "TREATMENT", 14, 25], ["refractory shock", "PROBLEM", 26, 42], ["high-dose corticosteroid administration", "TREATMENT", 60, 99], ["refractory shock", "OBSERVATION", 26, 42]]], ["Importantly, immunomodulatory and antiplatelet therapies are typically started after consultation with available specialists.", [["antiplatelet", "ANATOMY", 34, 46], ["antiplatelet", "CELL", 34, 46], ["immunomodulatory and antiplatelet therapies", "TREATMENT", 13, 56], ["immunomodulatory", "OBSERVATION_MODIFIER", 13, 29]]], ["Disposition should involve discussion with centers that have experience with KD and can provide multispecialty care, including pediatric rheumatologists, cardiologists, intensivists, infectious disease specialists, and hematologists.", [["infectious disease", "DISEASE", 183, 201]]], ["Patients with abnormal vital signs, any respiratory distress, neurologic deficit, renal or hepatic dysfunction, profoundly elevated inflammatory markers (e.g., CRP > 10 mg/dL), or elevation in cardiac biomarkers should be admitted or transferred to an appropriate facility.", [["respiratory", "ANATOMY", 40, 51], ["neurologic", "ANATOMY", 62, 72], ["renal", "ANATOMY", 82, 87], ["hepatic", "ANATOMY", 91, 98], ["cardiac", "ANATOMY", 193, 200], ["abnormal vital signs", "DISEASE", 14, 34], ["respiratory distress", "DISEASE", 40, 60], ["neurologic deficit", "DISEASE", 62, 80], ["renal or hepatic dysfunction", "DISEASE", 82, 110], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 82, 87], ["hepatic", "ORGAN", 91, 98], ["CRP", "GENE_OR_GENE_PRODUCT", 160, 163], ["cardiac", "ORGAN", 193, 200], ["inflammatory markers", "PROTEIN", 132, 152], ["CRP", "PROTEIN", 160, 163], ["Patients", "SPECIES", 0, 8], ["abnormal vital signs", "PROBLEM", 14, 34], ["any respiratory distress", "PROBLEM", 36, 60], ["neurologic deficit", "PROBLEM", 62, 80], ["renal or hepatic dysfunction", "PROBLEM", 82, 110], ["profoundly elevated inflammatory markers", "PROBLEM", 112, 152], ["CRP", "TEST", 160, 163], ["elevation in cardiac biomarkers", "PROBLEM", 180, 211], ["respiratory", "ANATOMY", 40, 51], ["distress", "OBSERVATION", 52, 60], ["renal", "ANATOMY", 82, 87], ["hepatic", "ANATOMY", 91, 98], ["dysfunction", "OBSERVATION", 99, 110], ["profoundly", "OBSERVATION_MODIFIER", 112, 122], ["elevated", "OBSERVATION_MODIFIER", 123, 131], ["inflammatory", "OBSERVATION_MODIFIER", 132, 144], ["elevation", "OBSERVATION_MODIFIER", 180, 189], ["cardiac", "ANATOMY", 193, 200]]], ["Outpatient evaluation may be appropriate for well-appearing children with suspected MIS-C who have reassuring vital signs and are able to have close clinical follow-up.Why Should an Emergency Physician Be Aware of This?We present a case of a 15-year-old girl who presented with MIS-C and developed coronary aneurysms despite early therapy.", [["coronary", "ANATOMY", 298, 306], ["coronary aneurysms", "DISEASE", 298, 316], ["children", "ORGANISM", 60, 68], ["girl", "ORGANISM", 254, 258], ["coronary aneurysms", "PATHOLOGICAL_FORMATION", 298, 316], ["children", "SPECIES", 60, 68], ["girl", "SPECIES", 254, 258], ["Outpatient evaluation", "TEST", 0, 21], ["vital signs", "TEST", 110, 121], ["MIS", "PROBLEM", 278, 281], ["coronary aneurysms", "PROBLEM", 298, 316], ["early therapy", "TREATMENT", 325, 338], ["coronary", "ANATOMY", 298, 306], ["aneurysms", "OBSERVATION", 307, 316]]], ["Originally thought to be a variant of KD, MIS-C is now recognized as a distinct clinical entity associated with SARS-CoV-2, which has been reported in neonates to late adolescents.", [["KD", "DISEASE", 38, 40], ["MIS-C", "GENE_OR_GENE_PRODUCT", 42, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["neonates", "ORGANISM", 151, 159], ["adolescents", "SPECIES", 168, 179], ["SARS-CoV", "SPECIES", 112, 120], ["a variant of KD", "PROBLEM", 25, 40], ["MIS", "PROBLEM", 42, 45], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["thought to be", "UNCERTAINTY", 11, 24]]], ["Early consideration and appropriate diagnostic evaluation in the ED are important, as these children are at high risk of multiple cardiovascular complications, including coronary artery aneurysms.", [["cardiovascular", "ANATOMY", 130, 144], ["coronary artery aneurysms", "ANATOMY", 170, 195], ["cardiovascular complications", "DISEASE", 130, 158], ["coronary artery aneurysms", "DISEASE", 170, 195], ["children", "ORGANISM", 92, 100], ["cardiovascular", "ANATOMICAL_SYSTEM", 130, 144], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 170, 185], ["children", "SPECIES", 92, 100], ["appropriate diagnostic evaluation", "TEST", 24, 57], ["multiple cardiovascular complications", "PROBLEM", 121, 158], ["coronary artery aneurysms", "PROBLEM", 170, 195], ["multiple", "OBSERVATION_MODIFIER", 121, 129], ["cardiovascular", "ANATOMY", 130, 144], ["complications", "OBSERVATION", 145, 158], ["coronary artery", "ANATOMY", 170, 185], ["aneurysms", "OBSERVATION", 186, 195]]], ["After identification of a patient with MIS-C, emergency physicians should provide appropriate resuscitation, if required, and determine the appropriate disposition based on the severity of illness.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["appropriate resuscitation", "TREATMENT", 82, 107], ["illness", "PROBLEM", 189, 196]]], ["Although evidence for providing aspirin, IVIG, and steroids is lacking, these therapies are commonly administered based on prior experience with KD and recommendations from professional societies.", [["aspirin", "CHEMICAL", 32, 39], ["steroids", "CHEMICAL", 51, 59], ["aspirin", "CHEMICAL", 32, 39], ["steroids", "CHEMICAL", 51, 59], ["aspirin", "SIMPLE_CHEMICAL", 32, 39], ["IVIG", "SIMPLE_CHEMICAL", 41, 45], ["steroids", "SIMPLE_CHEMICAL", 51, 59], ["aspirin", "TREATMENT", 32, 39], ["IVIG", "TREATMENT", 41, 45], ["steroids", "TREATMENT", 51, 59], ["these therapies", "TREATMENT", 72, 87], ["evidence for", "UNCERTAINTY", 9, 21]]], ["This case highlights several differences that emergency physicians should be aware of in the diagnosis of MIS-C and illustrates many of the subtleties in the diagnosis of this new condition.", [["MIS-C", "CELL", 106, 111], ["this new condition", "PROBLEM", 171, 189]]]], "69d40f20b93968cb2ff09644bf6a02cc1d95b180": [["INTRODUCTIONPorcine reproductive and respiratory syndrome (PRRS) and porcine epidemic diarrhea (PED) are arguably two of the most costly diseases in the U.S. swine industry today.", [["INTRODUCTIONPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["PRRS", "DISEASE", 59, 63], ["porcine epidemic diarrhea", "DISEASE", 69, 94], ["PED", "DISEASE", 96, 99], ["PRRS", "SPECIES", 59, 63], ["porcine", "SPECIES", 69, 76], ["swine", "SPECIES", 158, 163], ["PRRS", "SPECIES", 59, 63], ["swine", "SPECIES", 158, 163], ["INTRODUCTIONPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome", "PROBLEM", 37, 57], ["porcine epidemic diarrhea", "PROBLEM", 69, 94], ["respiratory syndrome", "OBSERVATION", 37, 57]]], ["Per year, PRRS alone has been estimated to cost the U.S. swine producers an estimated US$664 million (Holtkamp et al., 2013) , whereas PED has been attributed to the loss of over 8 million piglets since being discovered in the UnitedThe effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs I:Growth performance and digestibility 1 W. P. Schweer,* K Schwartz, \u2020 E. R. Burrough, \u2020 K. J. Yoon, \u2020 J. C. Sparks, \u2021 and N. K. Gabler* 2The effect of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus challenge on growing pigs I:States (Meyer, 2014) .", [["PRRS", "DISEASE", 10, 14], ["porcine reproductive and respiratory syndrome virus", "DISEASE", 247, 298], ["diarrhea", "DISEASE", 320, 328], ["porcine reproductive and respiratory syndrome", "DISEASE", 513, 558], ["diarrhea", "DISEASE", 586, 594], ["PRRS", "ORGANISM", 10, 14], ["swine", "ORGANISM", 57, 62], ["piglets", "ORGANISM", 189, 196], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 247, 298], ["porcine epidemic diarrhea virus", "ORGANISM", 303, 334], ["pigs", "ORGANISM", 356, 360], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 513, 564], ["porcine epidemic diarrhea virus", "ORGANISM", 569, 600], ["pigs", "ORGANISM", 622, 626], ["swine", "SPECIES", 57, 62], ["piglets", "SPECIES", 189, 196], ["porcine epidemic diarrhea virus", "SPECIES", 303, 334], ["pigs", "SPECIES", 356, 360], ["porcine epidemic diarrhea virus", "SPECIES", 569, 600], ["pigs", "SPECIES", 622, 626], ["PRRS", "SPECIES", 10, 14], ["porcine epidemic diarrhea virus", "SPECIES", 303, 334], ["porcine epidemic diarrhea virus", "SPECIES", 569, 600], ["porcine reproductive", "TREATMENT", 247, 267], ["respiratory syndrome virus", "PROBLEM", 272, 298], ["porcine epidemic diarrhea virus challenge", "PROBLEM", 303, 344], ["porcine reproductive", "PROBLEM", 513, 533], ["respiratory syndrome virus", "PROBLEM", 538, 564], ["porcine epidemic diarrhea virus challenge", "PROBLEM", 569, 610], ["respiratory syndrome", "OBSERVATION", 272, 292], ["respiratory syndrome", "OBSERVATION", 538, 558]]], ["In young pigs, PRRS has been shown to reduce growth performance and feed efficiency (Greiner et al., 2000; Escobar et al., 2004) and negatively affect intestinal morphology.", [["intestinal", "ANATOMY", 151, 161], ["PRRS", "DISEASE", 15, 19], ["pigs", "ORGANISM", 9, 13], ["PRRS", "ORGANISM", 15, 19], ["intestinal", "ORGAN", 151, 161], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["PRRS", "SPECIES", 15, 19], ["intestinal", "ANATOMY", 151, 161]]], ["These pigs also have an increased likelihood of secondary viral and bacterial infections due to the ability of PRRS to suppress the immune response (Van Reeth et al., 1996; Nakamine et al., 1998) .", [["viral and bacterial infections", "DISEASE", 58, 88], ["pigs", "ORGANISM", 6, 10], ["PRRS", "ORGANISM", 111, 115], ["pigs", "SPECIES", 6, 10], ["pigs", "SPECIES", 6, 10], ["PRRS", "SPECIES", 111, 115], ["secondary viral and bacterial infections", "PROBLEM", 48, 88], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["secondary", "OBSERVATION_MODIFIER", 48, 57], ["viral", "OBSERVATION", 58, 63], ["bacterial infections", "OBSERVATION", 68, 88]]], ["Unlike PRRS virus, the PED virus localizes to the gastrointestinal tract of pigs and induces watery diarrhea along with severe villous atrophy, leading to malabsorption (Madson et al., 2014) .", [["gastrointestinal tract", "ANATOMY", 50, 72], ["villous", "ANATOMY", 127, 134], ["PRRS virus", "DISEASE", 7, 17], ["diarrhea", "DISEASE", 100, 108], ["villous atrophy", "DISEASE", 127, 142], ["malabsorption", "DISEASE", 155, 168], ["PRRS virus", "ORGANISM", 7, 17], ["PED virus", "ORGANISM", 23, 32], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 50, 72], ["pigs", "ORGANISM", 76, 80], ["villous", "PATHOLOGICAL_FORMATION", 127, 134], ["pigs", "SPECIES", 76, 80], ["PRRS virus", "SPECIES", 7, 17], ["PED virus", "SPECIES", 23, 32], ["pigs", "SPECIES", 76, 80], ["PRRS virus", "PROBLEM", 7, 17], ["the PED virus", "PROBLEM", 19, 32], ["watery diarrhea", "PROBLEM", 93, 108], ["severe villous atrophy", "PROBLEM", 120, 142], ["malabsorption", "PROBLEM", 155, 168], ["PRRS virus", "OBSERVATION", 7, 17], ["gastrointestinal tract", "ANATOMY", 50, 72], ["watery", "OBSERVATION_MODIFIER", 93, 99], ["diarrhea", "OBSERVATION", 100, 108], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["villous", "OBSERVATION_MODIFIER", 127, 134], ["atrophy", "OBSERVATION", 135, 142], ["malabsorption", "OBSERVATION", 155, 168]]], ["Health challenged pigs often exhibit reduced appetite and feed intake and have altered nutrient utilization in a tissue-specific manner (Johnson, 2002) .", [["tissue", "ANATOMY", 113, 119], ["pigs", "ORGANISM", 18, 22], ["tissue", "TISSUE", 113, 119], ["pigs", "SPECIES", 18, 22], ["reduced appetite", "PROBLEM", 37, 53]]], ["Therefore, due to the significant prevalence of PRRS-positive pigs in the Midwest region of the United States, our objectives were 1) to develop a challenge model to study the effects of PED virus alone and coinfected with PRRS virus on pig performance and feed efficiency and 2) to characterize the impact PED and PRRS virus challenges have on nutrient and energy digestibility.Animals and Experimental DesignAll animal work was approved by the Iowa State University Institutional Animal Care and Use Committee (number 1-14-7710-S) and adhered to the ethical and humane use of animals for research.", [["PRRS", "DISEASE", 48, 52], ["PRRS", "DISEASE", 315, 319], ["PRRS", "ORGANISM", 48, 52], ["pigs", "ORGANISM", 62, 66], ["PED virus", "ORGANISM", 187, 196], ["PRRS virus", "ORGANISM", 223, 233], ["pig", "ORGANISM", 237, 240], ["pigs", "SPECIES", 62, 66], ["PRRS", "SPECIES", 223, 227], ["pig", "SPECIES", 237, 240], ["PRRS", "SPECIES", 48, 52], ["pigs", "SPECIES", 62, 66], ["PRRS virus", "SPECIES", 223, 233], ["pig", "SPECIES", 237, 240], ["PRRS virus", "SPECIES", 315, 325], ["PRRS", "PROBLEM", 48, 52], ["a challenge model", "TREATMENT", 145, 162], ["PED virus", "PROBLEM", 187, 196], ["PRRS virus", "TREATMENT", 223, 233], ["pig performance", "TREATMENT", 237, 252], ["PRRS virus challenges", "TREATMENT", 315, 336]]], ["All animal work was conducted at the Livestock Infectious Disease Isolation Facility at the Iowa State University College of Veterinary Medicine (Ames, IA).Animals and Experimental DesignForty-two Choice Genetics maternal line gilts (16 \u00b1 0.98 kg BW), na\u00efve for PRRS and PED, were selected and randomly assigned to 1 of 4 treatments for a 21-d growth study.", [["PRRS", "DISEASE", 262, 266], ["gilts", "ORGANISM", 227, 232], ["PRRS", "SPECIES", 262, 266], ["PRRS", "SPECIES", 262, 266], ["maternal line gilts", "TREATMENT", 213, 232], ["PRRS", "PROBLEM", 262, 266], ["4 treatments", "TREATMENT", 320, 332], ["a 21-d growth study", "TEST", 337, 356]]], ["Pigs were penned in pairs with each treatment in separate rooms to avoid viral cross-contamination.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["each treatment", "TREATMENT", 31, 45], ["viral cross-contamination", "PROBLEM", 73, 98], ["viral cross-contamination", "OBSERVATION", 73, 98]]], ["Treatments included 1) high health control gilts (CON; n = 3 pens), 2) PRRS virus inoculated gilts (PRRS; n = 6 pens), 3) PED-inoculated gilts (PED; n = 6 pens), and 4) gilts inoculated with PRRS and then PED (PRRS+PED coinfection [PRP] ; n = 6 pens).", [["gilts", "ANATOMY", 137, 142], ["PRRS", "DISEASE", 100, 104], ["PRRS", "DISEASE", 191, 195], ["PRRS+PED coinfection", "DISEASE", 210, 230], ["PRRS", "ORGANISM", 71, 75], ["gilts", "ORGANISM", 137, 142], ["gilts", "ORGANISM", 169, 174], ["PRRS", "ORGANISM", 191, 195], ["PRRS", "SPECIES", 71, 75], ["PRRS", "SPECIES", 191, 195], ["PRRS virus", "SPECIES", 71, 81], ["PRRS", "SPECIES", 100, 104], ["PRRS", "SPECIES", 191, 195], ["high health control gilts (CON; n = 3 pens)", "TREATMENT", 23, 66], ["PRRS virus inoculated gilts", "TREATMENT", 71, 98], ["PRRS", "PROBLEM", 191, 195], ["PED coinfection", "PROBLEM", 215, 230]]], ["After a 4-d acclimation period, treatments were administered as follows on d 0 after inoculation (dpi): pigs in treatment 2 and 4 were inoculated with a live field strain of PRRS virus (ORF5 RFLP 1-18-4 Wild-type), in which 500 genomic units were intramuscularly inoculated and 500 genomic units were nasally inoculated.", [["PRRS virus", "DISEASE", 174, 184], ["pigs", "ORGANISM", 104, 108], ["PRRS virus", "ORGANISM", 174, 184], ["pigs", "SPECIES", 104, 108], ["PRRS", "SPECIES", 174, 178], ["pigs", "SPECIES", 104, 108], ["PRRS virus", "SPECIES", 174, 184], ["a 4-d acclimation period", "TREATMENT", 6, 30], ["treatments", "TREATMENT", 32, 42], ["pigs in treatment", "TREATMENT", 104, 121], ["PRRS virus", "PROBLEM", 174, 184], ["ORF5 RFLP", "TEST", 186, 195]]], ["Treatments 1 and 3 received a saline solution sham inoculation at dpi 0.", [["saline", "SIMPLE_CHEMICAL", 30, 36], ["Treatments", "TREATMENT", 0, 10], ["a saline solution sham inoculation", "TREATMENT", 28, 62]]], ["On dpi 14, pigs in treatments 3 and 4 were intragastrically inoculated with 10 3 plaque-forming units of a plaquecloned PED virus isolate (USA/Iowa/18984/2013; Iowa State University, Ames, IA) representing 6 cell culture passages as previously described (Hoang et al., 2013; Madson et al., 2014) , whereas treatments 1 and 2 received a saline sham inoculation.Animals and Experimental DesignThroughout the study, all pigs were fed a corn-soybean meal diet containing the digestibility marker titanium dioxide and formulated to meet or exceed NRC (2012) requirements for AA, minerals, and vitamins (Table 1) .", [["plaque", "ANATOMY", 81, 87], ["cell", "ANATOMY", 208, 212], ["titanium dioxide", "CHEMICAL", 492, 508], ["AA", "CHEMICAL", 570, 572], ["titanium dioxide", "CHEMICAL", 492, 508], ["vitamins", "CHEMICAL", 588, 596], ["pigs", "ORGANISM", 11, 15], ["cell", "CELL", 208, 212], ["pigs", "ORGANISM", 417, 421], ["titanium dioxide", "SIMPLE_CHEMICAL", 492, 508], ["AA", "SIMPLE_CHEMICAL", 570, 572], ["minerals", "SIMPLE_CHEMICAL", 574, 582], ["vitamins", "SIMPLE_CHEMICAL", 588, 596], ["pigs", "SPECIES", 11, 15], ["pigs", "SPECIES", 417, 421], ["pigs", "SPECIES", 417, 421], ["dpi", "TREATMENT", 3, 6], ["pigs in treatments", "TREATMENT", 11, 29], ["a plaquecloned PED virus isolate", "TREATMENT", 105, 137], ["6 cell culture passages", "PROBLEM", 206, 229], ["a saline sham inoculation", "TREATMENT", 334, 359], ["the study", "TEST", 402, 411], ["a corn-soybean meal diet", "TREATMENT", 431, 455], ["the digestibility marker titanium dioxide", "TREATMENT", 467, 508], ["AA, minerals", "TREATMENT", 570, 582], ["vitamins", "TREATMENT", 588, 596]]], ["Pigs had ad libitum access to feed and water at all times.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4]]], ["Individual BW was collected at 0, 7, 14, and 21 dpi and pen feed intake was recorded.", [["Individual BW", "TEST", 0, 13], ["pen feed intake", "TEST", 56, 71]]], ["Additionally, weekly pen feed efficiency was calculated for each treatment.", [["weekly pen feed efficiency", "TREATMENT", 14, 40], ["each treatment", "TREATMENT", 60, 74]]], ["All pigs were euthanized at 21 dpi by sodium pentobarbital overdose (Fatal-Plus Solution; Vortech Pharmaceuticals, Dearborn, MI) followed by immediate exsanguination.Blood Collection and AnalysisBlood samples (10 mL) and fecal swabs were collected on all pigs at dpi 0, 14, and 21.", [["Blood", "ANATOMY", 166, 171], ["AnalysisBlood samples", "ANATOMY", 187, 208], ["fecal swabs", "ANATOMY", 221, 232], ["sodium pentobarbital", "CHEMICAL", 38, 58], ["overdose", "DISEASE", 59, 67], ["sodium pentobarbital", "CHEMICAL", 38, 58], ["pigs", "ORGANISM", 4, 8], ["sodium", "SIMPLE_CHEMICAL", 38, 44], ["pentobarbital", "SIMPLE_CHEMICAL", 45, 58], ["Blood", "ORGANISM_SUBSTANCE", 166, 171], ["AnalysisBlood samples", "CANCER", 187, 208], ["fecal swabs", "ORGANISM_SUBSTANCE", 221, 232], ["pigs", "ORGANISM", 255, 259], ["pigs", "SPECIES", 4, 8], ["pigs", "SPECIES", 255, 259], ["pigs", "SPECIES", 4, 8], ["sodium pentobarbital overdose", "TREATMENT", 38, 67], ["Fatal-Plus Solution", "TREATMENT", 69, 88], ["Vortech Pharmaceuticals", "TREATMENT", 90, 113], ["MI", "PROBLEM", 125, 127], ["Blood Collection", "TEST", 166, 182], ["AnalysisBlood samples", "TEST", 187, 208], ["fecal swabs", "TEST", 221, 232], ["exsanguination", "OBSERVATION", 151, 165], ["fecal", "ANATOMY", 221, 226]]], ["All blood samples were collected via jugular venipuncture into BD Vacutainer serum tubes (Becton, Dickinson and Company, Franklin Lakes, NJ) while pigs were snare restrained.", [["blood samples", "ANATOMY", 4, 17], ["jugular", "ANATOMY", 37, 44], ["serum", "ANATOMY", 77, 82], ["blood samples", "ORGANISM_SUBSTANCE", 4, 17], ["jugular venipuncture", "MULTI-TISSUE_STRUCTURE", 37, 57], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["tubes", "ORGANISM_SUBSTANCE", 83, 88], ["pigs", "ORGANISM", 147, 151], ["pigs", "SPECIES", 147, 151], ["pigs", "SPECIES", 147, 151], ["All blood samples", "TEST", 0, 17], ["BD Vacutainer serum tubes", "TREATMENT", 63, 88], ["jugular", "ANATOMY", 37, 44]]], ["After clotting, serum was separated by centrifugation (2,000 \u00d7 g for 15 min at 4\u00b0C) and stored at -80\u00b0C until analyzed or submitted to the Iowa State University Veterinary Diagnostic Laboratory (Ames, IA) for PRRS quantitative real-time qPCR) and serology analyses.", [["serum", "ANATOMY", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["serum", "TEST", 16, 21], ["serology analyses", "TEST", 247, 264]]], ["Fecal swabs were submitted to the Iowa State University Veterinary Diagnostic Laboratory for PED S gene qPCR analysis (Madson et al., 2014) .", [["Fecal swabs", "ANATOMY", 0, 11], ["Fecal swabs", "ORGANISM_SUBSTANCE", 0, 11], ["Fecal swabs", "TEST", 0, 11], ["PED S gene qPCR analysis", "TEST", 93, 117]]], ["Testing for PRRS virus and PED virus was performed with commercial reagents (VetMAX NA and EU PRRS virus real time PCR [Thermo Fisher Scientific, Waltham, MA] and EZ-PED/TGE MPX [Tetracore Inc., Rockville, MD]).", [["PRRS virus", "ORGANISM", 12, 22], ["PED virus", "ORGANISM", 27, 36], ["PRRS", "SPECIES", 12, 16], ["PRRS virus", "SPECIES", 12, 22], ["PED virus", "SPECIES", 27, 36], ["EU PRRS virus", "SPECIES", 91, 104], ["Testing", "TEST", 0, 7], ["PRRS virus", "PROBLEM", 12, 22], ["PED virus", "PROBLEM", 27, 36], ["commercial reagents", "TREATMENT", 56, 75], ["EU PRRS virus", "TREATMENT", 91, 104], ["PCR", "TEST", 115, 118], ["EZ-PED/TGE MPX", "TREATMENT", 163, 177]]], ["A commercial ELISA kit (HerdCheck PRRS X3; IDEXX Laboratories, Inc., Westbrook, ME) was used to detect anti-PRRS antibody according to manufacturer's instruction.Blood Collection and AnalysisAt dpi 21, serum insulin was measured using a Porcine Insulin ELISA kit (Mercodia AB, Uppsala, Sweden) according to manufacturer's instructions.", [["Blood", "ANATOMY", 162, 167], ["serum", "ANATOMY", 202, 207], ["anti-PRRS antibody", "GENE_OR_GENE_PRODUCT", 103, 121], ["Blood", "ORGANISM_SUBSTANCE", 162, 167], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["insulin", "GENE_OR_GENE_PRODUCT", 208, 215], ["Insulin", "GENE_OR_GENE_PRODUCT", 245, 252], ["anti-PRRS antibody", "PROTEIN", 103, 121], ["serum insulin", "PROTEIN", 202, 215], ["Porcine", "SPECIES", 237, 244], ["Porcine", "SPECIES", 237, 244], ["anti-PRRS antibody", "TREATMENT", 103, 121], ["Blood Collection", "TEST", 162, 178], ["AnalysisAt dpi", "TREATMENT", 183, 197], ["serum insulin", "TREATMENT", 202, 215], ["a Porcine Insulin", "TREATMENT", 235, 252]]], ["Serum glucose and NEFA concentrations were measured using the Wako Diagnostics kits (Wako Chemical Inc., Richmond, VA).", [["Serum", "ANATOMY", 0, 5], ["glucose", "CHEMICAL", 6, 13], ["NEFA", "CHEMICAL", 18, 22], ["glucose", "CHEMICAL", 6, 13], ["NEFA", "CHEMICAL", 18, 22], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 6, 13], ["NEFA", "SIMPLE_CHEMICAL", 18, 22], ["Serum glucose", "TEST", 0, 13], ["NEFA concentrations", "TEST", 18, 37]]], ["Blood urea nitrogen (BUN; BioAssay Systems, Hayward, CA) and glucagon (R&D Systems, Minneapolis, MN) was assessed using assay kits according to manufacturer's instructions.", [["Blood", "ANATOMY", 0, 5], ["urea nitrogen", "CHEMICAL", 6, 19], ["glucagon", "CHEMICAL", 61, 69], ["urea", "CHEMICAL", 6, 10], ["nitrogen", "CHEMICAL", 11, 19], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urea nitrogen", "SIMPLE_CHEMICAL", 6, 19], ["BUN", "SIMPLE_CHEMICAL", 21, 24], ["glucagon", "SIMPLE_CHEMICAL", 61, 69], ["Blood urea nitrogen", "TEST", 0, 19], ["BUN", "TEST", 21, 24], ["BioAssay Systems", "TEST", 26, 42], ["Hayward", "TEST", 44, 51], ["CA", "TEST", 53, 55], ["glucagon", "TEST", 61, 69], ["assay kits", "TREATMENT", 120, 130]]], ["All assays were read with a Synergy 4 plate reader using Gen 5 software (BioTek Instruments Inc., Winooski, VT).Apparent Total Tract Digestibility and Apparent Ileal DigestibilityFeces were collected and pooled within pig at 18 to 20 dpi and ileal digesta from the last 100 cm of the distal ileum was also collected for apparent ileal digestibility (AID) immediately following euthanasia (21 dpi).", [["Feces", "ANATOMY", 179, 184], ["ileal digesta", "ANATOMY", 242, 255], ["distal ileum", "ANATOMY", 284, 296], ["ileal", "ANATOMY", 329, 334], ["Feces", "CELL", 179, 184], ["pig", "ORGANISM", 218, 221], ["ileal digesta", "MULTI-TISSUE_STRUCTURE", 242, 255], ["ileum", "ORGAN", 291, 296], ["ileal", "MULTI-TISSUE_STRUCTURE", 329, 334], ["pig", "SPECIES", 218, 221], ["pig", "SPECIES", 218, 221], ["All assays", "TEST", 0, 10], ["a Synergy 4 plate", "TREATMENT", 26, 43], ["Total Tract Digestibility", "PROBLEM", 121, 146], ["Ileal Digestibility", "TREATMENT", 160, 179], ["Feces", "TEST", 179, 184], ["ileal digesta", "TREATMENT", 242, 255], ["Total", "OBSERVATION_MODIFIER", 121, 126], ["Tract Digestibility", "OBSERVATION", 127, 146], ["Ileal Digestibility", "OBSERVATION", 160, 179], ["ileal", "ANATOMY", 242, 247], ["digesta", "ANATOMY_MODIFIER", 248, 255], ["distal", "ANATOMY_MODIFIER", 284, 290], ["ileum", "ANATOMY", 291, 296], ["ileal", "ANATOMY", 329, 334], ["digestibility", "OBSERVATION", 335, 348]]], ["Approximately 100 mL of ileal digesta was collected, frozen, and then freeze-dried for AID analysis.", [["ileal digesta", "ANATOMY", 24, 37], ["ileal digesta", "MULTI-TISSUE_STRUCTURE", 24, 37], ["ileal digesta", "TREATMENT", 24, 37], ["AID analysis", "TEST", 87, 99], ["ileal digesta", "ANATOMY", 24, 37]]], ["Pooled fecal and diet samples were homogenized and dried in a mechanical convection oven at 100\u00b0C to determine apparent total tract digestibility (ATTD) of N, DM, OM, and GE.", [["fecal", "ANATOMY", 7, 12], ["samples", "ANATOMY", 22, 29], ["tract", "ANATOMY", 126, 131], ["fecal", "ORGANISM_SUBSTANCE", 7, 12], ["tract", "ORGANISM_SUBDIVISION", 126, 131], ["a mechanical convection oven", "TREATMENT", 60, 88], ["total tract digestibility", "PROBLEM", 120, 145], ["DM", "PROBLEM", 159, 161], ["fecal", "ANATOMY", 7, 12]]], ["Proximate analysis was performed on feed, ileal digesta, and fecal samples as previously described (Stein et al., 2007; Oresanya et al., 2008; Jacobs et al., 2011) .", [["ileal digesta", "ANATOMY", 42, 55], ["fecal samples", "ANATOMY", 61, 74], ["ileal digesta", "MULTI-TISSUE_STRUCTURE", 42, 55], ["fecal samples", "ORGANISM_SUBSTANCE", 61, 74], ["Proximate analysis", "TEST", 0, 18], ["ileal digesta", "TREATMENT", 42, 55], ["ileal digesta", "ANATOMY", 42, 55], ["fecal", "ANATOMY", 61, 66]]], ["Briefly, all samples were analyzed for DM (method 930.15; AOAC, 2005) , titanium dioxide as described by Leone (1973), N using TruMac N (Leco Corporation, St. Joseph, MO) , and GE using bomb calorimetry (Oxygen Bomb Calorimeter 6200; Parr Instruments, Moline, IL).", [["samples", "ANATOMY", 13, 20], ["DM", "DISEASE", 39, 41], ["titanium dioxide", "CHEMICAL", 72, 88], ["titanium dioxide", "CHEMICAL", 72, 88], ["Oxygen", "CHEMICAL", 204, 210], ["titanium dioxide", "SIMPLE_CHEMICAL", 72, 88], ["DM", "PROBLEM", 39, 41], ["AOAC", "TEST", 58, 62], ["titanium dioxide", "TREATMENT", 72, 88], ["Oxygen Bomb Calorimeter", "TREATMENT", 204, 227]]], ["Organic matter was determined using the ashing method and calculated as previously described (Faithfull, 2003) .", [["the ashing method", "TEST", 36, 53]]], ["Amino acid analysis of feed and digesta samples was performed by the Agricultural Experiment Station Chemical Laboratories at the University of Missouri-Columbia (Columbia, MO) using cation-exchange HPLC (L8900 Amino Acid Analyzer; Hitachi High-Technologies Corporation, Tokyo, Japan).", [["digesta samples", "ANATOMY", 32, 47], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino Acid", "CHEMICAL", 211, 221], ["Amino acid", "AMINO_ACID", 0, 10], ["digesta samples", "ORGANISM_SUBSTANCE", 32, 47], ["cation", "SIMPLE_CHEMICAL", 183, 189], ["Amino acid analysis", "TEST", 0, 19], ["digesta samples", "TEST", 32, 47], ["cation", "TEST", 183, 189], ["exchange HPLC", "TEST", 190, 203], ["Amino Acid Analyzer", "TEST", 211, 230], ["Hitachi", "TEST", 232, 239]]], ["For each of the 4 treatments, ATTD of DM, OM, N, and GE and AID of OM, DM, N, and AA were calculated using the index method (Oresanya et al., 2008) .Statistical AnalysisThe PROC MIXED procedure of SAS version 9.4 (SAS Inst.", [["DM", "DISEASE", 38, 40], ["AA", "SIMPLE_CHEMICAL", 82, 84], ["the 4 treatments", "TREATMENT", 12, 28], ["DM", "PROBLEM", 38, 40], ["OM, N, and GE and AID of OM", "PROBLEM", 42, 69], ["DM", "PROBLEM", 71, 73], ["AA", "PROBLEM", 82, 84], ["The PROC MIXED procedure", "TREATMENT", 169, 193], ["SAS version", "TEST", 197, 208]]], ["Inc., Cary, NC) was used to compare the overall treatment effects.", [["Cary, NC)", "TREATMENT", 6, 15]]], ["Pen was considered the experimental unit for performance, digestibility, and blood measures.", [["blood", "ANATOMY", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["digestibility", "TEST", 58, 71], ["blood measures", "TREATMENT", 77, 91]]], ["For ATTD and AID analysis, ADFI was used as a covariate.", [["ATTD and AID analysis", "TEST", 4, 25], ["ADFI", "TEST", 27, 31]]], ["Orthogonal contrast statements were used to determine the main effects of PRRS and PED infection as well as the interaction of the two infections.", [["PRRS", "DISEASE", 74, 78], ["PED infection", "DISEASE", 83, 96], ["infections", "DISEASE", 135, 145], ["PRRS", "ORGANISM", 74, 78], ["PRRS", "SPECIES", 74, 78], ["PRRS", "PROBLEM", 74, 78], ["PED infection", "PROBLEM", 83, 96], ["the two infections", "PROBLEM", 127, 145], ["infection", "OBSERVATION", 87, 96], ["infections", "OBSERVATION", 135, 145]]], ["All data are reported as least squares means \u00b1 SEM and considered significant if P \u2264 0.05 and a trend if P \u2264 0.10.Porcine Reproductive and Respiratory Syndrome Virus and Porcine Epidemic Diarrhea Virus InfectionAll animals were na\u00efve to PRRS and PED before inoculation based on serum and fecal swab qPCR analysis, respectively.", [["serum", "ANATOMY", 278, 283], ["Porcine Reproductive and Respiratory Syndrome Virus", "DISEASE", 114, 165], ["Epidemic Diarrhea Virus Infection", "DISEASE", 178, 211], ["PRRS", "DISEASE", 237, 241], ["Porcine Reproductive and Respiratory Syndrome Virus", "ORGANISM", 114, 165], ["Porcine Epidemic Diarrhea Virus", "ORGANISM", 170, 201], ["PRRS", "ORGANISM", 237, 241], ["serum", "ORGANISM_SUBSTANCE", 278, 283], ["Porcine", "SPECIES", 114, 121], ["Porcine", "SPECIES", 170, 177], ["Porcine Epidemic Diarrhea Virus Infection", "SPECIES", 170, 211], ["PRRS", "SPECIES", 237, 241], ["All data", "TEST", 0, 8], ["SEM", "TEST", 47, 50], ["P", "TEST", 81, 82], ["P", "TEST", 105, 106], ["Porcine Reproductive and Respiratory Syndrome Virus", "PROBLEM", 114, 165], ["Porcine Epidemic Diarrhea Virus Infection", "PROBLEM", 170, 211], ["inoculation", "TREATMENT", 257, 268], ["serum", "TEST", 278, 283], ["fecal swab qPCR analysis", "TEST", 288, 312], ["Respiratory Syndrome", "OBSERVATION", 139, 159], ["fecal", "ANATOMY", 288, 293]]], ["By design, CON and PED-only gilts remained PRRS negative throughout the study.", [["gilts", "ORGANISM", 28, 33], ["PRRS", "ORGANISM", 43, 47], ["PRRS", "SPECIES", 43, 47], ["PRRS", "PROBLEM", 43, 47], ["the study", "TEST", 68, 77]]], ["At 14 and 21 dpi, PRRS virus and antibodies were detected from serum of all pigs inoculated with PRRS ( Table 2) .", [["serum", "ANATOMY", 63, 68], ["PRRS", "DISEASE", 97, 101], ["PRRS virus", "ORGANISM", 18, 28], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["pigs", "ORGANISM", 76, 80], ["antibodies", "PROTEIN", 33, 43], ["PRRS", "SPECIES", 18, 22], ["pigs", "SPECIES", 76, 80], ["PRRS virus", "SPECIES", 18, 28], ["pigs", "SPECIES", 76, 80], ["PRRS", "SPECIES", 97, 101], ["PRRS virus", "PROBLEM", 18, 28], ["antibodies", "TEST", 33, 43], ["serum", "TEST", 63, 68]]], ["Analysis of fecal swabs by qPCR revealed that PED virus was prevalent in the PED-and PRPinoculated gilts, whereas the CON and PRRS treatments remained PED virus negative (Table 2) .Growth PerformanceThe effects of PRRS, PED, and PRP on ADG, ADFI, and G:F are summarized in Table 3 and Fig. 1 .", [["fecal swabs", "ANATOMY", 12, 23], ["PRRS", "DISEASE", 126, 130], ["PRRS", "DISEASE", 214, 218], ["fecal swabs", "ORGANISM_SUBSTANCE", 12, 23], ["PED virus", "ORGANISM", 46, 55], ["gilts", "ORGANISM", 99, 104], ["PRRS", "ORGANISM", 126, 130], ["G:F", "GENE_OR_GENE_PRODUCT", 251, 254], ["PED virus", "SPECIES", 46, 55], ["PRRS", "SPECIES", 126, 130], ["fecal swabs", "TEST", 12, 23], ["qPCR", "TEST", 27, 31], ["PED virus", "PROBLEM", 46, 55], ["PRPinoculated gilts", "PROBLEM", 85, 104], ["the CON and PRRS treatments", "TREATMENT", 114, 141], ["PED virus", "PROBLEM", 151, 160], ["fecal", "ANATOMY", 12, 17]]], ["During the 21-d test period, PRRS infection reduced ADG and ADFI by 30 and 26%, respectively (P < 0.05), but not G:F compared with CON pigs.", [["PRRS infection", "DISEASE", 29, 43], ["PRRS", "ORGANISM", 29, 33], ["G:F", "GENE_OR_GENE_PRODUCT", 113, 116], ["pigs", "ORGANISM", 135, 139], ["pigs", "SPECIES", 135, 139], ["PRRS", "SPECIES", 29, 33], ["PRRS infection", "PROBLEM", 29, 43], ["ADG", "TEST", 52, 55], ["ADFI", "TEST", 60, 64], ["infection", "OBSERVATION", 34, 43]]], ["Coinfection greatly affected overall performance, reducing ADG, ADFI, and G:F by 46, 30, and 23%, respectively (P < 0.05).", [["G:F", "GENE_OR_GENE_PRODUCT", 74, 77]]], ["Reduction in overall performance in the PRP pigs was more influenced by infection with PRRS virus than infection with PED virus.", [["infection", "DISEASE", 72, 81], ["PRRS virus", "DISEASE", 87, 97], ["infection", "DISEASE", 103, 112], ["pigs", "ORGANISM", 44, 48], ["PRRS virus", "ORGANISM", 87, 97], ["PED virus", "ORGANISM", 118, 127], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 44, 48], ["PRRS virus", "SPECIES", 87, 97], ["PED virus", "SPECIES", 118, 127], ["the PRP pigs", "TREATMENT", 36, 48], ["infection", "PROBLEM", 72, 81], ["PRRS virus", "PROBLEM", 87, 97], ["infection", "PROBLEM", 103, 112], ["PED virus", "PROBLEM", 118, 127], ["overall", "OBSERVATION_MODIFIER", 13, 20], ["performance", "OBSERVATION_MODIFIER", 21, 32], ["infection", "OBSERVATION", 72, 81]]], ["The overall 21-d pig performance for ADG, ADFI, and G:F was not significantly different among PED and CON pigs.", [["pig", "ORGANISM", 17, 20], ["G:F", "GENE_OR_GENE_PRODUCT", 52, 55], ["pigs", "ORGANISM", 106, 110], ["pigs", "SPECIES", 106, 110], ["pig", "SPECIES", 17, 20]]], ["However, the main effect of PED was significant for ADG and G:F (P = 0.001 and P = 0.008, respectively) and showed a tendency for ADFI (P = 0.076).", [["ADG", "TEST", 52, 55], ["G:F", "TEST", 60, 63], ["P", "TEST", 65, 66], ["P", "TEST", 79, 80], ["ADFI", "TEST", 130, 134], ["P", "TEST", 136, 137], ["main", "OBSERVATION_MODIFIER", 13, 17]]], ["This indicated that PED virus alone and in combination reduced pig performance compared with CON and PRRS pigs.", [["PED virus", "ORGANISM", 20, 29], ["pig", "ORGANISM", 63, 66], ["PRRS pigs", "ORGANISM", 101, 110], ["pig", "SPECIES", 63, 66], ["PRRS", "SPECIES", 101, 105], ["pigs", "SPECIES", 106, 110], ["pig", "SPECIES", 63, 66], ["PRRS", "SPECIES", 101, 105], ["PED virus", "PROBLEM", 20, 29], ["CON and PRRS pigs", "TREATMENT", 93, 110]]], ["There was no interaction, suggesting no additive effects of coinfection (PRP) on overall growth performance.", [["coinfection", "DISEASE", 60, 71], ["coinfection", "PROBLEM", 60, 71], ["no", "UNCERTAINTY", 10, 12], ["coinfection", "OBSERVATION", 60, 71]]], ["When comparing the initial impact of PED on performance (15-21 dpi, 7 d of PED infection), CON and PRRS pigs showed no difference (Table 3) .", [["infection", "DISEASE", 79, 88], ["pigs", "ORGANISM", 104, 108], ["pigs", "SPECIES", 104, 108], ["PRRS", "SPECIES", 99, 103], ["performance", "TEST", 44, 55], ["PED infection", "PROBLEM", 75, 88], ["CON and PRRS pigs", "TEST", 91, 108], ["no", "UNCERTAINTY", 116, 118]]], ["Control versus PED and PRP, however, resulted in sizable reductions in ADG (47 and 70%, respectively; P < 0.001), ADFI (29 and 45%, respectively; P = 0.003), and G:F (28 and 43%, respectively; P = 0.001), respectively.", [["G:F", "GENE_OR_GENE_PRODUCT", 162, 165], ["PRP", "TREATMENT", 23, 26], ["sizable reductions", "PROBLEM", 49, 67], ["ADG", "TEST", 71, 74], ["P", "TEST", 102, 103], ["ADFI", "TEST", 114, 118], ["P", "TEST", 146, 147], ["P", "TEST", 193, 194], ["sizable", "OBSERVATION_MODIFIER", 49, 56], ["reductions", "OBSERVATION_MODIFIER", 57, 67]]], ["Performance parameters of ADG, ADFI, and G:F during the final week of performance were significantly decreased by PED (P < 0.001, all measures); however, PRRS tended (P = 0.083) to increase ADG and significantly (P = 0.026) influenced ADFI.", [["PRRS", "DISEASE", 154, 158], ["G:F", "GENE_OR_GENE_PRODUCT", 41, 44], ["PRRS", "TEST", 154, 158], ["ADG", "TEST", 190, 193]]], ["There were no interactive effects during the final week of growth.Apparent Total Tract and Ileal DigestibilityDry matter, N, GE, and OM digestibility was assessed from 18 to 20 dpi by fecal grab samples (Table 4) .", [["fecal grab samples", "ANATOMY", 184, 202], ["Ileal", "MULTI-TISSUE_STRUCTURE", 91, 96], ["interactive effects", "PROBLEM", 14, 33], ["Total Tract", "TREATMENT", 75, 86], ["Ileal DigestibilityDry matter", "PROBLEM", 91, 120], ["OM digestibility", "PROBLEM", 133, 149], ["fecal grab samples", "TEST", 184, 202], ["no", "UNCERTAINTY", 11, 13], ["interactive effects", "OBSERVATION", 14, 33], ["Total", "OBSERVATION_MODIFIER", 75, 80], ["Tract", "OBSERVATION", 81, 86], ["Ileal", "ANATOMY", 91, 96], ["DigestibilityDry", "OBSERVATION", 97, 113], ["matter", "OBSERVATION", 114, 120]]], ["Over this period, ATTD coefficients of DM, N, GE, and OM were unaffected by PRRS (P > 0.10).", [["DM", "DISEASE", 39, 41], ["PRRS", "DISEASE", 76, 80], ["PRRS", "SPECIES", 76, 80], ["DM", "PROBLEM", 39, 41]]], ["However, PED decreased DM and GE digestibility by 7.8 and 11.4%, respectively (P < 0.01), whereas N and OM remained unaffected (P > 0.10).", [["DM", "DISEASE", 23, 25], ["PED decreased DM", "PROBLEM", 9, 25], ["GE digestibility", "TEST", 30, 46], ["P", "TEST", 128, 129], ["decreased", "OBSERVATION_MODIFIER", 13, 22], ["DM", "OBSERVATION", 23, 25]]], ["Coinfection reduced DM, N, GE, and OM digestibility by 9.0, 12.8, 11.9, and 3.5%, respectively (P < 0.05), from CON.", [["DM", "DISEASE", 20, 22], ["Coinfection reduced DM", "PROBLEM", 0, 22], ["OM digestibility", "TEST", 35, 51]]], ["Reductions in all ATTD coefficients of PRP pigs were influenced by the main effect of PED (P < 0.001, P = 0.004, P = 0.010, and P < 0.001, respectively) and not PRRS (P > 0.05).", [["PRRS", "DISEASE", 161, 165], ["pigs", "ORGANISM", 43, 47], ["pigs", "SPECIES", 43, 47], ["PRRS", "SPECIES", 161, 165], ["PRP pigs", "TREATMENT", 39, 47], ["P", "TEST", 102, 103], ["P", "TEST", 113, 114], ["P", "TEST", 128, 129], ["PRRS", "TEST", 161, 165], ["P", "TEST", 167, 168]]], ["No significant differences between PED and PRP were detected.Apparent Total Tract and Ileal DigestibilityDry matter, N, OM, and specific AA digestibility were assessed by collection of ileal digesta at 21 dpi (Table 5) .", [["Ileal", "ANATOMY", 86, 91], ["ileal digesta", "ANATOMY", 185, 198], ["AA", "CHEMICAL", 137, 139], ["Ileal", "MULTI-TISSUE_STRUCTURE", 86, 91], ["AA", "SIMPLE_CHEMICAL", 137, 139], ["ileal digesta", "MULTI-TISSUE_STRUCTURE", 185, 198], ["PRP", "TEST", 43, 46], ["Total Tract", "TREATMENT", 70, 81], ["Ileal DigestibilityDry matter", "PROBLEM", 86, 115], ["OM", "PROBLEM", 120, 122], ["specific AA digestibility", "PROBLEM", 128, 153], ["ileal digesta", "TREATMENT", 185, 198], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["Total", "OBSERVATION_MODIFIER", 70, 75], ["Tract", "OBSERVATION", 76, 81], ["Ileal", "ANATOMY", 86, 91], ["DigestibilityDry", "OBSERVATION", 92, 108], ["matter", "OBSERVATION", 109, 115], ["OM", "ANATOMY", 120, 122], ["AA digestibility", "OBSERVATION", 137, 153], ["ileal digesta", "ANATOMY", 185, 198]]], ["No AID differences were detected among treatments for DM, N, or OM.", [["DM", "DISEASE", 54, 56], ["AID differences", "PROBLEM", 3, 18], ["DM", "PROBLEM", 54, 56], ["OM", "PROBLEM", 64, 66]]], ["There were numerical differences, however, with PED and PRP having reduced DM (14 and 17%, respectively), N (9 and 4%, respectively), and OM (8 and 11%, respectively) compared with CON.", [["DM", "DISEASE", 75, 77], ["reduced DM", "PROBLEM", 67, 77]]], ["Interestingly, OM AID was effected by PED (P = 0.042).", [["OM AID", "PROTEIN", 15, 21]]], ["Similar to ATTD, PRRS had a minimal effect on AID measures compared with the CON pigs (P > 0.10).", [["PRRS", "DISEASE", 17, 21], ["PRRS", "ORGANISM", 17, 21], ["pigs", "ORGANISM", 81, 85], ["AID", "PROTEIN", 46, 49], ["pigs", "SPECIES", 81, 85], ["PRRS", "SPECIES", 17, 21], ["AID measures", "TREATMENT", 46, 58], ["minimal", "OBSERVATION_MODIFIER", 28, 35], ["effect", "OBSERVATION_MODIFIER", 36, 42]]], ["There were no statistical differences reported for any specific AA AID measured (Table 5) .", [["AA", "CHEMICAL", 64, 66], ["AA AID", "PROTEIN", 64, 70], ["statistical differences", "PROBLEM", 14, 37], ["no", "UNCERTAINTY", 11, 13]]], ["However, Lys AID tended (P = 0.095) to be reduced in PED pigs from PRRS and CON pigs, attributed to PED (P = 0.029).Blood MetabolitesBlood glucose, insulin, glucagon, and NEFA concentration and BUN were assessed at 21 dpi (Table 6 ).", [["Blood", "ANATOMY", 116, 121], ["Blood", "ANATOMY", 133, 138], ["Lys", "CHEMICAL", 9, 12], ["PRRS", "DISEASE", 67, 71], ["PED", "DISEASE", 100, 103], ["glucose", "CHEMICAL", 139, 146], ["NEFA", "CHEMICAL", 171, 175], ["Lys", "CHEMICAL", 9, 12], ["glucose", "CHEMICAL", 139, 146], ["NEFA", "CHEMICAL", 171, 175], ["Lys AID", "GENE_OR_GENE_PRODUCT", 9, 16], ["pigs", "ORGANISM", 57, 61], ["Blood", "ORGANISM_SUBSTANCE", 116, 121], ["Blood", "ORGANISM_SUBSTANCE", 133, 138], ["glucose", "SIMPLE_CHEMICAL", 139, 146], ["insulin", "GENE_OR_GENE_PRODUCT", 148, 155], ["glucagon", "GENE_OR_GENE_PRODUCT", 157, 165], ["NEFA", "SIMPLE_CHEMICAL", 171, 175], ["BUN", "SIMPLE_CHEMICAL", 194, 197], ["Lys AID", "PROTEIN", 9, 16], ["insulin", "PROTEIN", 148, 155], ["pigs", "SPECIES", 57, 61], ["pigs", "SPECIES", 80, 84], ["pigs", "SPECIES", 57, 61], ["PRRS", "SPECIES", 67, 71], ["Blood Metabolites", "TEST", 116, 133], ["Blood glucose", "TEST", 133, 146], ["insulin", "TREATMENT", 148, 155], ["glucagon", "TREATMENT", 157, 165], ["NEFA concentration", "TEST", 171, 189], ["BUN", "TEST", 194, 197]]], ["Blood urea nitrogen was increased (P < 0.001) 2-fold in PED and PRP pigs but was unaffected by PRRS (P > 0.10).", [["Blood", "ANATOMY", 0, 5], ["urea nitrogen", "CHEMICAL", 6, 19], ["PRRS", "DISEASE", 95, 99], ["urea", "CHEMICAL", 6, 10], ["nitrogen", "CHEMICAL", 11, 19], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urea", "SIMPLE_CHEMICAL", 6, 10], ["pigs", "ORGANISM", 68, 72], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 68, 72], ["PRRS", "SPECIES", 95, 99], ["Blood urea nitrogen", "TEST", 0, 19], ["PRP pigs", "TREATMENT", 64, 72], ["P", "TEST", 101, 102]]], ["Additionally, glucagon concentrations were increased (P < 0.001) 3-fold in PED and PRP treatments over CON, whereas the PRRS treatment did not affect blood glucagon concentrations.", [["blood", "ANATOMY", 150, 155], ["glucagon", "CHEMICAL", 14, 22], ["PRRS", "DISEASE", 120, 124], ["glucagon", "CHEMICAL", 156, 164], ["glucagon", "SIMPLE_CHEMICAL", 14, 22], ["PRP", "SIMPLE_CHEMICAL", 83, 86], ["PRRS", "ORGANISM", 120, 124], ["blood", "ORGANISM_SUBSTANCE", 150, 155], ["glucagon", "SIMPLE_CHEMICAL", 156, 164], ["PRRS", "SPECIES", 120, 124], ["glucagon concentrations", "TREATMENT", 14, 37], ["PED and PRP treatments", "TREATMENT", 75, 97], ["the PRRS treatment", "TREATMENT", 116, 134], ["blood glucagon concentrations", "TEST", 150, 179]]], ["A main effect of PED was detected for both BUN and glucagon (P < 0.001 for both measures) whereas the main effect of PRRS had no effect (P > 0.10).", [["glucagon", "CHEMICAL", 51, 59], ["PRRS", "DISEASE", 117, 121], ["BUN", "SIMPLE_CHEMICAL", 43, 46], ["glucagon", "SIMPLE_CHEMICAL", 51, 59], ["PRRS", "ORGANISM", 117, 121], ["PRRS", "SPECIES", 117, 121], ["BUN", "TEST", 43, 46], ["glucagon", "TREATMENT", 51, 59], ["PRRS", "PROBLEM", 117, 121], ["P", "TEST", 137, 138], ["main", "OBSERVATION_MODIFIER", 2, 6], ["effect", "OBSERVATION_MODIFIER", 7, 13]]], ["Blood NEFA concentration was increased 23% by the PRP treatment compared with the CON, PRRS, and PED treatments.", [["Blood", "ANATOMY", 0, 5], ["NEFA", "CHEMICAL", 6, 10], ["PRRS", "DISEASE", 87, 91], ["NEFA", "CHEMICAL", 6, 10], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["NEFA", "SIMPLE_CHEMICAL", 6, 10], ["PRP", "SIMPLE_CHEMICAL", 50, 53], ["PRRS", "SPECIES", 87, 91], ["Blood NEFA concentration", "TEST", 0, 24], ["the PRP treatment", "TREATMENT", 46, 63], ["PED treatments", "TREATMENT", 97, 111]]], ["This resulted in an interaction (P = 0.044), suggesting an additive effect of PRRS and PED in combination.", [["PRRS", "DISEASE", 78, 82], ["PRRS", "SPECIES", 78, 82], ["PRRS", "TREATMENT", 78, 82], ["PED", "TREATMENT", 87, 90]]], ["Blood glucose and insulin were unaffected by among treatments (P = 0.61 and P = 0.36, respectively).DISCUSSIONThe antibody response at 21 dpi was increased in PRP pigs versus PRRS-only pigs.", [["Blood", "ANATOMY", 0, 5], ["glucose", "CHEMICAL", 6, 13], ["glucose", "CHEMICAL", 6, 13], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 6, 13], ["insulin", "GENE_OR_GENE_PRODUCT", 18, 25], ["PRP pigs", "ORGANISM", 159, 167], ["PRRS", "ORGANISM", 175, 179], ["pigs", "ORGANISM", 185, 189], ["pigs", "SPECIES", 163, 167], ["pigs", "SPECIES", 185, 189], ["pigs", "SPECIES", 163, 167], ["PRRS", "SPECIES", 175, 179], ["pigs", "SPECIES", 185, 189], ["Blood glucose", "TEST", 0, 13], ["insulin", "TREATMENT", 18, 25], ["P", "TEST", 63, 64], ["P", "TEST", 76, 77], ["The antibody response", "TEST", 110, 131], ["PRP pigs", "TREATMENT", 159, 167]]], ["This could be due to a later peak antibody response as a result of concurrent PED virus infection, which has been seen when PRRSpositive pigs challenged with other viruses (Zhang et al., 2012) .", [["PED virus infection", "DISEASE", 78, 97], ["PED virus", "ORGANISM", 78, 87], ["PRRSpositive pigs", "ORGANISM", 124, 141], ["pigs", "SPECIES", 137, 141], ["pigs", "SPECIES", 137, 141], ["a later peak antibody response", "PROBLEM", 21, 51], ["concurrent PED virus infection", "PROBLEM", 67, 97], ["could be due to", "UNCERTAINTY", 5, 20], ["virus infection", "OBSERVATION", 82, 97]]], ["Significant reductions in ADG and ADFI, but not G:F, in PRRS virus infected pigs throughout the duration of the study agrees with previous studies our group and others have reported (Escobar et al., 2004 (Escobar et al., , 2006 .", [["PRRS virus infected", "DISEASE", 56, 75], ["G:F", "GENE_OR_GENE_PRODUCT", 48, 51], ["PRRS virus", "ORGANISM", 56, 66], ["pigs", "ORGANISM", 76, 80], ["PRRS virus infected pigs", "SPECIES", 56, 80], ["PRRS virus", "SPECIES", 56, 66], ["pigs", "SPECIES", 76, 80], ["Significant reductions", "PROBLEM", 0, 22], ["PRRS virus", "PROBLEM", 56, 66], ["the study", "TEST", 108, 117], ["reductions", "OBSERVATION_MODIFIER", 12, 22]]], ["This is the first reported characterization of growth performance and feed efficiency in PEDand PRRS+PED-infected pigs.", [["PEDand", "ORGANISM", 89, 95], ["PRRS", "ORGANISM", 96, 100], ["pigs", "ORGANISM", 114, 118], ["PRRS", "SPECIES", 96, 100], ["pigs", "SPECIES", 114, 118], ["PEDand PRRS", "SPECIES", 89, 100], ["pigs", "SPECIES", 114, 118], ["growth performance", "PROBLEM", 47, 65], ["infected pigs", "OBSERVATION", 105, 118]]], ["Reduced performance was expected, as pigs with increased immune activity show reductions in ADG, ADFI, and G:F, as reported by Williams et al. (1997a,b,c) .", [["pigs", "ORGANISM", 37, 41], ["ADG", "SIMPLE_CHEMICAL", 92, 95], ["G:F", "GENE_OR_GENE_PRODUCT", 107, 110], ["pigs", "SPECIES", 37, 41], ["pigs", "SPECIES", 37, 41], ["increased immune activity", "PROBLEM", 47, 72], ["reductions", "OBSERVATION_MODIFIER", 78, 88]]], ["Similarly, coinfection with PRRS has reduced growth performance (Van Reeth et al., 1996; Brockmeier et al., 2001) .DISCUSSIONRecent work from our group reported significant differences in ATTD with regards to PRRS virus infection (Gabler et al., 2013) ; however, the same results were not seen in these younger pigs in the current study, as PRRS virus infection showed no difference in ATTD.", [["coinfection", "DISEASE", 11, 22], ["PRRS", "DISEASE", 28, 32], ["ATTD", "DISEASE", 188, 192], ["PRRS virus infection", "DISEASE", 209, 229], ["PRRS virus infection", "DISEASE", 341, 361], ["ATTD", "DISEASE", 386, 390], ["PRRS", "ORGANISM", 28, 32], ["PRRS virus", "ORGANISM", 209, 219], ["pigs", "ORGANISM", 311, 315], ["PRRS virus", "ORGANISM", 341, 351], ["pigs", "SPECIES", 311, 315], ["PRRS", "SPECIES", 28, 32], ["PRRS virus", "SPECIES", 209, 219], ["PRRS virus", "SPECIES", 341, 351], ["coinfection", "PROBLEM", 11, 22], ["PRRS virus infection", "PROBLEM", 209, 229], ["the current study", "TEST", 319, 336], ["PRRS virus infection", "PROBLEM", 341, 361], ["coinfection", "OBSERVATION", 11, 22], ["reduced", "OBSERVATION_MODIFIER", 37, 44], ["growth", "OBSERVATION_MODIFIER", 45, 51], ["no", "UNCERTAINTY", 369, 371]]], ["However, PED, an enteric virus that replicates in villi enterocytes (Neumann et al., 2012) , exhibited reductions in DM and GE ATTD.", [["villi enterocytes", "ANATOMY", 50, 67], ["DM", "DISEASE", 117, 119], ["villi enterocytes", "TISSUE", 50, 67], ["an enteric virus", "PROBLEM", 14, 30], ["DM", "PROBLEM", 117, 119], ["enteric", "ANATOMY", 17, 24], ["virus", "OBSERVATION", 25, 30], ["villi enterocytes", "ANATOMY", 50, 67], ["reductions", "OBSERVATION_MODIFIER", 103, 113]]], ["Similarly, PRP pigs had reduced DM, N, and GE ATTD whereas OM was not different from CON.", [["DM", "DISEASE", 32, 34], ["pigs", "ORGANISM", 15, 19], ["pigs", "SPECIES", 15, 19], ["pigs", "SPECIES", 15, 19], ["reduced DM", "PROBLEM", 24, 34], ["GE ATTD", "PROBLEM", 43, 50]]], ["Also, there were no differences between PED and PRP treatments, which was somewhat unexpected.", [["PED and PRP treatments", "TREATMENT", 40, 62], ["no", "UNCERTAINTY", 17, 19]]], ["Differences in ATTD may be explained by rate of passage.", [["ATTD", "DISEASE", 15, 19], ["may be explained", "UNCERTAINTY", 20, 36]]], ["When livestock suffer from diarrhea, the rate of passage can be reduced by as much as 50% (Bush et al., 1963) and rate of passage is negatively correlated with total tract digestibility coefficients (Entringer et al., 1975) .", [["tract", "ANATOMY", 166, 171], ["diarrhea", "DISEASE", 27, 35], ["tract", "ORGANISM_SUBDIVISION", 166, 171], ["diarrhea", "PROBLEM", 27, 35], ["diarrhea", "OBSERVATION", 27, 35]]], ["A shortened time of passage does not allow as much time for sufficient enzymatic breakdown of feedstuffs, which leads to poor absorption and diarrhea (Blaxter and Wood, 1953 ; Weijers et al., 1959) .", [["diarrhea", "DISEASE", 141, 149], ["sufficient enzymatic breakdown of feedstuffs", "PROBLEM", 60, 104], ["poor absorption", "PROBLEM", 121, 136], ["diarrhea", "PROBLEM", 141, 149]]], ["It also reduces the amount of time spent in the large intestine for water reabsorption and bacterial fermentation (Levitan, 1969; Clausen et al., 1998; Marchelletta et al., 2013) .", [["intestine", "ANATOMY", 54, 63], ["intestine", "ORGAN", 54, 63], ["water", "SIMPLE_CHEMICAL", 68, 73], ["water reabsorption", "TREATMENT", 68, 86], ["amount", "OBSERVATION_MODIFIER", 20, 26], ["intestine", "ANATOMY", 54, 63]]], ["Although limited work has been done with industry applicable pathogens, lipopolysaccharide (LPS) has been used to mimic pathogen challenge in pigs.", [["lipopolysaccharide", "CHEMICAL", 72, 90], ["LPS", "CHEMICAL", 92, 95], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 72, 90], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["pigs", "ORGANISM", 142, 146], ["pigs", "SPECIES", 142, 146], ["pigs", "SPECIES", 142, 146], ["lipopolysaccharide (LPS)", "TREATMENT", 72, 96]]], ["These studies have reported that LPS induced inflammatory challenges attenuate OM, energy, and N ATTD (Rakhshandeh and de Lange 2012; .", [["LPS", "CHEMICAL", 33, 36], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["These studies", "TEST", 0, 13], ["LPS", "PROBLEM", 33, 36], ["inflammatory", "OBSERVATION_MODIFIER", 45, 57]]], ["This agrees with the present study in which PED and PRRS were the immunological agents.", [["PRRS", "DISEASE", 52, 56], ["PRRS", "ORGANISM", 52, 56], ["PRRS", "SPECIES", 52, 56], ["the present study", "TEST", 17, 34], ["the immunological agents", "TREATMENT", 62, 86]]], ["Williams et al. (1997a) also reported decreases in N digestibility using a rearing method with piglets exposed to environmental antigens.DISCUSSIONThere were apparent differences in ATTD between treatments, but interestingly, there were only numerical differences in AID of DM, N, and OM.", [["ATTD", "DISEASE", 182, 186], ["DM", "DISEASE", 274, 276], ["piglets", "ORGANISM", 95, 102], ["piglets", "SPECIES", 95, 102], ["decreases in N digestibility", "PROBLEM", 38, 66], ["a rearing method", "TREATMENT", 73, 89], ["treatments", "TREATMENT", 195, 205], ["DM", "PROBLEM", 274, 276], ["decreases", "OBSERVATION_MODIFIER", 38, 47]]], ["Apparent ileal digestibility of specific AA was also unaffected by treatment, with only Lys digestibility tending to be reduced in PED challenged pigs.", [["ileal", "ANATOMY", 9, 14], ["AA", "CHEMICAL", 41, 43], ["Lys", "CHEMICAL", 88, 91], ["Lys", "CHEMICAL", 88, 91], ["ileal", "MULTI-TISSUE_STRUCTURE", 9, 14], ["AA", "SIMPLE_CHEMICAL", 41, 43], ["pigs", "ORGANISM", 146, 150], ["pigs", "SPECIES", 146, 150], ["pigs", "SPECIES", 146, 150], ["ileal digestibility of specific AA", "PROBLEM", 9, 43], ["Lys digestibility", "TREATMENT", 88, 105], ["ileal", "ANATOMY", 9, 14], ["digestibility", "OBSERVATION", 15, 28], ["reduced", "OBSERVATION_MODIFIER", 120, 127]]], ["Similarly, in LPS-challenged pigs, AID was not different from nonchallenged pigs (Rakhshandeh et al., 2010) ; however, this differs from a previous study where pigs infected with Salmonella typhimurium had reduced AID of several AA (Lee, 2012) .", [["LPS", "CHEMICAL", 14, 17], ["LPS", "SIMPLE_CHEMICAL", 14, 17], ["pigs", "ORGANISM", 29, 33], ["AID", "GENE_OR_GENE_PRODUCT", 35, 38], ["pigs", "ORGANISM", 76, 80], ["pigs", "ORGANISM", 160, 164], ["Salmonella typhimurium", "ORGANISM", 179, 201], ["AID", "PROTEIN", 35, 38], ["AID", "PROTEIN", 214, 217], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 160, 164], ["Salmonella typhimurium", "SPECIES", 179, 201], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 160, 164], ["Salmonella typhimurium", "SPECIES", 179, 201], ["a previous study", "TEST", 137, 153], ["Salmonella typhimurium", "PROBLEM", 179, 201]]], ["A limitation of using AID is that endogenous losses cannot be accounted for.", [["AID", "PROTEIN", 22, 25], ["endogenous losses", "PROBLEM", 34, 51], ["endogenous losses", "OBSERVATION", 34, 51]]], ["Endogenous losses have been previously determined in pigs inoculated with S. typhimurium.", [["pigs", "ORGANISM", 53, 57], ["S. typhimurium", "ORGANISM", 74, 88], ["pigs", "SPECIES", 53, 57], ["S. typhimurium", "SPECIES", 74, 88], ["pigs", "SPECIES", 53, 57], ["S. typhimurium", "SPECIES", 74, 88], ["Endogenous losses", "PROBLEM", 0, 17], ["losses", "OBSERVATION", 11, 17]]], ["This study found that endogenous losses of all AA were increased 4-to 9-fold at 24 h after infection; however, by 72 h after infection, there were no differences in endogenous losses (Lee, 2012) .", [["AA", "CHEMICAL", 47, 49], ["infection", "DISEASE", 91, 100], ["infection", "DISEASE", 125, 134], ["AA", "SIMPLE_CHEMICAL", 47, 49], ["This study", "TEST", 0, 10], ["endogenous losses of all AA", "PROBLEM", 22, 49], ["infection", "PROBLEM", 91, 100], ["infection", "PROBLEM", 125, 134], ["endogenous", "OBSERVATION_MODIFIER", 22, 32], ["losses", "OBSERVATION_MODIFIER", 33, 39], ["infection", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 125, 134], ["no", "UNCERTAINTY", 147, 149], ["endogenous losses", "OBSERVATION", 165, 182]]], ["This may suggest that time of collection (21 dpi for PRRS and 7 dpi for PED) did not capture peak infection differences, which may influence AID.", [["infection", "DISEASE", 98, 107], ["AID", "PROTEIN", 141, 144], ["PRRS", "SPECIES", 53, 57], ["collection", "TEST", 30, 40], ["PRRS", "PROBLEM", 53, 57], ["peak infection differences", "PROBLEM", 93, 119], ["infection", "OBSERVATION", 98, 107]]], ["Villus height and crypt depth were severely reduced throughout the small intestine in PED and PRP pigs but minimally affected in PRRS pigs (Schweer et al., 2016) .", [["Villus", "ANATOMY", 0, 6], ["crypt", "ANATOMY", 18, 23], ["small intestine", "ANATOMY", 67, 82], ["PRRS", "DISEASE", 129, 133], ["Villus", "TISSUE", 0, 6], ["crypt", "TISSUE", 18, 23], ["small intestine", "ORGAN", 67, 82], ["pigs", "ORGANISM", 98, 102], ["PRRS", "ORGANISM", 129, 133], ["pigs", "ORGANISM", 134, 138], ["pigs", "SPECIES", 98, 102], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 98, 102], ["PRRS pigs", "SPECIES", 129, 138], ["Villus height", "TEST", 0, 13], ["crypt depth", "PROBLEM", 18, 29], ["severely reduced", "PROBLEM", 35, 51], ["PRP pigs", "TREATMENT", 94, 102], ["minimally affected", "PROBLEM", 107, 125], ["height", "OBSERVATION_MODIFIER", 7, 13], ["crypt depth", "OBSERVATION", 18, 29], ["severely", "OBSERVATION_MODIFIER", 35, 43], ["reduced", "OBSERVATION", 44, 51], ["small", "OBSERVATION_MODIFIER", 67, 72], ["intestine", "ANATOMY", 73, 82], ["minimally", "OBSERVATION_MODIFIER", 107, 116], ["affected", "OBSERVATION_MODIFIER", 117, 125]]], ["This leads to reduced surface area of the intestine, which may influence AID.", [["surface area", "ANATOMY", 22, 34], ["intestine", "ANATOMY", 42, 51], ["intestine", "ORGAN", 42, 51], ["AID", "GENE_OR_GENE_PRODUCT", 73, 76], ["AID", "PROTEIN", 73, 76], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["surface", "OBSERVATION_MODIFIER", 22, 29], ["area", "OBSERVATION_MODIFIER", 30, 34], ["intestine", "ANATOMY", 42, 51]]], ["Another diarrheal disease described in pigs, cryptosporidiosis, causes reductions in villi height and crypt hyperplasia and has been reported to decrease villous surface area 3-fold (Argenzio et al., 1990) .", [["villi", "ANATOMY", 85, 90], ["crypt", "ANATOMY", 102, 107], ["villous surface area", "ANATOMY", 154, 174], ["diarrheal disease", "DISEASE", 8, 25], ["cryptosporidiosis", "DISEASE", 45, 62], ["hyperplasia", "DISEASE", 108, 119], ["pigs", "ORGANISM", 39, 43], ["villi", "TISSUE", 85, 90], ["crypt hyperplasia", "PATHOLOGICAL_FORMATION", 102, 119], ["pigs", "SPECIES", 39, 43], ["pigs", "SPECIES", 39, 43], ["Another diarrheal disease", "PROBLEM", 0, 25], ["cryptosporidiosis", "PROBLEM", 45, 62], ["villi height", "PROBLEM", 85, 97], ["crypt hyperplasia", "PROBLEM", 102, 119], ["villous surface area", "PROBLEM", 154, 174], ["diarrheal disease", "OBSERVATION", 8, 25], ["cryptosporidiosis", "OBSERVATION", 45, 62], ["reductions", "OBSERVATION_MODIFIER", 71, 81], ["villi height", "OBSERVATION", 85, 97], ["crypt hyperplasia", "OBSERVATION", 102, 119], ["decrease", "OBSERVATION_MODIFIER", 145, 153], ["villous", "OBSERVATION_MODIFIER", 154, 161], ["surface", "OBSERVATION_MODIFIER", 162, 169], ["-fold", "OBSERVATION_MODIFIER", 176, 181]]], ["Although intestinal morphology was changed, there was no difference in aminopeptidase activity, suggesting that digestive enzymes were still functioning normally (Schweer et al., 2016) .", [["intestinal", "ANATOMY", 9, 19], ["digestive", "ANATOMY", 112, 121], ["intestinal", "ORGAN", 9, 19], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 71, 85], ["aminopeptidase", "PROTEIN", 71, 85], ["digestive enzymes", "PROTEIN", 112, 129], ["aminopeptidase activity", "TEST", 71, 94], ["digestive enzymes", "TEST", 112, 129], ["intestinal", "ANATOMY", 9, 19], ["morphology", "OBSERVATION", 20, 30], ["no", "UNCERTAINTY", 54, 56], ["difference", "OBSERVATION_MODIFIER", 57, 67], ["aminopeptidase activity", "OBSERVATION", 71, 94]]], ["Although there are limitations to single point estimates for metabolites and hormones, similarities in blood metabolites between CON and PRRS treatments were expected at 21 dpi (Roberts and Almond, 2003) .", [["blood", "ANATOMY", 103, 108], ["PRRS", "DISEASE", 137, 141], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["PRRS", "SPECIES", 137, 141], ["metabolites and hormones", "PROBLEM", 61, 85], ["blood metabolites", "TEST", 103, 120], ["CON and PRRS treatments", "TREATMENT", 129, 152]]], ["Reductions in feed intake, leading to a catabolic state, presumably caused increased blood glucagon and BUN in PED and PRP treatments.", [["blood", "ANATOMY", 85, 90], ["glucagon", "CHEMICAL", 91, 99], ["feed", "ORGANISM_SUBDIVISION", 14, 18], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["glucagon", "SIMPLE_CHEMICAL", 91, 99], ["BUN", "SIMPLE_CHEMICAL", 104, 107], ["a catabolic state", "PROBLEM", 38, 55], ["increased blood glucagon", "PROBLEM", 75, 99], ["BUN in PED", "TREATMENT", 104, 114], ["PRP treatments", "TREATMENT", 119, 133], ["feed intake", "OBSERVATION", 14, 25]]], ["This data conflicts with a previous report where pigs infected with rotavirus exhibited no difference in blood glucagon (Zijlstra et al., 1997) .", [["blood", "ANATOMY", 105, 110], ["rotavirus", "DISEASE", 68, 77], ["glucagon", "CHEMICAL", 111, 119], ["pigs", "ORGANISM", 49, 53], ["rotavirus", "ORGANISM", 68, 77], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["glucagon", "SIMPLE_CHEMICAL", 111, 119], ["pigs", "SPECIES", 49, 53], ["pigs", "SPECIES", 49, 53], ["rotavirus", "SPECIES", 68, 77], ["rotavirus", "PROBLEM", 68, 77], ["blood glucagon", "TEST", 105, 119]]], ["Although differences in BUN were reported here, pigs inoculated with Brachyspira hyodysenteriae, the causative agent of swine dysentery, reported no difference in serum total AA concentrations (Jonasson et al., 2007) .", [["serum", "ANATOMY", 163, 168], ["swine dysentery", "DISEASE", 120, 135], ["AA", "CHEMICAL", 175, 177], ["BUN", "SIMPLE_CHEMICAL", 24, 27], ["pigs", "ORGANISM", 48, 52], ["Brachyspira hyodysenteriae", "ORGANISM", 69, 95], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["AA", "SIMPLE_CHEMICAL", 175, 177], ["BUN", "PROTEIN", 24, 27], ["pigs", "SPECIES", 48, 52], ["Brachyspira hyodysenteriae", "SPECIES", 69, 95], ["swine", "SPECIES", 120, 125], ["pigs", "SPECIES", 48, 52], ["Brachyspira hyodysenteriae", "SPECIES", 69, 95], ["swine", "SPECIES", 120, 125], ["BUN", "TEST", 24, 27], ["Brachyspira hyodysenteriae", "PROBLEM", 69, 95], ["swine dysentery", "PROBLEM", 120, 135], ["difference in serum total AA concentrations", "PROBLEM", 149, 192], ["Brachyspira hyodysenteriae", "OBSERVATION", 69, 95], ["no", "UNCERTAINTY", 146, 148]]], ["Interestingly, blood NEFA in CON, PRRS, and PED treatments was not different, whereas it was increased in PRP pigs.", [["blood", "ANATOMY", 15, 20], ["NEFA", "CHEMICAL", 21, 25], ["PRRS", "DISEASE", 34, 38], ["NEFA", "CHEMICAL", 21, 25], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["NEFA", "SIMPLE_CHEMICAL", 21, 25], ["pigs", "ORGANISM", 110, 114], ["pigs", "SPECIES", 110, 114], ["pigs", "SPECIES", 110, 114], ["blood NEFA", "TEST", 15, 25], ["PED treatments", "TREATMENT", 44, 58]]], ["This suggests an additive effect of the PRRS and PED and an increase in immune stimulation-induced changes in metabolism.", [["PRRS", "DISEASE", 40, 44], ["PRRS", "SPECIES", 40, 44], ["the PRRS", "TREATMENT", 36, 44], ["immune stimulation", "TREATMENT", 72, 90], ["induced changes in metabolism", "PROBLEM", 91, 120], ["additive effect", "OBSERVATION", 17, 32], ["increase", "OBSERVATION_MODIFIER", 60, 68], ["immune stimulation", "OBSERVATION", 72, 90]]], ["This potentially results in an increase in lipolysis to provide substrates ATP production and fuel of immune cells (Doughty et al., 2006) as energy intake could be limiting.", [["immune cells", "ANATOMY", 102, 114], ["ATP", "CHEMICAL", 75, 78], ["ATP", "CHEMICAL", 75, 78], ["ATP", "SIMPLE_CHEMICAL", 75, 78], ["immune cells", "CELL", 102, 114], ["immune cells", "CELL_TYPE", 102, 114], ["an increase in lipolysis", "PROBLEM", 28, 52], ["substrates ATP production", "PROBLEM", 64, 89], ["immune cells", "PROBLEM", 102, 114], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["Fatty acid oxidation also plays an important in memory CD8+ cell generation (Pearce et al., 2009) .", [["memory CD8+ cell", "ANATOMY", 48, 64], ["Fatty acid", "CHEMICAL", 0, 10], ["Fatty acid", "CHEMICAL", 0, 10], ["Fatty acid", "SIMPLE_CHEMICAL", 0, 10], ["CD8", "GENE_OR_GENE_PRODUCT", 55, 58], ["CD8", "PROTEIN", 55, 58], ["Fatty acid oxidation", "PROBLEM", 0, 20], ["acid oxidation", "OBSERVATION", 6, 20]]], ["Increased NEFA has been previously reported in pigs coinfected with PRRS and Mycoplasma hyopneumoniae at 7 dpi compared with control and pair-fed pigs (Oliver, 2004) .", [["NEFA", "CHEMICAL", 10, 14], ["PRRS", "DISEASE", 68, 72], ["NEFA", "CHEMICAL", 10, 14], ["NEFA", "SIMPLE_CHEMICAL", 10, 14], ["pigs", "ORGANISM", 47, 51], ["PRRS", "ORGANISM", 68, 72], ["Mycoplasma hyopneumoniae", "ORGANISM", 77, 101], ["pigs", "ORGANISM", 146, 150], ["NEFA", "PROTEIN", 10, 14], ["pigs", "SPECIES", 47, 51], ["PRRS", "SPECIES", 68, 72], ["Mycoplasma hyopneumoniae", "SPECIES", 77, 101], ["pigs", "SPECIES", 146, 150], ["pigs", "SPECIES", 47, 51], ["PRRS", "SPECIES", 68, 72], ["Mycoplasma hyopneumoniae", "SPECIES", 77, 101], ["pigs", "SPECIES", 146, 150], ["Increased NEFA", "PROBLEM", 0, 14], ["PRRS", "PROBLEM", 68, 72], ["Mycoplasma hyopneumoniae", "PROBLEM", 77, 101], ["Mycoplasma hyopneumoniae", "OBSERVATION", 77, 101]]], ["This suggests that feed restriction only partially explains the increase in NEFA.", [["NEFA", "CHEMICAL", 76, 80], ["NEFA", "CHEMICAL", 76, 80], ["NEFA", "SIMPLE_CHEMICAL", 76, 80], ["the increase in NEFA", "PROBLEM", 60, 80], ["feed restriction", "OBSERVATION", 19, 35], ["increase", "OBSERVATION_MODIFIER", 64, 72]]], ["Blood glucose and insulin were unaffected by treatment.", [["Blood", "ANATOMY", 0, 5], ["glucose", "CHEMICAL", 6, 13], ["glucose", "CHEMICAL", 6, 13], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 6, 13], ["insulin", "GENE_OR_GENE_PRODUCT", 18, 25], ["Blood glucose", "TEST", 0, 13], ["insulin", "TREATMENT", 18, 25]]], ["Similarly, pigs infected with rotavirus had no differences in circulating insulin levels (Zijlstra et al., 1997) .", [["pigs", "ORGANISM", 11, 15], ["rotavirus", "ORGANISM", 30, 39], ["insulin", "GENE_OR_GENE_PRODUCT", 74, 81], ["pigs", "SPECIES", 11, 15], ["pigs", "SPECIES", 11, 15], ["rotavirus", "SPECIES", 30, 39], ["rotavirus", "PROBLEM", 30, 39], ["circulating insulin levels", "TEST", 62, 88], ["rotavirus", "OBSERVATION", 30, 39]]], ["Similar find-ings for blood glucose have been reported in pigs during B. hyodysenteriae infection (Jonasson et al., 2007) whereas others have reported an increase in glucose during infection (Somchit et al., 2003) .", [["blood", "ANATOMY", 22, 27], ["glucose", "CHEMICAL", 28, 35], ["infection", "DISEASE", 88, 97], ["glucose", "CHEMICAL", 166, 173], ["infection", "DISEASE", 181, 190], ["glucose", "CHEMICAL", 28, 35], ["glucose", "CHEMICAL", 166, 173], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["glucose", "SIMPLE_CHEMICAL", 28, 35], ["pigs", "ORGANISM", 58, 62], ["B. hyodysenteriae", "ORGANISM", 70, 87], ["glucose", "SIMPLE_CHEMICAL", 166, 173], ["pigs", "SPECIES", 58, 62], ["B. hyodysenteriae", "SPECIES", 70, 87], ["pigs", "SPECIES", 58, 62], ["B. hyodysenteriae", "SPECIES", 70, 87], ["blood glucose", "TEST", 22, 35], ["B. hyodysenteriae infection", "PROBLEM", 70, 97], ["an increase in glucose during infection", "PROBLEM", 151, 190], ["increase", "OBSERVATION_MODIFIER", 154, 162]]], ["Utilization of glucose is increased in tissues and immune cells during immune response, which can cause hypoglycemia (Mizock, 1995) ; however, no differences in blood glucose in the present study suggests these pigs were likely meeting their glucose demands via gluconeogenesis.DISCUSSIONIn summary, PRRS and PED virus challenges, alone or in combination (PRP), antagonize pig growth rates and feed intakes.", [["tissues", "ANATOMY", 39, 46], ["immune cells", "ANATOMY", 51, 63], ["blood", "ANATOMY", 161, 166], ["glucose", "CHEMICAL", 15, 22], ["hypoglycemia", "DISEASE", 104, 116], ["glucose", "CHEMICAL", 167, 174], ["glucose", "CHEMICAL", 15, 22], ["glucose", "CHEMICAL", 167, 174], ["glucose", "CHEMICAL", 242, 249], ["glucose", "SIMPLE_CHEMICAL", 15, 22], ["tissues", "TISSUE", 39, 46], ["immune cells", "CELL", 51, 63], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["glucose", "SIMPLE_CHEMICAL", 167, 174], ["pigs", "ORGANISM", 211, 215], ["glucose", "SIMPLE_CHEMICAL", 242, 249], ["PED virus", "ORGANISM", 309, 318], ["pig", "ORGANISM", 373, 376], ["immune cells", "CELL_TYPE", 51, 63], ["pigs", "SPECIES", 211, 215], ["pig", "SPECIES", 373, 376], ["pigs", "SPECIES", 211, 215], ["PRRS", "SPECIES", 300, 304], ["pig", "SPECIES", 373, 376], ["Utilization of glucose", "TEST", 0, 22], ["immune cells", "PROBLEM", 51, 63], ["hypoglycemia", "PROBLEM", 104, 116], ["blood glucose", "TEST", 161, 174], ["the present study", "TEST", 178, 195], ["PED virus challenges", "TREATMENT", 309, 329], ["antagonize pig growth rates", "TREATMENT", 362, 389], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["immune cells", "OBSERVATION", 51, 63]]], ["Pig ATTD coefficients were reduced by PED and a coinfection of PRRS and PED, but PRRS alone did not reduce ATTD.", [["PRRS", "DISEASE", 63, 67], ["PRRS", "DISEASE", 81, 85], ["ATTD", "DISEASE", 107, 111], ["Pig", "ORGANISM", 0, 3], ["ATTD", "GENE_OR_GENE_PRODUCT", 4, 8], ["PRRS", "ORGANISM", 63, 67], ["Pig", "SPECIES", 0, 3], ["Pig", "SPECIES", 0, 3], ["PRRS", "SPECIES", 63, 67], ["PRRS", "SPECIES", 81, 85], ["Pig ATTD coefficients", "TREATMENT", 0, 21]]], ["Similarly, PRRS, PED, or a combination of both did not significantly decrease AID coefficients of specific AA.", [["PRRS", "DISEASE", 11, 15], ["AA", "CHEMICAL", 107, 109], ["AID", "PROTEIN", 78, 81], ["PRRS", "SPECIES", 11, 15]]], ["Altogether, these results indicate that capability to digest nutrients (as determined by apparent digestibility) seems to be unaffected by systemic or enteric viral challenges.", [["enteric viral challenges", "TREATMENT", 151, 175], ["enteric", "OBSERVATION_MODIFIER", 151, 158], ["viral", "OBSERVATION", 159, 164]]], ["However, the reduction in feed intake resulting from PED and PRRS challenges is probably one of the main limitations for pigs not being able to maintain high growth rates during the 21-d test period.", [["PRRS", "DISEASE", 61, 65], ["pigs", "ORGANISM", 121, 125], ["pigs", "SPECIES", 121, 125], ["PRRS", "SPECIES", 61, 65], ["pigs", "SPECIES", 121, 125], ["the reduction in feed intake", "TREATMENT", 9, 37], ["PED and PRRS challenges", "TREATMENT", 53, 76], ["pigs", "TREATMENT", 121, 125], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["feed intake", "OBSERVATION", 26, 37]]]], "PMC7104689": [["IntroductionA novel coronavirus has spread through China, originating from the city of Wuhan and has caused many deaths so far.", [["deaths", "DISEASE", 113, 119], ["coronavirus", "ORGANISM", 20, 31], ["IntroductionA novel coronavirus", "PROBLEM", 0, 31], ["coronavirus", "OBSERVATION", 20, 31]]], ["It is a highly contagious virus that has spread rapidly and efficiently.", [["a highly contagious virus", "PROBLEM", 6, 31], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["contagious", "OBSERVATION_MODIFIER", 15, 25], ["virus", "OBSERVATION", 26, 31], ["spread", "OBSERVATION_MODIFIER", 41, 47], ["rapidly", "OBSERVATION_MODIFIER", 48, 55]]], ["Coronavirus disease 2019 (COVID-19) is caused by a virus (SARS-CoV-2) from the same family as the lethal coronaviruses that caused severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV).", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["coronaviruses", "DISEASE", 105, 118], ["acute respiratory syndrome", "DISEASE", 138, 164], ["SARS-CoV)", "DISEASE", 166, 175], ["Middle East respiratory syndrome", "DISEASE", 180, 212], ["SARS-CoV-2", "ORGANISM", 58, 68], ["coronaviruses", "ORGANISM", 105, 118], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 0, 34], ["SARS-CoV-2", "SPECIES", 58, 68], ["SARS-CoV", "SPECIES", 166, 174], ["Middle East respiratory syndrome (MERS-CoV", "SPECIES", 180, 222], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["a virus (SARS", "PROBLEM", 49, 62], ["the lethal coronaviruses", "PROBLEM", 94, 118], ["severe acute respiratory syndrome", "PROBLEM", 131, 164], ["SARS-CoV)", "PROBLEM", 166, 175], ["Middle East respiratory syndrome", "PROBLEM", 180, 212], ["virus", "OBSERVATION", 51, 56], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["respiratory syndrome", "OBSERVATION", 144, 164], ["Middle", "ANATOMY_MODIFIER", 180, 186], ["respiratory syndrome", "OBSERVATION", 192, 212]]], ["COVID-19 is a relatively large virus (120 nm) and is enveloped, containing a positive-sense single-stranded RNA [1].", [["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["a relatively large virus", "PROBLEM", 12, 36], ["large", "OBSERVATION_MODIFIER", 25, 30], ["virus", "OBSERVATION", 31, 36]]], ["The virus is transmitted through direct contact with the infected person\u2019s respiratory droplets (coughing and sneezing), as well as contact with infected surfaces.", [["respiratory droplets", "ANATOMY", 75, 95], ["person", "SPECIES", 66, 72], ["The virus", "PROBLEM", 0, 9], ["respiratory droplets", "PROBLEM", 75, 95], ["coughing", "PROBLEM", 97, 105], ["sneezing", "PROBLEM", 110, 118], ["virus", "OBSERVATION", 4, 9], ["infected", "OBSERVATION", 57, 65], ["respiratory droplets", "OBSERVATION", 75, 95], ["infected", "OBSERVATION", 145, 153]]], ["COVID-19 virus can survive for days on surfaces, but a simple disinfectant can eliminate this [2].", [["COVID-19 virus", "ORGANISM", 0, 14], ["COVID-19 virus", "SPECIES", 0, 14], ["COVID-19 virus", "TREATMENT", 0, 14], ["a simple disinfectant", "TREATMENT", 53, 74]]], ["COVID-19 signs and symptoms include fever, cough, and shortness of breath.", [["fever", "DISEASE", 36, 41], ["cough", "DISEASE", 43, 48], ["shortness of breath", "DISEASE", 54, 73], ["COVID", "TEST", 0, 5], ["symptoms", "PROBLEM", 19, 27], ["fever", "PROBLEM", 36, 41], ["cough", "PROBLEM", 43, 48], ["shortness of breath", "PROBLEM", 54, 73], ["fever", "OBSERVATION", 36, 41], ["cough", "OBSERVATION", 43, 48]]], ["In more severe cases, infection can lead to pneumonia, serious respiratory problems and ultimately, fatalities.", [["respiratory", "ANATOMY", 63, 74], ["infection", "DISEASE", 22, 31], ["pneumonia", "DISEASE", 44, 53], ["respiratory problems", "DISEASE", 63, 83], ["infection", "PROBLEM", 22, 31], ["pneumonia", "PROBLEM", 44, 53], ["serious respiratory problems", "PROBLEM", 55, 83], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["infection", "OBSERVATION", 22, 31], ["pneumonia", "OBSERVATION", 44, 53]]], ["Thousands of people have been reported to have been infected with the virus so far [3].", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["the virus", "PROBLEM", 66, 75], ["infected", "OBSERVATION", 52, 60]]], ["Apart from China, other cases of the disease, also known as COVID-2, have been reported in several countries, including Thailand, South Korea, Japan, Taiwan, Australia, Iran, and the United States.", [["COVID-2", "GENE_OR_GENE_PRODUCT", 60, 67], ["the disease", "PROBLEM", 33, 44], ["disease", "OBSERVATION", 37, 44]]], ["According to the Worldometer, as of 10th March 2020, there are over 114,430 identified cases of COVID-19 worldwide in 115 countries and territories [1].IntroductionOf these 115 countries, South Korea and Iran (outside of China) have the largest epidemic of COVID-19 and Italy, France and Spain are the countries with a major epidemic of COVID-19 in Europe [2].", [["COVID", "TEST", 96, 101], ["COVID", "TEST", 257, 262], ["COVID", "TEST", 337, 342], ["largest", "OBSERVATION_MODIFIER", 237, 244]]], ["COVID-19 spreads mainly from person-to-person during the latency period before the symptoms appear [4].", [["COVID-19", "DNA", 0, 8], ["person", "SPECIES", 29, 35], ["person", "SPECIES", 39, 45], ["the symptoms", "PROBLEM", 79, 91]]], ["There is much more to learn about the spread and severity of COVID-19.", [["COVID-19", "CHEMICAL", 61, 69], ["COVID", "TEST", 61, 66]]], ["COVID-19 can cause mild flu-like symptoms, including fever, cough, dyspnea, myalgia, and fatigue, while more serious forms can cause severe pneumonia, acute respiratory distress syndrome, septic shock, and organ failure, which can lead to death [5].", [["respiratory", "ANATOMY", 157, 168], ["organ", "ANATOMY", 206, 211], ["COVID-19", "CHEMICAL", 0, 8], ["flu-like symptoms", "DISEASE", 24, 41], ["fever", "DISEASE", 53, 58], ["cough", "DISEASE", 60, 65], ["dyspnea", "DISEASE", 67, 74], ["myalgia", "DISEASE", 76, 83], ["fatigue", "DISEASE", 89, 96], ["pneumonia", "DISEASE", 140, 149], ["acute respiratory distress syndrome", "DISEASE", 151, 186], ["septic shock", "DISEASE", 188, 200], ["organ failure", "DISEASE", 206, 219], ["death", "DISEASE", 239, 244], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["organ", "ORGAN", 206, 211], ["COVID", "TEST", 0, 5], ["mild flu-like symptoms", "PROBLEM", 19, 41], ["fever", "PROBLEM", 53, 58], ["cough", "PROBLEM", 60, 65], ["dyspnea", "PROBLEM", 67, 74], ["myalgia", "PROBLEM", 76, 83], ["fatigue", "PROBLEM", 89, 96], ["severe pneumonia", "PROBLEM", 133, 149], ["acute respiratory distress syndrome", "PROBLEM", 151, 186], ["septic shock", "PROBLEM", 188, 200], ["organ failure", "PROBLEM", 206, 219], ["death", "PROBLEM", 239, 244], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["flu", "OBSERVATION", 24, 27], ["myalgia", "OBSERVATION", 76, 83], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["pneumonia", "OBSERVATION", 140, 149], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["respiratory distress", "OBSERVATION", 157, 177], ["septic shock", "OBSERVATION", 188, 200], ["organ", "ANATOMY", 206, 211], ["failure", "OBSERVATION", 212, 219]]], ["Without a vaccine for COVID-19, transmission of the virus can be reduced with early detection and patient quarantine [6].", [["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["a vaccine", "TREATMENT", 8, 17], ["COVID", "TEST", 22, 27], ["the virus", "PROBLEM", 48, 57]]], ["There is epidemiological and clinical evidence to suggest a number of novel compounds, as well as medicines licensed for other conditions, that appear to have potential efficacy against COVID-19 [7,8].", [["COVID-19", "CHEMICAL", 186, 194], ["medicines", "TREATMENT", 98, 107], ["COVID", "TEST", 186, 191]]], ["However, in the absence of a safe and effective vaccine or medicine, reducing viral transmission is the only strategy available where general education, and implementing the appropriate prevention and control is key.", [["a safe and effective vaccine", "TREATMENT", 27, 55], ["medicine", "TREATMENT", 59, 67], ["general education", "TREATMENT", 134, 151]]], ["Precautions can help suppress the risk of infection, such as washing the hands frequently with soap and water or an alcohol-based disinfectant gel, coughing into the elbow or a folded napkin/tissue, avoiding close contact with those who have symptoms, and self-isolating, but medical help must be sought if difficulty in breathing is experienced [5].IntroductionCOVID-19 can be diagnosed with diagnostic test kits [9] and imaging techniques such as chest X-ray and pulmonary CT scans that facilitate early diagnosis of pneumonia in patients with COVID-19 [10\u201312].IntroductionThe case fatality rate (CFR), is a measure of the ability of a pathogen or virus to infect or damage a host in infectious disease and is described as the proportion of deaths within a defined population of interest, i.e. the percentage of cases that result in death [13].", [["elbow", "ANATOMY", 166, 171], ["tissue", "ANATOMY", 191, 197], ["pulmonary", "ANATOMY", 465, 474], ["infection", "DISEASE", 42, 51], ["alcohol", "CHEMICAL", 116, 123], ["pneumonia", "DISEASE", 519, 528], ["infectious disease", "DISEASE", 686, 704], ["deaths", "DISEASE", 743, 749], ["death", "DISEASE", 835, 840], ["alcohol", "CHEMICAL", 116, 123], ["alcohol", "SIMPLE_CHEMICAL", 116, 123], ["elbow", "ORGANISM_SUBDIVISION", 166, 171], ["tissue", "TISSUE", 191, 197], ["pulmonary", "ORGAN", 465, 474], ["patients", "ORGANISM", 532, 540], ["patients", "SPECIES", 532, 540], ["Precautions", "TREATMENT", 0, 11], ["infection", "PROBLEM", 42, 51], ["soap", "TREATMENT", 95, 99], ["disinfectant gel", "TREATMENT", 130, 146], ["coughing into the elbow", "PROBLEM", 148, 171], ["a folded napkin/tissue", "PROBLEM", 175, 197], ["symptoms", "PROBLEM", 242, 250], ["difficulty in breathing", "PROBLEM", 307, 330], ["IntroductionCOVID", "TEST", 350, 367], ["diagnostic test kits", "TEST", 393, 413], ["imaging techniques", "TEST", 422, 440], ["chest X-ray", "TEST", 449, 460], ["pulmonary CT scans", "TEST", 465, 483], ["pneumonia", "PROBLEM", 519, 528], ["COVID", "TEST", 546, 551], ["a pathogen", "PROBLEM", 636, 646], ["virus", "PROBLEM", 650, 655], ["infection", "OBSERVATION", 42, 51], ["elbow", "ANATOMY", 166, 171], ["chest", "ANATOMY", 449, 454], ["pulmonary", "ANATOMY", 465, 474], ["pneumonia", "OBSERVATION", 519, 528], ["infectious", "OBSERVATION", 686, 696]]], ["CFRs confers the extent of disease severity and CFR is necessary for setting priorities for public health in targeted interventions to reduce the severity of risk [14].", [["CFRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["CFRs", "PROTEIN", 0, 4], ["disease severity", "PROBLEM", 27, 43], ["targeted interventions", "TREATMENT", 109, 131], ["disease", "OBSERVATION", 27, 34]]], ["Initial studies reported an estimation of 3% for the global CFR of COVID-19 [15].", [["COVID-19", "CHEMICAL", 67, 75], ["Initial studies", "TEST", 0, 15], ["an estimation", "TEST", 25, 38], ["the global CFR", "TEST", 49, 63], ["COVID", "TEST", 67, 72]]], ["Estimating CFR from country-level data requires assessment of information about the delay between the report of the country-specific cases and death from COVID-19, as well as underestimating and under-reporting of death-related cases, which may not be known.", [["death", "DISEASE", 143, 148], ["death", "DISEASE", 214, 219], ["Estimating CFR", "TEST", 0, 14], ["assessment", "TEST", 48, 58], ["COVID", "TEST", 154, 159], ["death", "PROBLEM", 214, 219], ["may not be", "UNCERTAINTY", 241, 251]]], ["Given the importance of CFR and recovery rate (RR), in this current study the CFR and RR of different countries during a COVID-19 ongoing pandemic was observed using up-to-date country-level data.1.", [["recovery rate", "TEST", 32, 45], ["RR", "TEST", 47, 49], ["the CFR", "TEST", 74, 81], ["RR", "TEST", 86, 88], ["a COVID", "TEST", 119, 126], ["pandemic", "PROBLEM", 138, 146]]], ["Source of data and procedure ::: Materials and MethodsThe data were retrieved from accurate databases including Worldometer 2, WHO 3, the Center of Disease Control and Prevention [16], and the Morbidity and Mortality Weekly Report series (provided from Center of Disease Control and Prevention), according to the user\u2019s guide of data sources for patient registries [17].", [["patient", "ORGANISM", 346, 353], ["patient", "SPECIES", 346, 353], ["Methods", "TREATMENT", 47, 54], ["The data", "TEST", 54, 62], ["Disease Control", "TREATMENT", 148, 163], ["Disease Control", "TREATMENT", 263, 278], ["Disease", "OBSERVATION", 148, 155]]], ["Due to the rapid increase in data, the analysis in this study was performed on the 12th and 23rd of March 2020.1.", [["the rapid increase in data", "PROBLEM", 7, 33], ["the analysis", "TEST", 35, 47], ["this study", "TEST", 51, 61], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["Source of data and procedure ::: Materials and MethodsRaw data was mapped according to countries and CFR and RR were compared for countries with \u2265 1,000 cases.", [["MethodsRaw data", "TEST", 47, 62], ["CFR", "TEST", 101, 104], ["RR", "TEST", 109, 111]]], ["A comparison of CFR with different known viral diseases was performed.2.", [["viral diseases", "DISEASE", 41, 55], ["A comparison of CFR", "TEST", 0, 19], ["different known viral diseases", "PROBLEM", 25, 55], ["viral diseases", "OBSERVATION", 41, 55]]], ["Measuring the CFR and RR ::: Materials and MethodsThe formulas below were used to measure CFR and RR.ResultsThe total number of confirmed cases of COVID-19 was highest in China, followed by Italy and Iran on 12th March, but on 23rd March 2020, total COVID-19 confirmed cases was the highest in China, followed by Italy, USA, and Spain (Table 1).", [["the CFR", "TEST", 10, 17], ["Methods", "TREATMENT", 43, 50], ["The formulas below", "TREATMENT", 50, 68], ["CFR", "TEST", 90, 93], ["RR", "TEST", 98, 100], ["COVID", "TEST", 147, 152], ["total COVID", "TEST", 244, 255]]], ["However, Italy\u2019s CFR was the highest on both time points (12th March, 6.22% versus 23rd March, 9.26%).", [["highest", "OBSERVATION_MODIFIER", 29, 36]]], ["The data showed that Italy was the only European country reported on 12th March, but by the 23rd March 2020, Spain and France had the highest CFR of 6.16 and 4.21%, respectively, which was strikingly higher than the overall CFR of 3.61%.", [["The data", "TEST", 0, 8], ["the highest CFR", "TEST", 130, 145], ["the overall CFR", "TEST", 212, 227], ["higher", "OBSERVATION_MODIFIER", 200, 206]]], ["The highest RR was observed in China, with RR values of 76.12% and 89.85% in both analysis time points, respectively, compared with the overall RR of 55.83% and 29.3% on the 12th and 23rd March 2020, respectively.ResultsThe highest CFR was observed in Italy, followed by China, Iran, and USA on 12th March, which changed to Italy, Spain, France, Iran, and China on 23rd March (Figure 1).", [["The highest RR", "TEST", 0, 14], ["RR values", "TEST", 43, 52], ["the overall RR", "TEST", 132, 146], ["The highest CFR", "TEST", 220, 235], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["Among European countries, Spain and France also faced an increasing rate of CFR.", [["increasing", "OBSERVATION_MODIFIER", 57, 67]]], ["Although Morocco, Panama, and Iraq showed higher CFR values, there was only a small number of total cases, therefore the results of countries with highest outbreak and total cases of COVID-19 were preferentially reported.ResultsChina showed encouraging recovery rates from COVID-19 at both time points (76.12% and 89.85% on 12th and 23rd March 2020, respectively; Figure 2).", [["higher CFR values", "PROBLEM", 42, 59], ["COVID", "TEST", 183, 188], ["COVID", "TEST", 273, 278], ["higher", "OBSERVATION_MODIFIER", 42, 48], ["CFR values", "OBSERVATION", 49, 59], ["small", "OBSERVATION_MODIFIER", 78, 83]]], ["Although the COVID-19 outbreak has led to high rates of death in other Asian countries such as Iran, the recovery rate may be considered acceptable (34%).ResultsThe comparison of CFR between different known infectious and viral diseases was shown in Figure 3.", [["death", "DISEASE", 56, 61], ["infectious and viral diseases", "DISEASE", 207, 236], ["the COVID", "TEST", 9, 18], ["the recovery rate", "TEST", 101, 118], ["CFR", "TEST", 179, 182], ["viral diseases", "PROBLEM", 222, 236], ["infectious", "OBSERVATION_MODIFIER", 207, 217], ["viral diseases", "OBSERVATION", 222, 236]]], ["This revealed that the overall clinical concerns of COVID-19 may eventually be more like those of a severe seasonal flu (CFR of approximately 0.1%) or a pandemic flu, rather than SARS or MERS, which have had CFR of approximately 10% and 36%, correspondingly.DiscussionThis study aimed to observe the CFR of different countries during an ongoing COVID-19 pandemic using recent country-level data, showing that alongside the outbreak of this virus, there is a frame-shift and transition from China (as the first country faced with the outbreak) to other countries in other continents.DiscussionThe outbreak was declared a public health emergency of international concern on 30th January 2020 [18].", [["COVID-19", "CHEMICAL", 52, 60], ["flu", "DISEASE", 116, 119], ["flu", "DISEASE", 162, 165], ["SARS", "DISEASE", 179, 183], ["COVID-19", "CHEMICAL", 52, 60], ["COVID", "TEST", 52, 57], ["a severe seasonal flu", "PROBLEM", 98, 119], ["CFR", "TEST", 121, 124], ["a pandemic flu", "PROBLEM", 151, 165], ["SARS", "PROBLEM", 179, 183], ["CFR", "TEST", 208, 211], ["This study", "TEST", 268, 278], ["an ongoing COVID", "TEST", 334, 350], ["level data", "TEST", 384, 394], ["this virus", "PROBLEM", 435, 445], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["seasonal", "OBSERVATION_MODIFIER", 107, 115], ["flu", "OBSERVATION", 116, 119], ["pandemic", "OBSERVATION_MODIFIER", 153, 161], ["flu", "OBSERVATION", 162, 165]]], ["Confronting emerging diseases requires universal cooperation in identifying, controlling, and preventing these diseases.", [["Confronting emerging diseases", "PROBLEM", 0, 29], ["universal cooperation", "TREATMENT", 39, 60], ["these diseases", "PROBLEM", 105, 119], ["diseases", "OBSERVATION", 21, 29], ["diseases", "OBSERVATION", 111, 119]]], ["The Center for Disease Control obtained a number of factors to establish a geographic risk assessment for the spread of COVID-19 (Supplementary Figure 1).", [["Disease Control", "PROBLEM", 15, 30], ["a geographic risk assessment", "TEST", 73, 101], ["COVID", "TEST", 120, 125]]], ["For instance, China and Iran were categorized as countries where there was widespread ongoing transmission, with restrictions on entry.DiscussionThe data from this study supports the fact that the CFR of the COVID-19 pandemic seems to be less than Bird flu, Ebola, SARS, and MERS, but public health concerns remain due to its highly infectious nature, since a large proportion of cases are asymptomatic or mild, which promotes the spread of the disease worldwide.", [["Ebola", "DISEASE", 258, 263], ["SARS", "DISEASE", 265, 269], ["MERS", "DISEASE", 275, 279], ["Ebola", "ORGANISM", 258, 263], ["Bird flu", "SPECIES", 248, 256], ["this study", "TEST", 159, 169], ["the CFR", "TEST", 193, 200], ["the COVID", "TEST", 204, 213], ["pandemic", "PROBLEM", 217, 225], ["Ebola", "PROBLEM", 258, 263], ["SARS", "PROBLEM", 265, 269], ["MERS", "PROBLEM", 275, 279], ["asymptomatic", "PROBLEM", 390, 402], ["the disease worldwide", "PROBLEM", 441, 462], ["infectious", "OBSERVATION", 333, 343], ["large", "OBSERVATION_MODIFIER", 360, 365], ["asymptomatic", "OBSERVATION_MODIFIER", 390, 402], ["mild", "OBSERVATION_MODIFIER", 406, 410], ["spread", "OBSERVATION_MODIFIER", 431, 437], ["disease", "OBSERVATION", 445, 452]]], ["Cross-country comparisons of CFR and RR as important indicators of disease characteristics are vital for national and international priority setting and recognizing health system performance.", [["CFR", "TEST", 29, 32], ["RR", "TEST", 37, 39], ["disease characteristics", "PROBLEM", 67, 90], ["disease", "OBSERVATION", 67, 74]]], ["However, many factors can confound the current estimation for CFR and RR of COVID-19, namely, undetected cases or delayed case reporting, which can significantly affect the 2 indicators which are linked with a degree of preparedness and mitigation of both the general public and politicians.DiscussionSince the number of cases in the world is increasing in a heterogeneous form, to obtain a better picture for cross-country compression of medical care performance, we require a limiting denominator of CFR and RR to be applied to cases under official medical care with final disease outcome (death/ recovered or discharged).ConclusionDeath and severity of COVID-19 are associated with age and comorbidities across the world.", [["death", "DISEASE", 592, 597], ["CFR", "TEST", 62, 65], ["RR", "TEST", 70, 72], ["COVID", "TEST", 76, 81], ["CFR", "TEST", 502, 505], ["RR", "TREATMENT", 510, 512], ["COVID", "TEST", 656, 661]]], ["Especially in countries with the highest outbreaks, such as China, Italy, and Iran, strategies must be employed to ensure that high-risk groups, such as old people and those with other underlying diseases such as diabetes and cancer, received adequate protection from COVID-19.", [["cancer", "ANATOMY", 226, 232], ["diabetes", "DISEASE", 213, 221], ["cancer", "DISEASE", 226, 232], ["COVID-19", "CHEMICAL", 268, 276], ["people", "ORGANISM", 157, 163], ["cancer", "CANCER", 226, 232], ["people", "SPECIES", 157, 163], ["other underlying diseases", "PROBLEM", 179, 204], ["diabetes", "PROBLEM", 213, 221], ["cancer", "PROBLEM", 226, 232], ["COVID", "TEST", 268, 273], ["diseases", "OBSERVATION", 196, 204], ["diabetes", "OBSERVATION", 213, 221], ["cancer", "OBSERVATION", 226, 232]]], ["Therefore, early access to medical care when infected is vital for improving chances of survival.", [["medical care", "TREATMENT", 27, 39]]], ["Improving medical supplies to countries such as Iran, which is significantly influenced by US punitive policies, can reduce the deterioration of this politically sensitive situation [20].ConclusionFurthermore, taking detailed and accurate medical history, and scoring CFR alongside RR, may highlight the highest risk areas, and more efficiently direct the intervention to decrease the spread of the virus globally.", [["scoring CFR", "TEST", 260, 271], ["RR", "TEST", 282, 284], ["the highest risk areas", "PROBLEM", 300, 322], ["the intervention", "TREATMENT", 352, 368], ["virus", "OBSERVATION", 399, 404]]], ["This may enable the development of point-of-care tools to help clinicians in stratifying patients, based on possible requirements in the level of care to improve probabilities of survival from COVID-19 disease.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["COVID-19 disease", "PROBLEM", 193, 209]]]], "PMC7303046": [["IntroductionThe World Health Organization declared the coronavirus disease 2019 (COVID-19) a global pandemic on March 11, 2020 [1].", [["coronavirus disease", "DISEASE", 55, 74], ["coronavirus", "ORGANISM", 55, 66], ["the coronavirus disease", "PROBLEM", 51, 74], ["COVID", "TEST", 81, 86], ["coronavirus disease", "OBSERVATION", 55, 74]]], ["Outpatient medical visits, including those in otolaryngology practices, have been reduced drastically secondary to these measures in an effort to protect patients and providers, as well as preserve personal protective equipment [4].", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["these measures", "TREATMENT", 115, 129]]], ["Changes in regulations have prompted providers to offer more telehealth opportunities, and some otolaryngology practices have increased utilization of this method of care delivery [[[4], [5], [6]]].", [["[[4], [5], [6]]", "SIMPLE_CHEMICAL", 181, 196], ["this method of care delivery", "TREATMENT", 151, 179]]], ["For patients unable to access in-person or telehealth care, it is plausible that they might increasingly utilize internet search engines such as Google Search (Google Inc., Mountain View, California) to obtain information about symptoms, diagnoses, or treatments.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["telehealth care", "TREATMENT", 43, 58], ["symptoms", "PROBLEM", 228, 236], ["treatments", "TREATMENT", 252, 262]]], ["During this unprecedented situation, it is important to understand the alternative ways in which patients are obtaining medical information in order to develop strategies within the otolaryngology community for meeting their needs.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["GT has contributed to the emerging field of \u201cinfodemiology\u201d, showing utility in assessing outbreaks of influenza-like illness or providing unique insights into human behavior [[[8], [9], [10]]].", [["influenza-like illness", "DISEASE", 103, 125], ["human", "ORGANISM", 160, 165], ["[[8], [9], [10]]", "SIMPLE_CHEMICAL", 176, 192], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["influenza", "PROBLEM", 103, 112]]], ["This study aims to assess trends within the U.S. for Google Search queries of symptoms and complaints encountered commonly in otolaryngology practices comparing the time of COVID-19 pandemic with similar time periods in previous years.Google Trends data ::: MethodsGT determines the proportion of each search term among an anonymized sample of all search requests performed using Google Search [13].", [["This study", "TEST", 0, 10], ["symptoms", "PROBLEM", 78, 86], ["complaints", "PROBLEM", 91, 101]]], ["To account for geographical differences in total search volumes, GT normalizes each data point by dividing by the total searches within the time range and region.", [["GT", "DNA", 65, 67], ["total search volumes", "TEST", 43, 63]]], ["Relative Search Volume (RSV) is presented on a scale from 0 to 100 based on a term's proportion to all other searches, with the query's peak for the time range and geographic region set at 100 and all other data points divided by that peak value.", [["RSV", "SPECIES", 24, 27], ["the query's peak", "TEST", 124, 140], ["Search Volume", "OBSERVATION", 9, 22]]], ["For example, a value of 100 is the peak popularity for the term, while a value of 50 means that the term is half as popular.", [["a value", "TEST", 13, 20]]], ["These included a range of otolaryngology-related symptoms and complaints in technical and non-technical terminology as well as variations on a term to capture search activity more broadly.", [["related symptoms", "PROBLEM", 41, 57], ["complaints", "PROBLEM", 62, 72]]], ["Internet search activity data were obtained and downloaded from the GT website (https://trends.google.com/).", [["GT website", "DNA", 68, 78], ["Internet search activity data", "TEST", 0, 29]]], ["The GT search data are reported in weekly intervals, thus the start dates for each of the 7-week periods under investigation were: March 27, 2016 to May 14, 2016; March 26, 2017 to May 13, 2017; April 1, 2018 to May 19, 2018; March 31, 2019 to May 18, 2019; and March 29, 2020 to May 16, 2020.", [["The GT search data", "TEST", 0, 18]]], ["Because this study does not constitute human participants research, it was exempt from review based on criteria established by the Institutional Review Board of Drexel University.Statistical analysis ::: MethodsRSV data from the periods in 2016\u20132019 were pooled, the means calculated, and the RSV means from the corresponding COVID-19 timeframe in 2020 were calculated.", [["human", "ORGANISM", 39, 44], ["RSV", "ORGANISM", 293, 296], ["human", "SPECIES", 39, 44], ["participants", "SPECIES", 45, 57], ["human", "SPECIES", 39, 44], ["RSV", "SPECIES", 293, 296], ["this study", "TEST", 8, 18], ["MethodsRSV data", "TEST", 204, 219], ["the RSV means", "TEST", 289, 302], ["the corresponding COVID", "TEST", 308, 331]]], ["Comparison of the RSV means between these time periods was performed using a t-test of two independent samples assuming unequal variances with two-sided p-value <.05 considered statistically significant.", [["RSV", "ORGANISM", 18, 21], ["RSV", "SPECIES", 18, 21], ["the RSV means", "TEST", 14, 27], ["a t-test", "TEST", 75, 83], ["unequal variances", "PROBLEM", 120, 137], ["two-sided p-value", "TEST", 143, 160], ["significant", "OBSERVATION_MODIFIER", 191, 202]]], ["All computations were conducted in Microsoft Excel 2017 (Microsoft Corporation, Redmond, Washington).ResultsComparisons of the means of RSV and percentage change for respective search terms are described in Table 2.", [["RSV", "ORGANISM", 136, 139], ["RSV", "SPECIES", 136, 139], ["RSV", "PROBLEM", 136, 139], ["RSV", "OBSERVATION", 136, 139]]], ["Of the 5 (16.6%) search terms with statistically significant increases in RSV during the COVID-19 period, the largest percentage increase was for \u201ccan't smell\u201d (124.4%, \u03bc1-\u03bc2 = 24.8 [95% CI 14.0 to 35.6]; p = .006).", [["RSV", "ORGANISM", 74, 77], ["RSV", "SPECIES", 74, 77], ["statistically significant increases in RSV", "PROBLEM", 35, 77], ["can't smell", "TEST", 147, 158], ["\u03bc1", "TEST", 169, 171], ["CI", "TEST", 187, 189], ["p", "TEST", 205, 206], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["increases", "OBSERVATION_MODIFIER", 61, 70], ["RSV", "OBSERVATION", 74, 77], ["largest", "OBSERVATION_MODIFIER", 110, 117], ["percentage", "OBSERVATION_MODIFIER", 118, 128], ["increase", "OBSERVATION_MODIFIER", 129, 137]]], ["This was followed by \u201callergies\u201d (30.3%, \u03bc1-\u03bc2 = 17.3 [95% CI 6.0 to 28.6]; p = .03), \u201cvoice pain\u201d (26.1%, \u03bc1-\u03bc2 = 10.6 [95% CI 4.5 to 16.7]; p = .008), \u201cears ringing\u201d (19.0%, \u03bc1-\u03bc2 = 13.4 [95% CI 91. to 17.8]; p < .001) and \u201cear pain\u201d (14.5%, \u03bc1-\u03bc2 = 10.3 [95% CI 5.1 to 15.4]; p = .004).", [["ears", "ANATOMY", 154, 158], ["ear", "ANATOMY", 226, 229], ["allergies", "DISEASE", 22, 31], ["voice pain", "DISEASE", 87, 97], ["ear pain", "DISEASE", 226, 234], ["ears", "ORGAN", 154, 158], ["ear", "ORGAN", 226, 229], ["CI", "TEST", 59, 61], ["p", "TEST", 76, 77], ["\u201cvoice pain", "PROBLEM", 86, 97], ["CI", "TEST", 125, 127], ["p", "TEST", 142, 143], ["\u201cears", "TEST", 153, 158], ["\u03bc1", "TEST", 176, 178], ["\u03bc2", "TEST", 179, 181], ["CI", "TEST", 194, 196], ["\u201cear pain", "PROBLEM", 225, 234], ["CI", "TEST", 262, 264], ["ear", "ANATOMY", 226, 229]]], ["The weekly RSV of two terms with the greatest percentage increase during the time range investigated is illustrated in Fig. 1.", [["RSV", "SPECIES", 11, 14], ["greatest", "OBSERVATION_MODIFIER", 37, 45], ["percentage", "OBSERVATION_MODIFIER", 46, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65]]], ["Statistically significant decreases in RSV also were found for 8 (26.7%) search terms, with the largest percentage decrease for \u201claryngitis\u201d (59.8%, \u03bc1-\u03bc2 = \u221233.6 [95% CI \u221238.3 to \u221228.8]; p < .001).", [["laryngitis", "DISEASE", 129, 139], ["RSV", "ORGANISM", 39, 42], ["RSV", "SPECIES", 39, 42], ["significant decreases in RSV", "PROBLEM", 14, 42], ["\u201claryngitis", "PROBLEM", 128, 139], ["\u03bc1", "TEST", 149, 151], ["CI", "TEST", 168, 170], ["\u2212", "TEST", 180, 181], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["decreases", "OBSERVATION_MODIFIER", 26, 35], ["RSV", "OBSERVATION", 39, 42], ["largest", "OBSERVATION_MODIFIER", 96, 103], ["percentage", "OBSERVATION_MODIFIER", 104, 114], ["decrease", "OBSERVATION_MODIFIER", 115, 123], ["laryngitis", "OBSERVATION", 129, 139]]], ["This was followed by \u201cthyroid nodule\u201d (54.4%, \u03bc1-\u03bc2 = \u221241.1 [95% CI \u221248.4 to \u221233.8]; p < .001), \u201cthyroid cancer\u201d (45.6%, \u03bc1-\u03bc2 = \u221232.4 [95% CI \u221236.6 to \u221228.1]; p < .001), and \u201cENT\u201d (34.9%, \u03bc1-\u03bc2 = \u221229.4 [95% CI \u221234.7 to \u221224.2]; p < .001) and \u201cbig tonsils\u201d (32.1%, \u03bc1-\u03bc2 = \u221215.3 [95% CI \u221226.0 to \u22124.6]; p < .02).", [["thyroid nodule", "ANATOMY", 22, 36], ["thyroid cancer", "ANATOMY", 97, 111], ["tonsils", "ANATOMY", 247, 254], ["thyroid cancer", "DISEASE", 97, 111], ["thyroid nodule", "CANCER", 22, 36], ["thyroid cancer", "CANCER", 97, 111], ["tonsils", "ORGAN", 247, 254], ["\u201cthyroid nodule", "TEST", 21, 36], ["\u03bc1", "TEST", 46, 48], ["CI", "TEST", 65, 67], ["\u2212", "TEST", 77, 78], ["p", "TEST", 85, 86], ["\u201cthyroid cancer", "PROBLEM", 96, 111], ["\u03bc1", "TEST", 121, 123], ["\u2212", "TEST", 129, 130], ["CI", "TEST", 140, 142], ["\u2212", "TEST", 152, 153], ["p", "TEST", 160, 161], ["\u03bc1", "TEST", 189, 191], ["CI", "TEST", 208, 210], ["\u2212", "TEST", 220, 221], ["p", "TEST", 228, 229], ["big tonsils", "TEST", 243, 254], ["\u03bc1", "TEST", 264, 266], ["CI", "TEST", 283, 285], ["\u2212", "TEST", 295, 296], ["p", "TEST", 302, 303], ["thyroid", "ANATOMY", 22, 29], ["nodule", "OBSERVATION", 30, 36], ["thyroid", "ANATOMY", 97, 104], ["cancer", "OBSERVATION", 105, 111], ["big tonsils", "ANATOMY", 243, 254]]], ["The weekly RSV of two terms with the greatest percentage decrease during the time range investigated is illustrated in Fig. 2.ResultsThree pairs of non-technical and technical terms were examined: \u201cears ringing\u201d and \u201ctinnitus\u201d, \u201choarseness\u201d and \u201cdysphonia\u201d, and \u201ctrouble swallowing\u201d and \u201cdysphagia\u201d.", [["ears", "ANATOMY", 198, 202], ["tinnitus", "DISEASE", 217, 225], ["hoarseness", "DISEASE", 229, 239], ["dysphonia", "DISEASE", 246, 255], ["dysphagia", "DISEASE", 288, 297], ["ears", "ORGAN", 198, 202], ["RSV", "SPECIES", 11, 14], ["tinnitus", "PROBLEM", 217, 225], ["hoarseness", "PROBLEM", 229, 239], ["\u201cdysphonia\u201d", "PROBLEM", 245, 256], ["trouble swallowing", "PROBLEM", 263, 281], ["dysphagia", "PROBLEM", 288, 297], ["greatest", "OBSERVATION_MODIFIER", 37, 45], ["percentage", "OBSERVATION_MODIFIER", 46, 56], ["decrease", "OBSERVATION", 57, 65], ["hoarseness", "OBSERVATION", 229, 239], ["dysphonia", "OBSERVATION", 246, 255]]], ["\u201cEars ringing\u201d demonstrated a significant 19.0% increase in RSV (\u03bc1-\u03bc2 = 13.4 [95% CI 91. to 17.8]; p < .001) while \u201ctinnitus\u201d showed a nonsignifcant decrease of 1.4% (\u03bc1-\u03bc2 = \u22121.0 [95% CI \u22125.4 to 3.4]; p = .67).", [["RSV", "DISEASE", 60, 63], ["tinnitus", "DISEASE", 117, 125], ["RSV", "ORGANISM", 60, 63], ["RSV", "SPECIES", 60, 63], ["a significant 19.0% increase", "PROBLEM", 28, 56], ["RSV", "TEST", 60, 63], ["CI", "TEST", 83, 85], ["tinnitus", "PROBLEM", 117, 125], ["a nonsignifcant decrease", "PROBLEM", 134, 158], ["CI", "TEST", 186, 188], ["p", "TEST", 203, 204], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["increase", "OBSERVATION_MODIFIER", 48, 56], ["RSV", "OBSERVATION", 60, 63], ["decrease", "OBSERVATION_MODIFIER", 150, 158]]], ["In contrast, the non-technical term \u201choarseness\u201d had a non-significant 1.0% decrease in RSV (\u03bc1-\u03bc2 = \u22120.7 [95% CI \u221210.0 to 8.6]; p = .89) while \u201cdysphonia\u201d decreased significantly by 20.1% (\u03bc1-\u03bc2 = \u22124.8 [95% CI \u22127.9 to \u22121.7]; p = .006).", [["hoarseness", "DISEASE", 37, 47], ["RSV", "DISEASE", 88, 91], ["dysphonia", "DISEASE", 145, 154], ["RSV", "ORGANISM", 88, 91], ["RSV", "SPECIES", 88, 91], ["hoarseness", "PROBLEM", 37, 47], ["RSV", "TEST", 88, 91], ["CI", "TEST", 111, 113], ["p", "TEST", 129, 130], ["\u201cdysphonia", "PROBLEM", 144, 154], ["CI", "TEST", 208, 210], ["\u2212", "TEST", 219, 220], ["p", "TEST", 226, 227], ["dysphonia", "OBSERVATION", 145, 154], ["decreased", "OBSERVATION_MODIFIER", 156, 165]]], ["Finally, RSV for \u201ctrouble swallowing\u201d increased 4.3% without statistical significance (\u03bc1-\u03bc2 = 2.8 [95% CI \u22126.6 to 12.1]; p = .60), while \u201cdysphagia\u201d decreased significantly by 8.5% (\u03bc1-\u03bc2 = \u22126.5 [95% CI \u221211.1 to \u22121.8]; p = .02).DiscussionDuring the COVID-19 pandemic when \u201cstay-at-home\u201d orders and \u201csocial distancing\u201d guidelines drastically affected everyday life as well as otolaryngology practices in the U.S., we present evidence that internet search activity for many otolaryngology-related terms has changed significantly.DiscussionOf the 5 search terms with significant increases in RSV, \u201ccan't smell\u201d demonstrated the greatest increase.", [["dysphagia", "DISEASE", 139, 148], ["RSV", "DISEASE", 590, 593], ["RSV", "ORGANISM", 9, 12], ["RSV", "ORGANISM", 590, 593], ["RSV", "SPECIES", 9, 12], ["RSV", "SPECIES", 590, 593], ["RSV", "PROBLEM", 9, 12], ["\u201ctrouble swallowing", "PROBLEM", 17, 36], ["CI", "TEST", 104, 106], ["p", "TEST", 122, 123], ["\u201cdysphagia", "PROBLEM", 138, 148], ["CI", "TEST", 201, 203], ["\u2212", "TEST", 213, 214], ["p", "TEST", 220, 221], ["significant increases in RSV", "PROBLEM", 565, 593], ["significant", "OBSERVATION_MODIFIER", 565, 576], ["increases", "OBSERVATION_MODIFIER", 577, 586], ["RSV", "OBSERVATION", 590, 593], ["greatest", "OBSERVATION_MODIFIER", 626, 634], ["increase", "OBSERVATION_MODIFIER", 635, 643]]], ["A likely contributing factor to this increase was the inclusion of olfactory dysfunction as a possible symptom of COVID-19.", [["olfactory", "ANATOMY", 67, 76], ["olfactory dysfunction", "DISEASE", 67, 88], ["COVID-19", "CHEMICAL", 114, 122], ["olfactory", "ORGAN", 67, 76], ["olfactory dysfunction", "PROBLEM", 67, 88], ["COVID", "TEST", 114, 119], ["likely contributing", "UNCERTAINTY", 2, 21]]], ["By mid-March 2020, the American Academy of Otolaryngology-Head and Neck Surgery recommended including this symptom when screening for possible COVID-19 [14].", [["COVID-19", "CHEMICAL", 143, 151], ["Head and Neck Surgery", "TREATMENT", 58, 79], ["this symptom", "PROBLEM", 102, 114], ["screening", "TEST", 120, 129], ["COVID", "TEST", 143, 148], ["Head", "ANATOMY", 58, 62], ["Neck", "ANATOMY", 67, 71]]], ["Meta-analysis later indicated a 52% prevalence of olfactory dysfunction among infected patients [15].", [["olfactory", "ANATOMY", 50, 59], ["olfactory dysfunction", "DISEASE", 50, 71], ["olfactory", "ORGAN", 50, 59], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Meta-analysis", "TEST", 0, 13], ["olfactory dysfunction", "PROBLEM", 50, 71], ["olfactory dysfunction", "OBSERVATION", 50, 71], ["infected", "OBSERVATION_MODIFIER", 78, 86]]], ["This was discussed widely in the media, which likely contributed to the 124.4% increase in Google searches for \u201ccan't smell\u201d seen in this study [16].", [["\u201ccan't smell", "PROBLEM", 111, 123], ["this study", "TEST", 133, 143]]], ["The four additional search terms with significant increases in RSV were \u201callergies\u201d, \u201cvoice pain, \u201cears ringing\u201d and \u201cear pain\u201d.", [["ears", "ANATOMY", 99, 103], ["ear", "ANATOMY", 118, 121], ["RSV", "DISEASE", 63, 66], ["allergies\u201d", "DISEASE", 73, 83], ["voice pain", "DISEASE", 86, 96], ["ear pain", "DISEASE", 118, 126], ["RSV", "ORGANISM", 63, 66], ["ear", "ORGAN", 118, 121], ["RSV", "SPECIES", 63, 66], ["significant increases in RSV", "PROBLEM", 38, 66], ["allergies", "PROBLEM", 73, 82], ["voice pain", "PROBLEM", 86, 96], ["ear pain", "PROBLEM", 118, 126], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["increases", "OBSERVATION_MODIFIER", 50, 59], ["RSV", "OBSERVATION", 63, 66], ["ear", "ANATOMY", 118, 121], ["pain", "OBSERVATION", 122, 126]]], ["In attempting to understand this trend, it is interesting that all of these terms are non-technical and could be associated with patients being unable to attend appointments with otolaryngologists.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137]]], ["Similarly, emergency departments have seen 80% reductions in the number of otolaryngology-related consultations during the COVID-19 pandemic [17].", [["the COVID", "TEST", 119, 128]]], ["It is possible that the increases in search queries for these four non-technical terms could be attributed partially to patients resorting to internet searches in lieu of medical consultation to obtain information about symptoms or treatment.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["symptoms", "PROBLEM", 220, 228], ["treatment", "TREATMENT", 232, 241], ["increases", "OBSERVATION_MODIFIER", 24, 33]]], ["However, this association is speculative and warrants further investigations such as correlating GT searches for \u201callergies\u201d with regional pollen concentrations [18].", [["pollen", "ANATOMY", 139, 145], ["allergies\u201d", "DISEASE", 114, 124], ["further investigations", "TEST", 54, 76], ["\u201callergies", "PROBLEM", 113, 123], ["regional pollen concentrations", "TREATMENT", 130, 160]]], ["Nonetheless, this finding highlights the increasing use of the internet for certain non-technical symptoms during the COVID-19 period.", [["certain non-technical symptoms", "PROBLEM", 76, 106], ["increasing", "OBSERVATION_MODIFIER", 41, 51]]], ["With the marked variability in the quality of internet information on treatments for common otolaryngologic problems, this highlights the need for improvements to the web-based information available to patients [19].DiscussionOf the 30 terms investigated, 26.5% demonstrated significant decreases in RSV during the COVID-19 period.", [["RSV", "DISEASE", 300, 303], ["patients", "ORGANISM", 202, 210], ["RSV", "ORGANISM", 300, 303], ["patients", "SPECIES", 202, 210], ["RSV", "SPECIES", 300, 303], ["treatments", "TREATMENT", 70, 80], ["common otolaryngologic problems", "PROBLEM", 85, 116], ["significant decreases in RSV", "PROBLEM", 275, 303], ["marked", "OBSERVATION_MODIFIER", 9, 15], ["variability", "OBSERVATION_MODIFIER", 16, 27], ["significant", "OBSERVATION_MODIFIER", 275, 286], ["decreases", "OBSERVATION_MODIFIER", 287, 296], ["RSV", "OBSERVATION", 300, 303]]], ["In assessing the possible factors contributing to these trends, it may be important to recognize the 34.4% reduction in RSV for \u201cENT\u201d as the context for the decreases seen in the other terms.", [["RSV", "DISEASE", 120, 123], ["RSV", "ORGANISM", 120, 123], ["RSV", "SPECIES", 120, 123], ["RSV", "PROBLEM", 120, 123]]], ["This decrease in \u201cENT\u201d queries could reflect the reduction in referrals to otolaryngologists and the widespread cancellations of elective surgeries [20].", [["elective surgeries", "TREATMENT", 129, 147], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["reduction", "OBSERVATION_MODIFIER", 49, 58]]], ["Previous studies have shown that patients utilize more internet search terms after receiving a diagnosis as compared to before it has been given [21].", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Previous studies", "TEST", 0, 16]]], ["With fewer patients accessing otolaryngologists to receive diagnoses such as thyroid cancer or dysphonia, a decreased post-diagnosis search phenomenon could explain the reductions in certain search queries.", [["thyroid cancer", "ANATOMY", 77, 91], ["thyroid cancer", "DISEASE", 77, 91], ["dysphonia", "DISEASE", 95, 104], ["patients", "ORGANISM", 11, 19], ["thyroid cancer", "CANCER", 77, 91], ["patients", "SPECIES", 11, 19], ["thyroid cancer", "PROBLEM", 77, 91], ["dysphonia", "PROBLEM", 95, 104], ["a decreased post-diagnosis search phenomenon", "PROBLEM", 106, 150], ["thyroid", "ANATOMY", 77, 84], ["cancer", "OBSERVATION", 85, 91], ["dysphonia", "OBSERVATION", 95, 104], ["decreased", "OBSERVATION_MODIFIER", 108, 117]]], ["This is further supported by the findings for the three pairs of non-technical and technical terms compared in this study.", [["this study", "TEST", 111, 121]]], ["The only significant RSV increase for these was the non-technical term \u201cears ringing\u201d, while the only significant RSV decreases occurred with the technical terms \u201cdysphonia\u201d and \u201cdysphagia.\u201d", [["dysphonia", "DISEASE", 163, 172], ["dysphagia", "DISEASE", 179, 188], ["RSV", "ORGANISM", 21, 24], ["ears", "ORGAN", 72, 76], ["RSV", "ORGANISM", 114, 117], ["RSV", "SPECIES", 21, 24], ["RSV", "SPECIES", 114, 117], ["significant RSV increase", "PROBLEM", 9, 33], ["significant RSV decreases", "PROBLEM", 102, 127], ["dysphonia", "PROBLEM", 163, 172], ["dysphagia", "PROBLEM", 179, 188], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["RSV", "OBSERVATION", 21, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["RSV", "OBSERVATION", 114, 117], ["decreases", "OBSERVATION_MODIFIER", 118, 127]]], ["RSV reductions for these terms, as well as \u201cthyroid nodule\u201d, could provide insight into patients' diagnostic needs that may have been addressed insufficiently during this period.", [["thyroid nodule", "ANATOMY", 44, 58], ["RSV", "ORGANISM", 0, 3], ["thyroid nodule", "CANCER", 44, 58], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["RSV", "SPECIES", 0, 3], ["RSV reductions", "TREATMENT", 0, 14], ["\u201cthyroid nodule", "PROBLEM", 43, 58], ["thyroid", "ANATOMY", 44, 51], ["nodule", "OBSERVATION", 52, 58]]], ["Prompt attention to this matter may be warranted, as a portion of these diagnoses may represent underlying cancer and delays in care for head and neck cancer are associated with decreased survival [22].DiscussionSome institutions have increased telehealth utilization 100-fold during the COVID-19 period to compensate for the reduction of in-office encounters, but this degree of technological adaptation has not been seen nationally [[4,23]].", [["cancer", "ANATOMY", 107, 113], ["head and neck cancer", "ANATOMY", 137, 157], ["cancer", "DISEASE", 107, 113], ["head and neck cancer", "DISEASE", 137, 157], ["cancer", "CANCER", 107, 113], ["head and neck cancer", "CANCER", 137, 157], ["underlying cancer", "PROBLEM", 96, 113], ["head and neck cancer", "PROBLEM", 137, 157], ["decreased survival", "PROBLEM", 178, 196], ["may represent", "UNCERTAINTY", 82, 95], ["cancer", "OBSERVATION", 107, 113], ["neck", "ANATOMY", 146, 150], ["cancer", "OBSERVATION", 151, 157], ["increased", "OBSERVATION_MODIFIER", 235, 244]]], ["There is a substantial amount of literature addressing the unique challenges to implementing telehealth in otolaryngology practices, and these GT findings could be incorporated into these strategies to meet patients' needs both during the COVID-19 pandemic and after it has resolved [[[24], [25], [26]]].", [["patients", "ORGANISM", 207, 215], ["[[24], [25], [26]]", "SIMPLE_CHEMICAL", 284, 302], ["patients", "SPECIES", 207, 215], ["the COVID", "TEST", 235, 244], ["substantial", "OBSERVATION_MODIFIER", 11, 22], ["amount", "OBSERVATION_MODIFIER", 23, 29]]], ["Looking beyond the ongoing pandemic, GT represents a potentially powerful source of insight into population-level searches for medical information that could guide timing of public health policies and improve understanding of regional differences in otolaryngology-related patient needs.DiscussionThis report has limitations.", [["patient", "ORGANISM", 273, 280], ["patient", "SPECIES", 273, 280], ["public health policies", "TREATMENT", 174, 196]]], ["Therefore, the observed changes in this study cannot be quantified to determine actual numbers of searches.", [["this study", "TEST", 35, 45]]], ["Data are reported from a population sample determined by GT, and thus may not represent accurately the entire population of the region under investigation.", [["a population sample", "TEST", 23, 42], ["GT", "TEST", 57, 59], ["may not represent", "UNCERTAINTY", 70, 87]]], ["Additionally, there is inherent bias when using GT data as they are generated by a population that is literate, technologically competent, has access to the internet, and has selected Google as a search engine.", [["GT data", "TEST", 48, 55], ["inherent", "OBSERVATION_MODIFIER", 23, 31], ["bias", "OBSERVATION", 32, 36]]], ["The underlying motivations to perform a Google search vary widely and could include obtaining information on symptoms experienced by individuals, responding to media coverage, seeking information for academic interests, or many other motivations.", [["symptoms", "PROBLEM", 109, 117], ["media coverage", "TREATMENT", 160, 174]]], ["These motivations cannot be discerned directly from GT data, which limits the interpretation of the information.", [["GT data", "TEST", 52, 59]]], ["Nevertheless, the trends suggest that patients are responding to COVID-19-related restrictions in otolaryngology care by changing their patterns of self-education through the internet.ConclusionThe COVID-19 pandemic has challenged the ability of otolaryngologists to provide care to many patients in the U.S. This study demonstrates that Google search activity for many otolaryngology-related terms during this period has increased or decreased significantly as compared to previous years.", [["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 288, 296], ["COVID", "TREATMENT", 65, 70], ["otolaryngology care", "TREATMENT", 98, 117], ["This study", "TEST", 309, 319], ["increased", "OBSERVATION_MODIFIER", 422, 431], ["decreased", "OBSERVATION_MODIFIER", 435, 444], ["significantly", "OBSERVATION_MODIFIER", 445, 458]]], ["These trends may suggest unmet needs of patients that otolaryngology practices should consider and attempt to address through expanded telehealth utilization.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["otolaryngology practices", "TREATMENT", 54, 78]]], ["It also suggests that otolaryngologists may need to be prepared to address the information and misinformation that patients have acquired, which is likely to affect the substance of future in-person or telehealth encounters.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["person", "SPECIES", 192, 198]]], ["Additional investigations are needed to better understand how patients utilize the internet to obtain medical information, to improve the quality of available web resources, and to determine the effects of such self-education on patients' future behaviors in caring for their otolaryngologic disorders.Author contributions", [["otolaryngologic disorders", "DISEASE", 276, 301], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 229, 237], ["Additional investigations", "TEST", 0, 25], ["their otolaryngologic disorders", "PROBLEM", 270, 301]]]]}